# EDGAR Filing Document

**Accession Number:** 0002077992
**File Stem:** 0001096906-25-001189
**Filing Date:** 2025-7
**Character Count:** 677264
**Document Hash:** 3955dc29b927e75d563ee7ce122edb52
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001096906-25-001189.hdr.sgml**: 20250725

**ACCESSION NUMBER**: 0001096906-25-001189

**CONFORMED SUBMISSION TYPE**: 1-A

**PUBLIC DOCUMENT COUNT**: 16

**FILED AS OF DATE**: 20250725

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** SpotitEarly, Inc.
- **CENTRAL INDEX KEY:** 0002077992

**ORGANIZATION NAME:**
- **EIN:** 333773069
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 1-A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 024-12646
- **FILM NUMBER:** 251152401

**BUSINESS ADDRESS:**
- **STREET 1:** 61 W. PALISADE AVE.
- **CITY:** ENGLEWOOD
- **STATE:** NJ
- **ZIP:** 07631
- **BUSINESS PHONE:** (929) 241-9035

**MAIL ADDRESS:**
- **STREET 1:** 61 W. PALISADE AVE.
- **CITY:** ENGLEWOOD
- **STATE:** NJ
- **ZIP:** 07631

## Part

**PART II**

SEC File No. ______

**OFFERING CIRCULAR DATED**

**SPOTITEARLY, INC.**

61 W. Palisade Ave.

Englewood, NJ 07631

(551) 355-6554

https://www.spotitearly.com

***Early Detection is One Breath Away***

**UP TO 9,712,509 SHARES OF SERIES A-1 PREFERRED STOCK**

**$7.15 PER SHARE**

**PLUS UP TO 777,000 BONUS SHARES**

**Minimum Investment $1,000**

By this offering, SpotitEarly, Inc., a Delaware Corporation (the "Company"), is offering up to 9,712,509 shares of our Series A-1 Preferred Stock ("Preferred A-1 Stock"), at an offering price of $7.15 per share (the "Offered Shares") pursuant to Tier 2 of Regulation A of the Securities Act of 1933 (the "Securities Act"). This Offering will terminate on the earlier of the date on which the maximum offering amount is sold or the date at which the Offering is earlier terminated by the Company in its sole discretion (such earlier date, the "Termination Date"). At least every 12 months after this offering has been qualified, the Company will file a post-qualification amendment to include the Company's recent financial statements. The minimum purchase requirement per investor is $1,000; however, the Company can waive the minimum purchase requirement on a case-by-case basis in our sole discretion.

By means of this Offering Circular we are also offering up to 777,000 shares of our Series A-1 Preferred Stock to be issued as bonus shares to certain investors pursuant to a bonus program. Investors participating in the Bonus Program may receive an effective discount of up to $0.57 per share, or 20%. See "Plan of Distribution" for more information.

**These securities are speculative securities. Investment in the Company's stock involves significant risks. You should purchase these securities only if you can afford a complete loss of your investment. See the "** **[Risk Factors](#rf)** **" section on page 26 of this Offering Circular.**

We are offering our Preferred A-1 Stock on a best efforts' basis. This means that there is no minimum number of Offered Shares that must be sold by us for this Offering to close; thus, we may receive no or minimal proceeds from this offering. All proceeds from this offering will become immediately available to us and may be used as they are accepted. Purchasers of the Offered Shares will not be entitled to a refund and could lose their entire investments. The proceeds of this Offering will be placed into an escrow account. The Company will engage Enterprise Trust Bank as escrow agent ("Escrow Agent") to hold any funds that are tendered by investors. As there is no minimum offering, upon the approval of any subscription for the Offered Shares, the Company shall immediately accept escrowed funds and deposit the proceeds into the bank account of the Company and may dispose of the proceeds in accordance with the "[Use](#up)[of](#up)[Proceeds](#up)" section of this Offering Circular.

Subscriptions are irrevocable and the purchase price is non-refundable. All proceeds received by the Company from subscribers for the Offered Shares will be available for use by the Company upon acceptance of subscriptions by the Company.

Sale of these shares will commence within two calendar days of the qualification date and it will be a continuous Offering pursuant to Rule 251(d)(3)(i)(F) of the Securities and Exchange Commission ("SEC").

Our Officers and directors will not receive any commission or any other remuneration in connection with this Offering.

------

This Offering Circular shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the laws of any such state.

The Company is using the S-1 (Part I) format in this Offering Circular.

---

| | | | |
|:---|:---|:---|:---|
|  | **Number of Shares** <br>**offered by** <br>**the Company** | **Per Unit or** <br>**Share** | **Total Maximum** <br>**(USD in thousands)** |
| Offered Shares | **9712509** | $7.15 | $69444 |
| Offering Expenses<sup>(4)</sup> |  | $0.00 | $10444 |
| Net Proceeds to Company – |  | $7.15 | $59000 |
| Bonus Shares | 777000 | $0.00(1) | $- |
| Proceeds to Company-Bonus Shares<sup>(2</sup> <sup>)</sup> |  | 0.00 | 0.00 |
| Total Proceeds to Company |  |  | $59000 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) No additional consideration will be received by the Company for the issuance of Bonus Shares and the Company will absorb the cost of the issuance of the Bonus Shares. See "Plan of Distribution" for further details. The Company will not receive any consideration for the additional Bonus Shares. The Bonus Shares represent an effective discount of $0.57 per share or 20%. No fees or commissions will be paid with respect to sale of the Bonus Shares.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Although the Company will not receive any consideration for the Bonus Shares, the value of such Bonus Shares $(5,556) thousands, will be included towards the $75 million maximum amount for any given year.

**The Company has engaged Enterprise Trust Bank as an escrow agent (the "Escrow Agent") to hold funds tendered by investors, and may hold a series of closings on a rolling basis at which we receive the funds from the escrow agent and issue the Securities to investors. The offering will terminate at the earlier of the date at which the maximum offering amount has been sold or the date at which the offering is earlier terminated by the Company in its sole discretion. After each closing, funds tendered by investors will be available to the Company.**

If the Company chooses to offer the shares of common stock through selected dealers, information regarding any arrangement with a selected dealer will be disclosed in an amendment to this Offering Circular. The Company has no current arrangements to do so.

Our Board of Directors used its business judgment in setting a value of $7.15 per share to the Company as the public offering price for the Preferred A-1 Stock to be sold in this Offering. The public offering price bears no relationship to our book value or any other measure of our current value or worth.

------

**THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION DOES NOT PASS UPON THE MERITS OF OR GIVE ITS APPROVAL TO ANY SECURITIES OFFERED OR THE TERMS OF THE OFFERING, NOR DOES IT PASS UPON THE ACCURACY OR COMPLETENESS OF ANY OFFERING CIRCULAR OR OTHER SOLICITATION MATERIALS. THESE SECURITIES ARE OFFERED PURSUANT TO AN EXEMPTION FROM REGISTRATION WITH THE COMMISSION; HOWEVER, THE COMMISSION HAS NOT MADE AN INDEPENDENT DETERMINATION THAT THE SECURITIES OFFERED ARE EXEMPT FROM REGISTRATION.**

SpotitEarly Inc. is a biotech company at the forefront of early cancer detection. The Company is dedicated to transforming the approach to cancer screening through its innovative bio-AI hybrid platform that combines the high sensitivity of canine olfaction with the precision of artificial intelligence (AI). SpotitEarly's mission is to make early, non-invasive, and accurate cancer pre-screening accessible to everyone, everywhere — thereby significantly improving cancer screening, and in turn improving outcomes and reducing the global burden of cancer.

July 25, 2025

------

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **Page**  |
| [CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS](#csr) | 6 |
| [SUMMARY](#sum) |  |
| [THE OFFERING](#off) | 7 |
| [USE OF PROCEEDS](#up) | 8 |
| [DILUTION](#dil) | 9 |
| [MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#mda) | 10 |
| [BUSINESS](#bus) | 13 |
| [RISK FACTORS](#rf) | 27 |
| [MANAGEMENT](#man) | 36 |
| [PRINCIPAL SHAREHOLDERS](#ps) | 44 |
| [DESCRIPTION OF SECURITIE](#ds)S | 45 |
| [PLAN OF DISTRIBUTION](#pd) | 49 |
| [SHARES ELIGIBLE FOR FUTURE SALE](#sef) | 53 |
| [LEGAL MATTERS](#lm) | 53 |
| [EXPERTS](#exp) | 54 |
| [INDEMNIFICATION](#ind) | 54 |
| [WHERE YOU CAN FIND MORE INFORMATION](#wyc) | 54 |
| [INDEX TO FINANCIAL STATEMENTS](#index) | 54 |

---

------

We are offering to sell, and seeking offers to buy, our securities only in jurisdictions where such offers and sales are permitted. You should rely only on the information contained in this Offering Circular. We have not authorized anyone to provide you with any information other than the information contained in this Offering Circular. The information contained in this Offering Circular is accurate only as of its date, regardless of the time of its delivery or of any sale or delivery of our securities. Neither the delivery of this Offering Circular nor any sale or delivery of our securities shall, under any circumstances, imply that there has been no change in our affairs since the date of this Offering Circular. This Offering Circular will be updated and made available for delivery to the extent required by the federal securities laws.

In this Offering Circular, unless the context indicates otherwise, references to "SpotitEarly, Inc.," "we," the "Company," "our" and "us" refer to the business and operations of SpotitEarly, Inc.

This Offering Circular is part of an Offering Statement filed with the SEC, using a continuous offering process. Periodically, as we have material developments, we will provide an Offering Circular supplement or amendment that may add, update or change information contained in this Offering Circular. Any statement that we make in this Offering Circular will be modified or superseded by any inconsistent statement made by us in a subsequent Offering Circular supplement or amendment. The Offering Statement we filed with the SEC includes exhibits that provide more detailed descriptions of the matters discussed in this Offering Circular. You should read this Offering Circular and the related exhibits filed with the SEC and any Offering Circular supplement, together with additional information contained in our annual reports, semi-annual reports and other reports and information statements that we will file periodically with the SEC. See the section of this Offering Circular entitled "[Where You Can Find More Information](#wyc)" for more details.

**STATE LAW EXEMPTION AND PURCHASE RESTRICTIONS**

Our Preferred A-1 Stock is being offered and sold only to "qualified purchasers" (as defined in Regulation A). As a Tier 2 offering pursuant to Regulation A, this Offering will be exempt from state law "Blue Sky" review, subject to meeting certain state filing requirements and complying with certain anti-fraud provisions, to the extent that our Preferred A-1 Stock offered hereby is offered and sold only to "qualified purchasers" or at a time when our Preferred A-1Stock is listed on a national securities exchange. "Qualified purchasers" include: (i) "accredited investors" under Rule 501(a) of Regulation D under the Securities Act ("Regulation D") and (ii) all other investors so long as their investment in our Preferred A-1 Stock does not represent more than 10% of the greater of their annual income or net worth (for natural persons), or 10% of the greater of annual revenue or net assets at fiscal year-end (for non-natural persons). We reserve the right to reject any investor's subscription in whole or in part for any reason, including if we determine in our sole and absolute discretion that such investor is not a "qualified purchaser" for purposes of Regulation A.

To determine whether a potential investor is an "accredited investor" for purposes of satisfying one of the tests in the "qualified purchaser" definition, the investor must be a natural person who has:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.an individual net worth, or joint net worth with the person's spouse, that exceeds $1,000,000 at the time of the purchase, excluding the value of the primary residence of such person; *or*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.earned income exceeding $200,000 in each of the two most recent years or joint income with a spouse exceeding $300,000 for those years and a reasonable expectation of the same income level in the current year.

If the investor is not a natural person, different standards apply. See Rule 501 of Regulation D for more details.

For purposes of determining whether a potential investor is a "qualified purchaser," annual income and net worth should be calculated as provided in the "accredited investor" definition under Rule 501 of Regulation D. In particular, net worth in all cases should be calculated excluding the value of an investor's home, home furnishings and automobiles.

------

**CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS**

Some of the statements in this Offering Circular constitute forward-looking statements. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar matters that are not historical facts. In some cases, you can identify forward-looking statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "should," "will" and "would" or the negatives of these terms or other comparable terminology.

You should not place undue reliance on forward looking statements. The cautionary statements set forth in this Offering Circular, including in "Risk Factors" and elsewhere, identify important factors which you should consider in evaluating our forward-looking statements. These factors include, among other things:

The speculative nature of our business;

Concerns about our ability to continue as a "going concern;"

Our ability to effectively execute our business plan;

Our ability to manage our expansion, growth and operating expenses;

Our ability to finance our businesses;

Our ability to promote our businesses;

Our ability to compete and succeed in highly competitive and evolving businesses;

Our ability to respond and adapt to changes in technology and customer behavior; and

Although the forward-looking statements in this Offering Circular are based on our beliefs, assumptions and expectations, taking into account all information currently available to us, we cannot guarantee future transactions, results, performance, achievements or outcomes. No assurance can be made to any investor by anyone that the expectations reflected in our forward-looking statements will be attained, or that deviations from them will not be material and adverse. We undertake no obligation, other than as may be required by law, to amend this Offering Circular or otherwise make public statements updating our forward-looking statements.

------

**THE OFFERING**

---

| | |
|:---|:---|
| **Securities offered:** | A maximum of 9,712,509 shares of Series A-1 Preferred Stock (the "Preferred A-1 Stock"), plus a maximum of 777,000 Series A-1 Bonus Shares. |
| **Number of shares of Preferred A-1 Stock outstanding before the offering** | 1,458 Shares.  |
| **Number of shares of Preferred A-1 Stock to be outstanding after the offering** | 10,490,967 shares, if all Offered Shares are sold. Amount includes the potential issuance of 777,000 Bonus Shares. |
| **Price per share:** | $7.15 |
| **Maximum offering amount:** | $69444000  |
| **Use of proceeds:** | If we sell all of the shares being offered, our net proceeds (after payment of any estimated offering expenses) will be approximately $59 million. We will use these net proceeds for clinical trials and the expansion of our technology platform, activities needed to market and sell our test kits and for general corporate purposes. |
| **Risk factors:** | Investing in our Preferred A-1 Stock involves a high degree of risk, including:<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Immediate and substantial dilution and <br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·No market for our common stock. <br>See the "[Risk Factors](#rf)" section of this Offering Circular. |

---

**NOTE:** **THE INFORMATION IN THIS OFFERING CIRCULAR INCLUDES THE COMPANY'S WHOLLY OWNED SUBSIDIARY, SPOTITEARLY, LTD., WHICH WAS ACQUIRED ON APRIL 9, 2025.**

------

**USE OF PROCEEDS**

We plan to use these net proceeds from this Offering for the following, depending upon the amount raised in this Offering:

**Amount Raised**

(USD in thousands)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **$10000** | **$25000** | **$50000** | **$69444** |
| Offering Expenses | $1500 | $3750 | $7500 | $10444 |
| Clinical Trials and expansion of our technology platform | $4250 | $9570 | $17000 | $23600 |
| Commercial readiness | $2550 | $7430 | $17000 | $23600 |
| General corporate purpose and working capital | $1700 | $4250 | $8500 | $11800 |

---

Clinical Trials and Expansion of Technology Platform

With a portion of the proceeds from this Offering, the Company plans to conduct two subsequent studies in the U.S., focused on early detection of breast and lung cancer. These clinical trials are not ones which would be required for FDA clearance but which may validate the efficacy of the SpotitEarly test. As such, the data from these trials may be used as supportive data in FDA submissions.

Commercial Readiness

Proceeds allocated to commercial readiness will be used for activities needed to begin marketing and sales of the Company's test.

The precise amounts that we will devote to each of the foregoing items, and the timing of expenditures, will vary depending on numerous factors. Any line item amounts not expended completely shall be held in reserve as working capital and subject to reallocation to other line-item expenditures as required for ongoing operations.

The expected use of net proceeds from this Offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve and change. The amounts and timing of our actual expenditures, specifically with respect to working capital, may vary significantly depending on numerous factors. As a result, our management will retain broad discretion over the allocation of the net proceeds from this Offering.

In the event we do not sell all of the shares being offered, we may seek additional financing from other sources in order to support the intended use of proceeds indicated above. If we secure additional equity funding, investors in this Offering would be diluted. In all events, there can be no assurance that additional financing would be available to us when wanted or needed and, if available, on terms acceptable to us.

------

**DILUTION**

If you purchase shares in this offering, your ownership interest in our Preferred A-1 Stock will be diluted immediately, to the extent of the difference between the price of the Preferred Stock and the net tangible book value per share of our Preferred A-1 Stock after this offering.

SpotitEarly Ltd net tangible book value per share as of December 31, 2024 was $(0.28). Net tangible book value per share equals the amount of our total tangible assets less total liabilities, divided by the total number of shares of our common stock outstanding, all as of the date specified.

The following table illustrates the per share dilution to new investors, assuming the sale of, respectively, of 100%, 75%, 50% and 25% of the Offered Shares (after estimated offering expenses):

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Percentage of Offered Preferred A-1 Stock**<br>**that are sold** | **100%** | **75%** | **50%** | **25%** |
| Offering price  | $7.15  | $7.15  | $7.15  | $7.15  |
| Net tangible book value per share as <br>of December 31, 2024 <sup>(1)</sup> | $(0.28)  | $(0.28)  | $(0.28)  | $(0.28)  |
| Net tangible book value per share after this Offering | $0.14  | $0.66  | $1.36  | $1.79  |
| Increase in net tangible book value per share attributable to new investors in this Offering | $0.41  | $0.94  | $1.64  | $2.07  |
| Dilution per share to new investors | $7.01  | $6.49  | $5.79  | $5.36  |

---

(1)Based on net tangible book value as of December 31, 2024 of $(13,497) thousands and 8,684,618 outstanding common shares and 11,409,198 of preferred shares of all classes prior to this Offering.

------

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF**

**FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and the related notes included elsewhere in this Offering Circular. The following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs. Our actual results could differ significantly from those discussed in the forward-looking statements. Unless otherwise indicated, the latest results discussed below are as of December 31, 2024.

**Results of Operations**

Overview

The Company was incorporated in Delaware on November 26, 2024 as a holding corporation for SpotitEarly, Ltd, an Israeli limited company. The following discussion and analysis includes the financial information of SpotitEarly, Ltd., which became a wholly owned subsidiary of the Company on April 9, 2025.

YEAR ENDED DECEMBER 31, 2024

Material changes in the line items in our Statement of Income and Comprehensive Income for the year ended December 31, 2024 as compared to the same period last year are discussed below:

---

| | | |
|:---|:---|:---|
| Item | Increase (I) or Decrease (D) | Reason |
| Research and Development Expenses | D | Research and Development grants received <br>during 2024 |
| General and Administrative Expenses | I | Marketing expenses and professional services related to the registration processes. |

---

Liquidity and Capital Resources

The table below sets forth our sources and (uses) of cash for the years ended December 31, 2024 and 2023:

---

| | | |
|:---|:---|:---|
|  | 2024 | 2023 |
|  | **(USD in thousands)** | **(USD in thousands)** |
| Cash used in operations | $(3413)  | $(3370)  |
| Cash used in investing | $(37)  | $(98)  |
| Proceeds from issuance of convertible securities | $2500  | $5000  |
| Effect of exchange rates | $(59)  | $(37)  |

---

As of December 31, 2024, we had cash and cash equivalents of $5,240 thousands, compared to $6,249 thousands as of December 31, 2023

During the year ended December 31, 2024, we raised a total of $2,500 thousands through issuance of convertible securities. This compares to $5,000 thousands raised from issuance of convertible securities in 2023.

Net cash used in operating activities was $(3,413) thousands in 2024, as compared to $(3,370) thousands in 2023. Net cash used in investing activities was $(37) thousands in 2024, compared to $(98) thousands in the prior year.

We have evaluated our current cash burn rate and believe we have sufficient resources to maintain operations for the near term based (until mid-2026) on current cash, and continued support from investors. However, this assessment is subject to uncertainties, and we may be required to seek further funding sooner than anticipated.

To address liquidity needs, management is actively pursuing financing options, including this equity offering, Equity, debt issuances, credit facilities, and strategic partnerships. There is no assurance funding will be available in sufficient amounts or on favorable terms. However, management believes continued investor support and future revenues will

------

provide the resources necessary to sustain operations and execute the Company's growth plan. The funding we require may result in further dilution in the equity ownership of our shareholders. As of the date of this Offering Circular, we did not have any commitments or arrangements from any person to provide us with any additional capital.

**Off-Balance Sheet Financing Arrangements**

We do not have any off-balance sheet arrangements that are reasonably likely to have a current or future effect on our financial condition, revenues, and results of operations, liquidity or capital expenditure.

**Trends**

The factors that will most significantly affect our future operating results, liquidity and capital resources will be:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Our ability to successfully raise capital through Regulation A and Regulation D financing processes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Obtaining necessary FDA approvals for our products; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·The successful commercial launch and market acceptance of our products.

Failure or delays in any of these areas could materially and adversely impact our financial condition, growth prospects, and ability to execute our business strategy..

Other than the foregoing, we do not know of any trends, events or uncertainties that have had, or are reasonably expected to have, a material impact on:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·revenues or expenses;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·any material increase or decrease in liquidity; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·expected sources and uses of cash.

**Contractual Obligations**

As of June 30, 2025 we did not have any material capital obligations.

**Significant Accounting Policies**

For a discussion of our significant accounting policies please see Note 2 to the financial statements included as part of this Offering Circular. Management has determined there were no critical accounting policies.

**Accounting Estimates**

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets, liabilities and contingencies at the date of the financial statements as well as expenses during the reporting period. As a result, management is required to routinely make judgments and estimates about the effects of matters that are inherently uncertain. Actual results may differ from these estimates under different conditions or assumptions.

------

**Recently Issued Accounting Pronouncements**

In December 2023, the FASB issued ASU No. 2023-08, "Intangibles-Goodwill and Other-Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets." This ASU is intended to improve the accounting for certain crypto assets by requiring an entity to measure those crypto assets at fair value each reporting period with changes in fair value recognized in net income. The ASU also improves the information provided to investors about an entity's crypto asset holdings by requiring disclosure about significant holdings, contractual sale restrictions, and changes during the reporting period. Upon adoption, a cumulative-effect adjustment is made to the opening balance of retained earnings as of the beginning of the annual reporting period of adoption. This ASU becomes effective for annual periods beginning after December 15, 2024, including interim periods, with early adoption permitted. Upon adoption of ASU 2023-08, the Company is expecting to recognize a cumulative-effect adjustment increasing its crypto assets value and retained earnings by $577,000 as of the beginning of fiscal year 2025.

In November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses. This update aims to enhance the transparency of financial reporting by requiring public business entities (PBEs) to provide disaggregated disclosure of certain income statement expense captions into specified categories in disclosures within the footnotes to the financial statements. The ASU is effective for annual fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. Adoption of this ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact of adopting this ASU on its financial statements and disclosures

**Going Concern**

The Company's financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. To date, the Company has not generated revenues from its activities and has incurred substantial operating losses. Management expects the Company to continue to generate operating losses for the foreseeable future until it substantially grows its sales in the US market.

Such conditions raise substantial doubts about the Company's ability to continue as a going concern for at least a year after the issuance date of the accompanying financial statements. Management plans to address these conditions by raising funds. However, there is no assurance that such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives. The financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount or classification of liabilities that may be required should the Company be unable to continue as a going concern.

------

**BUSINESS**

**Company description**

**SpotitEarly Inc.** is a biotech company at the forefront of early cancer detection. The Company is dedicated to transforming the approach to cancer screening through its innovative Bio-AI hybrid platform that combines the precision of artificial intelligence (AI), with the high sensitivity of canine olfaction. SpotitEarly's mission is to make early, non-invasive, and accurate cancer screening accessible to everyone, everywhere, thereby significantly improving cancer screening, and in turn improving outcomes and reducing the global burden of cancer.

The SpotitEarly Group consists of SpotitEarly Inc., a U.S.-based company, and its wholly owned operating subsidiary, SpotitEarly Ltd., based in Israel. In April 2025 SpotitEarly, Inc. acquired all of the outstanding stock of SpotitEarly, Ltd. in exchange for 8,648,618 shares of its common stock and 8,305,151 shares of its Series Seed and Series Seed 1 preferred stock. SpotitEarly Inc. was incorporated in Delaware in November 2024, and its subsidiary, SpotitEarly Ltd., was incorporated in Israel in June 2020. SpotitEarly Inc. is responsible for commercialization efforts in the U.S., including, clinical trials, strategic partnerships, marketing and future operations in the U.S. and the global market. It also serves as the main corporate, financing, and headquarters entity of the Group, overseeing global strategy, investor relations, and corporate governance. SpotitEarly Ltd. leads the research, development, and execution of the Company's core technology. This structure allows the Group to align cutting-edge R&D with effective go-to-market execution and regulatory engagement across geographies.

The Company's core technology centers around the detection of volatile organic compounds (VOCs) present in human breath, which are known indicators of metabolic changes associated with cancer, including in the early stages of the disease. Our approach focuses on identifying the unique odor signature of these VOCs, enabling a non-invasive, accurate, and affordable self-administered screening test that can be performed at home or in a clinical setting.

SpotitEarly Inc., the U.S. parent entity, is the issuer of the securities offered under this Offering Circular. All references to the Company include the Company's wholly owned subsidiary, SpotitEarly Ltd.

**Definitions**

Bio-AI Hybrid Platform/ LUCID

A bio-AI hybrid platform, known as the LUCID platform, combines the analytical power of AI with the olfactory capabilities of trained canines to detect cancer through breath analysis. It is a proprietary platform developed by SpotitEarly, designed to provide a reliable, scalable, and accurate method for early cancer detection, incorporating advanced hardware and software components, as well as big data collection and analysis. Using different sensors and advanced AI and ML algorithms, LUCID collects and analyzes hundreds of live non-invasive behavioral and physiological signals from trained sniffer dogs as they screen samples in the laboratory facility and generates an accurate laboratory result indicating the presence or absence of cancer in each sample. This patent-pending proprietary platform is transforming the exceptional sensitivity of canines in detecting cancer's unique odor signature into a commercial-grade, highly accurate screening test for the early detection of cancer.

Horizontal and Vertical packs

A horizontal pack is designed to detect the presence of a cancer signal for multiple cancers**.** A vertical pack is used to detect the signal for a specific cancer.

CLIA

Under the Clinical Laboratory Improvement Amendments (CLIA), the Centers for Medicare & Medicaid Services (CMS) oversees the accreditation, inspection, and certification of clinical laboratories. CLIA certification may be granted regardless of the laboratory's geographic location. SpotitEarly conducts its screening operations in a high-capacity CLIA-registered laboratory located in Israel (Registration No. 99D2307137). Operating within a CLIA-compliant framework reflects the Company's commitment to the highest laboratory standards and clinical-grade protocols. To support future scalability and expansion, the Company plans to establish a CLIA-certified laboratory in the United States by 2027.

------

LDT (laboratory developed test)

The Company has developed a Laboratory Developed Test (LDT) for early cancer detection, which is performed in its CLIA-registered, high-complexity laboratory. LDTs are not subject to FDA premarket review under its current policy of enforcement discretion.

**Pain and Solution**

Current cancer screening methods face significant deficiencies, including limited scope, low adoption rates, and accessibility challenges. SpotitEarly believes it addresses these shortcomings with its innovative bio-AI hybrid platform, combining canine olfaction and AI analysis of breath samples.

**Deficiencies in Current Cancer Screening**

**Limited Scope:** Current screening paradigms primarily focus on a limited number of cancers, such as breast, cervical, colorectal, lung, and prostate, which account for only about half of all cancer cases and 43% of cancer deaths. A significant proportion of all cancers, approximately 57%, lack effective screening methods.

Traditional screening methods are often specific to a single cancer type, such as mammograms for breast cancer or colonoscopies for colorectal cancer. This approach necessitates multiple tests for different cancers, increasing the complexity and cost of screening. As a result, a large number of cancers are detected only after symptoms appear, often at later stages when treatment options may be less effective. For example, lung cancer has the highest rate of late-stage detection at 66%, followed by colorectal at 59%.

**Low Adoption Rates:** Despite the availability of screening for certain cancers, screening rates remain low, with only about 14% of cancers in the U.S. diagnosed through recommended screenings. This indicates a significant gap between the potential benefits of screening and actual participation in the screening process. Factors contributing to low screening rates include fear, discomfort, inaccessibility and the invasive nature of some traditional screening procedures. For instance, mammograms can be uncomfortable, and colonoscopies are invasive and require preparation. Many people also experience anxiety related to screening tests, or have limited access to health professionals.

**Accessibility Challenges:** Access to healthcare, including cancer screening, remains a significant global challenge, with disparities affecting underserved communities. These populations therefore often experience higher rates of late-stage diagnoses and poorer survival outcomes. Geographical barriers, such as remote or rural areas with limited healthcare facilities, and lack of transportation, hinder access to traditional screening methods. Economic barriers, such as the high cost of traditional screening and diagnostic tests, also prevent access to screening for many.

**Inconvenience:** Current methods can be inconvenient and time-consuming, requiring clinic visits and potentially long waiting times. Traditional screening methods often require taking time off from work and other responsibilities, further limiting participation.

**Diagnostic Accuracy Issues:** Some traditional screening methods can have high false-positive rates leading to unnecessary anxiety and follow-up procedures. While some traditional methods can be effective, they are not always optimal. For example, mammograms struggle with high-density breasts that hinder their accuracy.

**SpotitEarly's Approach**

SpotitEarly is working to address these deficiencies through its innovative LUCID platform, which combines proprietary hardware and advanced AI models with canine olfaction (i.e. sense of smell) to detect the unique odor signature of cancer-emitted VOCs in breath samples. The system's AI-driven screening lab results substantially improve upon the baseline performance of the sniffer dogs, transforming their exceptional sensitivity into a commercial-grade, highly accurate screening test for the early detection of cancer. Key aspects of its disruptive approach include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Multiple-Cancer Detection:** SpotitEarly's test will be designed to detect multiple cancer types based on one sample, addressing a critical gap in current screening methods that target single cancer types. Initially, the

------

test will focus on the four most common cancers- lung, breast, prostate, and colorectal - which account for half of all new cancer cases in the U.S.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Non-Invasive Testing:** The breath-based test eliminates the need for invasive procedures, making screening more approachable, less intimidating, and more comfortable. This addresses the fear and discomfort associated with traditional screening methods, and encourages broader participation. The SpotitEarly test is self-administered and, once on the market, can be completed in just a few minutes, either at home or in a clinical setting, streamlining the screening process.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**High Sensitivity and Specificity:** In a double blind clinical trial involving 1400 participants, the sensitivity and specificity were over 93% for four common cancer types - lung, breast, prostate and colorectal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Improved Accessibility and Equity:** The LUCID platform is designed for scalability, portability, and turnkey deployment, enabling implementation in any facility that operates sniffer dogs for target odor detection. It can be deployed in labs operated directly by SpotitEarly or in the future - by third-party partners, supporting various operational models. The system's modular design allows a single facility to process over a million tests annually and enables easy replication across regions, including both urban and rural settings. The Company is committed to breaking down barriers in healthcare access, making early detection more equitable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Data-Driven Continuous Improvement:** The LUCID platform collects vast amounts of data, which is used to continually refine the AI algorithms, enhancing accuracy and diagnostic potential over time. The AI isn't static, it evolves and gets smarter with every test. This continuous improvement cycle ensures that the test's performance remains optimal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Improved Patient Experience:** The ease of use of SpotitEarly's test, especially for underserved populations, is critical. The Company's breath-based approach is non-intrusive and can be done at home, minimizing friction with the healthcare system. The test results can be provided in a timely manner, which helps to reduce anxiety for patients and healthcare providers.

In summary, SpotitEarly's technology has the potential to disrupt the cancer detection industry by providing a non-invasive, accurate, accessible, and cost-effective method for early cancer detection. By addressing the limitations of current screening methods, SpotitEarly can improve patient outcomes and reduce the overall burden of cancer. The Company's focus on multiple-cancer detection, combined with its commitment to equity and inclusion, positions it as a potential leader in transforming cancer screening.

**Core Technology and Scientific Foundation**

**LUCID Platform:** SpotitEarly's proprietary LUCID platform is a new system that integrates advanced AI and machine learning (ML) algorithms with canine scent detection, to identify VOCs odor signature in breath samples. The platform is designed to provide a reliable, scalable, and accurate method for early cancer detection, incorporating advanced hardware and software components, as well as big data collection and analysis. Using different sensors and advanced AI and ML algorithms, LUCID collects and analyzes hundreds of live non-invasive behavioral and physiological signals from trained sniffer dogs as they screen samples in the laboratory facility and generates an accurate laboratory result indicating the presence or absence of cancer in each sample. This patent-pending proprietary platform is transforming the exceptional sensitivity of canines in detecting cancer's unique odor signature into a commercial-grade, highly accurate screening test for the early detection of cancer.

This platform is designed for global scalability, ensuring reliable and accurate results across various laboratory settings. The LUCID platform also includes a data and test management system that manages tests, stores data, and makes decisions throughout the testing process.

------

**Breath-Based specimen:** The technology uses a simple, non-invasive breath test to analyze VOCs that are released from cells into the microenvironment and circulation during the development of cancerous tumors. Breath samples are collected using a breath collection mask. Patients are instructed to breathe into the mask for 3 minutes, and send the sample back to the SpotitEarly lab using the storage component supplied within the breath collection kit.

**Canines and their olfaction system**

Dogs possess an exceptional sense of smell, far surpassing that of humans and even advanced analytical chemistry, which enables them to detect cancer from exhaled breath. Their olfactory system is uniquely equipped with anatomical, physiological, and genetic characteristics that give them an unparalleled ability to detect and differentiate a vast array of odor compounds, including the volatile organic compounds (VOCs) associated with cancer. Here's a breakdown of why dogs are so effective at this task:

Anatomical Advantages:

**Extensive Olfactory Epithelium**: Dogs have a highly developed olfactory epithelium, the tissue inside the nasal cavity that houses olfactory receptors, which is elongated and contains concha bones that greatly increase its surface area. This expanded surface area allows for a greater number of olfactory receptors, significantly enhancing their ability to detect odors. The olfactory cortex in dogs is also significantly larger and more complex than in humans, occupying about 30% of their cortex. This allows them to combine scent data with other sensory inputs for improved accuracy.

**Specialized Nostrils**: The shape of a dog's nostrils ensures the entry of a sufficient amount of odor molecules into the airflow of the nasal cavity. These nostrils are designed to efficiently channel air containing odor molecules towards the olfactory receptors.

**Olfactory Receptors**: Dogs have approximately 300 million olfactory receptors, compared to about 6 million in humans. These receptors are highly sensitive and capable of detecting a wide range of odor molecules at extremely low concentrations, as low as one part per trillion. Dogs can detect approximately half a million odorous compounds.

**Olfactory Bulb**: The olfactory bulb, a part of the forebrain that processes smell information, is also much larger in dogs than in humans, enabling a more detailed analysis of scents. Their olfactory brain region is about 40 times larger than in humans.

**Unique Airflow**: When dogs sniff, they inhale and exhale rapidly, creating airflow that optimally delivers odor molecules to their olfactory receptors. They can sniff 5 to 10 times per second, allowing them to continuously analyze the scents in their environment.

Physiological Advantages:

**Low Detection Threshold**: Dogs can detect odors at extremely low concentrations, with a sensitivity threshold of 0.001ppt or less, compared to an electronic nose which \*has a detection threshold of 0.1ppb. This remarkable sensitivity allows them to perceive subtle odor differences that are undetectable by most other means.

**Filtering Background Odors:** Dogs can filter out background odors and focus on specific target scents. This ability to identify relevant smells amidst a collage of environmental stimuli is a critical trait for detecting cancer-related VOCs. The olfactory system of dogs can filter out background odors while still remaining responsive to new odors.

**Real-time Analysis**: Dogs can analyze scents in real-time, allowing them to update their smell map of their environment continuously. This real time analysis, combined with their ability to analyze subtle differences in odor profiles, enables them to effectively detect cancer VOCs.

Genetic Advantages:

**Olfactory Receptor Genes**: Dogs possess a large number of olfactory receptor genes, with the correct ratio between active and inactive genes of odorant receptor proteins. The specific genetic makeup of dogs enhances their sensitivity to volatile organic compounds (VOCs).

------

**Cognitive Ability**: Unlike artificial machine learning, dogs have developed cognition that allows them to identify odor patterns and memorize them, and can arrange them by topic. This capability is essential in detecting diseases like cancer, since the VOCs are not single biomarkers, but rather patterns of many compounds. Dogs' natural cognition for identifying odor patterns, allows them to sort them in a dedicated training process to distinguish physiological conditions like cancer.

How Dogs Detect Cancer in Exhaled Breath:

**Detection Process**: When a trained dog is presented with a breath sample, it uses its exceptional olfactory system to identify the presence of cancer-specific VOCs. The dog can filter out any irrelevant odors and focus on the unique scent patterns emitted by the cancer VOCs. If the dog detects the target odor pattern, it signals this through a trained behavior, such as sitting. Multiple dogs may analyze the sample independently to enhance the reliability of the results. This ability to analyze subtle differences in odor profiles helps them to distinguish disease-related VOCs from background scents.

**Pattern Recognition**: Dogs are not identifying a single molecule but rather recognizing a complex pattern of VOCs associated with cancer. This pattern recognition ability allows them to be highly accurate in their detection.

**Consistency and Reliability**: Once trained, dogs demonstrate an impressive ability to remember scent patterns over time. Regular retraining and practice sessions help maintain their sharpness and ensure their responses remain accurate and dependable.

**Double-Blind Testing**: To ensure unbiased results, the samples tested in the clinical study described below, were presented in a random order unknown to both the dog handler and the research director. This was performed using a double blind test, so that neither the dog handler nor the test administrator know when or where the target odor will appear and thus cannot influence the dog's reaction. The study was a two arm clinical trial, the first arm represented the target population and was the source of most negative samples. All participants from this arm tested negative for cancer after a day of screening tests at a cancer screening center. The second arm was enriched and was the source of most positive samples. All positive samples in the trial were confirmed as cancer positive by biopsy. This process ensured that the dog's response was not influenced by any cues from the handler or the testing environment.

Why canines specifically?

While several mammals possess a keen sense of smell, dogs are particularly well-suited for cancer detection for a combination of reasons that go beyond just olfactory capability. These reasons encompass their unique anatomy, physiology, trainability, and behavioral characteristics, making them superior to other mammals for this specific task. Here's a detailed explanation:

**1. Trainability and Behavioral Characteristics:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**High Trainability:** Canines, particularly breeds like Labradors and Beagles, are highly trainable and motivated to work with humans. They possess a strong desire to please, making them excellent candidates for operant conditioning techniques. This desire to work alongside humans and their high ability to learn through operant conditioning, makes them well suited for detection tasks. They are trained using a reward based system where they are given positive reinforcement to associate the cancer VOCs with a reward.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Operant Conditioning:** Canines are trained using operant conditioning, which involves associating a specific behavior (like sitting down) with the detection of a target odor. Positive reinforcement (rewards) increases the likelihood of the dog repeating the desired behavior when the target odor is detected again. This makes them excellent biological detectors for many purposes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Selective Focus:** Through training, dogs can learn to filter out irrelevant smells and focus solely on the specific VOCs associated with diseases like cancer. They can quickly learn to ignore other stimuli in the work environment. This ability to hone in on specific target scents amidst numerous environmental odors allows them to be very efficient at detection tasks.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Independent Decision Making:** Canines, particularly beagles, are more independent and are less likely to seek reassurance from their handler's behavior. This allows them to make detection decisions more independently. They are less likely to be influenced by their handler, which increases the reliability of their analysis.

**2. Practical Considerations:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Mobility and Efficiency:** Dogs are mobile and can move along the odor concentration gradient until they reach the source of the smell. They can quickly cover ground and detect targets from a distance, making them very efficient in scent detection. They can analyze hundreds of breath samples in a single day, a speed and efficiency that is unmatched by other methods or animals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Cost-effectiveness:** Training dogs is highly cost-efficient compared to developing and deploying complex medical devices. This makes them a more practical option for widespread screening.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Suitability for a Clinical Environment:** Dogs are capable of performing in a controlled laboratory environment, and can easily be adapted to work with breath samples, as they have a strong desire to work with their handlers and are capable of working for long periods of time while maintaining concentration. They can be easily moved between testing locations and are able to work in a methodical manner that maintains consistency and efficiency.

**Why not use an electronic nose?**

While electronic noses ("E-noses") hold promise, they haven't yet achieved the level of sensitivity, specificity, and reliability required for widespread commercial use, particularly in complex applications like cancer detection. Several factors contribute to this, including technological limitations, challenges in replicating biological olfactory processes, and the complex nature of VOC patterns in human breath. Here's a detailed explanation:

1. Limited Sensor Capabilities Compared to Biological Olfaction:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Number of Sensors:** E-noses typically incorporate a limited number of sensors, often in the range of units or dozens. This contrasts sharply with the canine olfactory system, which boasts around 300 million olfactory receptors, and a large olfactory cortex. This vast difference in the number of sensory units inherently limits the amount of olfactory information an e-nose can gather, making it difficult to match the nuanced sensing capability of a dog. The sheer number of biological sensors allows dogs to detect a much wider range of volatile organic compounds (VOCs) and subtle variations within them.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Sensor Sensitivity & Selectivity:** The detection threshold of an electronic nose is around 0.1 ppb (parts per billion), whereas dogs can detect concentrations as low as 0.001 ppt (parts per trillion). Current e-nose sensors often lack the sensitivity and chemical selectivity needed to detect VOCs at the extremely low concentrations found in human breath, especially in early-stage cancer. They frequently suffer from unwanted chemical interactions between VOCs and the sensors. E-noses struggle to match the specialized receptors in biological noses that are fine-tuned to detect very specific molecules. Dogs have a far wider range of sensors that are able to extract nuanced olfactory information, facilitating specialization in detection and interpretation of odor signals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Sensor Drift and Reproducibility:** Electronic sensors are prone to "sensor drift," meaning their response changes over time, requiring frequent recalibration. Achieving precise recalibration is a challenge. It is difficult to produce identical sensors consistently to yield reliable results. This lack of reproducibility makes it hard to obtain consistent and reliable data over time, which is essential for any clinical diagnostic tool. Dogs, on the other hand, maintain consistency in their detection capabilities with proper training.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Limited Temporal Stability:** E-noses have limited temporal stability, meaning their ability to maintain consistent readings over time is limited. The sensors can be influenced by external factors that affect the consistency of readings. Dogs, due to the nature of their biological sensing and ability to adapt, don't exhibit this limitation.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Lack of Robustness and Adaptability:** E-noses often lack robustness and adaptability, showing a sensitivity to changes in temperature, humidity, and other environmental factors that can affect sensor readings. Additionally, E-noses are susceptible to environmental variables such as temperature and humidity variations during transportation, storage, and testing. The biological olfactory system is robust, with dogs able to detect specific VOCs even in complex environments without significant impact from ambient conditions. Dogs are capable of rapidly modulating their sensing to adapt to changes in their environment.

2. Challenges in Mimicking Biological Olfactory Processes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Complex VOC Patterns:** Cancer and other diseases produce complex mixtures of VOCs, not single biomarkers, and these patterns can vary significantly between individuals, making the task of identifying a "master biomarker template" extremely challenging. Biological systems, like dogs, seem to be able to focus on these complex patterns and can identify them even with variability in the samples. E-noses struggle to recognize these complex, subtle odor patterns that are not based on single biomarkers or a clear range of concentrations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Background Odors and Interference:** Unlike dogs, e-noses cannot easily separate background odors and interferences from the specific VOCs that they are trying to detect. Dogs have an innate ability to focus on a specific odor pattern even in complex odor environments, an ability that e-noses have not yet been able to replicate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Data Analysis and Pattern Recognition:** The data generated by e-noses requires sophisticated machine learning algorithms to interpret, which is not always as effective as the cognitive abilities of a biological olfactory system. While machine learning is effective in identifying patterns, one of the biggest problems has been the lack of uniformity and standardization in sampling and analysis. The data analysis from electronic nose sensor arrays requires careful computational modelling and analysis, which can be complicated and time-consuming. Dogs have a highly evolved cognition in the context of identifying odor patterns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Lack of Cognition and Memory:** Dogs have developed cognition that enables them to memorize complex patterns and sort them by topic, such as cancer. They have cognitive abilities to sort out these patterns. Unlike artificial machine learning, dogs' unique cognitive abilities make them excellent at recognizing patterns that relate to a specific physiological condition such as cancer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Sample Preparation:** Electronic noses require strict breath sampling methods, as well as substantial pre-processing procedures including sample pre-concentration and dehumidification. Dogs can accomplish this separation even in complex odor environments without the need for sample pre-processing.

3. Practical and Logistical Limitations:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Cost and Complexity:** Analytical instruments like GC-MS (gas chromatography-mass spectrometry) are expensive, require significant expertise to operate correctly, and have limited throughput. Though it is important to note that GC-MS is currently the gold standard for VOC analysis, it is time-consuming, requires sample pre-concentration, and expensive consumables. As of the date of this Offering Circular, to the knowledge of the Company, GC-MS instruments are not currently being commercially used to detect cancer in breath samples.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Time-Consuming Process:** E-nose testing is also more time consuming compared to the rapid scent detection abilities of dogs. Dogs analyze samples in as little as 5 seconds per patient. Electronic analysis requires more time, particularly when searching for complex odor patterns that aren't focused on single biomarkers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Standardization and Reproducibility:** The lack of uniformity and standardization in sampling and analysis methods has been a long-standing problem in the field that has not allowed for reproducibility, creation of broad databases, and the development of accurate algorithms. This limitation significantly impedes the development of reliable algorithms to identify cancer from VOCs.

------

4. Current State of Research and Development of Electronic Noses:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Limited Clinical Validation:** While there has been substantial research on e-noses for VOC detection, there is a lack of large-scale, blinded, clinical validation studies, and a lack of reproducibility between studies looking for disease biomarkers. This is a critical gap that hinders the implementation of e-noses in clinical practice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Focus on Target VOCs:** Some current e-nose systems are now focusing on targeting specific VOCs, using technologies such as FAIMS, which is showing promise, but is still not as effective as dogs. These emerging technologies improve stability, sensitivity, and selectivity over previous e-nose systems, but still have their limitations, especially when compared to biological detection.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Need for Advanced Technology:** Despite technological advancements, a mobile device capable of reaching a dog's level of sensitivity and discrimination in identifying low concentrations of VOCs is still not available. There is still a long way to go before electronic nose technology is able to overcome the limitations of current sensor technology.

**Product and Service Offerings:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Multi-Cancer Detection Test:** SpotitEarly's initial clinical study focused on multiple-cancer detection including colorectal, lung, breast, and prostate cancers. These cancers account for approximately half of all new cancer cases in the US. By targeting these prevalent cancers, SpotitEarly aims to address a significant portion of the market. The Company plans to expand the platform to detect other diseases using breath analysis in the future. The initial go to market strategy will focus on Breast cancer. More cancers will be added to the test with the progress of the relevant clinical studies.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**At-Home Sample Collection:** SpotitEarly's test is designed for at-home sample collection. The breath samples can be used by patients anywhere, including at-home, according to the instructions for use, without the supervision of a healthcare professional, and then sent to the company's laboratory for analysis. This approach will minimize the inconvenience and anxiety associated with traditional screening methods.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Data Analysis and Reporting:** SpotitEarly uses advanced data analysis techniques to identify discriminating features, and develops classifiers using machine learning algorithms. The Company's analytical workflow involves stringent quality control checks, ensuring high reproducibility and reliability of breath sample analysis. The platform incorporates measures to maximize the signal-to-noise ratio, such as using a standardized breath collection method and analytical pipeline. The Company's laboratory, located in Israel, is CLIA registered (Registration No. 99D2307137).**Results Reporting**: If a signal for cancer will be detected, a specially trained healthcare professional will contact the patient or the medical practitioner to explain the findings and discuss next steps. If no signal for cancer is detected, the customer service team will discuss the results and answer any questions doctors might have, and will also provide reminders for future pre-screenings recommendations.

**SpotitEarly's Market Opportunity:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Large and Growing Market:** SpotitEarly's market growth plan strategically positions the company to scale rapidly in the cancer screening and diagnostics sector through incremental market entry and expansion. The global diagnostics market is substantial, with a total addressable market (TAM) of $143B. The North American diagnostics market is also significant, with a serviceable addressable market (SAM) of $60B. We will also explore applications of our LUCID technology beyond oncology.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Unmet Needs:** Current cancer screening methods, such as mammograms for Breast Cancer, and PSA blood test for Prostate Cancer, have limitations including high false-positive rates, discomfort, and limited effectiveness at early stages, or for dense breast tissue. Lung cancer, one of the leading causes for cancer death in the USA, has a screening test (LDCT – Low Dose CT) that is only intended for high-risk populations of heavy smokers between the ages of 55-74. A large percentage of survey participants have complained about the high out-of-pocket costs of traditional screening methods, and some decide to forgo the tests to

------

control costs. There is a clear need for a new, non-invasive screening system that can improve patient compliance, reduce costs, and provide greater accessibility.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Competitive Advantage:** SpotitEarly's technology offers a non-invasive, accurate, and cost-effective method for early cancer detection, with superior sensitivity and specificity compared to existing methods. The test is designed to be more accessible than traditional screening methods, overcoming barriers of cost, complexity, and access to care. The Company's approach addresses the need for more frequent testing to manage anxiety and save on costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Target Audience:** The first test we will offer is a Breast Cancer screening test. The initial target audience for the launch is women aged 40-65, with a focus on the higher-income, well-educated segment. However, the technology is designed to serve large populations, in both urban and rural settings, with the modular design of the labs enabling replication worldwide. As we expand to other cancers, our target audience will grow accordingly.

Competition

SpotitEarly's competitive landscape includes traditional screening methods and other companies developing multi-cancer early detection (MCED) technologies. The Company's competitive advantages, or "moats", stem from its unique combination of canine scent detection, AI-powered data analysis, and a focus on accessibility and scalability.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Traditional Screening Methods:** SpotitEarly's test competes with established cancer screening methods such as mammograms, ultrasounds and blood tests. These methods are often invasive, expensive, and may not be readily accessible to all populations. Additionally, some of these traditional methods, such as mammograms, are optimized for specific types of cancer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Liquid Biopsy Competitors**: SpotitEarly faces competition from companies developing blood-based MCED tests. Companies in this space include GRAIL, Exact Sciences, Freenome, Guardant Health, AnchorDx, ArcherDx, Burning Rock Biotech Limited, GENECAST, Laboratory for Advanced Medicine, and Singlera Genomics. These companies utilize technologies like next-generation gene sequencing, artificial intelligence, and big data to detect cancer signals in blood samples.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Breath Analysis Competitors**: Other companies are also working on breath analysis for disease detection. Owlstone Medical, for example, has developed a breathalyzer for early disease detection that uses volatile organic compound (VOC) biomarkers. Nanose Medical is also developing products for disease diagnosis.

SpotitEarly's Competitive Advantages:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Bio-AI Hybrid Approach:** SpotitEarly's core competitive advantage lies in its "Bio-AI hybrid" approach, which combines the olfactory capabilities of trained canines with advanced AI. This combination aims to provide a highly sensitive and specific method for detecting cancer through the analysis of VOCs in breath samples. The use of dogs leverages the most sophisticated odor sensors available, while AI is used to analyze complex data and improve the accuracy of the test. The Company's technology pairs advanced AI with canine olfaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Canine Olfaction:** The use of dogs to detect VOCs associated with cancer gives SpotitEarly a unique advantage. Dogs have an extremely sensitive sense of smell that can detect subtle changes in VOCs that are indicative of cancer. This method is believed to be more reliable than traditional electronic noses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**AI-Powered Technology:** SpotitEarly's data from canine scent detection is then combined with AI analysis. The LUCID platform processes and interprets vast amounts of data, including VOC measurements and canine behavioral signals. This AI component is critical for increasing accuracy, providing scalability, and ensuring continuous improvement through machine learning.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Scalability and Accessibility:** SpotitEarly's test is designed for global scalability and accessibility. The breath test is non-invasive, cost-effective, and can be easily administered in various settings, including at home or in clinical settings. The LUCID platform enables a single lab to process over a million tests annually

------

and is designed to be easily replicated worldwide. This focus on accessibility means the Company can reach underserved populations with limited access to traditional screening methods.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**First Mover Advantage:** SpotitEarly's approach is unique, combining canine scent detection with AI, giving the Company a first mover advantage that other companies in the space are unlikely to be able to replicate. The extensive knowledge, experience, and multidisciplinary collaboration required ensure that SpotitEarly can remain at the cutting edge of innovation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Cost Effectiveness**: SpotitEarly's technology offers a high degree of specificity and sensitivity for early cancer detection at a relatively low cost. Its use of AI further streamlines the process. The Company is also focused on keeping its facilities and processes low cost and easy to send anywhere.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Data Security:** SpotitEarly is committed to safeguarding patient data and complies with global data protection regulations, including HIPAA. This is important because the use of AI in diagnostics depends on large datasets and patients need to trust that their data is safe.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Intellectual Property:** The Company has a patent pending for its technology, which offers some legal protection for its innovation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Strong Team**: The SpotitEarly group has a diverse team of approximately 35 people, including strong entrepreneurial and commercialization backgrounds along with expertise in AI and data science, bio-chemistry, hardware engineering, medicine, zoology, cancer research and expertise in canine training. The team includes 8 PhDs and 2 MDs, reinforcing its depth of scientific and clinical expertise. This cross-disciplinary collaboration fosters innovation, high grade execution and helps to maintain the Company's competitive edge.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Focus on Equity**: SpotitEarly is focused on breaking down barriers in access to healthcare. By offering an affordable, non-invasive alternative to traditional screening methods, the Company seeks to make early detection more equitable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Commitment to Clinical Validation**: SpotitEarly is committed to rigorous clinical research to validate the accuracy and reliability of its technology. The Company plans to expand clinical trials to ensure its tests are applicable to diverse populations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Public Trust**: SpotitEarly must build public trust in its novel technology, which combines AI with canine scent detection, and must address concerns about data security and transparency.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Experienced Leadership:** SpotitEarly's team brings together a blend of skills across business, clinical research, technology, and laboratory operations. The leadership team includes experienced professionals with expertise in commercialization, diagnostics, technology, and healthcare. The Company is committed to building a world where early cancer detection isn't just a possibility but a reality.

**Clinical Validation**

SpotitEarly completed a prospective double blind study, known as the Rainbow Study, that demonstrated the effectiveness of a bio-AI hybrid platform combining artificial intelligence and trained detection canines for non-invasive detection of different types of cancer, and was conducted from December 2021 to December 2023 at three clinical sites. The results were published in *Scientific Reports* by the *Nature* Publishing Group-https://www.nature.com/articles/s41598-024-79383-2.

Key findings include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Participants: The study analyzed breath samples from 1,386 participants, males and females, age 18-94, 75.6% of whom tested negative for cancer, while 24.4% tested positive. Four primary cancers were studied: breast, lung, colorectal, and prostate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Performance: The test achieved an overall sensitivity of 93.9% and specificity of 94.3% for the four trained cancer types. Sensitivity values for each type were:

------

oBreast and lung cancer: 95.0%

oColorectal cancer: 90.0%

oProstate cancer: 93.0%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Early-stage cancer detection (stages 0–2) sensitivity was 94.8%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Exploratory Findings: The system showed an 81.8% sensitivity in identifying other cancer types not included in the training, suggesting shared volatile organic compound (VOC) patterns across cancers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Methodology: Breath samples were collected via a simple surgical mask method and analyzed using the bio-AI hybrid platform, which integrates canine detection behavior with AI analysis. The AI enhanced the accuracy and consistency of results by analyzing canine behavioral and physiological responses. All samples were tested under a double blind setting, in which the Company had no indication of the samples whatsoever.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Repeatability: Test consistency was high, with 95.1% identical results in repeated testing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Comparison with Alternatives: The study highlighted superior sensitivity and specificity compared to liquid biopsy-based multi-cancer early detection methods like Galleri, which showed lower sensitivity, especially for early-stage cancers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Scalability: The system demonstrated potential for high-throughput testing due to its rapid canine responses, compact testing environment, and AI-driven efficiency.

The study concluded that SpotitEarly's bio-AI hybrid platform is a scalable, cost-effective, and accurate method for early cancer detection, with potential to improve population screening compliance and expand to additional cancer types. Since the completion of the Rainbow study, the LUCID AI component has been further developed and enhanced. The Company plans to conduct several follow up clinical studies in the U.S. and Israel. Data from these trials may be used as supportive data used in future FDA submissions.

Regulation

SpotitEarly conducts its screening operations in a high-complexity, CLIA-registered laboratory (CLIA Registration No. 99D2307137). While breath-based tests are not currently classified as a distinct category under the CLIA framework, the Company's test is operated in accordance with CLIA quality standards applicable to high-complexity testing. Operating within a CLIA-compliant environment reflects the Company's commitment to rigorous laboratory practices and clinical-grade protocols.

The Company plans to initially offer its test as a Laboratory Developed Test (LDT), processed in its CLIA-registered lab. Under current regulatory policy, LDTs are not subject to FDA premarket review, allowing the Company to offer its testing services without prior FDA approval.

U.S. commercialization is targeted for Q2/Q3 2026, following the completion of the ongoing breast cancer clinical trial and collection of additional data from U.S. participants. This current trial builds on a prospective, double-blind clinical study involving 1,360 participants, completed in December 2023, which demonstrated the effectiveness of the test in detecting breast, lung, colorectal, and prostate cancers.

The Company is also aware that the regulatory status of LDTs is evolving: On May 6, 2024, FDA issued a detailed phased-in final rule extending its regulatory oversight to tests performed in CLIA certified laboratories. Accordingly, the Company developed a regulatory plan of compliance with the regulation. However, on March 31, 2025, a federal district court struck down the regulation as exceeding FDA's authority, ruling that FDA does not have authority to regulate testing services performed in a CLIA certified laboratory. As a result, the current status of LDTs remains unchanged and they do not require FDA approval. FDA's time to appeal has not run, and it is not known how FDA will respond to this court ruling, given the recent change in administration and what seems to be a softer regulatory posture toward laboratory-developed tests. Despite the information provided above, the Company generally believes

------

that FDA approval of its tests will be an important step providing validation and credibility to potential users. Therefore, at present, the Company still plans to acquiesce to FDA regulation and, specifically, to seek FDA regulatory approvals for each new indication for use. Notwithstanding the above, SpotitEarly tests have not yet been approved by the FDA. The Company plans to submit regulatory approvals for each new indication for use.

While the FDA has created expedited programs for breakthrough therapies, SpotitEarly's technology will still need to navigate the regulatory approval process, which can be time-consuming and costly. Additionally, the Company will need to meet regulatory standards for software as a medical device and must establish transparency with respect to how its AI-powered platform makes decisions.

SpotitEarly is currently preparing for its Pre-Submission to the FDA. Once the FDA has reviewed the Company's Pre-Submission, it is expected that the FDA will inform the Company as to what is needed before the Company can sell its test on a commercial basis. The Company will first seek FDA regulatory approval for its Lung Cancer test. Additional cancers will be considered for future FDA submissions.

In order to sell its test in countries other than the U.S., we will be required to seek regulatory approval from the proper regulation authority in the targeted countries. Such an approval process is expected to launch soon with the Israeli ministry of health.

Go-to-Market Strategy

The Company aims to commercialize its early cancer detection test through a combination of online sales, partnerships with healthcare providers, and strategic alliances.

Initial Launch Strategy: Physician Network

SpotitEarly plans to initially launch its test in the U.S. through a Physician Network model. This approach will involve:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Online Sales via Physician-Ordered Test Platform**: The test will be sold online through a platform that requires a physician's order. This ensures medical oversight while still providing easy access for consumers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Emphasis on User Experience:** SpotitEarly will focus on a seamless and user-friendly experience for customers. The breath collection process is designed to be simple and non-invasive, allowing patients to perform the test at home.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Expanding Reach through Multiple Channels:**

o**Referrals:** Encouraging word-of-mouth referrals from satisfied customers.

o**Advocacy Groups:** Collaborating with patient advocacy groups to promote awareness and adoption.

o**Online Campaigns and Ads:** Using digital marketing to reach potential customers.

o**Key Opinion Leaders (KOLs):** Partnering with influential figures in the medical community to build credibility and trust.

o**Educational Programs/Webinars:** Hosting online events to educate the public about the importance of early cancer detection and the benefits of SpotitEarly's test.

o**Funded Programs:** Exploring opportunities for sponsored testing, to further expand access to underserved communities through collaborations with Non-Governmental Organizations ("NGOs") supporting these communities. An NGO is a nonprofit organization that operates independently of any government and whose purpose is typically to address social or political issues.

o**Community Activities**: Engaging with local communities through various activities to raise awareness.

------

Longer-Term Strategy: Business-to-Business (B2B) Models

In the longer term, SpotitEarly plans to leverage several B2B models to broaden its market reach:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Insurers:** SpotitEarly will target the Medicare and Medicaid programs, leveraging the potential cost savings associated with early detection. SpotitEarly is already in advanced discussions with employers for Letters of Intent to purchase tests once approved.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Strategic Partnerships:** Forming alliances with diagnostic industry leaders to leverage their extensive distribution networks and established market presence. This would also enable SpotitEarly's tests to be marketed under the umbrella of trusted industry names. SpotitEarly also plans to negotiate distribution and white-label agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Health Systems/Clinics**: SpotitEarly is currently collaborating with multiple health systems that expressed interest in distributing our tests. We plan to partner with additional major health systems in the US, university health systems, private clinics, screening centers, community health centers, and mobile clinics. Integrating the test into the workflows of healthcare professionals helps to ensure the tests will be used by relevant populations who might not otherwise seek out screening, while simultaneously ensuring that those results will be acted upon appropriately.

Phased Approach to Test Rollout

SpotitEarly's growth strategy involves a phased rollout of its potential multi-cancer detection test, starting with specific cancer types and expanding over time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Initial Focus on Breast and Lung Cancers:** The Company will first focus on breast and lung cancers, which are two of the most common cancers. Industry experts and market research informed this initial focus. The Company will later focus on colorectal and prostate cancers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Multiple-Cancer Detection Packs**: The Company is planning to use a "horizontal" pack approach for the multiple cancers while creating "vertical" packs for specific cancer types.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Expansion Beyond Cancer:** SpotitEarly's LUCID platform is not limited to cancer and can be expanded to other diseases that release VOCs in exhaled breath as well as other non-health related target odors (such as the detection of explosives, narcotics, different chemical substances, environmental conditions, etc).

Path to Commercialization

SpotitEarly's path to commercialization involves several key steps:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Regulatory Approvals:** Based on the recent ruling discussed above, SpotitEarly test, which is an LDT, does not require FDA's approval. However, the Company will be pursuing FDA approval in order to enhance adoption in the US and globally. SpotitEarly plans to submit regulatory approvals for each new indication of use, as relevant clinical data becomes available.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Manufacturing and Scalability:** SpotitEarly has designed its LUCID platform for scalability with the aim to process over a million breath samples per year in a single lab. The compact size of the testing environment allows for easy replication, facilitating laboratory scale-up. The Company is also focused on operational growth, building additional labs, and training more detection dogs. The breath collection process is designed for simplicity and allows for at-home testing, which increases convenience and scalability.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Pricing Strategy:** SpotitEarly will adopt a tiered pricing model to ensure accessibility across various socioeconomic groups, with prices ranging from $250 to $500. The pricing structure considers market demand, comparable test costs, and a sustainable business approach. To support affordability, the company will offer discounts for lower-income households. Additionally, future plans include developing a single test covering the major cancers, maximizing efficiency and profitability per test.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Building Trust:** SpotitEarly needs to build trust in its technology and address concerns around data privacy. The Company is committed to safeguarding patient data and complying with global data protection regulations. The Company also recognizes that it will need to get its message across in a crowded market.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Sales in foreign countries:** SpotitEarly does not plan to sell its test in a foreign country until it has obtained approval from the foreign country.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Key Elements of SpotitEarly's Approach:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Accessibility**: The non-invasive nature of the breath test, coupled with its at-home administration, makes it easily accessible to a wide range of populations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Affordability**: The Company is committed to providing a cost-effective alternative to traditional screening methods. Its approach to pricing includes tiered options, and its emphasis on a low cost per test is intended to make screening more widely available.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Accuracy**: The combination of canine olfaction and AI provides high levels of sensitivity and specificity for detecting cancer at early stages. SpotitEarly's technology has achieved sensitivity rates exceeding 90% for several common cancers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Multiple-Cancer Detection**: SpotitEarly aims to detect multiple cancers using a single sample. This will address the limitation of current single-cancer tests and is a potential breakthrough for proactive care.

**Social Impact and Mission**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Accessibility and Equity:** SpotitEarly aims to make early cancer detection accessible to underserved populations globally, reducing disparities in healthcare outcomes. The Company's focus on cost-effective, non-invasive screening is intended to reduce disparities in cancer outcomes. The technology can be easily replicated worldwide, ensuring the solution can reach underserved populations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Proactive Care:** The Company's vision is a world where regular screening becomes as routine as an annual physical exam. The test is designed to encourage more people to participate in early detection and screening programs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Reduced Anxiety:** The Company is working to reduce anxiety stemming from the screening physical situation and interactions with healthcare professionals. By offering flexibility in timing and location, the test minimizes friction with healthcare bureaucracy and allows for more frequent testing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Improved Outcomes:** Early detection of cancer can increase survival rates from 10% to as high as 90%. SpotitEarly's technology aims to provide early screening insights to help reduce the global cancer burden.

**Intellectual Property and Technology Development**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Patent Protection:** SpotitEarly has a patent pending with USPTO: WO2023239834A1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·**Continued Innovation:** The Company is committed to continued research and development, and is expanding its VOC database to broaden its detection capabilities. The Company seeks to identify VOCs for new diseases and to support clinical trials to validate findings. The Company will build additional labs, train more detection dogs, and expand the LUCID platform capabilities.

**Seasonality**

We do not expect any seasonality in our business.

------

**Other Information** 

The Company's address is 61 W. Palisade Ave., Englewood, NJ 07631 and its telephone number is (551) 355-6554.

As of the date of this Offering Circular, the Company, and its wholly owned subsidiary SpotitEarly, Ltd., had 23 employees.

The Company's website is https://www.spotitearly.com. Information on the Company's website is not part of this Offering Circular.

**RISK FACTORS**

Investors should be aware that this Offering involves certain risks, including those described below, which could adversely affect the value of the Company's Preferred A-1 stock. The Company does not make, nor has it authorized any other person to make, any representation about the future market value of the Company's Preferred A-1 Stock. In addition to the other information contained in this Offering Circular, the following factors should be considered carefully in evaluating an investment in the Company's Preferred A-1 Stock.

We are an early-stage company and have not yet achieved profitability.

As of the date of this Offering Circular and since our inception, we have not yet generated revenue and have incurred net losses, as expected for a company in the product development stage. Any forecasts we make concerning our operations may prove to be inaccurate. Our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in the early stage of development. As a result of these risks, challenges, and uncertainties, the value of your investment could be significantly reduced or completely lost.

Our test is currently under development and has not yet been approved by the FDA.

We plan to initially offer our test as a Laboratory Developed Test (LDT) through a CLIA-registered laboratory. Under current regulatory frameworks, this allows us to provide testing services without prior FDA approval, enabling earlier market entry. However, the regulatory status of LDTs is evolving, and future changes may require us to seek FDA clearance or approval sooner than currently expected.

While the FDA has created expedited programs for breakthrough therapies, our technology will still need to navigate the regulatory approval process, which can be time-consuming and costly. Additionally, we will need to meet regulatory standards for software as a medical device and must establish transparency about how our AI-powered platform makes decisions. Obtaining regulatory approval can be a lengthy and complex process with no guarantee of success. Failure to obtain necessary approvals would significantly hinder market entry and commercialization. There is also the possibility of changes in regulations that might affect us. We have not yet determined what the FDA will require before the FDA allows us to sell our tests on a commercial basis in the U.S. As a result, it is not possible at this time to estimate the time it will take, or the cost to obtain approval from the FDA, which will allow us to sell our test on a commercial basis in the U.S. Nevertheless, obtaining approval from the FDA and comparable agencies in foreign countries is a time consuming and expensive process.

The time required to obtain approvals from foreign countries may be shorter or longer than that required for FDA approval, and requirements may differ from FDA requirements. We may be unable to obtain requisite approvals from the FDA and foreign regulatory authorities, and even if obtained, such approvals may not be on a timely basis. If we fail to obtain timely clearance or approval for our test, we will not be able to market and sell our test, which will limit our ability to generate revenue.

While our clinical trial shows promising results, the test's performance needs to be further validated in larger, more diverse populations.

The test's ability to detect cancers in real-world settings, outside of controlled clinical trials, needs confirmation. In addition, the test's sensitivity and specificity may vary in different populations or settings. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of our clinical trials may not be predictive of the results of later-stage clinical trials. A number of companies in our industry have suffered significant setbacks in advanced clinical trials due to lack of

------

efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our current and future clinical trials may not be successful.

The cost of developing, validating, and commercializing a new diagnostic test can be substantial.

There may be difficulties in raising funds for ongoing operations, research and expansion and making early detection accessible to all populations.

The need to collect, transport, and analyze breath samples can pose logistical hurdles.

Maintaining the quality and consistency of samples during transit is crucial. Even though, as of the date of this Offering Circular, we had the ability to process thousands of tests, there may be difficulties in scaling operations and establishing labs to process breath samples to meet global demand.

Our technology relies on a combination of canine olfaction, AI, and integrating VOC measurements and canine behavioral signals.

If there are problems in either the canine detection method or the AI platform, the test may not be reliable. Furthermore, maintaining accuracy across multiple labs worldwide could prove difficult.

The collection and storage of patient data, including medical history, breath samples, and test results, raise concerns about security and privacy.

While our system has been designed to comply with applicable privacy and security regulations — including the implementation of industry-standard safeguards and data protection measures — the collection and storage of sensitive patient data, such as medical history, breath samples, and test results, still present inherent risks of data beaches, unauthorized access or misuse of sensitive information.

We will face competition from established companies.

While our breath-based test demonstrated superior results in detecting early-stage disease across four major types of cancer, in a prospective double-blind study involving 1360 participants, established companies like GRAIL and Exact Sciences, have significant resources and experience in the diagnostics market and are developing liquid biopsy tests for multi-cancer early detection. The public may not adopt or accept our test due to lack of awareness or skepticism. We also face competition from other multi-cancer early detection tests (MCEDs) some of which are based on liquid biopsies. Competition from these companies and others may pose a threat to our future market position.

The potential for overdiagnosis and false positives with MCED tests is a concern.

Overdiagnosis can lead to unnecessary medical interventions, while false positives can cause anxiety and stress.

Future technological advancements may affect market position.

While canine scent detection, when combined with AI and machine learning (ML) models, currently offers advantages such as accuracy, affordability, and scalability, it is important to recognize that technologies like electronic noses — which have so far failed to commercialize at scale — may become more sensitive and accurate in the future.

Much of our intellectual property is protected as trade secrets or confidential know-how, and our pending patent applications may not result in issued patents.

We consider proprietary trade secrets and/or confidential and unpatented know-how to be important to our business, certain aspects of which may not be suitable for patent filings and must be protected as trade secrets and/or confidential know-how. This type of information must be protected diligently by us to protect our disclosure to competitors, since legal protections after disclosure may be minimal or non-existent. Accordingly, much of the value of this intellectual property is dependent upon our ability to keep our trade secrets and know-how confidential. In addition to our trade secret strategy, we have filed two international (PCT) patent applications, which are currently pending. However, there is no guarantee that these applications will result in granted patents, or that any granted claims will provide meaningful protection.

------

Failure to obtain or maintain trade secrets and/or confidential know-how could adversely affect our competitive position. Moreover, competitors may independently develop substantially equivalent proprietary information and may even apply for patent protection in respect of the same. If successful in obtaining such patent protection, competitors could limit the use of our trade secrets and/or confidential know-how.

Our commercial success depends, in part, upon attaining significant market acceptance of our test among physicians and patients.

Even if we obtain regulatory approval for our test, our test may not gain market acceptance among physicians and patients, which are critical to commercial success. Market acceptance of our test depends on a number of factors, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the accuracy of our test as demonstrated in clinical trials;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the timing of market introduction of our test as well as competitive products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the potential and perceived advantages of our test over alternative tests.

If our test is approved but fails to achieve an adequate level of acceptance by physicians and patients, we will not be able to generate significant revenues, and we may not become or remain profitable.

Even if we obtain regulatory approval for our test, we will be subject to stringent, ongoing government regulation.

If our test receives regulatory approval, either in the United States or internationally, our test will be subject to limitations on the approved indicated uses for which the test may be marketed or to the conditions of approval and may contain requirements for potentially costly post-marketing testing, and surveillance of the safety and efficacy of the test. We will continue to be subject to extensive regulatory requirements. These regulations are wide-ranging and govern, among other things:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·product design, development and manufacture;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·product application and use;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·adverse experience monitoring and reporting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·product advertising and promotion;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·manufacturing, including compliance with good manufacturing practices;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·record keeping requirements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·registration and listing of products with the FDA and other state and national agencies; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·storage and shipping

We must continually adhere to federal regulations known as current Good Manufacturing Practices, or cGMPs, and their foreign equivalents, which are enforced by the FDA and other national regulatory bodies through their facilities inspection programs. If our facilities cannot pass a pre-approval inspection by regulators or fail such inspections in the future, the FDA or other national regulators will not approve the marketing applications for our test, or may withdraw any prior approval. In complying with cGMP and foreign regulatory requirements, we will be obligated to expend time, money and effort in production, record-keeping and quality control to ensure that our test meet applicable specifications and other requirements.

If we do not comply with regulatory requirements at any stage, whether before or after marketing approval is obtained, we may be subject to, among other things, license suspension or revocation, criminal prosecution, seizure, injunction, fines, be forced to remove our test from the market or experience other adverse consequences. This could materially harm our financial results and reputation. If we identify adverse effects after our test are on the market, or if manufacturing problems occur, regulatory approval may be suspended or withdrawn. We may be required to conduct additional clinical trials. If we encounter any of the foregoing problems, our business and results of operations will be harmed.

------

The FDA and other governmental authorities' policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our test. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. We cannot predict the extent of adverse government regulations which might arise from future legislative or administrative action. Without government approval, we will be unable to sell any of our tests.

The current and future relationships with healthcare professionals and potential customers in the United States and elsewhere may be subject, directly or indirectly, to applicable healthcare laws and regulations.

If we begin selling our test, we will be subject to additional healthcare statutory and regulatory requirements and oversight by federal and state governments as well as foreign governments in the jurisdictions in which we conduct our business. Healthcare providers and physicians in the United States and elsewhere will play a primary role in the recommendation and prescription of our test if we obtain marketing approval. The current and future arrangements with healthcare professionals and potential customers may expose us to broadly applicable healthcare laws, including, without limitation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·federal civil and criminal false claims laws, including the federal False Claims Act, which impose criminal and civil penalties, including civil whistleblower actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a healthcare offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·HIPAA, which also imposes obligations on covered entities, including healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the U.S. federal physicians payment transparency requirements, sometimes called the "Sunshine Act" and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies that are reimbursable under Medicare, Medicaid, or the Children's Health Insurance Program to report to the Centers for Medicare & Medicaid Services, or CMS, information related to physician payments and "other transfers of value" to physicians and teaching hospitals and, for transfers of value to other healthcare providers, as well as the ownership and investment interests held by physicians and their immediate family members;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry's voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government which otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the U.S. federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under federal healthcare programs; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·state and foreign laws that govern the privacy and security of health information in certain circumstances, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

Efforts to ensure that our future business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that the business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of these laws or any other governmental regulations, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, imprisonment, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of the operations, all of which could significantly harm our business. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also adversely affect our business.

Cost of Complying with Government Regulations

Our business is subject to numerous and frequently changing federal, state and local laws and regulations. We routinely incur significant costs in complying with these regulations. The complexity of the regulatory environment in which we operate and the related cost of compliance are increasing due to additional legal and regulatory requirements, our expanding operation and increased enforcement efforts. Further, uncertainties exist regarding the future application of certain of these legal requirements to our business. New or existing laws, regulations and policies, liabilities arising thereunder and the related interpretations and enforcement practices, particularly those dealing with environmental protection and compliance, taxation, zoning and land use, workplace safety, public health, recurring debit and credit card charges, information security, consumer protection, and privacy and labor and employment, among others, or changes in existing laws, regulations, policies and the related interpretations and enforcement practices, particularly those governing the sale of products and consumer protection, may result in significant added expenses or may require extensive system and operating changes that may be difficult to implement and/or could materially increase our cost of doing business.

Financial Projections Require Caution

Prospective investors are urged to consider that any financial projections which might be discussed by the Company or its officers, employees, etc. should not be understood as any guarantee or assurance made on behalf of the Company. Projections based on past performance data or mathematical models are subject to externalities and risks of which the compiler may not or could not be aware. Such projections would not and should not be construed as indications or guarantees of future financial performance, nor should they be understood as such by prospective investors. Prospective investors should be aware of the inherent inaccuracies of forecasting. Although the Company has a reasonable basis for projections it might make and provide them herewith in good faith, prospective investors may wish to consult independent market professionals about the Company's potential future performance.

------

Damage to our reputation could negatively impact our business, financial condition and results of operations.

Our reputation and the quality of our brand are critical to our business and success in existing markets and will be critical to our success as we enter new markets. Any incident that erodes consumer loyalty for our brand could significantly reduce its value and damage our business. We may be adversely affected by any negative publicity, regardless of its accuracy. Also, there has been a marked increase in the use of social media platforms and similar devices, including blogs, social media websites and other forms of internet-based communications that provide individuals with access to a broad audience of consumers and other interested persons. The availability of information on social media platforms is virtually immediate, as is its impact. Information posted may be adverse to our interests or may be inaccurate, each of which may harm our performance, prospects or business. The harm may be immediate and may disseminate rapidly and broadly, without affording us an opportunity for redress or correction.

Risks Associated with the Increased Use of AI Technologies.

While the use of AI technologies is in the early stages of widespread adoption and continues to rapidly evolve, companies are increasingly considering the extent to which AI will be used in their operations. Risks related to AI include operational risks such as the potential for errors or inaccuracies in work product developed with AI; privacy-related risks, such as compliance with required privacy notices or receipt of consents; risks related to intellectual property rights with respect to both the inputs to the program (including leakage of confidential or proprietary information or infringement) and the program outputs (including infringement by and ownership rights to AI work product); risks related to AI's impact on the workforce; content related risks for public AI generated outputs; and ethical risks related to the potential for inherent biases in the algorithm or programming, among others. The complexity of, and lack of transparency into, many AI models and the speed of technological advancements may make it difficult for companies to understand and assess their proper operation and fully recognize the related risks.

In addition, the legal and regulatory environment relating to AI is uncertain and rapidly evolving, both in the US and internationally, and includes new regulations targeted specifically at AI as well as updates to or developments in intellectual property, privacy, consumer protection, employment, and other laws regarding the use of AI. These laws and regulations could require changes in the Company's implementation of AI technology, increase compliance costs and/or increase the risk of non-compliance. Any of these risks could expose a company to liability or adverse legal or regulatory consequences and reputational harm. There is also the risk of AI-related competition and threats to current business models, as evolving AI technologies may increase competition, alter consumer demand or render existing technologies obsolete.

Risks Involving Cybersecurity

Cybersecurity incidents, data misuse, and ransomware attacks continue to be top of mind for both companies and investors, particularly in light of evolving technologies such as AI. Unauthorized access and data breaches pose threats of theft, misuse, or loss of sensitive data, including personal, financial, and proprietary information which can result in operational disruptions, impact a company's reputation, customer trust, and financial condition, and lead to legal liabilities, regulatory fines, and costly remediation efforts. Reliance on third-party vendors can introduce additional vulnerabilities. Further, timely detection, identification, and response to evolving cyber threats remain challenging, requiring significant resources for cybersecurity measures, technology upgrades, training, and incident response. Cybersecurity insurance may offer some protection, but it may not fully cover all losses or liabilities.

Risks of US Trade Policies and Tariffs:

President Trump has implemented a 10-20% tariff on US imports, from Israel, Mexico and Canada, and a higher tariff on Chinese products. Whether and to what extent these tariffs will be imposed remains to be seen, but as a result of tariffs, materials and goods that US companies import may face higher prices, which could lead to reduced margins or increased prices that could cause decreased consumer demand. President Trump has discussed pursuing an agenda that focuses on deregulation, particularly with respect to environmental and climate change-related regulations.

------

**Geopolitical Risk**

SpotitEarly Inc. is a U.S. company; however, we have significant operations in Israel. While the region has recently experienced periods of conflict and instability, our operations and efforts to raise capital have not been materially affected to date. Future escalations could impact business continuity, or our ability to raise capital. We cannot predict the duration or outcome of current or future regional tensions.

We continue to monitor regional developments and maintain operational plans to support business continuity where needed.

The Company's offering is being conducted on a "best efforts" basis.

There is no minimum amount which is required to be raised in this Offering and all proceeds from the sale of the securities offered will be delivered to the Company as they are received. If only a small number of securities offered are sold, the amount received from this Offering may provide little benefit to the Company. Even if all securities offered are sold, the Company will need additional capital.

Any future sale of the Company's equity securities will dilute the ownership of existing shareholders, may be on better terms than the shares offered by this Offering Circular, and may be at prices substantially below the offering price of the Company's Series A-1 Preferred Stock. The failure of the Company to obtain the capital which it requires may result in the slower implementation of the Company's business plan.

The Company may not be able to effectively manage its growth, which would impair results of operations.

The Company intends to expand the scope of its operating activities significantly. If the Company is successful in executing its business plan, it will experience business growth that could place a significant strain on operations, finances, management, and other resources.

The ability to effectively manage growth may require the Company to substantially expand the capabilities of administrative and operational resources and to attract, train, manage, and retain qualified management and other personnel. There can be no assurance that the Company will be successful in recruiting and retaining new employees or retaining existing employees.

The Company cannot provide assurances that management will be able to manage this growth effectively. The failure to successfully manage growth could materially adversely affect its business, financial condition or results of operations.

The Company is dependent on its management and the loss of any of its officers could harm the Company's business.

The Company's future success depends largely upon the experience, skill, and contacts of the Company's officers. The loss of the services of these officers may have a material adverse effect upon the Company's business.

Our management owns approximately 54.7% of our outstanding voting stock and could elect all of our directors who in turn elect all of our officers.

This percentage of stock ownership could carry any vote on any matter requiring stockholder approval, including the election of directors who in turn elect all officers. As a result, our management will effectively control the Company.

Arbitrary establishment of offering price:

The offering price of the Preferred A-1 Stock has been arbitrarily established by the Company, considering such matters as past offerings, the state of the Company's product and business development and the general condition of the industry in which it operates. The offering price bears little relationship to the assets, net worth, or any other objective criteria of value applicable to the Company.

------

We may not be able to continue as a going concern.

We have identified conditions and events — primarily our expected continued future losses as we are continuing to develop our product — that raise substantial doubt about our ability to continue as a going concern. Our ability to remain operational is contingent on obtaining additional financing and successfully executing our business plan.

We may become subject to litigation, which could materially and adversely affect us.

In the future, we may become subject to litigation or enforcement actions, including claims relating to our operations, securities offerings and otherwise in the ordinary course of business. Some of these claims may result in significant defense costs and potentially significant judgments against us, some of which are not, or cannot be, insured against. We cannot be certain of the ultimate outcomes of any claims that may arise in the future. Resolution of these types of matters against us may result in our having to pay significant fines, judgments, or settlements, which, if uninsured, or if the fines, judgments and settlements exceed insured levels, could adversely impact our earnings and cash flows. Certain litigation or the resolution of certain litigation may affect the availability or cost of some of our insurance coverage, expose us to increased risks that would be uninsured, and materially and adversely impact our ability to attract directors and officers.

As of the date of this Offering Circular, there was no public market for our Preferred A-1 Stock. In addition, the Company does not expect a market to develop for its Preferred A-1 Stock for several years.

An active trading market for the Company's shares of common stock may never develop or be sustained, and as a result, you may be unable to sell your shares of our Preferred A-1 Stock. A public trading market having the desirable characteristics of depth, liquidity and orderliness depends upon the existence of willing buyers and sellers at any given time, such existence being dependent upon the individual decisions of buyers and sellers over which neither the Company nor any market maker has control. The failure of an active and liquid trading market to develop and continue would likely have a material adverse effect on the value of the Company's stock. An inactive market may also impair the Company's ability to raise capital to continue to fund operations by issuing shares and may impair the Company's ability to acquire other companies or technologies by using the Company's shares as consideration.

The potential issuance of Bonus Shares in our Offering will result in some investors paying less for their shares than other investors.

Certain investors who purchase shares in this Offering are entitled to receive additional shares of common stock (the "Bonus Shares") that effectively provide a discount on price based on the amount invested. The number of Bonus Shares will be determined by the amount of money they invest in this Offering. These categories for Bonus Shares are non-cumulative and an investor will only be eligible for the category that offers the greatest number of Bonus Shares. Bonus Shares will effectively act as a discount to the price at which the Company is offering its stock. The maximum amount of Bonus Shares an investor may qualify for is 8%. For more details, including all of the Bonus Shares being offered, see *Plan of Distribution*. Consequently, the value of shares of investors who pay the full price or are entitled to a smaller amount of Bonus Shares in this Offering will be immediately diluted by investments made by investors entitled to the discount, who will pay less for their shares in the Company.

------

Disclosure requirements pertaining to penny stocks may reduce the level of trading activity in the market for the Company's Preferred A-1 Stock and investors may find it difficult to sell their shares.

Trades of the Company's Preferred A-1 Stock, should a market ever develop, will be subject to Rule 15g-9 of the Securities and Exchange Commission, which rule imposes certain requirements on broker/dealers who sell securities subject to the rule to persons other than established customers and accredited investors. For transactions covered by the rule, brokers/dealers must make a special suitability determination for purchasers of the securities and receive the purchaser's written agreement to the transaction prior to sale. The Securities and Exchange Commission also has rules that regulate broker/dealer practices in connection with transactions in "penny stocks". Penny stocks generally are equity securities with a price of less than $5.00 (other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in that security is provided by the exchange or system). The penny stock rules require a broker/ dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document prepared by the Commission that provides information about penny stocks and the nature and level of risks in the penny stock market. The broker/dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker/dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer's account. The bid and offer quotations, and the broker/dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer's confirmation.

You may have difficulty depositing your shares with a broker or selling shares of the Company's Preferred A-1 Stock which you acquire in this Offering.

Many securities brokers will not accept securities for deposits and will not sell securities which:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·are considered penny stocks, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·trade in the over-the-counter market

Further, for a securities broker which will, under certain circumstances, sell securities which fall under any or all of the categories listed above, the customer, before the securities broker will accept the shares for deposit, must often complete a questionnaire detailing how the customer acquired the shares, provide the securities broker with an opinion of an attorney concerning the ability of the shares to be sold in the public market, and pay a "legal review" fee which in some cases can exceed $1,000.

For these reasons, investors in this Offering may have difficulty selling shares of the Company's Preferred A-1 Stock.

We are an Emerging Growth Company as defined in the JOBS Act.

As long as we remain an Emerging Growth Company, we may take advantage of certain exemptions from various reporting and regulatory requirements that are applicable to other public companies that are not emerging growth companies. We cannot predict if investors will find our Preferred A-1 Stock less attractive if we choose to rely on these exemptions. If some investors find our Preferred A-1 Stock less attractive as a result of any choices to reduce future disclosure, there may be a less active trading market for our Preferred A-1 Stock and our stock price may be more volatile.

------

**MANAGEMENT**

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position** |
| Shlomi Madar | 46 | Chief Executive Officer and a Director |
| Shai Lankry | 49 | Chief Financial Officer and a Director |
| J. Leonard Lichtenfeld | 79 | Chief Medical Officer |
| Assaf Ruf | 37 | Vice President of Research and Development |
| Roi Ophir | 53 | Director |
| Ariel Ben Dayan | 50 | Director |
| Alon Lifschitz | 50 | Director |

---

Our directors are appointed for a one-year term holding office until the next annual general meeting of our shareholders or until their successors are elected or appointed. Our officers are appointed by our board of directors and serve at the discretion of the board.

***Dr. Shlomi Madar, Chief Executive Officer, Director.***

Dr. Shlomi Madar has been the Chief Executive Officer and a director of the Company since March 2025. Between May 2023 and January 2025 Dr. Madar was the Vice President of Business Development for North America for the Company. Between October 2023 and January 2025 Mr. Madar was a consultant (East Coast representative) for Weizmann Institute of Science, a research and development institution known for innovations in biotechnology and life sciences. Between January 2023 and January 2025 Mr. Madar was the Vice President, Strategic Alliances, for OncoHost, a company specializing in precision oncology and personalized cancer treatment solutions. Between January 2022 and December 2022 Mr. Madar was the Vice President of Healthcare Solutions for DayTwo, a company providing treatment for chronic metabolic disorders. From November 2020 to January 2022 Mr. Madar was the Head of Customer Success and Partnership Alliances for Immunai, a company leveraging single-cell genomics and AI for immunotherapy development. We believe Mr. Madar's experience with biotechnology, life sciences and cancer treatment qualifies him to be a director.

***Shai Lankry, Chief Financial Officer, Director.***

Shai Lankry has been the Company's Chief Financial Officer since January 2025. Since 2023, Mr. Lankry has been the Chief Executive Officer of LCS LLC, a business providing part time chief financial officer services to a number of corporations. From 2018 to 2023 Mr. Lankry was the Chief Financial Officer of Gamida Cell Ltd. From July 2024 to December 2024 Mr. Lankry was the Chief Financial Officer for Pharma Two B Ltd. Mr. Lankry is a licensed CPA in Israel and holds an M.B.A. in Finance from Tel-Aviv University. We believe Mr. Lankry is qualified to be a director due to his experience in accounting and finance. Shai Lankry is our financial expert as that term is defined by the Securities and Exchange Commission.

***J. Leonard Lichtenfeld, Chief Medical Officer***

J. Leonard Lichtenfeld has been the Company's Chief Medical Officer since March 2024. Between November 2018 and September 2020 Mr. Lichtenfeld held various positions with the American Cancer Society, including interim Chief Medical Officer and Deputy Chief Medical Officer. Between September 2020 and April 2021, Mr. Lichtenfeld was a part time advisor to several companies. Between April 2021 and July 2023, Mr. Lichtenfeld was the Chief Medical Officer for Jasper Health. Between July 2023 and July 2024 Mr. Lichtenfeld was an advisory board member for the Company's wholly owned subsidiary SpotitEarly Ltd. Since March 2024 Mr. Lichtenfeld has been the Chief Medical officer for the Company's wholly owned subsidiary SpotitEarly, Ltd.

------

***Assaf Ruf, Vice President of Research and Development.***

Assaf Ruf is an experienced R&D leader with 14 years in management, including 8+ years in product and program leadership and 6 years directing complex R&D projects. He leads the Hardware & System team at Blue River Technology (John Deere), overseeing mechatronics and system engineering for autonomous earth-moving vehicles. Previously, Asaf managed cross-functional teams of 35+ engineers and delivered over 30 products in large-scale defense and aerospace projects. He holds an M.Sc. in Mechanical Engineering (cum laude) and a B.Sc. in Mathematics & Computer Science. His strengths include R&D, system architecture, mechanical design, and data-driven problem solving.

***Roi Ophir, Director***

Roi Ophir has served as one of the Company's directors since March 2025. Since June 2020, Mr. Ophir has also served as Chairman of the Board of Directors of SpotitEarly, Ltd., the Company's wholly owned subsidiary. Mr. Ophir is a serial tech entrepreneur, business executive and investor, with over 25 years of experience building tech startups from the ground up and bringing them to global markets. Since 2007, he has focused specifically on developing AI-powered products designed to disrupt markets and positively influence consumer behavior. We believe Mr. Ophir is well qualified to serve as a director due to his deep familiarity with the Company's technology, as well as his extensive entrepreneurial and commercial expertise.

***Ariel Ben Dayan, Director***

Ariel Ben Dayan has served as a director of the Company since March 2025. Since June 2020, Mr. Ben Dayan has also been a director of the Company's wholly owned subsidiary, SpotitEarly, Ltd., and served as its CEO until March 2025. Mr. Ben Dayan previously served as the commander of the K9 unit in the Israel Defense Forces (IDF) and brings extensive business experience. In addition to his role at SpotitEarly, Mr. Ben Dayan serves as a director of two public Israeli companies and one private U.S. company. We believe Mr. Ben Dayan is well qualified to serve as a director due to his leadership experience as CEO and director of SpotitEarly, Ltd., as well as his broad operational and governance expertise.

***Alon Lifshitz, Director***

Alon Lifshitz has been a director of the Company since March 2025. Since July 2017, Mr. Lifshitz has been a founding partner of Hanaco II, LP**,** a venture capital fund. We believe Mr. Lifshitz is qualified to be a director due to his experience in the venture capital industry.

Messrs. Ophir, Ben Dayan and Lifshitz are independent directors, as that term is defined in Section 803 of the NYSE American Company Guide.

Dr. Madar plans to devote his full time to our business.

Shai Lankry, J. Leonard Lichtenfeld and Asaf Ruf are expected to devote a considerable amount of their time to our business.

Our directors are appointed for a one-year term holding office until the next annual general meeting of our shareholders or until their successors are elected or appointed. Our officers are appointed by our board of directors and serve at the discretion of the board.

Our Board of Directors does not have standing audit, nominating or compensation committees, committees performing similar functions, or charters for such committees. Instead, the functions that might be delegated to such committees are carried out by our directors, to the extent required. Our directors believe that the cost associated with such committees has not been justified under our current circumstances.

Our Board of Directors has the ultimate responsibility to evaluate and respond to risks facing us. Our Board of Directors fulfills its obligations in this regard by meeting on a regular basis and communicating, when necessary, with our officers.

------

Holders of our common stock can send written communications to our entire Board of Directors, or to one or more Board members, by addressing the communication to "the Board of Directors" or to one or more directors, specifying the director or directors by name, and sending the communication to our corporate office. Communications addressed to the Board of Directors as whole will be delivered to each Board member. Communications addressed to a specific director (or directors) will be delivered to the director (or directors) specified.

A security holder communication not sent to the Board of Directors as a whole is not relayed to Board members which did not receive the communication.

 **Board Composition**

We have no formal policy regarding board diversity. In selecting board candidates, we seek individuals who will further the interests of our Shareholders through an established record of professional accomplishment, the ability to contribute positively to our collaborative culture, knowledge of our business and understanding of our prospective markets.

**Board Leadership Structure and Risk Oversight**

The board of directors oversees our business and considers the risks associated with our business strategy and decisions. The board currently implements its risk oversight function as a whole. Each of the board committees when established will also provide risk oversight in respect of its areas of concentration and reports material risks to the board for further consideration.

**Code of Ethics**

We have adopted a code of ethics which applies to our directors, executive officers, consultants and employees. Our code of ethics can be reviewed on our website, www.Spotitearly.com.

**Insider Trading Policy**

We do not have an Insider Trading Policy since as of the date of this Offering Circular there was no public market for our common or preferred stock and a market is not expected to develop for our common or preferred stock for at least the next twelve months.

------

**Compensation of Directors and Executive Officers**

*Unless the context otherwise requires, any reference in this section of this Offering Circular to the "Company" "we," "us" or "our" refers to Spotitearly, Inc. As an "emerging growth company," we have opted to comply with the executive compensation disclosure rules applicable to "emerging growth companies" and "smaller reporting companies" as such terms are defined in the Securities Act and the Exchange Act, and the rules promulgated thereunder.*

To achieve the Company's goals, the Company has designed its compensation and benefits program to attract, retain, incentivize and reward deeply talented and qualified executives who share its philosophy and desire to work towards achieving the Company's goals. The Company believes its compensation program should promote the success of the Company and align executive incentives with the long-term interests of its Shareholders. The Company's current compensation arrangements consist principally of a base salary, an annual cash incentive bonus and equity compensation, as described below.

The Company's Board has historically determined the compensation of the Company's executive officers. For the years ended December 31, 2023 and 2024, the Company's named executive officers were Dr. Shlomi Madar, Chief Executive Officer, Shai Lankry, Chief Executive Officer, Leonard Lichtenfeld, Chief Medical Officer and Assaf Ruf, Vice President.

This section provides an overview of the Company's executive compensation arrangements with its executive officers, including a narrative description of the material factors necessary to understand the information disclosed in the summary compensation table below. This section may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs.

Our executive officers will be compensated through the following four components:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Base Salary

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Short-Term Incentives (cash bonuses)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Long-Term Incentives (equity-based awards)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Benefits

These components provide a balanced mix of base compensation and compensation that is contingent upon our executive officer's individual performance. A goal of the compensation program is to provide executive officers with a reasonable level of security through base salary and benefits. We want to ensure that the compensation programs are appropriately designed to encourage executive officer retention and motivation to create shareholder value. We believe that our shareholders are best served when we can attract and retain talented executives by providing compensation packages that are competitive but fair.

Base Salaries

Base salaries generally have been targeted to be competitive when compared to the salary levels of persons holding similar positions in other publicly traded companies of comparable size. The executive officer's respective responsibilities, experience, expertise, and individual performance are considered.

Short-Term Incentives

Cash bonuses may be awarded at the sole discretion of the Board of Directors based upon a variety of factors that encompass both individual and company performance.

Long-Term Incentives

Equity incentive awards help to align the interests of our employees with those of our shareholders. Equity based awards are made under our Equity Incentive Plan. Options are granted with exercise prices equal to the closing price of our common stock on the date of grant and may be subject to a vesting schedule as determined by the Board of Directors which administers the plan.

------

We believe that grants of equity-based compensation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·enhance the link between the creation of shareholder value and long-term executive incentive compensation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·provide focus, motivation, and retention incentive; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·provide competitive levels of total compensation

In addition to cash and equity compensation programs, executive officers participate in the health and welfare benefit programs available to other employees.

The following summary compensation table sets forth all compensation earned by the Company's officers during the years ended December 31, 2024 and 2023. The Company was established in November 2024; accordingly, no compensation was awarded or paid prior to that time, except as noted below. The table reflects amounts paid by the Company's wholly owned subsidiary, SpotitEarly Ltd. Amounts in the table are in thousands of U.S. dollars.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Name and <br>Principal Position | <br>Year | Salary<br>(1) | Bonus<br>(2) | Stock<br>Awards<br>(3) | Option <br>Awards<br>(4) | Non-Equity<br>Incentive Plan<br>Compensation<br>(5) | All Other<br>Compensation<br>(6) | Total |
| Shlomi Madar <sup>(6)</sup> | 2024 |  |  |  |  |  |  |  |
| Chief Executive Officer | 2023 |  |  |  |  |  |  |  |
| Shai Lankry <sup>(6)</sup> | 2024 |  |  |  |  |  |  |  |
| Chief Financial Officer | 2023 |  |  |  |  |  |  |  |
| J. Leonard Lichtenfeld | 2024 | $22  | $32  | $54  |  |  |  |  |
| Chief Medical Officer | 2023 |  |  |  |  |  |  |  |
| Assaf Ruf <sup>(6)</sup> | 2024 |  |  |  |  |  |  |  |
| Vice President of Research & Development | 2023 |  |  |  |  |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The dollar value in thousands of base salary (cash and non-cash) earned.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)The dollar value in thousands of bonus (cash and non-cash) earned.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)The dollar value in thousands of all stock awarded during the periods covered by the table is calculated according to ASC 718-10-30-3 which represented the grant date fair value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)The fair value of all stock options granted during the periods covered by the table are calculated on the grant date in accordance with ASC 718-10-30-3 which represented the grant date fair value.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)All other compensation that could not be properly reported in any other column.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)This person was not an officer of SpotitEarly, Ltd in 2024 or 2023 and did not become an officer of the Company until 2025.

There are no compensatory plans or arrangements, including payments to be received from the Company with respect to any executive Officer, that would result in payments to such person because of his or her resignation, retirement or other termination of employment with the Company, or its subsidiaries, any change in control, or a change in the person's responsibilities following a change in control of the Company.

------

The following shows the amount that we expect to pay to our officers and the amount of time these persons expect to devote to our business during the twelve months ending May 31, 2026.

---

| | | |
|:---|:---|:---|
|  | Projected Monthly | <br>Percent of Time  |
| Name | Compensation<br> (USD in thousands) | to Be<br>Devoted to our Business |
| Shlomi Madar  | $25  | 100%  |
| Shai Lankry | $7  | 20%  |
| J. Leonard Lichtenfeld | $5  | 20%  |
| Assaf Ruf | $4  | 20%  |

---

***Outstanding Equity Awards at Fiscal Year-End***

None of our officers or directors held any options at December 31, 2024.

**Equity Incentive Plan**

We have an Equity Incentive Plan (the "Plan") that reserves shares of common stock for issuance to plan participants in the form of incentive and non-qualified stock options, stock appreciation rights ("SARs"), and stock grants and units. Each stock option awarded allows the holder to purchase one share of our common stock. The number of shares reserved for issuance under the Plan is 5,000,000.

The Plan is administered by our Board of Directors (or any committee subsequently appointed by the Board) and is vested with the authority to interpret the provisions of the Plan and supervise the administration of the Plan. In addition, the Board is empowered to select those persons who will participate in the Plan, to determine the number of shares subject to each award and to determine when, and upon what conditions, awards granted under the Plan will vest, terminate, or otherwise be subject to forfeiture and cancellation. The terms and conditions of any awards issued, including the price of the shares underlying each award are governed by the provisions of the Plan and any agreements with the Plan participants.

*Incentive Stock Options*

All of our employees are eligible to be granted incentive stock options pursuant to the Plan. Options granted pursuant to the Plan terminate at such time as may be specified when the option is granted.

The exercise price of each option cannot be less than 100% of the fair market value of our common stock at the time of the granting of the option provided, however, if the optionee, at the time the option is granted, owns stock possessing more than 10% of the total combined voting power of all classes of our stock, the purchase price of the option shall not be less than 110% of the fair market value of the stock at the time of the granting of the option.

The total fair market value of the shares of common stock (determined at the time of the grant of the option) for which any employee may be granted options which are first exercisable in any calendar year may not exceed $100,000.

At the discretion of the Board of Directors, options granted pursuant to the Plan may include installment exercise terms for any option such that the option becomes fully exercisable in a series of cumulating portions. The Board may also accelerate the date upon which any option (or any part of any option) is first exercisable. However, no option, or any portion thereof may be exercisable until one year following the date of grant. In no event shall an option granted to an employee then owning more than 10% of our common stock be exercisable by its terms after the expiration of five years from the date of grant, nor shall any other option granted pursuant to the Plans be exercisable by its terms after the expiration of ten years from the date of grant.

------

*Non-Qualified Stock Options*

Our employees, directors and officers, and consultants or advisors are eligible to receive non-qualified stock options pursuant to the Plan, provided however that bona fide services must be rendered by such consultants or advisors and such services must not be in connection with a capital-raising transaction or promoting our common stock.

At the discretion of our Board of Directors options granted pursuant to the Plan may include installment exercise terms for any option such that the option becomes fully exercisable in a series of cumulating portions. The Board may also accelerate the date upon which any option (or any part of any option) is first exercisable.

 

*Stock Grants*

A stock grant award gives the participant the right to receive shares of stock, subject to any vesting restrictions imposed by the Board of Directors. The purchase price, if any, for a stock grant award shall be payable in cash or in any other form of consideration acceptable to the Board. A stock grant award may be granted or sold in respect of past services or other valid consideration, or in lieu of any cash compensation owed to a participant.

*Other Information Regarding the Plan*

In the discretion of the Board, any option granted pursuant to the Plan may include installment exercise terms such that the option becomes fully exercisable in a series of cumulating portions. The Board may also accelerate the date upon which any option (or any part of any options) is first exercisable. Any shares issued pursuant to the Plan and any options granted pursuant to the Plan or will be forfeited if the "vesting" schedule established by the Board administering the Plan at the time of the grant is not met. For this purpose, vesting means the period during which the employee must remain as our employee or the period of time a non-employee must provide services to us. At the time an employee ceases working for us (or at the time a non-employee ceases to perform services for us), any shares or options not fully vested will be forfeited and cancelled. At the discretion of the Board payment for the shares of common stock underlying options may be paid through the delivery of shares of our common stock having an aggregate fair market value equal to the option price, provided such shares have been owned by the option holder for at least one year prior to such exercise. The exercise may be made through a "cashless" exercise or a combination of cash and shares of common stock at the discretion of the Board.

Awards are generally non-transferable except upon death of the recipient. Shares issued pursuant to the Plan will generally not be transferable until the person receiving the shares satisfies the vesting requirements imposed by the Board when the shares were issued.

Our Board of Directors may at any time, and from time to time, amend, terminate, or suspend one or more of the Plans in any manner it deems appropriate, provided that such amendment, termination or suspension will not adversely affect rights or obligations with respect to shares or options previously granted.

The following table shows the weighted average exercise price of the outstanding options granted pursuant to the Company's Equity Incentive Plan as of December 31, 2024, the Company's recently completed fiscal year:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Plan | Total Shares<br> Reserved<br> Under the Plan | Number of<br>Securities to<br> be Issued Upon<br>Exercise<br> of Outstanding<br>Options | Weighted-<br> Average<br> Exercise Price<br>of Outstanding<br>Options | Number of Securities<br> Remaining Available for<br> Future Issuances<br>Under Equity<br>Compensation<br> Plans (Excluding<br> Securities Reflected<br>in Column (a)) |
|  |  | **(a)** | **(b)** | **(c)** |
| Equity Incentive Plan | 5000000 | **-** | **-** | **-** |

---

------

As of the date of this Offering Circular, there were options to purchase 2,111,790 shares of the Company's common stock granted pursuant to the Plan. The following officers and directors have been granted options pursuant to the Plan:

---

| | | | |
|:---|:---|:---|:---|
|  | Shares Issuable Upon | Option | Option |
| Name | Exercise of Options | Exercise Price | Expiration Date |
| Shlomi Madar | 29766 | $1.34  | 2/25/2034 |
| Shlomi Madar | 168849 | $3.25  | 7/09/2035 |
| Len Lichtenfeld | 99219 | $1.34  | 2/25/2034 |
| Shai Lankry | 49610 | $3.25  | 7/09/2035 |
| Asaf Ruf | 33073 | $3.25  | 7/09/2035 |

---

The Company's Equity Incentive Plan has not been approved by the Company's shareholders.

Compensation of Directors

Directors are permitted to receive fixed fees and other compensation for their services as Directors. The Board of Directors has the authority to fix the compensation of Directors. As of the date of this Offering Circular, no amounts have been paid to, or accrued to, Directors in such capacity.

Employment Agreements

Our executive officers currently serve under consultancy agreements. We have not entered into any employment agreements with our executive officers or other employees to date. We may enter into employment agreements with such persons in the future.

------

**PRINCIPAL SHAREHOLDERS**

The following table shows the ownership, as of the date of this Offering Circular, of those persons owning beneficially 5% or more of our common, and all classes of preferred stock and the number and percentage of outstanding shares owned by each of our directors and officers and by all officers and directors as a group. Each owner has sole voting and investment power over their shares of common stock.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Seed | Percent of |  |  |
|  | Common | Preferred | Total Shares | Outstanding |
| Name and Address | Shares Owned<sup>(1)</sup> | Shares Owned<sup>(2)</sup> | Owned <sup>(1)</sup> | Shares |
| Shlomi Madar<br>61 W Palisade Ave. <br> Englewood, NJ 07631 | 198615  | --  | 198615  | 1.0%  |
| Shai Lankry <br> 61 W Palisade Ave. <br> Englewood, NJ 07631 | 49610  | – | 49610  | 0.2%  |
| J. Leonard Lichtenfeld <br> 977 Clifton Rd., N.E. <br> Atlanta, GA 30307 | 99219  | – | 99219  | 0.5%  |
| Assaf Ruf<br> Sunnyvale, CA 94087 | 33073  | – | 33073  | 0.2%  |
| Roi Ophir<br> Veidat Katowitz 31 <br> Tel Aviv, Israel | 2752775  | 257122  | 3009897  | 15.0%  |
| Ariel Ben Dayan <br> Igal Alon 9 <br> Kiryat Ono, Israel | 2752775  | 135327  | 2888102  | 14.4%  |
| Alon Lifschitz<sup>(3)</sup> <br> Derech Hasadot 10B <br> Kfar Shmaryahu, <br> Israel 691000 |  |  | 3860469  | 19.2%  |
| Ohad Sharon <br> Hamaapil <br> Israel 3885700 | 2539241  | – | 2539241  | 12.6%  |
| Sidney W. Swartz<sup>(4)</sup> <br> Two International Place <br> Boston, MA 02110 | 1182790  | – | 1182790  | 5.9%  |
| All Officers and Directors as a group (7 Persons) | 5886067  | 4252918  | 10138985  | 50.5%  |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Includes shares issuable upon the exercise of options granted to the following persons:

---

| | |
|:---|:---|
| Name | Shares Issuable Upon <br>Exercise of Options |
| Shlomi Madar | 198,615 |
| Shai Lankry | 49,610 |
| J. Leonard Lichtenfeld | 99,219 |
| Asaf Ruf | 33,073 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Each Series Seed Preferred Share is entitled to one vote. See "Description of Securities" for more information concerning the Company's Series Seed Preferred Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Shares are registered in the name of Hanaco II, L.P., a limited partnership controlled by Mr. Lifschitz.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Represents shares owned by the Sidney W. Swartz Investment Nominee Trust and the Sidney W. Swartz Family Trust.

**INTEREST OF MANAGEMENT AND OTHERS IN CERTAIN TRANSACTIONS**

Other than grants of stock options, we have not entered into any transactions in which the management or related persons have an interest outside of the ordinary course of our operations.

**DESCRIPTION OF SECURITIES**

Common Stock

The Company is authorized to issue 50,000,000 shares of common stock. Holders of common stock are each entitled to cast one vote for each share held of record on all matters presented to shareholders. Cumulative voting is not allowed; hence, the holders of a majority of the outstanding common stock can elect all directors.

Holders of common stock are entitled to receive such dividends as may be declared by the Board of Directors out of funds legally available therefore and, in the event of liquidation, to share pro rata in any distribution of the Company's assets after payment of liabilities. The board is not obligated to declare a dividend. It is not anticipated that dividends will be paid in the foreseeable future.

Holders of common stock do not have preemptive rights to subscribe to additional shares if issued by the Company. There is no conversion, redemption, sinking fund or similar provisions regarding the common stock. All outstanding shares of common stock are fully paid and non-assessable.

As of the date of this Offering Circular, the Company had 8,648,618 outstanding shares of common stock.

Preferred Stock

The Company is authorized to issue up to 30,000,000 shares of Series A-1 and Series A-2 preferred stock.

By means of this Offering Circular the Company is offering up to 9,712,509 shares of its Series A-1 preferred stock, plus up to 777,000 shares of Series A-1 Preferred shares which will be issued as a bonus to certain investors.

Voting

Each Series A-1 Preferred Share does not have any voting rights, except as provided by law.

------

Dividends

The holders of the Series A-1 Preferred Shares, in preference to the holders of common shares, shall be entitled to receive, when, as and if declared by the Company's Board of Directors out of funds legally available for the purpose, dividends which will be determined by the Company's Board of Directors.

Certain Restrictions

Whenever dividends declared or other distributions payable on the Series A-1 Preferred Shares are in arrears, thereafter and until all unpaid dividends and distributions on Series A-1 Preferred Shares shall have been paid in full, the Company shall not:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) declare or pay dividends, or make any other distributions, on any shares of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A-1 Preferred Shares;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) declare or pay dividends, or make any other distributions, on any shares of stock ranking on a parity (either as to dividends or upon liquidation, dissolution or winding up) with the Series A-1 Preferred Shares, except dividends paid ratably on the Series A-1 Preferred Shares and all such parity stock on which dividends are payable or in arrears in proportion to the total amounts to which the holders of all such shares are then entitled; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) redeem or purchase or otherwise acquire for consideration shares of any stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A-1 Preferred Shares.

Liquidation, Dissolution or Winding Up

Upon any liquidation, dissolution or winding up of the Company, no distribution shall be made to the holders of shares of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A-1 Preferred Shares Preferred Shares unless, prior thereto:

each holder of a Series A-1 Preferred Share shall have received the higher of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the amount paid for each Series A-1 Preferred Share, plus an amount equal to declared and unpaid dividends; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the amount that would be received if each Series A-1 Preferred Share was converted into the Company's common stock.

Conversion

All outstanding Series A-1 Preferred Shares shall automatically be converted into shares of the Company's Common Stock, at the then effective conversion rate upon the earliest to occur of the following:

(i)the closing of an underwritten offering of the shares of the Company's Common Stock to the general public pursuant to a registration statement under the Securities Act of 1933, as amended or under equivalent securities law of another jurisdiction, (ii) the consummation of an Initial Business Combination (each of (i) and (ii), an "IPO"), or (iii) the listing of the Company's common stock on the NYSE, the NYSE American or the NASDAQ. "Initial Business Combination" means a business combination transaction (whether by merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination) involving the Company and a blank check company that has been formed for the purpose of effecting such a transaction or a subsidiary of such a blank check company, provided that immediately following the consummation of such initial business combination the Common Stock of the Company or its parent entity is listed for trading on a stock exchange or any public trading marketing;

(ii)The date and time, or the occurrence of an event, specified by vote or written consent of the holders of at least a majority of the then issued and outstanding shares of Preferred Shares, voting together as a single class on an as-converted basis.

------

In the event the Company shall at any time declare or pay any dividend on common shares payable in common shares, or effect a subdivision or combination or consolidation of the outstanding common shares (by reclassification or otherwise) into a greater or lesser number of common shares, then in each such case the number of common shares issuable upon the conversion of the Series A-1 and Series A-2 Preferred Shares immediately prior to such event shall be adjusted by multiplying such number by a fraction, the numerator of which is the number of common shares outstanding immediately after such event and the denominator of which is the number of common shares that were outstanding immediately prior to such event.

In the event the Company shall at any time issue additional shares of common stock (including options for common stock or securities convertible into common stock, subject to certain exemptions ("Additional Shares"), without consideration or for a consideration per share less than the Conversion Price of the Series A-1 Preferred Stock in effect immediately prior to such issuance, then the Conversion Price of the Series A-1 Preferred Stock shall be reduced, concurrently with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:

CP2 = CP1\* (A + B) / (A + C).

For purposes of the foregoing, the following definitions shall apply:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)"CP2" shall mean the Conversion Price of the Series A-1 Preferred Stock in effect immediately after such issuance or deemed issuance of Additional Shares of Common Stock

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)"CP1" shall mean the Conversion Price of the Series A-1 Preferred Stock in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)"A" shall mean the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)"B" shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued or deemed issued at a price per share equal to CP1 (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP1); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)"C" shall mean the number of such Additional Shares of Common Stock issued in such transaction.

In the event the Company shall at any time declare or pay any dividend on common shares payable in common shares, or effect a subdivision or combination or consolidation of the outstanding common shares (by reclassification or otherwise) into a greater or lesser number of common shares, then in each such case the "CP2 " referred to above shall be adjusted by multiplying such number by a fraction, the numerator of which is the number of common shares outstanding immediately before such event and the denominator of which is the number of common shares that were outstanding immediately after such event. The "CP2 " will be adjusted each time the Company affects a transaction referred to above.

As of the date of this Offering Circular the Company had 1,457 outstanding shares of its Series A-1 preferred stock.

As of the date of this Offering Circular, the Company had 3,102,509 outstanding shares of its Series A-2 preferred stock. The terms of the Series A-1 Preferred Shares are identical to those of the Series A-1 Preferred Shares with the exception of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·each Series A-2 Preferred share is entitled to one vote on any matter to be presented to the Company's shareholders;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·upon any liquidation, dissolution or winding up of the Company, no distribution shall be made to the holders of shares of stock ranking junior (either as to dividends or upon liquidation, dissolution or winding up) to the Series A-2 Preferred Shares Preferred Shares unless, prior thereto, each holder of a Series A-2 Preferred Share shall have received the higher of:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·125% of the amount paid for each Series A-2 Preferred Share, plus an amount equal to declared and unpaid dividends; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the amount that would be received if each Series A-2 Preferred Share was converted into the Company's common stock.

The Company currently has 8,305,151 outstanding shares of Series Seed and Series Seed 1 preferred stock (the "Seed Preferred Shares"). Each Seed Preferred Share is entitled to one vote per share and is convertible, at the option of the holder, into one share of the Company's common stock. The holders of the Seed Preferred Shares are entitled to elect one of the Company's directors. The holders of the Seed Preferred Shares are entitled to cash dividends when as, and if declared by the Company's directors. If cash dividends are declared, each holder of a Seed Preferred Share is entitled to receive a dividend in an amount equal to the dividend declared, paid or set aside on such common stock multiplied by the number of shares of common stock issuable upon the conversion of a Seed Preferred Share.

**Dividend Policy**

We have never declared or paid cash dividends on our capital stock. We currently intend to retain any future earnings for use in the operation of our business and do not intend to declare or pay any cash dividends in the foreseeable future. Any further determination to pay dividends on our capital stock will be at the discretion of our Board of Directors, subject to applicable laws, and will depend on our financial condition, results of operations, capital requirements, general business conditions, and other factors that our Board of Directors considers relevant.

**Transfer Agent and Registrar**

Our transfer agent is Colonial Stock Transfer, whose address is 7840 S 700 E., Sandy, UT 84070. The Transfer Agent's telephone number is (801) 355- 5740 and its website is www.colonialstock.com.

------

**PLAN OF DISTRIBUTION**

**Plan of Distribution**

The Company is offering up to 9,712,509 shares of Series A-1 Preferred Stock and up to 777,000 Bonus Shares. No additional consideration will be received in connection with the issuance of the Bonus Shares and the Company will absorb the cost of the issuance of the Bonus Shares. Persons who desire information about the offering may find it at www.manhattanstreetcapital.com. This Offering Circular will be furnished to prospective investors via download 24 hours per day, 7 days per week on the ManhattanStreetCapital.com website.

**Commissions and Discounts**

The following table shows the total discounts and commissions paid in connection with this offering by the Company, assuming all Units are sold and warrants are exercised:

---

| | | |
|:---|:---|:---|
|  | **Per Unit** | **Total** |
| Public offering price | $7.15  | $69444(1)  |
| Commissions<sup>(2)</sup> | $-  | $-  |
| Proceeds, before offering expenses | $7.15  | $69444(1)  |

---

(1) Proceeds from sale of Series A-1 Preferred Stock. US dollars in thousands

(2) No commissions will be paid on the sale of the Offered Shares or the issuance of the Bonus Shares.

**Pricing of the Offering**

As of the date of this Offering Circular there was no public market for our Series A-1 Preferred Stock. The public offering price was determined by the Company. The principal factors considered in determining the public offering price include:

-the information set forth in this Offering Circular and otherwise available;

-our history and prospects and the history of and prospects for the industry in which we compete;

-our past and present financial performance;

-our prospects for future earnings and the present state of our development;

-the general condition of the securities markets at the time of this Offering;

-the recent market prices of, and demand for, publicly traded common stock of generally comparable companies; and

-other factors deemed relevant by us.

**Offering Period, Extension and Expiration Date**

This Offering will start within 48 hours of the Qualification Date and will terminate on the earlier of the date on which the maximum offering amount is sold or the date at which the Offering is earlier terminated by the Company in its sole discretion (such earlier date, the "Termination Date"). At least every 12 months after this Offering has been qualified, the Company will file a post-qualification amendment to include the Company's recent financial statements.

**Bonus Shares**

Certain investors are eligible to receive (without charge) additional shares of preferred stock ("Bonus Shares") equal to a percentage of the number of shares purchased, depending upon the amount invested by such investors. The table below shows the number of bonus shares that certain investors will receive depending on the amount invested. The Company will absorb the cost of the issuance of any Bonus Shares.

------

---

| | |
|:---|:---|
| **Investment Range** | **Bonus Shares (%)** |
| Less than $4,999 | - |
| $5,000 to $9,999 | 3% |
| $10,000 to $24,999 | 4% |
| $25,000 to $49,999 | 5% |
| $50,000 to $99,999 | 6% |
| $100,000 and above | 8% |

---

Although the Company will not receive any consideration for the Bonus Shares, the value of such Bonus Shares ($5,556 thousands) will be included towards the $75 million maximum amount for any given year.

**The Online Platform**

The Company has engaged Manhattan Street Capital ("Manhattan Street Capital" or "MSC") to act as an advisor. No broker dealer, placement agent or underwriter has been engaged.

MSC will perform the following administrative and technology related functions in connection with this Offering, but not for underwriting or placement agent services. MSC will contract the services of Enterprise Bank and Stripe; for the purpose of payment processing and storage of confidential investor data. The following administrative and technology related functions that MSC will perform are listed below:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Accept investor data from potential investors on our behalf;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Reject investors that do not pass anti-money laundering ("AML") or that do not provide the required information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Process subscription agreements and reject investors that do not complete subscription agreements;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Reject investments from potential investors who do not meet requirements for permitted investment limits for investors pursuant to Regulation A, Tier 2;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Reject investments from potential investors with inconsistent, incorrect or otherwise flagged (e.g. for underage or AML reasons) subscriptions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Receive and transmit investor data to Enterprise Bank to store investor details and data confidentially and not disclose to any third party except as required by regulators, by law or in our performance under this Agreement (e.g. as needed for AML)

The Company will pay MSC the following for its services:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·A fee of $300 per month for data hosting, transaction reporting, and compliance record keeping.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·A technology, administration and service fee of $25 per investor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·For investments made by US IRA accounts, Trusts or by US LLCs or LPs, (Series A investors) a technology, administration, and service fee of $100.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·For investments made by US Investment Entities such as VC firms, Private Equity firms, Family Offices, investment management companies and similar entities (Series B investors) a technology, administration, and service fee of $5,000.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·A project management fee of $10,000 per month until the offering is terminated;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Warrants with a ten year term and an exercise price of $5.55 per share. The number of shares to be issued upon the exercise of the warrants will be determined by multiplying 25 by the number of investments in this Offering and dividing the same by 5.55. In the case of Series A investors the 25 will be replaced by 100. In the case of Series B investors the 25 will be replaced by 5,000.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Know Your Customer (KYC) and Anti Money Laundering (AML) fees ranging from $5 to $70 per investor.

The Company intends to pay the cash fees from the proceeds of the offering. All fees are due to MSC regardless of whether investors are rejected after AML verification or the success of the offering.

MSC does not directly solicit or communicate with investors with respect to offerings posted on its site, although it does advertise the existence of offerings on its platform, which may include identifying issuers listed on the platform. Our Offering Circular will be furnished to prospective investors in this Offering via download 24 hours a day, 7 days a week on the www.manhattanstreetcapital.com website.

------

MSC has not investigated the desirability or advisability of investment in the shares nor approved, endorsed, or passed upon the merits of purchasing the Shares. MSC is not participating as an underwriter and under no circumstance will it solicit any investment in us, recommend our securities or provide investment advice to any prospective investor, or make any securities recommendations to investors. MSC is not distributing any securities offering prospectuses or making any oral representations concerning the securities offering prospectus or the securities offering. Based upon MSC's anticipated limited role in this Offering, it has not and will not conduct extensive due diligence of this securities offering and no investor should rely on MSC's involvement in this Offering as any basis for a belief that it has done extensive due diligence. MSC does not expressly or impliedly affirm the completeness or accuracy of our Form 1-A and/or Offering Circular presented to investors by us. All inquiries regarding this Offering should be made directly to us.

**Electronic Offer, Sale and Distribution of Our Shares**

The final offering circular and subscription agreement will be furnished to prospective investors and will be available for viewing and download 24 hours per day, seven days per week through the MSC online platform located at www.manhattanstreetcapital.com/originclear (the "MSC Platform" or the "Platform") operated by MSC.

**How to Subscribe**

You will be required to complete a subscription agreement in order to invest. The subscription agreement includes a representation by the investor to the effect that, if you are not an "accredited investor" as defined under securities law, you are investing an amount that does not exceed the greater of 10% of your annual income or 10% of your net worth (excluding your principal residence).

If you decide to subscribe for the Preferred Stock in this Offering, you should complete the following steps:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.Go to www.manhattanstreetcapital.com/spotitearly.a, click on the "Invest Now" button;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Complete the online investment form;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.Deliver funds directly by check, wire, debit card, or electronic funds transfer via ACH to the specified account;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.Once funds or documentation are received an automated AML verification will be performed to verify the identity and status of the investor;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.Once AML is verified, investor will electronically receive, review, execute and deliver to us a Subscription Agreement.

Any potential investor will have ample time to review the Subscription Agreement, along with their counsel, prior to making any final investment decision. In the interest of allowing interested investors as much time as possible to complete the paperwork associated with a subscription, the Company has not set a maximum period of time to decide whether to accept or reject a subscription.

If a subscription is rejected, all funds will be returned to subscribers within thirty days of such rejection without deduction or interest. Upon acceptance by us of a subscription, a confirmation of such acceptance will be sent to the subscriber.

**Escrow Agent**

Payments will be processed by Enterprise Trust as the Escrow Agent for this Offering. Upon each closing, funds will be deposited immediately available to us at our nominated account. If a subscription is rejected, funds will be returned to subscribers within thirty days of such rejection without deduction or interest. Upon acceptance by us of a subscription, we will send confirmation of such acceptance to the subscriber.

The Company has agreed to pay Enterprise Trust Bank as the Escrow Agent:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·a one time set up fee of $1,000.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Any applicable fees for fund transfers (ACH $2, check $10, a credit/debit card fee ranging between 2.9% and 4.4%, a wire transfer fee of $25 or $45 for international fund transfers).

------

If the subscription agreement is not complete or there is other missing or incomplete information, the funds will not be released until the investor provides all required information. In the case of a debit card payment, provided the payment is approved, Escrow Agent will have up to three days to ensure all the documentation is complete. Escrow Agent will generally review all subscription agreements on the same day, but not later than the day after the submission of the subscription agreement.

All funds tendered (by check, wire, debit card, or electronic funds transfer via ACH to the specified account or deliver evidence of cancellation of debt) by investors will be deposited into an escrow account at the Escrow Agent for the benefit of the company. All funds received by ACH or wire transfer will be restricted for three to twelve days to clear the banking system prior to deposit into an account at the Escrow Agent.

The Company maintains the right to accept or reject subscriptions in whole or in part, for any reason or for no reason, including, but not limited to, in the event that an investor fails to provide all necessary information, even after further requests from the Company, and in the event the company receives oversubscriptions in excess of the maximum offering amount.

The Escrow Agent has not investigated the desirability or advisability of investment in the shares nor approved, endorsed or passed upon the merits of purchasing the Preferred Stock. The Escrow Agent is not participating as an underwriter and under no circumstance will it solicit any investment in the company, recommend the company's securities or provide investment advice to any prospective investor, or make any securities recommendations to investors. Escrow Agent is not distributing any offering circulars or making any oral representations concerning this Offering Circular or this Offering. Based upon Escrow Agent's anticipated limited role in this Offering, it has not and will not conduct extensive due diligence of this offering and no investor should rely on the involvement of Escrow Agent in this Offering as any basis for a belief that it has done extensive due diligence. Escrow Agent does not expressly or impliedly affirm the completeness or accuracy of the Offering Statement and/or Offering Circular presented to investors by the company. All inquiries regarding this Offering should be made directly to the company.

Upon confirmation that an investor's funds have cleared, the Company will instruct the Transfer Agent to issue shares to the investor. The Transfer Agent will notify an investor when shares are ready to be issued and the Transfer Agent has set up an account for the investor.

**Other Selling Restrictions**

Other than in the United States, no action has been taken by us that would permit a public offering of our Preferred Stock in any jurisdiction where action for that purpose is required. Our Preferred Stock may not be offered or sold, directly or indirectly, nor may this Offering Circular or any other offering material or advertisements in connection with the offer and sale of shares of our Preferred Stock be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this Offering Circular comes are advised to inform themselves about and to observe any restrictions relating to this Offering and the distribution of this Offering Circular. This Offering Circular does not constitute an offer to sell or a solicitation of an offer to buy our Preferred Stock in any jurisdiction in which such an offer or solicitation would be unlawful.

**Investment Limitations**

Generally, no sale may be made to you in this Offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or net worth. This limit does not apply to accredited investors and non-individual persons. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing, we encourage you to refer to www.investor.gov.

Because this is a Tier 2, Regulation A Offering, most investors must comply with the 10% limitation on investment in the Offering. The only investor in this Offering exempt from this limitation is an "accredited investor" as defined under Rule 501 of Regulation D under the Securities Act (an "Accredited Investor"). If you meet one of the following tests you should qualify as an Accredited Investor:

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)You are a natural person who has had individual income in excess of $200,000 in each of the two most recent years, or joint income with your spouse in excess of $300,000 in each of these years, and have a reasonable expectation of reaching the same income level in the current year;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)You are a natural person and your individual net worth, or joint net worth with your spouse, exceeds $1,000,000 at the time you purchase Offered Shares (please see below on how to calculate your net worth);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)You are an executive officer or general partner of the issuer or a manager or executive officer of the general partner of the issuer;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)You are an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, or the Code, a corporation, a Massachusetts or similar business trust or a partnership, not formed for the specific purpose of acquiring the Offered Shares, with total assets in excess of $5,000,000;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)You are a bank or a savings and loan association or other institution as defined in the Securities Act, a broker or dealer registered pursuant to Section 15 of the Exchange Act, an insurance company as defined by the Securities Act, an investment company registered under the Investment Company Act of 1940 (the "Investment Company Act"), or a business development company as defined in that act, any Small Business Investment Company licensed by the Small Business Investment Act of 1958 or a private business development company as defined in the Investment Advisers Act of 1940;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)You are an entity (including an Individual Retirement Account trust) in which each equity owner is an accredited investor;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)You are a trust with total assets in excess of $5,000,000, your purchase of Offered Shares is directed by a person who either alone or with his purchaser representative(s) (as defined in Regulation D promulgated under the Securities Act) has such knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the prospective investment, and you were not formed for the specific purpose of investing in the Offered Shares.

**SHARES ELIGIBLE FOR FUTURE SALE**

In general, a person who has beneficially owned restricted shares of our Preferred Stock for at least twelve months, in the event we are a reporting company under Regulation A, or at least six months, in the event we have been a reporting company under the Securities Exchange Act of 1934 for at least 90 days before the sale, would be entitled to sell such securities, provided that such person is not deemed to be an affiliate of ours at the time of sale or to have been an affiliate of ours at any time during the 90 days preceding the sale. A person who is an affiliate of ours at such time would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of shares that does not exceed the greater of 1% of the number of shares of our Preferred Stock then outstanding; or the average weekly trading volume of our Preferred Stock during the four calendar weeks preceding the filing by such person of a notice on Form 144 with respect to the sale.

Rule 144 trades must also comply with the manner of sale, notice and other provisions of Rule 144, to the extent applicable.

**LEGAL MATTERS**

Certain legal matters with respect to the shares of the Series A-1 Preferred Stock offered by the Company will be passed upon by Hart & Hart, LLC, Denver, Colorado.

------

**EXPERTS**

The financial statements of SpotitEarly Inc. Inc. as of December 31, 2024, and for the period from November 26 (inception) to December 31, 2024, and the financial statements of SpotitEarly Ltd. as of December 31, 2024 and 2023, and for each of the two years in the period ended December 31, 2024, included in this Offering Statement have been audited by Brightman Almagor Zohar & Co., a firm in the Deloitte global network, an independent auditor, as stated in their reports. Such financial statements are included in reliance upon the reports of such firm given their authority as experts in accounting and auditing.

**INDEMNIFICATION**

The Delaware General Business Corporation Act and the Company's Bylaws provide that the Company may indemnify any and all of its officers, directors, employees or agents or former officers, directors, employees or agents, against expenses actually and necessarily incurred by them, in connection with the defense of any legal proceeding or threatened legal proceeding, except as to matters in which such persons shall be determined to not have acted in good faith and in the Company's best interest.

Insofar as indemnification by us for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us pursuant to provisions of our articles of incorporation and bylaws, or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that one of our directors, officers or controlling persons is successful in the defense of any action, suit or proceeding in connection with the securities being offered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**ONGOING REPORTING AND SUPPLEMENTS TO THIS OFFERING CIRCULAR**

We are required to make annual and semi-annual filings with the Commission. We will make annual report filings on Form 1-K within 120 days after the end of the fiscal year. The annual report will include audited financial statements for the previous fiscal year. We will make semi-annual filings on Form 1-SA, which will be due by September 28<sup>th</sup> each year, which will include unaudited financial statements for the six months to June 30. We will also file a Form 1-U to announce important events such as the loss of a senior officer, a change in auditors or certain types of capital-raising. We will be required to keep making these reports unless we file a Form 1-Z to exit the reporting system, which we will only be able to do if we have less than 300 Shareholders of record and have filed at least one Form 1-K.

We may supplement the information in this Offering Circular by filing a Supplement with the Commission. We hereby incorporate by reference into this Offering Circular all such Supplements, and the information on any Form 1-K, 1-SA or 1-U filed after the date of this Offering Circular.

All these filings will be available on the Commission's EDGAR filing system. You should read all the available information before investing.

**WHERE YOU CAN FIND MORE INFORMATION**

We have filed with the SEC a Regulation A Offering Statement on Form 1-A under the Securities Act with respect to the shares of common stock offered hereby. This Offering Circular, which constitutes a part of the Offering Statement, does not contain all of the information set forth in the Offering Statement or the exhibits and schedules filed therewith. For further information about us and the common stock offered hereby, we refer you to the Offering Statement and the exhibits and schedules filed therewith. Statements contained in this Offering Circular regarding the contents of any contract or other document that is filed as an exhibit to the Offering Statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the Offering Statement. Upon the completion of this Offering, we will be required to file periodic reports and other information with the SEC pursuant to the Securities Exchange Act of 1934. The SEC maintains an Internet website that contains reports and other information about issuers, including us, that file electronically with the SEC. The address of this site is www.sec.gov.

------

**SPOTITEARLY INC.**

**FINANCIAL STATEMENTS**

**AS OF DECEMBER 31, 2024**

------

**SPOTITEARLY INC.**

**FINANCIAL STATEMENTS**

**AS OF DECEMBER 31, 2024**

**INDEX TO THE FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
|  | **Page** |
| **[Independent auditors' report](#report)** | F-3 |
| FINANCIAL STATEMENTS AS OF DECEMBER 31, 2024 |  |
| [Balance sheet](#bs) | F-5 |
| [Statement of Operations and Comprehensive Loss](#sop) | F-6 |
| [Statement of Stockholders' Deficit](#ssd) | F-7 |
| [Notes to the financial statements](#note) | F-8 |

---

------

![](spot1a_1.jpg)

**Auditors' report to the shareholders of**

**Spotitearly INC.**

**Opinion**

We have audited the financial statements of Spotitearly Inc. (the "Company"), which comprise the balance sheet as of December 31, 2024, and the related statements of operations and comprehensive loss and stockholders' deficit, for the period from November 26 (inception) to December 31, 2024, and the related notes to the financial statements (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024, and the results of its operations for the period from November 26 (inception) to December 31, 2024, in accordance with accounting principles generally accepted in the United States of America.

**Basis for Opinion**

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

**Substantial Doubt About the Company's Ability to Continue as a Going Concern**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1.B to the financial statements, the Company has limited capital resources, and has stated that substantial doubt exists about the Company's ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans regarding these matters are also described in Note 1.B. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter.

**Responsibilities of Management for the Financial Statements**

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date that the financial statements are issued.

**Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

------

In performing an audit in accordance with GAAS, we:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Exercise professional judgment and maintain professional skepticism throughout the audit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

/s/ Brightman Almagor Zohar & Co.

Certified Public Accountants

A Firm in the Deloitte Global Network

Tel Aviv, Israel

July 25, 2025

------

**SPOTITEARLY INC.**

**BALANCE SHEET**

**(USD in thousands, except share and per share data)**

---

| | |
|:---|:---|
| **Assets:** | |
| **Total assets** | **December 31,**<br> **2024**<br>-  |
| **Liabilities and stockholders' deficit:** |  |
| Related party | (\*) |
| **Total liabilities** | (\*) |
| **Stockholders' deficit:** |  |
| Common Stock $0.00001 par value – authorized 100 stocks, no stocks issued and outstanding at December 31, 2024  | -  |
| Accumulated deficit | (\*) |
| **Total stockholder's deficit** | (\*) |
| **Total liabilities and stockholders' deficit** | -  |

---

(\*) Less than 1.

**The accompanying notes are an integral part of these financial statements.‎**

------

**SPOTITEARLY INC.**

**STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS**

**(USD in thousands, except share and per share data)**

---

| | |
|:---|:---|
|  | **2024** |
| General and administrative  | (\*) |
| Total operating expenses | (\*) |
| **Operating loss** | (\*) |
| **Net loss and comprehensive loss** | (\*) |
| Basic and diluted net loss per share attributable to common stockholders | -  |

---

(\*) Less than 1.

**The accompanying notes are an integral part of these financial statements.‎**

------

**SPOTITEARLY INC.**

**STATEMENT OF STOCKHOLDERS' DEFICIT**

**(USD in thousands, except share and per share data)**

---

| | | | |
|:---|:---|:---|:---|
|  | **Common** <br>**stocks** | **Accumulated** <br>**deficit** | **Stockholders'** <br>**deficit** |
| **November 26, 2024 (inception)** | - | **-** | **-** |
| Net loss for the period | - | (\*) | (\*) |
| **Balance as of December 31, 2024** | **-** | **(\*)** | **(\*)** |

---

(\*) Less than 1.

------

**SPOTITEARLY INC.**

**NOTES TO THE FINANCIAL STATEMENTS**

**(USD in thousands, except share and per share data)**

**NOTE 1** **- DESCRIPTION OF BUSINESS AND GENERAL**

**A.** **Incorporation and description of business:**

SpotitEarly Inc. (the "Company") was formed as a Delaware corporation on November 26, 2024.

On April 9, 2025, the Company acquired all of the share capital of the SpotitEarly Ltd. pursuant to a reorganization transaction in which all holders of the SpotitEarly Ltd.'s ordinary shares, preferred shares, share options and convertible securities exchanged their holdings for shares of common stock, preferred stock, stock options and convertible securities in the Company (the "Reorganization"). The outstanding and fully diluted ownership remained the same after the Reorganization, and the rights attached to SpotitEarly Ltd's shares, share-options, the various types of preferred shares and convertible securities retained substantially the same rights. As a result of the Reorganization, the Company became the parent entity of the SpotitEarly Ltd.

Upon Reorganization, the Company's stock capital was as follows:

---

| | | |
|:---|:---|:---|
|  | **Number of stocks authorized** | **Number of stocks**<br> **issued and outstanding** |
| Convertible series seed preferred stocks  | 3401794 | 3401794 |
| Convertible series seed-1 preferred stocks | 4903357 | 4903357 |
| Common stocks | 11694849 | 8684618 |

---

**B.** **Going concern**

The accompanying financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. As of the date these financial statements are issued, the Company and its subsidiary (together, the "Group") has limited capital resources, not generated revenues from its activities and incurred substantial operating losses. Management expects the Group to continue to generate substantial operating losses for the foreseeable future until it completes the development of its products and obtains regulatory approvals to market such products.

Such conditions raise substantial doubts about the Company's ability to continue as a going concern for at least a year after the issuance date of the accompanying financial statements. Management plans to address these conditions by raising funds. However, there is no assurance that such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount or classification of liabilities that may be required should the Company be unable to continue as a going concern.

**NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

The accompanying financial statement is presented in conformity with accounting principles generally accepted in the United States of America.

Since the Company has not commenced operations and has no cash or cash equivalents, a statement of cash flows has not been presented.

------

**SPOTITEARLY INC.**

**NOTES TO THE FINANCIAL STATEMENTS**

**(USD in thousands, except share and per share data)**

**NOTE 3 - SUBSEQUENT EVENTS**

In July 2025, the Company's board of directors approved that the total number of shares of all classes of stock that the Company is authorized to issue shall be as follows:

---

| | |
|:---|:---|
|  | **Number of stocks** <br>**authorized** |
| Series seed preferred stocks  | 3401794 |
| Series seed-1 preferred stocks | 4903357 |
| Series A-1 preferred stock | 13986013 |
| Series A-2 preferred stock | 7708836 |
| Common stocks | 50000000 |

---

Since January 1, 2025, through July 25, 2025, the Board of Directors of the Company approved a grant of 251,532 options exercisable to common stocks to certain employees and advisors. The exercise price of the options is $3.25, and they vest over a period of four years.

In accordance with ASC 855 "Subsequent Events," the Company evaluated subsequent events through July 25, 2025. The Company concluded that no other subsequent events have occurred that would require recognition or disclosure in the financial statements.

------

**SPOTITEARLY LTD.**

**FINANCIAL STATEMENTS**

**AS OF DECEMBER 31, 2024**

------

**SPOTITEARLY LTD.**

**FINANCIAL STATEMENTS**

**AS OF DECEMBER 31, 2024**

**INDEX TO THE FINANCIAL STATEMENTS**

---

| | |
|:---|:---|
|  | **Page** |
| **[Independent auditors' report](#report1)** | F-12 |
| FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023: |  |
| [Balance sheets](#bs1) | F-14 |
| [Statements of Operations and Comprehensive Loss](#sop1) | F-15 |
| [Statements of Convertible Preferred Shares and Shareholders' Deficit](#scp) | F-16 |
| [Statements of Cash Flows](#soc1) | F-17 |
| [Notes to the financial statements](#note1) | F-18 – F-36 |

---

------

![](spot1a_1.jpg)

**Independent auditors' report to the shareholders of**

**SpotitEarly Ltd.**

**Opinion**

We have audited the financial statements of SpotitEarly Ltd. (the "Company"), which comprise the balance sheets as of December 31, 2024 and 2023, and the related statements of operations and comprehensive loss, convertible preferred shares and shareholders' deficit, and cash flows for the years then ended, and the related notes to the financial statements (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

**Basis for Opinion**

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

**Substantial Doubt About the Company's Ability to Continue as a Going Concern**

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1.b to the financial statements, the Company has incurred recurring losses from operations, has a net capital deficiency, and has stated that substantial doubt exists about the Company's ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans regarding these matters are also described in Note 1.b. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter.

**Responsibilities of Management for the Financial Statements**

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date that the financial statements are issued.

------

**Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Exercise professional judgment and maintain professional skepticism throughout the audit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

/s/ Brightman Almagor Zohar & Co.

Certified Public Accountants

A Firm in the Deloitte Global Network

Tel Aviv, Israel

July 25, 2025

------

**SPOTITEARLY LTD.**

**BALANCE SHEETS**

**(USD in thousands, except share and per share data)**

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of December 31,** |
|  | **2024** | **2023** |
| **Assets** |  |  |
| **Current assets:** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $5240  | $6249  |
| &nbsp;&nbsp;&nbsp;Restricted cash | 70  | 70  |
| &nbsp;&nbsp;&nbsp;Investments in marketable securities | 1187  | 870  |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 396  | 431  |
| **Total current assets** | 6893  | 7620  |
| Property and equipment, net | 168  | 188  |
| Other assets | 201  | 201  |
| **Total Assets** | $7262  | $8009  |
| **Liabilities, convertible preferred share, and shareholders' deficit** |  |  |
| **Current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $97  | $129  |
| &nbsp;&nbsp;&nbsp;Employees and related liabilities | 163  | 174  |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 512  | 103  |
| **Total current liabilities** | 772  | 406  |
| Convertible securities | 12057  | 8189  |
| **Total Liabilities** | $12829  | $8595  |
| Contingent liabilities and commitments (Note 6) |  |  |
| Convertible preferred shares, no par value; 8,305,151 shares authorized, issued and outstanding; $7,254 and $6,882 liquidation preference as of December 31, 2024 and 2023, respectively | 8380  | 8380  |
| **Shareholders' deficit:** |  |  |
| Ordinary shares, no par value, authorized: 11,694,849 shares; issued and outstanding: 8,684,618 and 8,258,324 shares as of December 31, 2024 and 2023, respectively | -  | -  |
| Additional paid-in capital | 2912  | 1773  |
| Accumulated deficit | (16859)  | (10739)  |
| **Total shareholders' deficit** | (13947)  | (8966)  |
| **Total liabilities, convertible preferred shares and shareholders' deficit** | $7262  | $8009  |

---

**The accompanying notes are an integral part of these financial statements.‎**

------

**SPOTITEARLY LTD.**

**STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

**(USD in thousands, except share and per share data)**

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2024** | **2023** |
| Research and development | $3874  | $3264  |
| General and administrative | 1211  | 938  |
| Total operating expenses | 5085  | 4202  |
| **Operating loss** | 5085  | 4202  |
| Interest income | 64  | 151  |
| Other expenses, net | 1099  | 155  |
| **Net loss and comprehensive loss** | **$** **6120**  | **$** **4206**  |
| Basic and diluted net loss per share attributable to ordinary shareholders | 0.734  | 0.509  |

---

**The accompanying notes are an integral part of these financial statements.‎**

------

**SPOTITEARLY LTD.**

**STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND SHAREHOLDERS' DEFICIT**

**(USD in thousands, except share and per share data)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | <br> **Convertible Preferred** <br>**Shares** | <br> **Convertible Preferred** <br>**Shares** | <br> **Ordinary**<br>**Shares** | <br> **Ordinary**<br>**Shares** |  |  |  |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Additional paid-in**<br>**capital** | <br> **Accumulated deficit** | <br> **Shareholders' deficit** |
| **Balance as of January 1, 2023** | **8305151**  | **$** **8380**  | **8258324**  | -  | **$** **858**  | **$** **(6533)**  | **$** **(5675)**  |
| Share-based compensation | -  | -  | -  | -  | 915  | -  | 915  |
| Net loss for the period  | -  | -  | -  | -  | -  | (4206)  | (4206)  |
| **Balance as of December 31, 2023** | **8305151**  | **$** **8380**  | **8258324**  | **-**  | **$** **1773**  | **$** **(10739)**  | **$** **(8966)**  |
| Issuance of ordinary shares for share options exercised  | -  | -  | 426294  | -  | (\*) | -  | (\*) |
| Share-based compensation | -  | -  | -  | -  | 1139  | -  | 1139  |
| Net loss for the period  | -  | -  | -  | -  |  | (6120)  | (6120)  |
| **Balance as of December 31, 2024** | **8305151**  | **$** **8380**  | **8684618**  | -  | **$** **2912**  | **$** **(16859)**  | **$** **(13947)**  |

---

**(\*) Less than $1**

**The accompanying notes are an integral part of these financial statements.‎**

------

**SPOTITEARLY LTD.**

**STATEMENTS OF CASH FLOWS**

**(USD in thousands)**

---

| | | |
|:---|:---|:---|
|  | **Year Ended**<br> **December 31,** | **Year Ended**<br> **December 31,** |
|  | **2024** | **2023** |
| **Cash flows from operating activities:** |  |  |
| **Net loss** | $(6120)  | $(4206)  |
| **Adjustments to reconcile net loss to net cash used in operating activities:**  |  |  |
| Depreciation and amortization  | 57  | 93  |
| Share-based compensation expenses | 1139  | 915  |
| Change in fair value of convertible securities | 1368  | 189  |
| Gain from the change in fair value of marketable securities | (317)  | (148)  |
| Effect of exchange rates | 59  | 37  |
| **Change in operating assets and liabilities:** |  |  |
| Prepaid expenses and other current assets | 35  | (356)  |
| Accounts payable | (32)  | 111  |
| Employees and related liabilities | (11)  | 13  |
| Accrued expenses and other current liabilities | 409  | (18)  |
| **Net cash used in operating activities** | (3413)  | (3370)  |
| **Cash flows from investing activities:** |  |  |
| Purchase of property and equipment | (37)  | (98)  |
| **Net cash provided by (used in) investing activities** | (37)  | (98)  |
| **Cash flows from financing activities:** |  |  |
| Proceeds from issuance of convertible securities  | 2500  | 5000  |
| **Net cash provided by financing activities** | 2500  | 5000  |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (59)  | (37)  |
| Net increase (Decrease) in cash and cash equivalents  | (950)  | 1532  |
| Cash, cash equivalents and restricted cash at the beginning of the year | 6319  | 4824  |
| Cash, cash equivalents and restricted cash at the end of the year | $5310  | 6319$ |
| **Reconciliation of cash, cash equivalents and restricted cash to amounts reported on the balance sheets** |  |  |
| Cash and cash equivalents | $5240  | $6249  |
| Restricted cash | 70  | 70  |
|  | $5310  | $6319  |

---

**The accompanying notes are an integral part of these financial statements.**

------

**SPOTITEARLY LTD.**

**NOTES TO THE FINANCIAL STATEMENTS**

**(USD in thousands, except share and per share data)**

**NOTE 1** **- DESCRIPTION OF BUSINESS AND GENERAL**

**a.** **Incorporation and description of business:**

SpotitEarly Ltd. (the "Company") is a medical technology company incorporated in Israel. The Company is developing an innovative cancer screening test platform that utilizes specially trained dogs to detect early-stage cancer through breath samples. The Company's solution integrates operant conditioning techniques with proprietary sample collection methods and artificial intelligence (AI) to enable a non-invasive, accurate, and scalable method for cancer detection.

The Company's core activity involves the research, development, and clinical validation of its cancer detection technology. The platform uses a multi-layered approach combining canine olfaction, AI algorithms, and a proprietary breath sampling device. The Company has conducted preclinical and clinical studies primarily targeting early detection of multiple cancers, including lung, breast, prostate, and colorectal cancers.

On April 9, 2025, Spotitearly Inc. an entity incorporated in Delaware, U.S. in November 2024 ("Spotitearly U.S."), acquired all of the share capital of the Company pursuant to a reorganization transaction in which all holders of the Company's ordinary shares, preferred shares, share options and convertible securities exchanged their holdings for shares of common stock, preferred stock, stock options and convertible securities in the Spotitearly U.S. (the "Reorganization"). The outstanding and fully diluted ownership remained the same after the Reorganization, and the rights attached to the shares, share-options, the various types of preferred shares and convertible securities retained substantially the same rights. As a result of the Reorganization, the Spotitearly U.S. became the parent entity of the Company.

As the Company was owned immediately prior to consummation of the Reorganization by the same shareholders of Spotitearly U.S. immediately after consummation of the Reorganization, the share exchange is considered as a transaction between entities under common control.

The Reorganization is not reflected in the Company's financial statements as of and for the year ended 2024. The Reorganization will be applied retrospectively in the financial statements of Spotitearly U.S. for periods ending after April 9, 2025, such that the financial information of the Company will be presented in those financial statements of Spotitearly U.S.

**b.** **Going concern:**

The accompanying financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. To date, the Company has not generated revenues from its activities and has incurred substantial operating losses. Management expects the Company to continue to generate substantial operating losses for the foreseeable future until it completes the development of its products and obtains regulatory approvals to market such products.

------

Such conditions raise substantial doubts about the Company's ability to continue as a going concern for at least a year after the issuance date of the accompanying financial statements. Management plans to address these conditions by raising funds. However, there is no assurance that such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives. The accompanying financial statements do not include any adjustments relating to the recoverability and classification of assets, carrying amounts or the amount or classification of liabilities that may be required should the Company be unable to continue as a going concern.

**NOTE 2 -SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**a.** **Basis of presentation:**

The accompanying financial statements are prepared in accordance with U.S. GAAP.

**b.** **Use of estimates:**

The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

Significant items subject to such estimates and assumptions include share-based compensation and the determination of the fair value of the Company's Ordinary Shares and share options and the fair value of convertible securities.

Management believes that the estimates, and judgments they made, are reasonable based upon information available to them at the time that these estimates and judgments are made. To the extent that there are material differences between these estimates and actual results, the Company's financial statements will be affected.

**c.** **Financial statements in U.S. dollars:**

The functional and reporting currency of the Company is the United States dollar ("USD" or "U.S. dollar") as the U.S. dollar is the currency of the primary economic environment in which the Company has operated and expects to continue to operate in the foreseeable future.

The Company balances and transactions denominated in U.S. dollars are presented at their original amounts. Non-U.S. dollar transactions and balances have been remeasured to U.S. dollars in accordance with Accounting Standards Codification ("ASC") 830 of the Financial Accounting Standards Board ("FASB"). All transaction gains and losses from remeasurement of monetary balance sheet items denominated in non-U.S. dollar currencies are included within other expense, net in the statements of operations.

**d.** **Cash and cash equivalents:**

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, and restricted cash. The Company's cash and cash equivalents consist of demand deposits with financial institutions. The associated risk of concentration is mitigated by banking with creditworthy institutions.

Cash equivalents are short-term highly liquid investments that are readily convertible to cash with maturities of three months or less as of the date acquired.

------

**e.** **Restricted cash**

Restricted cash primarily consists of amounts used to secure the Company's corporate credit cards, and are invested in highly liquid deposits, with maturities of three months or less.

**f.** **Marketable securities:**

The Company invests in various marketable equity securities. Marketable securities are measured at their fair value, with the change in fair value being recorded as other expenses, net within the statements of operations and comprehensive loss. During the years ended December 31, 2024 and 2023, the Company recorded net gain from the change in fair value of marketable securities of $317 and $148, respectively.

The Company estimates the fair value of the marketable securities using quoted market prices in active markets which represent a Level 1 input within the fair value hierarchy.

**g.** **Severance pay:**

According to the Israeli Severance Pay Law, 1963 ("Severance Pay Law"), all of the Company's employees are entitled to severance payment, following the termination of their employment. Under the Severance Pay Law, the severance payment is calculated as one-month salary for each year of employment, or a portion thereof. The Company's liability for severance pay is covered by the provisions of Section 14 of the Severance Pay Law ("Section 14").

Under Section 14 employees are entitled to monthly deposits, at a rate of 8.33% of their monthly salary, contributed on their behalf to their insurance funds. Payments in accordance with Section 14 release the Company from any future severance payments in respect of those employees.

Therefore, the Company does not recognize a liability for severance pay due to its employees beyond the monthly deposits they are required to make and deposits under Section 14 are not recorded as an asset in the Company's balance sheets. Severance expenses amounted to $81 and $98 for the years ended December 31, 2024 and 2023, respectively.

**h.** **Property and equipment:**

Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated based on the straight-line method over the estimated useful lives which as follows:

---

| | |
|:---|:---|
|  | **Years** |
| Computers and software | 3 |
| Furniture and equipment | 7-15 |
| Leasehold improvements | (\*) |

---

(\*) Shorter of the estimated useful life of the asset, or remaining term of the underlying lease, which is up to 1 year.

The Company reviews its long-lived assets for impairment whenever events or circumstances have occurred that indicate that the estimated useful lives of the long-lived assets may warrant revision or that the carrying value of these assets may be impaired. To compute whether assets have been impaired, the estimated undiscounted future cash flows of the assets or asset group are compared to the carrying value.

------

If the undiscounted future cash flows are less than the carrying value, an impairment loss is recognized based on the amount in which the carrying amount exceeds the fair value of the asset or asset group, based on discounted cash flows. There were no events or circumstances that required the Company's long-lived assets to be tested for impairment during any of the periods presented.

**i.** **Leases:**

The Company determines if an arrangement is a lease at inception by determining if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration and other facts and circumstances. The Company classifies leases at their inception as either capital or operating leases. During the reporting periods, the Company has only operating leases.

For operating leases, right-of-use ("ROU") assets and lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As the Company's leases do not provide an implicit rate, the Company uses the incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is a hypothetical rate based on the Company's understanding of what its credit rating would be. The ROU assets also include any lease payments made prior to commencement and are recorded net of any lease incentives received. The lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options.

The lease agreements may contain variable costs such as common area maintenance, insurance, real estate taxes or other costs. Variable lease costs are expensed as incurred on the statements of operations.

For operating leases that contain renewals, or other lease incentives, the Company recognizes the rent expense on a straight-line basis over the term of the lease. Additionally, incentives received are treated as a reduction of costs over the term of the agreement.

Payments for variable lease costs are expensed as incurred and are not included in the operating lease ROU assets and lease liabilities.

The Company utilized the practical expedient in ASC 842, Leases ("ASC 842") and elected not to record leases with an initial term of 12 months or less on the balance sheet. Therefore, for short-term leases with a term of 12 months or less, operating lease ROU assets and lease liabilities are not recognized, and the Company records such lease payments in the statements of operations on a straight-line basis over the lease term.

Rent expenses for the years ended December 31, 2024 and 2023 were $78 and $64, respectively.

**j.** **Other assets**

Other assets represent crypto assets held by the Company which include crypto currencies such as Bitcoin and Ethereum and are accounted for as intangible assets with indefinite useful lives. Crypto assets are initially measured at cost.

Crypto assets are subject to impairment losses if the fair value of the assets decrease below the carrying value at any time during the period. The fair value is measured using the quoted price of the crypto asset at the time its fair value is being measured in the Company's principal market. The Company assigns costs to transactions on a first-in, first-out basis.

------

Crypto assets were recorded as non-current assets within the balance sheets as of December 31, 2024 and 2023 and no impairment expanse have been recorded in connection with the Company's crypto assets on the statements of operations and comprehensive loss during the year ended December 31, 2024 and 2023.

**k.** **Convertible securities**

Convertible securities related to SAFEs issued by the Company. SAFE requires conversion into shares of the Company upon the occurrence of certain events. The number of shares to be issued upon conversion of the SAFE is not fixed and will be dependent upon the nature of the event that occurred that resulted in its conversion, the fair value of shares as of the event's date, and other factors as defined in the related agreement. The SAFE agreements provide the holder with an option to redeem the SAFE for cash in the event of a change of control, and therefore, they are classified as liabilities in accordance with ASC 480 "*Distinguishing Liabilities from Equity*". SAFE are measured at fair value at each balance sheet date until settlement, with revaluations recognized as a component of financial (income) expenses, net in the statements of operations and comprehensive loss. Upon conversion of the SAFE into ordinary shares or to convertible preferred shares, the Company will reclassify the fair value of the SAFE to equity.

**l.** **Fair value of financial instruments:**

The Company measures and discloses the fair value of financial assets and liabilities in accordance with ASC Topic 820, "Fair Value Measurement." Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.

The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:

---

| | |
|:---|:---|
| Level 1 | quoted prices (unadjusted) in active markets for identical assets or liabilities. |
| Level 2 | inputs other than quoted prices included within Level 1 that are observable directly or indirectly. |
| Level 3 | inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data). |

---

Balances included in the financial statements measured at fair value on a recurring basis include marketable securities and convertible securities. When developing fair value measurements, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. However, for estimating the fair value of convertible securities the Company utilizes unobservable inputs in determining fair value due to the lack of observable inputs in the market, which requires greater judgment in measuring fair value. In instances where there is limited or no observable market data, fair value measurements for assets and liabilities are based primarily upon the Company's own estimates, and the measurements reflect information and assumptions that management believes a market participant would use in pricing the asset or liability.

------

**m.** **General and administrative:**

General and administrative expenses consist primarily of compensation-related expenses for management, finance, accounting, legal and other administrative personal. Also, it consists of expenses for facilities, professional services fees, insurance costs, and other general overhead costs, including depreciation, to support the Company's operations. General and administrative expenses are expensed as incurred with the exception of share-based compensation, which is recognized over the requisite service period.

**n.** **Research and development costs:**

Research and development expenses consist primarily of laboratory equipment and costs associated with acquiring and training of dogs used in research and development activities and have no alternative use, as well as personal related expenses associated with the Company's research and development staff, including salaries, benefits, stock-based compensation and allocated overhead. Research and development costs are expensed as incurred, except for share-based compensation, which is recognized over the requisite service period.

**o.** **Income tax:**

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income or expense in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized based on management's consideration of all positive and contradictory evidence available. As of December 31, 2024, and 2023, a full valuation allowance was established by the Company to reduce the deferred tax assets to the amount supported by future reversals of existing taxable temporary differences.

The Company evaluates uncertainty in income tax positions based on a more-likely-than-not recognition standard. If that threshold is met, the tax position is then measured at the largest amount that is greater than 50% likely of being realized upon ultimate settlement. If applicable, the Company records interest and penalties as a component of income tax expense. The Company applies a more-likely-than-not recognition threshold to uncertain tax positions based on the technical merits of the income tax positions taken. The Company does not recognize a tax benefit unless it is more likely than not that the tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit that is recorded for these positions is measured at the largest amount of benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company believes that its tax positions are all highly certain of being upheld upon examination. As such, as of December 31, 2024 and 2023, the Company has not recorded any liability for unrecognized tax benefits.

**p.** **Share-based compensation:**

The Company measures and records the expense related to share-based compensation awards made to employees, directors, and non-employee service providers based on estimated fair value of those awards as determined on the date of grant. The Company recognizes share-based compensation expense over to the vesting period and uses the straight-line method to recognize share-based compensation. Forfeitures are recorded as they occur. The Company uses the Black-Scholes-Merton ("Black-Scholes") option-pricing model to determine the fair value of share options.

------

The Black-Scholes option-pricing model requires the use of highly subjective and complex assumptions, which determine the fair value of share-based compensation awards, including the ordinary share price, expected volatility of the underlying ordinary share and expected option term (the time from the grant date until the share options are exercised or expire), and expected divided yield. The Company calculates the fair value of share options granted using the following assumptions:

**Ordinary Share Price** – Since the Company's ordinary shares are not publicly traded the fair value of the shares has been determined by management with the assistance of a third party valuation firm.

**Expected Volatility** - The Company estimated volatility for share option grants by evaluating the average historical volatility of a peer group of companies for the period immediately preceding the option grant for a term that is approximately equal to the share option's expected term.

**Expected Term** - The expected term of the Company's options represents the period that the share- based awards are expected to be outstanding. The Company has elected to use the "simplified" method for share options granted to employees and directors, as the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns

and post-vesting employment termination behavior. Under this approach, the midpoint of the share options vesting term and contractual expiration period to compute the expected term. The simplified method makes the assumption that the employee will exercise share options evenly over the period when the share options are vested and ending on the date when the share options expire. The expected term for share options granted to non-employees is based on the contractual term.

**Risk-Free Interest Rate** - The risk-free interest rate is based on the implied yield currently available on US Treasury zero-coupon issues with a term that is equal to the option's expected term at the grant date.

**Dividend Yield** -The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend yield has been estimated to be zero.

**q.** **Risks and uncertainties:**

The Company is subject to a number of risks and uncertainties common to early-stage biotechnology companies. These include, but are not limited to, the inherent risk of failure in preclinical studies and clinical trials; the need to obtain regulatory approval before any product candidates can be marketed; and the uncertainty surrounding successful commercialization and market acceptance of any future products. The Company relies on third parties for key functions, including research, clinical trial execution, and manufacturing, and is dependent on the continued service of key personnel. Additionally, the Company faces significant competition, may encounter challenges in protecting its intellectual property, and operates within a complex and evolving regulatory environment. The business is also dependent on its ability to raise additional capital to fund ongoing operations and development activities, and may be adversely affected by market conditions, currency fluctuations, and dilution risks associated with future financings.

**r.** **Concentrations of risk:**

Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents, restricted cash and marketable securities. Bank deposits are held by financial institutions and these deposits may at times not be insured. The Company limits its credit risk associated with cash and cash equivalents, as well as restricted cash and marketable securities, by placing them with creditworthy financial institutions. The Company has not experienced any losses on its deposits of cash or cash equivalents.

------

**s.** **Net loss per share attributable to ordinary shareholders**

The Company computes net loss per share using the two-class method required for participating securities. The two-class method requires income available to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.

The Company considers its convertible preferred shares to be participating securities as the holders of the convertible preferred shares would be entitled to dividends that would be distributed to the holders of ordinary shares, on a pro-rata basis assuming conversion of all convertible preferred shares into ordinary shares. These participating securities do not contractually require the holders of such shares to participate in the Company's losses. As such, net loss for the periods presented was not allocated to the Company's participating securities.

The Company's basic net loss per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury shares method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share since the effects of potentially dilutive shares of ordinary shares are anti-dilutive in all periods presented.

**t.** **Recently adopted accounting standards:**

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures. This ASU improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. This ASU is effective for our annual fiscal year 2024, and interim periods starting in fiscal year 2025. A public entity should apply the amendments in this ASU retrospectively to all prior periods presented in the financial statements. The new guidance was adopted by the Company for fiscal year 2024 annual financial statements and this standard was applied retrospectively for the prior period presented in the financial statements. See Note 11 – Segment Reporting for further information.

**u.** **Recently issued accounting standards not yet adopted:**

In December 2023, the FASB issued ASU No. 2023-08, "Intangibles-Goodwill and Other-Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets." This ASU is intended to improve the accounting for certain crypto assets by requiring an entity to measure those crypto assets at fair value each reporting period with changes in fair value recognized in net income. The ASU also improves the information provided to investors about an entity's crypto asset holdings by requiring disclosure about significant holdings, contractual sale restrictions, and changes during the reporting period. Upon adoption, a cumulative-effect adjustment is made to the opening balance of retained earnings as of the beginning of the annual reporting period of adoption. This ASU becomes effective for annual periods beginning after December 15, 2024, including interim periods, with early adoption permitted. Upon adoption of ASU 2023-08, the Company is expecting to recognize a cumulative-effect adjustment increasing its crypto assets value and retained earnings by $577 as of the beginning of fiscal year 2025.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"), to require disaggregated information about a reporting entity's effective tax rate reconciliation, as well as information on income taxes paid. The new requirements should be applied on a prospective basis with an option to apply them retrospectively. ASU 2023-09 will be effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is in the process of evaluating the impact ASU 2023-09 will have on its consolidated financial statements and related disclosures.

------

In November 2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), Disaggregation of Income Statement Expenses. This update aims to enhance the transparency of financial reporting by requiring public business entities (PBEs) to provide disaggregated disclosure of certain income statement expense captions into specified categories in disclosures within the footnotes to the financial statements. The ASU is effective for annual fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. Adoption of this ASU should be applied on a prospective basis, although retrospective application is permitted. The Company is currently evaluating the impact of adopting this ASU on its financial statements and disclosures.

**NOTE 3 - PROPERTY AND EQUIPMENT**

Property and equipment consists of the following:

---

| | | |
|:---|:---|:---|
|  | **As of December 31,** | **As of December 31,** |
|  | **2024** | **2023** |
| **Cost:** |  |  |
| Computers and software | $41  | $36  |
| Furniture and equipment | 235  | 220  |
| Leasehold improvements | 179  | 162  |
|  | 455  | 418  |
| Less: Accumulated depreciation | 287  | 230  |
|  | $168  | $188  |

---

Total depreciation expense for the years ended December 31, 2024 and 2023, was $57 and $93, respectively. The Company has not acquired any property and equipment under finance leases.

**NOTE 4 - CONVERTIBLE SECURITIES**

Since inception, the Company has entered into certain SAFE agreements with existing and new investors.

Upon the event the Company issues and sells preferred shares at a fixed pre-money valuation ("Equity Financing Event"), the SAFE will automatically converted into preferred shares. The number of preferred shares issued upon conversion is calculated by dividing the SAFE amount by the conversion price which is the lower of (i) a fixed discounted price, or (ii) a price per share equal to the valuation cap divided by total number of outstanding shares immediately after the Equity Financing Event, calculated on an as-converted and fully diluted basis, and including shares reserved and available for future grant under the Company's equity incentive plan (see note 7).

The SAFE agreements provide holders with an option to redeem their SAFE for cash in the event of a change of control or an initial public offering.

At the event of dissolution prior to an Equity Financing Event, holders of SAFEs will be entitled to receive an amount equal to the SAFE amount before any distribution of assets to holders of outstanding ordinary shares or preferred shares.

------

The following table summarizes the terms of SAFE outstanding as of December 31, 2024:

---

| | | | |
|:---|:---|:---|:---|
| **Date issued** | **Safe amount** | **Conversion** <br>**Discounted rate** | **Conversion** <br>**Valuation cap** |
| September-November 2022 | $3000  | 25% | $56000  |
| April – September 2023 | 5000  | 20% | 64400  |
| November 2024 (1) | 2500  | 25% | 100000  |
| Total  | $10500  |  |  |

---

(1)Under the November 2024 SAFE, one of the investors was also granted an option to invest an additional $500 in a SAFE with the same terms, in the event that the Company raises $9,000 in an equity financing. As of December 31, 2024, this option to invest additional $500 had not been exercised.

The option is accounted for as a freestanding derivative instrument which is measured at fair value and presented at the balance sheet within convertible securities.

The SAFEs were valued at the end of the year using a probability-weighted expected return model, which incorporated significant unobservable inputs.

---

| | | |
|:---|:---|:---|
|  | December 31, | December 31, |
|  | 2024 | 2023 |
| Fair value of Ordinary Share (\*) | $1.71  | $1.29  |
| Weighted average cost of capital | 22%  | 21.9%  |
| Risk free rate | 4.86%  | 4.2%  |

---

(\*) Including inputs and assumptions on the likelihood of a SAFE mandatory conversion, qualified equity financing or dissolution.

**NOTE 5 - FAIR VALUE MEASUREMENTS**

The following table provides the liabilities carried at fair value measured on a recurring basis:

**Fair Value Measured as of December 31, 2024**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Financial assets at fair value:** | Level 1 | Level 2 | Level 3 | Total |
| Marketable securities | $1187 |  | - | $1187 |
| **Total financial assets at fair value** | 1187 |  | - | 1187 |
| **Financial liabilities at fair value:** | Level 1 | Level 2 | Level 3 | Total |
| Convertible securities (\*) | - |  | 12057 | 12057 |
| **Total financial liabilities at fair value** | - |  | 12057 | 12057 |

---

**Fair Value Measured as of December 31, 2023**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Financial assets at fair value:** | Level 1 | Level 2 | Level 3 | Total |
| Marketable securities | $870 |  |  | $870 |
| **Total financial assets at fair value** | 870 |  |  | 870 |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Financial liabilities at fair value:** | Level 1 | Level 2 | Level 3 | Total |
| Convertible securities |  |  | 8189 | 8189 |
| **Total financial liabilities at fair value** |  |  | 8189 | 8189 |

---

(\*) The fair value of the convertible securities also includes the fair value of an investor option to invest additional $500 in the SAFE under the terms of the November 2024 SAFE agreements (see note 4).

The changes in the fair value of the Company's Level 3 financial liabilities, which are measured on a recurring basis are as follows:

---

| | |
|:---|:---|
|  | Convertible securities |
| **January 1, 2023** | $3000 |
| Proceeds from issuance of SAFE | 5000 |
| Change in fair value of convertible securities | 189 |
| **December 31, 2023** | **8189** |
| Proceeds from issuance of SAFEs | 2500 |
| Change in fair value of convertible securities | 1368 |
| **December 31, 2024** | $**12057** |

---

There were no transfers between fair value measurement levels during the years ended December 31, 2024 and 2023.

The estimated fair value of the Company's cash and cash equivalents, restricted cash, other current assets, accounts payable, employees and related liabilities and accrued expense and other current liabilities approximates their carrying values as these financial instruments are highly liquid or short-term in nature.

**NOTE 6** **- CONTINGENT LIABILITIES AND COMMITMENTS** 

**A.** **Litigation**

There are no pending claims or legal proceedings involving the Company.

**B.** **Lease Commitments – Operating Leases**

The Company leases spaces in Israel for its office, laboratory, and kennel under an operating lease. For each of the periods presented in the financial statements, the company was engaged in a 12 month lease agreement which had no extension option, thus, these leases were subject to the practical expedient of ASC 842 and no right of use asset and lease liability were recognized.

In December 2024, the company extended its existing leases for a period of 12 months which will end on December 31, 2025, with no extension options.

Total rent expenses under the operating leases were $78 and $64 for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, the Company has no obligation associated with its lease agreements for future lease payments.

------

**C.** **Israeli Innovation Authority (the "IIA"):**

The Company has received grants from the Israel Innovation Authority (IIA) to support its research and development (R&D) activities. According to the terms of the grants, the Company is obligated to pay royalties to the IIA at a rate of 3% of revenues generated from the sales of products and services developed under the funded projects, up to the amount of the total grants received plus interest. Until December 31, 2023, the grants were linked to the exchange rate of the dollar and bore the London Interbank Offered Rate until December 31, 2023. From January 1, 2024, these IIA grants are linked to the 12-month Secured Overnight Financing Rate or at an alternative rate published by the Bank of Israel plus 0.71513%.

During 2023, a grant of $1,002 (ILS 3,764) was approved for the Company to participate in its R&D expenses for the years 2023 and 2024. As of December 31, 2023, and December 31, 2024, the Company received amounts of $333 (ILS 1,318) and $367 (1,340 ILS), respectively, against this grant. An additional amount of $302 (ILS 1,107) was received during 2025.

During 2024, an additional grant was approved to support the Company's R&D expenses for the years 2025 through 2027. As of December 31, 2024, an advance payment of $302 (ILS 1,223) had been received.

Grants received were recognized as a reduction of research and development expenses in the statements of operations and comprehensive loss, when the related conditions for recognition were met.

The Company has not yet commenced sales related to the funded projects and, accordingly, no royalties have been paid or accrued as of the reporting date.

As of December 31, 2024, total grants received by the Company from the IIA, including accumulated interest, amounted to approximately $1,110 (ILS 4,047).

**NOTE 7 - SHAREHOLDERS' EQUITY** 

**A.** **Ordinary Shares:**

The Ordinary Shares of the Company, of no par value each (the "Ordinary Shares") confer upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the right to receive dividends, if declared and to participate in the distribution of the distributable assets of the Company upon liquidation of the Company, subject to the preferential rights of the holders of the Preferred Shares (as defined below).

**B.** **Issuance of share capital:**

At inception, the Company issued 10,000,000 Ordinary Shares to its founders for no consideration (the "Founder Shares").

Shortly after inception, the Company entered into share restriction agreement ("SRA") with its founders. According to the agreement, the Company had the right to repurchase 100% of the Founder Shares from each of the founders, other than with respect to the shares of one of the founders, which the Company had the right to repurchase 95% of his aggregate number of Founder Shares, for no consideration. The right to repurchase the Founder

Shares was execrable for a period of 90 days following the termination of the founder's engagement with the Company for any reason. The Company's right to repurchase the Founder Shares expires over a period of 36 months, subject to certain adjustments, as defined in the SRA and all subject to the terms therein.

------

In August 2021, following the termination of the engagement between the Company and one of its founders, the Company exercised its rights and repurchased 1,741,676 Founder Shares for no consideration.

In February 2022, in the framework of the Series Seed SPA, the SRA was amended such that the Company's right to repurchase shares applied to 5,599,999 Founder Shares held by the founders (in the aggregate, i.e, 1,866,666 Ordinary Shares for two of the founders and 1,866,667 Ordinary Shares for the third founder) and exercisable for a period of 120 days following the termination of the founder's engagement with the Company for any reason (subject to certain partial acceleration in the event of termination by the Company other than for Cause (as defined in the SRA), resignation by the Founder for Good Reason (as defined in the SRA), death or Disability (as defined in the SRA)). In accordance with the amended SRA, the Company's right to repurchase

the shares expires over 36 months, where the right to repurchase 1/3 of the shares expires upon the lapse of 12 months and the right to repurchase 2/3 of the shares expires on a monthly basis over 24 months beginning thereafter, subject to certain adjustments, as defined in the amended SRA, and all subject to the terms therein.

As of December 31, 2024, 311,167 shares can be repurchased by the Company at the occurrence of the aforementioned events (subject to the terms and conditions of the SRA).

In connection with the amendment of the SRA, the Company recorded a share-based compensation expenses in the amount of $449 and $448 for the year ended December 31, 2024 and 2023, respectively.

**C.** **Issuance of warrants:**

In December 2022, the board of directors approved a donation to Tmura, an Israeli non-profit organization. The donation is in the form of warrants exercisable to 17,700 shares of ordinary shares. The exercise price of the warrants is ILS 0.01. The fair value of the warrants at issuance date at the amount of $20 was recorded to additional paid in capital.

**NOTE 8 - CONVERTIBLE PREFERRED SHARES**

Series Seed and Seed-1 Preferred Shares (the "Preferred Shares") are convertible into Ordinary Shares on a one-for-one basis and confer upon their holders all rights conferred upon the holders of Ordinary Shares in the Company on an as converted basis as well as those rights attributed to the Preferred Shares in the Article of Association, as amended, including the rights to participate in a distribution of any distributable assets upon the consummation of a liquidation, dissolution, winding up, or a Liquidation Event of the Company, and to receive an amount equal to the greater of (i) their original issue price plus 6% annual interest on the original issue price, less any amount previously paid in preference, before any distribution is made to holders of Ordinary Shares; or (ii) the amount such holder of Preferred Shares would have received with respect to each such Preferred Share had the shares of such series of Preferred Shares been converted into Ordinary Shares immediately prior to such Liquidation Event. The Preferred Shares are not mandatorily redeemable, nor redeemable at the option of the holder after a specified date, but a Liquidation Event, which may occur not solely within the Company's control, would constitute a redemption event. Therefore, all Preferred Shares have been presented outside of permanent equity. The Preferred Shares were not adjusted to their redemption value, since it is not probable that redemption event will occur.

In February 2022, the Company entered into Series Seed SPA with certain new investors. Pursuant to the Series Seed SPA, the Company issued 3,401,794 Series Seed Preferred shares of, in consideration of $3,952, net of $48 issuance cost.

------

In the framework of the Series Seed SPA, the Company converted previously issued SAFEs in the amount of $2,174 into 4,903,357 Series Seed-1 Preferred Shares, representing a price per share of $0.44337. The fair value of the SAFE upon conversion was $4,428. At conversion date, the SAFE was reclassified to convertible preferred shares.

As of December 31, 2024, preferred shares consist of the following (in thousands, except for shares data):

---

| | | | |
|:---|:---|:---|:---|
|  | **Shares Authorized, Issued and Outstanding** | **Aggregated Liquidation Preference** | **Aggregated Liquidation Preference** |
|  |  | 31/12/2024 | 31/12/2023 |
| Series Seed | 3401794 | $4700  | $4459  |
| Series Seed -1 | 4903357 | 2554  | 2423  |
|  | 8305151 | $7254  | $6882  |

---

**NOTE 9 - SHARE-BASED PAYMENTS**

In 2021, the Company's Board of Directors approved the Company's 2021 Share Option plan (the "Plan") whereby the Company may grant share options to purchase its ordinary shares, for the purpose of providing incentives to the Company's directors, officers, employees, office holders, service providers and their employees, or charitable entities.

The maximum number of share options of ordinary shares that may be issued under the Plan is 3,280,335 shares. As of December 31, 2024, there were 742,251 share options available for issuance.

The following table presents a summary of share options activity for the years ended December 31, 2024 and 2023:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | Share Options | Weighted Average Exercise Price Per Share Option | Weighted Average Remaining Contractual Life | Aggregate Intrinsic Value |
| Outstanding as of January 1, 2023 | 1961268 | $0.003  | 8.78 | $1.15  |
| Granted | 466099 | 0.003  |  |  |
| Exercised | - | -  |  |  |
| Expired | - | -  |  |  |
| Forfeited | (79376) | 0.003  |  |  |
| Outstanding as of December 31, 2023 | 2347991 | 0.003  | 7.98 | 1.29  |
| Granted | 359451 | 0.769  |  |  |
| Exercised | (426294) | 0.003  |  |  |
| Expired | - | -  |  |  |
| Forfeited | (169358) | 0.003  |  |  |
| Outstanding as of December 31, 2024 | 2111790 | 0.139  | 7.31 | 1.57  |
| Vested and Exercisable as of December 31, 2024 | 1364877 | $0.056  | 7.18 | $1.65  |

---

------

The vesting of 1,100,000 options granted to an executive officer of the Company, are subject to acceleration at the event of a Merger Transaction, as defined in the Plan, as long as the executive officer is still engaged by the Company.

The aggregate intrinsic value was calculated as the difference between the exercise price of the share options and the fair value of the underlying Class Ordinary Shares as December 31, 2024 and 2023. The weighted-average grant-date fair value of share options granted during the years ended December 31, 2024, and 2023 was $1.71 and $1.29, respectively.

The following table sets forth the total share-based compensation expense resulting from share options granted to employees, directors and non-employee service providers included in the Company's statements of operations:

---

| | | |
|:---|:---|:---|
|  | **Year ended December 31,** | **Year ended December 31,** |
|  | **2024** | **2023** |
| Research and development | $547 | $414 |
| General and administrative | 143 | 53 |
| Total share-based compensation expenses | $690 | $467 |

---

As of December 31, 2024, and 2023, unamortized share-based compensation expense was $816 and $1,095, respectively, related to non-vested share options, which is expected to be recognized over weighted average period of 1.49 and 2.17 years, respectively.

The Company estimates the fair value of share option awards on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each share option. The assumptions used to estimate the fair value of share options granted are as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2024** | **2023** | **2023** |
| Expected volatility | 67.57% |  | N/A% |
| Expected dividends | 0% |  | N/A% |
| Expected term (in years) | 5.63-10 |  | N/A |
| Risk free rate | 4.26%-4.28% |  | N/A% |
| Fair value of ordinary shares | $1.35 - 1.54 | $— | 1.15 - 1.24 |

---

------

**NOTE 10 - TAXES ON INCOME**

**a.** **Tax rates applicable to the income of the Company:**

The Israeli corporate income tax rate was 23% in 2024 and 2023.

The following table displays net deferred income tax:

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
|  | **2024** | **2023** |
| Deferred tax assets: |  |  |
| Net operating loss carryforward | $1708  | $812  |
| Research and development | 605  | 619  |
| Vacation accrual | 10  | 10  |
| Gross deferred tax assets | 2323  | 1441  |
| Valuation allowance | (2323)  | (1441)  |
| Net deferred tax assets | $-  | $-  |

---

**b.** **A reconciliation of the Company's Israeli corporate income tax rate to effective tax rate is as follows:**

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2024** | **2023** |
| Loss before taxes | $6120  | $4206  |
| Israel corporate income tax rate | 23% | 23% |
| Theoretical tax benefit | 1408  | 967  |
| Revaluation of convertible securities | (315)  | (43)  |
| Share based compensation expenses | (262)  | (210)  |
| Other | 51  | 83  |
| Change in valuation allowance | (882)  | (797)  |
| Tax expense | $-  | $-  |
| Effective tax rate | 0% | 0% |

---

**c.** **Carry forward losses for tax purposes and other temporary differences:**

As of December 31, 2024, the Company's Israeli tax loss carryforward was approximately $7.4 million. Such losses can be carried forward indefinitely to offset against future taxable income of the Company.

Based on the available evidence, management believes that it is more likely than not that its deferred tax assets will not be realized and accordingly, a full valuation allowance has been provided.

**d.** **Final tax assessments:**

As of December 31, 2024, all of Company's tax assessments in Israel are not final.

------

**e.** **Uncertain tax positions:**

The Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to examination by a taxation authority. As of December 31, 2024, and 2023, the Company has not recorded any uncertain tax position liability.

**NOTE 11 - SEGMENT REPORTING**

Segment information is prepared on the same basis that the Company's chief operating decision maker ("CODM"), the Chief Executive Officer, manages the business, makes business decisions and assesses performance. The Company has one operating and reportable segment specializing in the development of a multi-cancer early detection screening test as described in Note 1(a). All of the Company's assets are located in Israel.

The CODM assesses performance for this segment and decides how to allocate resources based on net loss. The measure of segment assets is reported on the balance sheet as cash and cash equivalents. The Chief Executive Officer performs the assessment of segment performance by using the reported measure of segment profit or loss to monitor actual results.

The table below summarizes the significant expense categories regularly reviewed by the CODM for the years ended December 31, 2024 and 2023:

---

| | | |
|:---|:---|:---|
|  | **2024** | **2023** |
| Significant segment expenses  |  |  |
| Lab related expenses (\*) | $239  | $182  |
| Other research and development expenses (\*) | 3069  | 2596  |
| General and administrative expenses (\*) | 584  | 400  |
| Other segment items:  |  |  |
| Other operating expenses | 1193  | 1024  |
| Interest income | (64)  | (151)  |
| Other expenses, net | 1099  | 155  |
| **Net loss** | $**6120**  | $**4206**  |

---

(\*) Excludes share-based compensation and depreciation and amortization expenses, which are presented as other operating expenses.

------

**NOTE 12 - NET LOSS PER SHARE ATTRIBUTABLE TO SHAREHOLDERS**

Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The Company considers all series of the convertible preferred stock to be participating securities. Under the two-class method, the net loss attributable to ordinary shareholders is not allocated to the convertible preferred stock as the holders of the convertible preferred stock do not have a contractual obligation to share in the Company's losses. Basic net loss per share attributable to ordinary shareholders is computed by dividing the net loss by the weighted-average number of shares of ordinary shares outstanding during the period, less shares subject to repurchase. The diluted net loss per share attributable to ordinary shareholders is computed by giving effect to all potential dilutive ordinary share equivalents outstanding for the period. For purposes of this calculation, the convertible preferred stock are considered to be potential ordinary share equivalents but have been excluded from the calculation of diluted net loss per share attributable to ordinary shareholders as their effect is anti-dilutive.

---

| | | |
|:---|:---|:---|
|  | **Year ended** | **Year ended** |
|  | **December 31, 2024** | **December 31, 2023** |
| **Numerator:** |  |  |
| Net loss | $6120  | $4206  |
| **Denominator:** |  |  |
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 8341633  | 8258324  |
| **Basic and diluted loss per ordinary share** | $0.734  | $0.509  |

---

Since the Company was in a net loss position for the year ended December 31, 2023 and 2024, there is no difference between the number of shares used to calculate basic and diluted loss per share. The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive are as follows:

---

| | | |
|:---|:---|:---|
|  | **Year ended** | **Year ended** |
|  | **December 31, 2024** | **December 31, 2023** |
| Share options | 2111790  | 2347991  |
| Convertible securities (\*)  | 3102588  | 2606050  |
| Convertible preferred shares | 8305151  | 8305151  |
| **Total** | 13519529  | 13259192  |

---

(\*) The weighted average number of ordinary shares in connection with the convertible securities for the years ended December 31, 2024 and 2023 are based on conversion of the SAFE amount at a share price equal to the valuation cap divided by total number of outstanding shares at year end, calculated on an as-converted and fully diluted basis, and including shares reserved and available for future grant under the Company's equity incentive plan.

------

**NOTE 13 - SUBSEQUENT EVENTS** 

In accordance with ASC 855 "Subsequent Events," the Company evaluated subsequent events through July 25, 2025. The Company concluded that no subsequent events have occurred that would require recognition or disclosure in the financial statements.

------

**PROFORMA FINANCIAL STATEMENTS**

No pro forma financial statements are presented reflecting the acquisition of SpotitEarly Ltd. by SpotitEarly Inc. Since, as of December 31, 2024, the SpotitEarly, Inc. did not have any assets, liabilities, revenue or expenses, and as a result, any pro forma financial statements reflecting the acquisition of SpotitEarly Ltd. by SpotitEarly, Inc. would be identical to the financial statements of SpotitEarly, Ltd.

------

**PART III—EXHIBITS**

**Index to Exhibits**

---

| | |
|:---|:---|
| Number | Exhibit Description |
| 2.1 | [Third Amended and Restated Certificate of Incorporation](spot_ex2z1.htm)  |
| 2.2 | [Bylaws](spot_ex2z2.htm)  |
| 4 | [Subscription Agreement](spot_ex4.htm) |
| 6 | [Engagement Agreement by and between the Company and Manhattan Street Capital,](spot_ex6.htm) |
| 7 | [Security Transfer Agreement](spot_ex7.htm) |
| 8 | [Escrow Agreement](spot_ex8.htm) |
| 11.1 | [Auditors Consent](spot_ex11z1.htm) |
| 11.2 | [Consent of Attorneys](spot_ex11z2.htm) |
| 12 | [Legal Opinion](spot_ex12.htm) |
| 99.1 | [Equity Incentive Plan](spot_ex99z1.htm) |
| 99.2 | [Code of Ethics](spot_ex99z2.htm) |

---

------

## Ex1A-2A

**EXHIBIT 2.1**

**THIRD AMENDED AND RESTATED** 

**CERTIFICATE OF INCORPORATION OF**

**SPOTITEARLY, INC.**

(Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware)

SpotItEarly, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the "**General Corporation Law**"), does hereby certify:

**1.**That the name of this corporation is SpotItEarly, Inc., and that this corporation was originally incorporated pursuant to the General Corporation Law on November 26, 2024, under the name SpotItEarly, Inc.

**2.**That the Board of Directors of this corporation (the "**Board of Directors**") duly adopted resolutions proposing to amend and restate the Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows:

**RESOLVED**, that the Certificate of Incorporation of this corporation be amended and restated in its entirety to read as follows:

**FIRST:** The name of this corporation is SpotItEarly, Inc. (the "**Corporation**").

**SECOND:** The address of the registered office of the Corporation in the State of Delaware is 1000 N. West Street, Suite 1400, in the City of Wilmington, County of New Castle, DE, 19801. The name of its registered agent at such address is MWE Corporate Services, LLC.

**THIRD:** The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law.

**FOURTH:** The total number of shares of all classes of stock which the Corporation shall have the authority to issue is (i) 50,000,000 shares of Common Stock, $0.00001 par value per share ("**Common Stock**"), and (ii) 30,000,000 shares of Preferred Stock, $0.00001 par value per share, 3,401,794 shares of which are hereby designated as "**Series Seed Preferred Stock**", 4,903,357 shares of which are hereby designated as "**Series Seed-1 Preferred Stock**", 13,986,013 shares of which are hereby designated as "**Series A-1 Preferred Stock**", and 7,708,836 shares of which are hereby designated as "**Series A-2 Preferred Stock**".

**FIFTH:** The following is a statement of the designations and the powers, preferences and special rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation.

**A.** **COMMON STOCK**

1. General. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the powers, preferences and special rights of the holders of the Preferred Stock set forth herein.

2. Voting. Except as otherwise provided herein or by applicable law, the holders of the Common Stock shall be entitled to one vote for each share of Common Stock held as of the applicable record date for each meeting of stockholders (and written actions in lieu of meetings). There shall be no cumulative voting. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of this Amended and Restated Certificate of Incorporation (this "**Certificate of Incorporation**")) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law.

------

**B.** **PREFERRED STOCK**

The shares of the Preferred Stock shall have the powers, preferences and special rights set forth in this Part B of this Article [Fourth](#_bookmark0)[.](#_bookmark0) Unless otherwise indicated, references to "sections" or "Sections" in this Part B of this Article [Fourth](#_bookmark0) refer to sections and subsections of Part B of this Article [Fourth](#_bookmark0)[.](#_bookmark0) References to "Preferred Stock" mean the Series Seed Preferred Stock, the Series Seed-1 Preferred Stock, the Series A-1 Preferred Stock and the Series A-2 Preferred Stock.

1. Dividends.

The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in this Certificate of Incorporation) the holders of the Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Preferred Stock in an amount at least equal to (i) in the case of a dividend on Common Stock, the product of (A) the dividend declared, paid or set aside on such Common Stock and (B) the number of shares of Common Stock issuable upon conversion of a share of such Preferred Stock; (ii) in the case of a dividend on a class or series of capital stock that is convertible into Common Stock, the product of (A) the dividend declared, paid or set aside per share of such class or series of capital stock and (B) the number of shares of Common Stock issuable upon conversion of a share of such Preferred Stock, divided by the number of shares of Common Stock issuable upon conversion of a share of such class or series of capital stock; or (iii) in the case of a dividend on any class or series that is not convertible into Common Stock, the product of (A) the amount of the dividend payable on each share of such class or series of capital stock divided by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (B) the applicable Original Issue Price (as defined below); provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Preferred Stock pursuant to this Section shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest Preferred Stock dividend for the applicable series of Preferred Stock. The "**Series Seed Original Issue Price**" shall mean $1.17585 per share, and the "**Series Seed-1 Original Issue Price**" shall mean $0.44337 per share, and the "**Series A-1 Original Issue Price**" and "**Series A-2 Original Issue Price**" shall mean, with respect to each share of Series A-1 Preferred Stock and/or Series A-2 Preferred Stock, the price originally paid for such shares upon issuance by the Company; in each case, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the applicable Preferred Stock. Each of the Series Seed Original Issue Price, the Series Seed-1 Original Issue Price, the Series A-1 Original Issue Price and the Series A-2 Original Issue Price, shall also be referred as an "**Original Issue Price**", as applicable.

2. Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales.

2.1Preferential Payments to Holders of Preferred Stock. Until an IPO, in the event of (a) any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of each series of Preferred Stock then outstanding shall be entitled to be paid out of the funds and/or assets of the Corporation available for distribution to its stockholders, and (b) a Deemed Liquidation Event (as defined below), the holders of shares of each series of Preferred Stock then outstanding shall be entitled to be paid out of the consideration payable to stockholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, on a *pari passu* basis based on their respective Liquidation Amounts (as defined below) and before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share of each such series of Preferred Stock equal to the greater of (i) (a) (i) with respect to the Series Seed Preferred Stock and Series Seed-1 Preferred Stock, the applicable Original Issue Price of such share, plus 6% annual interest on the Original Issue Price of such share of Preferred Stock accruing from February 27, 2022, (ii) with respect to the Series A-1 Preferred Stock, the applicable Original Issue Price of such share; and (iii) with respect to the Series A-2 Preferred Stock, the applicable Original Issue Price of such share, multiplied by 1.25; plus (b) any dividends declared but unpaid thereon, minus (c) any dividend amounts previously paid by the Company with respect to such share of Preferred Stock (if any) and minus (d) any amounts previously paid with respect to such share of Preferred Stock pursuant to this Section 2, or (ii) such amount per share as would have been payable had all shares of such series of Preferred Stock (and all shares of all other series of Preferred Stock that would receive a larger distribution per share if such series of Preferred Stock were converted

------

into Common Stock) been converted into Common Stock pursuant to Section [4](#_bookmark8) immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (the amount payable pursuant to this sentence is hereinafter referred to, for each series of Preferred Stock, as applicable, as the "**Liquidation Amount**"). If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the funds and/or assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Preferred Stock the full amount to which they shall be entitled under this Section 2.1, the holders of shares of Preferred Stock shall share ratably in any distribution of the funds and/or assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

2.2Payments to Holders of Common Stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, after the payment in full of all Liquidation Amounts required to be paid to the holders of shares of Preferred Stock, the remaining funds and/or assets of the Corporation available for distribution to its stockholders or, in the case of a Deemed Liquidation Event, the consideration not payable to the holders of shares of Preferred Stock pursuant to Section [2.1](#_bookmark2) or the remaining Available Proceeds, as the case may be, shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares of Common Stock held by each such holder.

2.3Deemed Liquidation Events.

2.3.1Definition. Each of the following events shall be considered a "**Deemed Liquidation Event**": (i) the closing of a transaction involving the sale of all or substantially all of the Corporation 's assets; or (ii) the merger or consolidation of the Corporation with another entity, as a result of which the stockholders of the Corporation prior to such event do not own, by virtue of their shareholdings in the Corporation prior to such event, a majority of the shares of the surviving entity (which surviving entity may be the Corporation), or (iii) sale, assignment or disposal by the Corporation of all or substantially all of the issued and outstanding shares of the Corporation; or (iv) the transfer, sale, lease, grant or other disposition of or the grant of an exclusive license over all or substantially all of its assets with the same economic effect to that of a sale of all or substantially all of the assets of the Corporation and its subsidiaries taken as a whole; or (v) any other transaction, except for a financing round, following which the stockholders of the Corporation prior to the closing of such transaction own, directly and indirectly, by virtue of their shareholdings in the Corporation prior to such transaction, less than 50% (fifty percent) of the voting power of the surviving entity; in each case other than a sale to a wholly owned subsidiary of the Corporation or a reorganization for the purpose of change of domicile that does not affect the percentage ownership interest of the stockholders.

2.3.2Effecting a Deemed Liquidation Event.

(a)The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in Section [2.3.1(a)(i)](#_bookmark4) or Section [2.3.1(b)](#_bookmark4) unless the agreement or plan with respect to such transaction, or terms of such transaction (any such agreement, plan or terms, the "**Transaction Document**"), provide that the consideration payable to the stockholders of the Corporation in such Deemed Liquidation Event shall be allocated to the holders of capital stock of the Corporation in accordance with Sections [2.1](#_bookmark2) and [2.2](#_bookmark3).

(b)In the event of a Deemed Liquidation Event referred to in Section 2.3.1(a)(ii) or 2.3.1(c), if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within 90 days after such Deemed Liquidation Event, then (i) the Corporation shall send a written notice to each holder of Preferred Stock no later than the 90th day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following clause (ii) to require the redemption of such shares of Preferred Stock, and (ii) if the holders of at least a majority of the then issued and outstanding shares of Voting Preferred Shares (as defined below), voting together as a single class on an as converted basis (the "**Preferred Majority**") so request in a written instrument delivered to the Corporation not later than 120 days after such Deemed Liquidation Event, the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, any other expenses reasonably related to such Deemed Liquidation Event or any other expenses incident to the dissolution of the Corporation as provided herein, in each case as determined in good faith by the Board of Directors), together with any other funds and/or assets of the Corporation available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to stockholders (the "**Available Proceeds**") on the 150th day after such

------

Deemed Liquidation Event (the "**DLE Redemption Date**"), to redeem all outstanding shares of Preferred Stock at a price per share equal to the applicable Liquidation Amount; provided, that if the definitive agreements governing such Deemed Liquidation Event contain contingent indemnification obligations on the part of the Corporation and prohibit the Corporation from distributing all or a portion of the Available Proceeds while such indemnification obligations remain outstanding, then the DLE Redemption Date shall automatically be extended to the date that is ten business days following the date on which such prohibition expires. Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, the Corporation shall redeem a pro rata portion of each holder's shares of Preferred Stock to the fullest extent of such Available Proceeds, based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the Available Proceeds were sufficient to redeem all such shares, and shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders. Prior to the distribution or redemption provided for in this Section 2.3.2(b), the Corporation shall not expend or dissipate the Available Proceeds for any purpose, except to discharge expenses incurred in connection with such Deemed Liquidation Event. In connection with a distribution or redemption provided for in Section 2.3.2, the Corporation shall send written notice of the redemption (the "**Redemption Notice**") to each holder of record of Preferred Stock. Each Redemption Notice shall state:

(i)the number of shares of Preferred Stock held by the holder that the Corporation shall redeem on the date specified in the Redemption Notice;

(ii)the redemption date and the price per share at which the shares of Preferred Stock are being redeemed;

(iii)for holders of shares in certificated form that the holder is to surrender to the Corporation, in the manner and at the place designated, his, her or its certificate or certificates representing the shares of Preferred Stock to be redeemed.

If the Redemption Notice shall have been duly given, and if payment is tendered or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding that any certificates evidencing any of the shares of Preferred Stock so called for redemption shall not have been surrendered, all rights with respect to such shares shall forthwith after the date terminate, except only the right of the holders to receive the payment without interest upon surrender of any such certificate or certificates therefor.

2.3.3Amount Deemed Paid or Distributed. The amount deemed paid or distributed to the holders of capital stock of the Corporation upon any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities to be paid or distributed to such holders pursuant to such Deemed Liquidation Event. The value of such property, rights or securities shall be determined in good faith by the Board of Directors of the Corporation, including the approval of the Preferred Director (as defined herein).

2.3.4Allocation of Escrow and Contingent Consideration. In the event of a Deemed Liquidation Event, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the "**Additional Consideration**"), the Transaction Document shall provide that (a) the portion of such consideration that is not Additional Consideration (such portion, the "**Initial Consideration**") shall be allocated among the holders of capital stock of the Corporation in accordance with Sections 2.1 and 2.2 as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b) any Additional Consideration which becomes payable to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with Sections 2.1 and 2.2 after taking into account the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this Section 2.3.4, consideration placed into escrow or an expense fund or retained as a holdback to be available for satisfaction of indemnification or similar obligations in connection with such Deemed Liquidation Event shall be deemed to be Initial Consideration.

------

3. Voting.

3.1General. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of a meeting), each holder of outstanding shares of Preferred Stock, other than the Series A-1 Preferred Stock (such shares of Preferred Stock shall be referred to as the "**Voting Preferred Stock**"), shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Voting Preferred Stock held by such holder are convertible (as provided in Section 4 below) as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of this Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class and on an as-converted to Common Stock basis. For the avoidance of doubt, the Series A-1 Preferred Stock does not carry voting rights, except as may be required by the Delaware General Corporation Law or as expressly provided in this Certificate of Incorporation.

3.2Election of Directors.

(a)(i) The holders of record of the shares of Series Seed Preferred Stock and Series Seed-1 Preferred Stock, exclusively and voting together as a separate class on an as-converted to Common Stock basis, shall be entitled to elect (1) one director of the Corporation (the "**Preferred Director**"), provided however, that notwithstanding the foregoing, in the event that Hanaco II L.P. together with its Affiliates (as such term is defined in the Corporation's Voting Agreement) ("**Hanaco**"), holds less than 5% (five percent) of the issued and outstanding shares of capital stock of the Corporation, on an as-converted basis, then the holders of Preferred Stock shall not be entitled to elect a director under this Subsection 3.2(a)(i) and (ii) the holders of record of the shares of Common Stock, exclusively and as a separate class, shall be entitled to elect four (4) directors of the Corporation (the "**Common Directors**").

(b)Any director elected as provided in Section 3.2(a)(i) or Section 3.2(a)(ii) or appointed by the proviso of Section 3.2(a) may be removed without cause by, and only by, the affirmative vote of the holders of a majority of the shares of the class or series of capital stock entitled to elect such director or directors, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders.

(c)If the holders of shares of Preferred Stock or Common Stock, as the case may be, fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors pursuant to Section [3.2](#_bookmark6)(a) (and to the extent any of such directorships is not otherwise filled by a director appointed in accordance with the proviso in Section 3.2(a)), then any directorship not so filled shall remain vacant until such time as the holders of the Preferred Stock or Common Stock, as the case may be, fill such directorship in accordance with Section [3.2](#_bookmark6)(a). At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class or series of capital stock entitled to elect such director shall constitute a quorum for the purpose of electing such director.

(d)The "**Requisite Directors**" shall mean the Board of Directors including the Preferred Director if then seated.

3.3Preferred Stock Protective Provisions. At any time when any shares of Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation, domestication, transfer, continuance, recapitalization, reclassification, waiver, statutory conversion, or otherwise, effect any of the following acts or transactions without (in addition to any other vote required by law or this Certificate of Incorporation) the written consent or affirmative vote of the Preferred Majority:

3.3.1Create or issue any class or series of shares or other securities having rights or a preference equal or superior to the Preferred Stock, in each case other than in connection with a bona fide equity financing transaction at a price per share that is equal to or greater than two (2) times the Series Seed Original Issue Price (such a financing transaction, a "**Qualified Financing**");

3.3.2approve a merger, reorganization, sale of the Company or all or substantially all of the Corporation's share capital or assets, unless such transaction is a Deemed Liquidation Event in the scope of which the Corporation's valuation is at least $70,000,000 (a "**Qualified M&A**");

------

3.3.3 approve the reclassification or recapitalization of the outstanding capital stock of the Corporation (other than stock splits, stock dividends and other technical changes in the Corporation's capital stock), other than in connection with a Qualified Financing;

3.3.4increase of the number of the Corporation's directors, other than in connection with Qualified Financing;

3.3.5amend or otherwise modify of this Certificate of Incorporation in a manner which adversely affects the rights of the Preferred Stock (for the avoidance of any doubt, without derogating from any other protective provisions specified herein the creation, authorization and/or issuance of any class or series of shares, including a class or series of shares which is superior to or in a parity with the Preferred Stock, the increase in the size of the Board of Directors or the inclusion of any additional class(es) or series of shares in the definition of "Preferred Stock" or similar definitions, shall not in and of itself be deemed and amendment or modification which adversely affects the rights of the Preferred Stock);

3.3.6unless approved by the Requisite Directors, the transfer or grant of an unlimited, worldwide exclusive license to all or substantially all the Company's intellectual property other than in the Company's ordinary course of business, other than in connection with a Qualified M&A;

3.3.7the approval of any interested party transaction with any Founder (as defined in the Voting Agreement) that is a director, including without limitation any transaction or change in the consulting or employment engagement with any Founder that is a director, and unless approved by the Requisite Directors, any interested party transaction with any other Founder or the CEO, CTO or CFO;

3.3.8unless approved by the Requisite Directors, the approval of the Corporation's annual budget and any material change to the Corporation's business;

3.3.9take any action with respect to any direct or indirect subsidiary of the Corporation that if taken by the Corporation would require approval pursuant to this Section [3.3, unless such approval has been obtained,](#_bookmark7)*[mutatis mutandis](#_bookmark7)*[.](#_bookmark7)

4. Optional Conversion.

The holders of the Voting Preferred Stock shall have conversion rights as follows (the "**Conversion Rights**"):

4.1Right to Convert.

4.1.1Conversion Ratio. Each share of Voting Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such whole number of fully paid and non-assessable shares of Common Stock (calculated pursuant to [4.2](#_bookmark10) below), as is determined by dividing the applicable Original Issue Price by the applicable Conversion Price (as defined below) in effect at the time of conversion. The "**Conversion Price**" applicable to each series of Preferred Stock as of the Original Issue Date shall initially be equal to the applicable Original Issue Price of such series. Such initial Conversion Price for a series of Preferred Stock, and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided in this Section 4. For the avoidance of doubt, the shares of Series A-1 Preferred Stock shall not have a Conversion Right pursuant to this Section 4.1, but shall be subject to the Mandatory Conversion pursuant to Section 5 below, and the provisions of this Section 4.1.1 and Section 4.2 shall apply with respect thereto to the extent applicable in accordance with Section 5 below, *mutatis mutandis*.

4.1.2Termination of Conversion Rights. In the event of a notice of redemption of any shares of Preferred Stock pursuant to Section [2.3.2(b)](#_bookmark5), the Conversion Rights of the shares designated for redemption shall terminate at the close of business on the last full day preceding the date fixed for redemption, unless the redemption price is not fully paid on such redemption date, in which case the Conversion Rights for such shares shall continue until such price is paid in full. In the event of a liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event,

------

the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred Stock; provided that the foregoing termination of Conversion Rights shall not affect the amount(s) otherwise paid or payable in accordance with Section [2.1](#_bookmark2) to the holders of Preferred Stock pursuant to such liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event.

4.2Fractional Shares. The number of shares of Common Stock issuable to a holder of Preferred Stock upon conversion of such Preferred Stock shall be the nearest whole share, after aggregating all fractional interests in shares of Common Stock that would otherwise be issuable upon conversion of all shares of that same series of Preferred Stock being converted by such holder (with any fractional interests after such aggregation representing 0.5 or greater of a whole share being entitled to a whole share). For the avoidance of doubt, no fractional interests in shares of Common Stock shall be created or issuable as a result of the conversion of the Preferred Stock pursuant to Section [4.1.1](#_bookmark9).

4.3Mechanics of Conversion.

4.3.1Notice of Conversion. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of Common Stock (if such voluntary conversion is permitted pursuant to this Certificate of Incorporation), such holder shall (a) provide written notice to the Corporation's transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent) that such holder elects to convert all or any number of such holder's shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (b), if such holder's shares are certificated, surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent). Such notice shall state such holder's name or the names of the nominees in which such holder wishes the shares of Common Stock to be issued. If required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. Unless a later time and date is otherwise specified by the Corporation, the close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) shall be the time of conversion (the "**Conversion Time**"), and the shares of Common Stock issuable upon conversion of the specified shares shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as practicable after the Conversion Time (i) issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, and (ii) pay all declared but unpaid dividends on the shares of Preferred Stock converted.

4.3.2Reservation of Shares. The Corporation shall at all times when the Preferred Stock shall be outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to this Certificate of Incorporation. Before taking any action that would cause an adjustment reducing the Conversion Price for any series of Preferred Stock below the then par value of the shares of Common Stock issuable upon conversion of such series of Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and non-assessable shares of Common Stock at such adjusted Conversion Price.

------

4.3.3Effect of Conversion. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor and to receive payment of any dividends declared but unpaid thereon.

4.3.4No Further Adjustment. Upon any such conversion, no adjustment to the Conversion Price shall be made for any declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion.

4.3.5Taxes. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this Section 4. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid.

4.4Adjustments to Preferred Stock Conversion Price for Diluting Issues.

4.4.1Special Definitions. For purposes of this Article [Fourth](#_bookmark0), the following definitions shall apply:

(a)"**Additional Shares of Common Stock**" shall mean all shares of Common Stock issued (or, pursuant to Section 4.4.3 below, deemed to be issued) by the Corporation after the Original Issue Date (as defined below), other than (1) the following shares of Common Stock and (2) shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1) and (2), collectively, "**Exempted Securities**"):

(i)as to any series of Preferred Stock, shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on such series of Preferred Stock (including dividends payable in connection with dividends on other classes or series of stock);

(ii)shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock that is covered by Section 4.5, 4.6, 4.7 or 4.8;

(iii)shares of Common Stock, Options or Convertible Securities issued pursuant to any credit arrangements, equipment lease, or debt or loan financing, in each case, from a bank or similar financial institution approved by the Requisite Directors;

(iv)shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the Corporation or any of its subsidiaries pursuant to a share option plan for allocation to existing and future employees, consultants, service providers and directors of the Corporation and its subsidiaries, as may be adopted by the Board of Directors from time to time and approved in accordance with applicable laws and regulations, or any other incentive plan of the Corporation, option grant arrangements or the like, approved by the Board of Directors and adopted in accordance with applicable laws and regulations ;

(v)shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security;

(vi)shares of Common Stock, Options or Convertible Securities issued as acquisition consideration pursuant to the acquisition of another corporation or entity by the Corporation, provided that such issuances are approved by the Requisite Directors;

(vii)shares of Common Stock issued in connection with an IPO;

------

(viii)shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Requisite Directors.

(ix)shares of Common Stock, Options or Convertible Securities issued to a strategic investor as approved by the Requisite Directors;

(x)shares or Options to purchase shares of Series A-1 Preferred Stock and/or Series A-2 Preferred Stock

(xi)shares of Common Stock, Options or Convertible Securities issued in any other issuance approved by the Preferred Majority to be classified as an Exempted Securities.

(b)"**Convertible Securities**" shall mean any evidences of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options.

(c)"**Option**" shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.

(d)"**Original Issue Date**" shall mean the date on which the first share of Series A-1 Preferred Stock or Series A-2 Preferred Stock was issued.

4.4.2No Adjustment of Preferred Stock Conversion Price. No adjustment in the Conversion Price of any series of Preferred Stock shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the Preferred Majority agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.

4.4.3Deemed Issue of Additional Shares of Common Stock.

(a)If the Corporation at any time or from time to time after the Original Issue Date shall issue any Options or Convertible Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date.

(b)If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Conversion Price of any series of Preferred Stock pursuant to the terms of Section 4.4.4, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1) any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or (2) any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the Conversion Price of such series of Preferred Stock computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such Conversion Price for such series of Preferred Stock as would have obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this clause (b) shall have the effect of increasing the Conversion Price applicable to a series of Preferred Stock to an amount which exceeds the lower of (i) the Conversion Price for such series of Preferred Stock in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii) the Conversion Price for such series of Preferred Stock that would have resulted from any issuances of Additional Shares of Common Stock (other than

------

deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date.

(c)If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to the Conversion Price of a series of Preferred Stock pursuant to the terms of Section 4.4.4 (either because the consideration per share (determined pursuant to Section 4.4.5) of the Additional Shares of Common Stock subject thereto was equal to or greater than the applicable Conversion Price then in effect, or because such Option or Convertible Security was issued before the Original Issue Date), are revised after the Original Issue Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1) any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (2) any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in Section 4.4.3(a) shall be deemed to have been issued effective upon such increase or decrease becoming effective.

(d)Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Conversion Price of any series of Preferred Stock pursuant to the terms of Section 4.4.4, the Conversion Price of such series of Preferred Stock shall be readjusted to such Conversion Price for such series of Preferred Stock as would have obtained had such Option or Convertible Security (or portion thereof) never been issued.

(e)If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is potentially subject to adjustment based upon subsequent events, any adjustment to the Conversion Price of a series of Preferred Stock provided for in this Section 4.4.3 shall be effected at the time of such issuance or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in clauses (b) and (c) of this Section 4.4.3). If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to the Conversion Price of a series of Preferred Stock that would result under the terms of this Section 4.4.3 at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the Conversion Price for such series of Preferred Stock that such issuance or amendment took place at the time such calculation can first be made. In the event an Option or Convertible Security contains alternative conversion terms, such as a cap on the valuation of the Corporation at which such conversion will be effected, or circumstances where the Option or Convertible Security may be repaid in lieu of conversion, then the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of such Option or Convertible Security shall be deemed not calculable until such time as the applicable conversion terms are determined.

4.4.4Adjustment of Conversion Price Upon Issuance of Additional Shares of Common Stock. In the event the Corporation shall at any time after the Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to Section 4.4.3), without consideration or for a consideration per share less than the Conversion Price of a series of Preferred Stock in effect immediately prior to such issuance or deemed issuance, then the Conversion Price for such series of Preferred Stock shall be reduced, concurrently with such issue, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:

CP2 = CP1\* (A + B) / (A + C).

------

For purposes of the foregoing formula, the following definitions shall apply:

(a)"CP2" shall mean the Conversion Price of such series of Preferred Stock in effect immediately after such issuance or deemed issuance of Additional Shares of Common Stock

(b)"CP1" shall mean the Conversion Price of such series of Preferred Stock in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock;

(c)"A" shall mean the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);

(d)"B" shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued or deemed issued at a price per share equal to CP1 (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP1); and

(e)"C" shall mean the number of such Additional Shares of Common Stock issued in such transaction.

4.4.5Determination of Consideration. For purposes of this Section 4.4, the consideration received by the Corporation for the issuance or deemed issuance of any Additional Shares of Common Stock shall be computed as follows:

(a)Cash and Property: Such consideration shall:

(i)insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation, excluding amounts paid or payable for accrued interest;

(ii)insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of such issue, as determined in good faith by the Board of Directors; and

(iii)in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (i) and (ii) above, as determined in good faith by the Board of Directors.

(b)Options and Convertible Securities. The consideration per share received by the Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to Section 4.4.3, relating to Options and Convertible Securities, shall be determined by dividing:

(i)The total amount, if any, received or receivable by the Corporation as consideration for the issue of such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities, by

(ii)the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities.

------

4.4.6Multiple Closing Dates. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to the Conversion Price of a series of Preferred Stock pursuant to the terms of Section 4.4.4, and such issuance dates occur within a period of no more than ninety (90) days from the first such issuance to the final such issuance, then, upon the final such issuance, the Conversion Price of such series of Preferred Stock shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances within such period).

4.5Adjustment for Stock Splits and Combinations. If the Corporation shall at any time or from time to time after the Original Issue Date effect a subdivision of the outstanding Common Stock, the Conversion Price of each series of Preferred Stock in effect immediately before that subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time after the Original Issue Date combine the outstanding shares of Common Stock, the Conversion Price of each series of Preferred Stock in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this subsection shall become effective at the close of business on the date the subdivision or combination becomes effective.

4.6Adjustment for Certain Dividends and Distributions. In the event the Corporation at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event the Conversion Price of each series of Preferred Stock in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the Conversion Price of each such series of Preferred Stock then in effect by a fraction:

(1)the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and

(2)the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution.

Notwithstanding the foregoing, (a) if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the Conversion Price of each series of Preferred Stock shall be recomputed accordingly as of the close of business on such record date and thereafter the Conversion Price of each series of Preferred Stock shall be adjusted pursuant to this Section 4.6 as of the time of actual payment of such dividends or distributions; and (b) no such adjustment shall be made if the holders of such series of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of such series of Preferred Stock had been converted into Common Stock on the date of such event.

4.7Adjustments for Other Dividends and Distributions. In the event the Corporation at any time or from time to time after the Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of Section 1 do not apply to such dividend or distribution, then and in each such event the holders of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event.

------

4.8Adjustment for Merger or Reorganization, etc. Subject to the provisions of Section 2.3, if there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by Sections 4.4, 4.6 or 4.7), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of each series of Preferred Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one share of such series of Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board of Directors) shall be made in the application of the provisions in this Section 4 with respect to the rights and interests thereafter of the holders of the Preferred Stock, to the end that the provisions set forth in this Section 4 (including provisions with respect to changes in and other adjustments of the Conversion Price of each series of Preferred Stock) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of the Preferred Stock.

4.9Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment of the Conversion Price of a series of Preferred Stock pursuant to this Section [4](#_bookmark8), the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than ten days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of such series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which such series of Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock (but in any event not later than 10 days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i) the Conversion Price then in effect for each series of Preferred Stock held by such holder, and (ii) the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of each such series of Preferred Stock.

4.10Notice of Record Date. In the event:

(a)the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or series or any other securities, or to receive any other security; or

(b)of any capital reorganization of the Corporation, any reclassification of the Common Stock of the Corporation, or any Deemed Liquidation Event; or

(c)of the voluntary or involuntary dissolution, liquidation or winding-up of the Corporation,

then, and in each such case, the Corporation will send or cause to be sent to the holders of the Preferred Stock a notice specifying, as the case may be, (i) the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii) the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up is proposed to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or winding-up, and the amount per share and character of such exchange applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least ten (10) days prior to the record date or effective date for the event specified in such notice.

------

5. Mandatory Conversion.

5.1Trigger Events. All outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to Sections [4.1.1](#_bookmark9) and [4.2](#_bookmark10)[,](#_bookmark10) upon the earliest to occur of (the time of such conversion is referred to herein as the "**Mandatory Conversion Time**"):

(a)Immediately prior to the earlier to occur of (i) the closing of the first underwritten offering of the shares of Common Stock to the general public pursuant to a registration statement under the Securities Act of 1933, as amended or under equivalent securities law of another jurisdiction, or (ii) the consummation of an Initial Business Combination (each of (i) and (ii), an "**IPO**"). "**Initial Business Combination**" means a business combination transaction (whether by merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination) involving the Corporation and a blank check company that has been formed for the purpose of effecting such a transaction or a subsidiary of such a blank check company, provided that immediately following the consummation of such initial business combination the Common Stock of the Corporation or its parent entity is listed for trading on a stock exchange or any public trading marketing; and

(b)the date and time, or the occurrence of an event, specified by vote or written consent of the Preferred Majority.

5.2Procedural Requirements. All holders of record of shares of Preferred Stock shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this Section 5. Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock being converted that holds such shares in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Preferred Stock converted pursuant to Section 5.1, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this Section 5.2. As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a) issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (b) pay any declared but unpaid dividends on the shares of Preferred Stock converted.

6. Redemption. Other than as set forth in Section 2.3.2(b), the Preferred Stock is not redeemable at the option of the holder or the Corporation.

7. Redeemed or Otherwise Acquired Shares. Unless approved by the Board of Directors and the Preferred Majority, any shares of Preferred Stock that are redeemed, converted or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption, conversion or acquisition. The Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.

8. Waiver. Except as otherwise set forth herein, any of the rights, powers, preferences and other terms of the Preferred Stock set forth herein may be waived on behalf of all holders of Preferred Stock by the affirmative written consent or vote of the Preferred Majority.

------

9. Notices. Any notice required or permitted by the provisions of this Article [Fourth](#_bookmark0) to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission.

**FIFTH:** Subject to any additional vote required by this Certificate of Incorporation or the Bylaws of the Corporation, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation.

**SIXTH:** Subject to any additional vote required by this Certificate of Incorporation, the number of directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. . Until the earliest of (i) the Mandatory Conversion Time, (ii) such time as no Preferred Stock is otherwise outstanding, or (iii) such time that no holder of Preferred Stock is entitled to elect a Preferred Director, any committee of the Board of Directors shall include any then-serving Preferred Director who wishes to serve on such committee, unless the sole purpose of the committee is to consider a matter where such Preferred Director has a conflict of interest, as reasonably determined by the Board of Directors, or such Preferred Director chooses not to serve or has otherwise recused himself or herself from such committee

**SEVENTH:** Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.

**EIGHTH:** Meetings of stockholders may be held within or outside the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept (subject to any provision of applicable law) outside of the State of Delaware at such place or places or in such manner or manners as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation.

**NINTH:** To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this Article Ninth to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended.

Any amendment, repeal or elimination of the foregoing provisions of this Article Ninth by the stockholders of the Corporation shall not adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such director occurring prior to, such amendment, repeal or elimination.

**TENTH:** To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which the General Corporation Law permits the Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section 145 of the General Corporation Law.

Any amendment, repeal, modification or elimination of the foregoing provisions of this Article [Tenth](#_bookmark12) shall not (a) adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification or

elimination; or (b) increase the liability of any director, officer or agent of the Corporation with respect to any acts or omissions of such director, officer or agent occurring prior to, such amendment, repeal, modification or elimination.

**ELEVENTH:** The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity. An "**Excluded** 

------

**Opportunity**" is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of (i) any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii) any holder of Preferred Stock or any partner, member, director, stockholder, employee, affiliate or agent of any such holder, other than someone who is an officer or employee of the Corporation or any of its subsidiaries (collectively, the persons referred to in clauses (i) and (ii) are "**Covered Persons**"), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person's capacity as a director of the Corporation while such Covered Person is performing services in such capacity. Any repeal or modification of this Article [Eleventh](#_bookmark13) will only be prospective and will not affect the rights under this Article [Eleventh](#_bookmark13) in effect at the time of the occurrence of any actions or omissions to act giving rise to liability. Notwithstanding anything to the contrary contained elsewhere in this Certificate of Incorporation, in addition to any other vote required by law or this Certificate of Incorporation, the affirmative vote of the Preferred Majority will be required to amend or repeal, or to adopt any provisions inconsistent with this Article [Eleventh](#_bookmark13).

**TWELFTH:** Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation's stockholders, (iii) any action asserting a claim against the Corporation, its directors, officers or employees arising pursuant to any provision of the Delaware General Corporation Law or the Corporation's certificate of incorporation or bylaws or (iv) any action asserting a claim against the Corporation, its directors, officers or employees governed by the internal affairs doctrine, except for, as to each of (i) through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction.

**THIRTEENTH**: If any provision or provisions of this Certificate of Incorporation shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Certificate of Incorporation (including, without limitation, each portion of any sentence of this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.

\*\*\*\*\*

------

**3.**That the foregoing amendment and restatement was approved by the holders of the requisite number of shares of this corporation in accordance with Section 228 of the General Corporation Law.

**4.**That this Certificate of Incorporation, which restates and integrates and further amends the provisions of this Corporation's Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law.

**IN WITNESS WHEREOF**, this Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this Corporation on this 11th day of July, 2025.

By: /s/ Roi Ophir

Roi Ophir, Chairman of the Board

------

## Ex1A-2B

**EXHIBIT 2.2**

**BYLAWS**

**OF**

**SPOTITEARLY, INC.**

**ARTICLE I**

**OFFICES**

**Section l. Offices**:

The principal office of the Corporation shall be determined by the Board of Directors, and the Corporation shall have other offices at such places as the Board of Directors may from time to time determine.

**ARTICLE II**

**STOCKHOLDERS' MEETINGS**

**Section l. Place**:

The place of stockholders' meetings shall be the principal office of the Corporation unless another location shall be determined and designated from time to time by the Board of Directors.

**Section 2. Annual Meeting**:

The annual meeting of the stockholders of the Corporation for the election of directors to succeed those whose terms expire, and for the transaction of such other business as may properly come before the meeting, shall be held no later than one year after the end of the Corporation's fiscal year on a date to be determined by the Board of Directors.

**Section 3. Special Meetings**:

Special meetings of the stockholders for any purpose or purposes may be called by the President, the Board of Directors, or the holders of ten percent (l0%) or more of all the shares entitled to vote at such meeting, by the giving of notice in writing as hereinafter described.

**Section 4. Voting:**

At all meetings of stockholders, voting may be viva vote; but any qualified voter may demand a stock vote, whereupon such vote shall be taken by ballot and the Secretary shall record the name of the stockholder voting, the number of shares voted, and, if such vote shall be by proxy, the name of the proxy holder. Voting may be in person or by proxy appointed in writing, manually signed by the stockholder or his or her duly authorized attorney-in-fact.

Each stockholder shall have such rights to vote as the Articles of Incorporation provide for each share of stock registered in his or her name on the books of the Corporation. The Corporation may establish a record date, not to exceed, in any case, 70 days preceding the meeting, for the determination of stockholders entitled to vote. The Secretary of the Corporation shall make, at least ten (l0) days before each meeting of stockholders, a complete list of the stockholders entitled to vote at such meeting or any adjournment thereof, arranged in alphabetical order, with the address of and the number of shares held by each, which list, for a period of ten (l0) days prior to such meeting, shall be kept on file at the principal office of the Corporation and shall be subject to inspection by any stockholder at any time during usual business hours. Such list shall also be produced and kept open at the time and place of the meeting and shall be subject to the inspection of any stockholder during the whole time of the meeting.

------

Beneficial owners of this Corporation's common stock registered in the name of Depository Trust & Clearing Corporation or any other clearing organization will be recognized as stockholders entitled to vote in person or by proxy at any meeting provided that the following procedures are followed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·If the stockholder is voting at the meeting, the stockholder provides a valid government issued identification document and brokerage statement identifying the stockholder as the holder of shares of this Corporation's common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·If a person is voting on behalf of a stockholder at the meeting, the person provides a signed proxy card and brokerage statement identifying the stockholder voting by proxy as the holder of shares of this Corporation's common stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·If the stockholder is voting by proxy, the stockholder sends a signed proxy card and brokerage statement identifying the stockholder as the holder of shares of this Corporation's common stock.

Each share of this Corporation's common stock that is listed on any brokerage statement provided in person or by proxy will be entitled to one vote at any meeting.

**Section 5. Order of Business**:

The order of business at any meeting of stockholders shall be as follows, unless otherwise determined by the Corporation's Chief Executive Officer:

l.Call the meeting to order.

2. Report of a corporate officer as to the number of shares represented at the meeting and the existence or lack of a quorum.

3. Election of directors, if appropriate.

4. Reports of officers or committees, if any.

5. Old or new business.

6. Adjournment.

To the extent that these Bylaws do not apply, Roberts' Rules of Order shall prevail.

**Section 6. Notices** **:**

Written or printed notice stating the place, day, and hour of the meeting and, in case of a special meeting, the purpose or purposes for which the meeting is called, shall be delivered not less than l0 nor more than 70 days before the date of the meeting, either personally or by mail, by or at the direction of the President, the Secretary, or the officer or persons calling the meeting, to each stockholder of record entitled to vote at such meeting. If mailed, such notice shall be deemed to be delivered when deposited in the United States mail addressed to the shareholder at his or her address as it appears on the stock transfer books of the Corporation, with postage thereon prepaid.

------

**Section 7. Quorum** **:**

A quorum at any annual or special meeting shall consist of the representation in person or by proxy of 33 1/3% of the issued and outstanding capital stock of the Corporation entitled to vote at such meeting. In the event a quorum be not present, the meeting may be adjourned by those present for a period not to exceed sixty (60) days at any one adjournment; and no further notice of the meeting or its adjournment shall be required.

**ARTICLE III**

**BOARD OF DIRECTORS**

**Section l. Organization and Powers**:

The Board of Directors shall constitute the policy-making or legislative authority of the Corporation. Management of the affairs, property, and business of the Corporation shall be vested in the Board of Directors, which shall consist of not less than one nor more than ten members, who shall be elected at the annual meeting of stockholders by a plurality vote for a term of one (l) year, and shall hold office until their successors are elected and qualify. The number of directors shall be established from time-to-time by a resolution of the directors. Directors need not be stockholders. Directors shall have all powers with respect to the management, control, and determination of policies of the Corporation that are not limited by these Bylaws, the Articles of Incorporation, or by statute, and the enumeration of any power shall not be considered a limitation thereof.

**Section 2. Vacancies**:

Any vacancy in the Board of Directors, however caused or created, shall be filled by the affirmative vote of a majority of the remaining directors, though less than a quorum of the Board, or at a special meeting of the stockholders called for that purpose. The directors elected to fill vacancies shall hold office for the unexpired term and until their successors are elected and qualify.

**Section 3. Regular Meetings**:

A regular meeting of the Board of Directors shall be held, without other notice than this Bylaw, immediately after and at the same place as the annual meeting of stockholders or any special meeting of stockholders at which a director or directors shall have been elected. The Board of Directors will meet quarterly.

**Section 4. Special Meetings**:

Special meetings of the Board of Directors may be held at the principal office of the Corporation, or such other place as may be fixed by resolution of the Board of Directors for such purpose, at any time on call of the President or of any member of the Board, or may be held at any time and place without notice, by unanimous written consent of all the members, or with the presence and participation of all members at such meeting. A resolution in writing signed by all the directors shall be as valid and effectual as if it had been passed at a meeting of the directors duly called, constituted, and held.

**Section 5. Notices**:

Notices of both regular and special meetings, except when held by unanimous consent or participation, shall be sent by the Secretary to each member of the Board not less than three days before any such meeting and notices of special meetings may state the purposes thereof. No failure or irregularity of notice of any regular meeting shall invalidate such meeting or any proceeding thereat.

------

**Section 6. Quorum and Manner of Acting**:

A quorum for any meeting of the Board of Directors shall be a majority of the Board of Directors as then constituted. Any act of the majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors. Any action of such majority, although not at a regularly called meeting, and the record thereof, if assented to in writing by all of the other members of the Board, shall always be as valid and effective in all respects as if otherwise duly taken by the Board of Directors.

**Section 7. Order of Business**:

The order of business at any regular or special meeting of the Board of Directors, unless otherwise prescribed for any meeting by the Board, shall be as follows:

l.Reading and disposal of any unapproved minutes.

2. Reports of officers and committees.

3. New business.

4. Adjournment.

To the extent that these Bylaws do not apply, Roberts' Rules of Order shall prevail.

**ARTICLE IV**

**OFFICERS**

**Section 1. Officers**:

The officers of the Corporation shall be those designated by the Board of Directors. The officers shall have the powers, responsibilities and duties as may be designed by the Board or the Corporation's Chief Executive Officer. In the discretion of the Board, one person may hold more than one office and two or more persons may serve in any one office.

Notwithstanding the above, the Chief Executive Officer or the Secretary will have responsibility for the preparation and maintenance of minutes of the directors' and shareholders' meetings and other records and information required to be kept by the Corporation pursuant to C.R.S. 7-116-101 and for authenticating records of the Corporation.

**Section 2. Vacancies or Absences**:

If a vacancy in any office arises in any manner, the directors then in office may choose, by a majority vote, a successor to hold office for the unexpired term of the officer. If any officer shall be absent or unable for any reason to perform his or her duties, the Board of Directors, to the extent not otherwise inconsistent with these Bylaws, may direct that the duties of such officer during such absence or inability shall be performed by such other officer or subordinate officer as seems advisable to the Board.

------

**ARTICLE V**

**STOCK**

**Section 1. Regulations**:

The Board of Directors shall have power and authority to take all such rules and regulations as they deem expedient concerning the issue, transfer, and registration of certificates for shares of the capital stock of the Corporation. The Board of Directors may appoint a Transfer Agent and/or a Registrar and may require all stock certificates to bear the signature of such Transfer Agent and/or Registrar.

**Section 2. Restrictions on Stock**:

The Board of Directors may restrict any stock issued by giving the Corporation or any stockholder "first right of refusal to purchase" the stock, by making the stock redeemable or by restricting the transfer of the stock, under such terms and in such manner as the directors may deem necessary and as are not inconsistent with the Articles of Incorporation or by statute. Any stock so restricted must carry a stamped legend setting out the restriction or conspicuously noting the restriction and stating where it may be found in the records of the Corporation.

**ARTICLE VI**

**DIVIDENDS AND FISCAL YEAR**

**Section l. Dividends**:

Dividends may be declared by the directors and paid out of any funds legally available therefor, as may be deemed advisable from time to time by the Board of Directors of the Corporation. Before declaring any dividends, the Board of Directors may set aside out of net profits or earned or other surplus such sums as the Board may think proper as a reserve fund to meet contingencies or for other purposes deemed proper and to the best interests of the Corporation.

**Section 2. Fiscal Year**:

The Board of Directors by resolution shall determine the fiscal year of the Corporation.

**ARTICLE VII**

**AMENDMENTS**

These Bylaws may be altered, amended, or repealed by the Board of Directors by resolution of a majority of the Board.

**ARTICLE VIII**

**INDEMNIFICATION**

The Corporation shall indemnify any and all of its directors or officers, or former directors or officers, or any other person, to the fullest extent provided by the laws of Delaware.

**ARTICLE IX**

**CONFLICTS OF INTEREST**

No contract or other transaction of the Corporation with any other persons, firms or corporations, or in which the Corporation is interested, shall be affected or invalidated by the fact that any one or more of the directors or officers of the Corporation is interested in or is a director or officer of such other firm or corporation; or by the fact that any director or officer of the Corporation, individually or jointly with others, may be a party to or may be interested in any such contract or transaction.

------

## Ex1A-4

**EXHIBIT 4**

**SPOTITEARLY, INC.**

**SUBSCRIPTION AGREEMENT**

**THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE PREFERRED SHARES, AND NO PUBLIC MARKET MAY DEVELOP FOLLOWING THIS OFFERING.**

**THE PREFERRED SHARES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR ANY STATE SECURITIES OR BLUE SKY LAWS AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND STATE SECURITIES OR BLUE SKY LAWS. THE PREFERRED SHARES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR THE ADEQUACY OR ACCURACY OF THE SUBSCRIPTION AGREEMENT OR ANY OTHER MATERIALS OR INFORMATION MADE AVAILABLE TO SUBSCRIBERS IN CONNECTION WITH THIS OFFERING.** 

**SUBSCRIBERS WHO ARE NOT "ACCREDITED INVESTORS" (AS THAT TERM IS DEFINED IN SECTION 501 OF REGULATION D PROMULGATED UNDER THE ACT) ARE SUBJECT TO LIMITATIONS ON THE AMOUNT THEY MAY INVEST, AS SET OUT IN SECTION 4. THE COMPANY IS RELYING ON THE REPRESENTATIONS AND WARRANTIES SET FORTH BY EACH SUBSCRIBER IN THIS SUBSCRIPTION AGREEMENT AND THE OTHER INFORMATION PROVIDED BY SUBSCRIBER IN CONNECTION WITH THIS OFFERING TO DETERMINE THE APPLICABILITY TO THIS OFFERING OF EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT.**

**THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY'S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS "ESTIMATE," "PROJECT," "BELIEVE," "ANTICIPATE," "INTEND," "EXPECT" AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT'S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY'S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.** 

**THE OFFERING MATERIALS DO NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY STATE OR JURISDICTION IN WHICH THE PREFERRED SHARES ARE NOT BEING OFFERED.**

**THE COMPANY RESERVES THE RIGHT IN ITS SOLE DISCRETION AND FOR ANY REASON WHATSOEVER TO MODIFY, AMEND AND/OR WITHDRAW ALL OR A PORTION OF THE OFFERING AND/OR ACCEPT OR REJECT IN WHOLE OR IN PART ANY PROSPECTIVE INVESTMENT IN THE PREFERRED SHARES OR TO ALLOT TO ANY PROSPECTIVE INVESTOR LESS THAN THE AMOUNT OF PREFERRED SHARES SUCH INVESTOR DESIRES TO PURCHASE. EXCEPT AS OTHERWISE INDICATED, THE OFFERING MATERIALS SPEAK AS OF THEIR DATE. NEITHER THE DELIVERY NOR THE PURCHASE OF THE PREFERRED SHARES SHALL, UNDER** 

------

**ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THAT DATE.**

1. SUBSCRIPTION.

(a) The undersigned ("Subscriber") hereby irrevocably subscribes for and agrees to purchase such number of Preferred Shares as set forth on the subscription page (the "Preferred Shares") of SpotItEarly, Inc., a Delaware corporation (the "Company"), at a purchase price of $7.15 per preferred share (the "Per Price").

(b) Subscriber understands that the Preferred Shares are being offered pursuant to an Offering Circular dated ______ (as amended, the "Offering Circular") filed with the SEC as part of the Offering Statement. By executing this Subscription Agreement, Subscriber acknowledges that Subscriber has received this Subscription Agreement, copies of the Offering Circular and Offering Statement including exhibits thereto and any other information required by the Subscriber to make an investment decision.

(c) The Subscriber's subscription may be accepted or rejected in whole or in part, at any time prior to a Closing Date (as hereinafter defined), by the Company at its sole discretion. In addition, the Company, at its sole discretion, may allocate to Subscriber only a portion of the number of Preferred Shares Subscriber has subscribed for. The Company will notify Subscriber whether this subscription is accepted (whether in whole or in part) or rejected. If Subscriber's subscription is rejected, Subscriber's payment (or portion thereof if partially rejected) will be returned to Subscriber without interest and all of Subscriber's obligations hereunder shall terminate. This subscription shall only be effective upon (1) completion of any additional documents and providing of any additional information as requested, (2) payment of the subscription amount, (3) acceptance of the subscription agreement by the Company and (4) receipt of the subscription amount by the Company.

(d) The Company may accept subscriptions until ______ unless otherwise extended by the Company in its sole discretion in accordance with applicable SEC regulations for such other period required to sell the Maximum Offering (the "Termination Date"). The Company may elect at any time to close all or any portion of this offering, on various dates at or prior to the termination of this Offering (each a "Closing Date").

(e) In the event of rejection of this subscription in its entirety, or in the event that the sale of the Preferred Shares (or any portion thereof) is not consummated for any reason, this Subscription Agreement shall have no force or effect, except for Section 5 hereof, which shall remain in force and effect.

(f) The terms of this Subscription Agreement shall be binding upon Subscriber and its transferees, heirs, successors and assigns (collectively, "Transferees"); provided that for any such transfer to be deemed effective, the Transferee shall have executed and delivered to the Company in advance an instrument in a form acceptable to the Company in its sole discretion, pursuant to which the proposed Transferee shall acknowledge, agree, and be bound by the representations and warranties of Subscriber, and the terms of this Subscription Agreement.

2. PURCHASE PROCEDURE.

The purchase price for the Preferred Shares shall be paid either (a) in full, simultaneously with Subscriber's subscription or (b) on a monthly basis in the amount set forth on the signature page. Subscriber shall deliver payment for the aggregate purchase price of the Preferred Shares by a check for available funds made payable as directed by the Company, by ACH electronic transfer, credit card, debit card, or wire transfer to an account designated by the Company, or by any combination of such methods. Payment for the Preferred Shares shall be received as directed by the Company, from the undersigned by check, ACH electronic transfer credit card, debit card, or wire transfer of immediately available funds at least two days prior to the applicable Closing Date, in the amount or amounts as set forth on the signature page hereto. The undersigned shall receive notice and evidence of the digital entry of the number of the Preferred Shares owned by undersigned reflected on the books and records of the Company, which books and records shall bear a notation that the Preferred Shares were sold in reliance upon Regulation A. If the Subscriber elects to purchase on a monthly basis, the Subscriber may terminate the Subscriber's monthly payment at any time.

------

3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

The Company represents and warrants to Subscriber that the following representations and warranties are true and complete in all material respects as of the date of each Closing Date, except as otherwise indicated. For purposes of this Agreement, an individual shall be deemed to have "knowledge" of a particular fact or other matter if such individual is actually aware of such fact. The Company will be deemed to have "knowledge" of a particular fact or other matter if one of the Company's current officers has, or at any time had, actual knowledge of such fact or other matter.

(a) Organization and Standing. The Company is a corporation duly formed, validly existing and in good standing under the laws of the State of Delaware. The Company has all requisite power and authority to own and operate its properties and assets, to execute and deliver this Subscription Agreement, and any other agreements or instruments required hereunder. The Company is duly qualified and is authorized to do business and is in good standing as a foreign corporation in all jurisdictions in which the nature of its activities and of its properties (both owned and leased) makes such qualification necessary, except for those jurisdictions in which failure to do so would not have a material adverse effect on the Company or its business.

(b) Issuance of the Preferred Shares. The issuance, sale and delivery of the Preferred Shares in accordance with this Subscription Agreement has been duly authorized by all necessary corporate action on the part of the Company. The Preferred Shares, when so issued, sold and delivered against payment therefor in accordance with the provisions of this Subscription Agreement will be duly and validly issued, fully paid and non-assessable.

4. REPRESENTATIONS AND WARRANTIES OF SUBSCRIBER. By executing this Subscription Agreement, Subscriber (and, if Subscriber is purchasing the Preferred Shares subscribed for hereby in a fiduciary capacity, the person or persons for whom Subscriber is so purchasing) represents and warrants, which representations and warranties are true and complete in all material respects as of such Subscriber's respective Closing Date(s):

(a) Requisite Power and Authority. Such Subscriber has all necessary power and authority under all applicable provisions of law to execute and deliver this Subscription Agreement and other agreements required hereunder and to carry out their provisions. All action on Subscriber's part required for the lawful execution and delivery of this Subscription Agreement and other agreements required hereunder have been or will be effectively taken prior to the Closing Date. Upon their execution and delivery, this Subscription Agreement and other agreements required hereunder will be valid and binding obligations of Subscriber, enforceable in accordance with their terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors' rights, and (ii) as limited by general principles of equity that restrict the availability of equitable remedies.

(b) Investment Representations. Subscriber understands that the Preferred Shares have not been registered under the Securities Act. Subscriber also understands that the Preferred Shares are being offered and sold pursuant to an exemption from registration contained in the Securities Act based in part upon Subscriber's representations contained in this Subscription Agreement.

(c) Illiquidity and Continued Economic Risk. Subscriber acknowledges and agrees that there is no public market for the Preferred Shares and that there is no guarantee that a market for their resale will ever exist. Subscriber must bear the economic risk of this investment indefinitely. Subscriber acknowledges that Subscriber is able to bear the economic risk of losing Subscriber's entire investment in the Preferred Shares. Subscriber also understands that an investment in the Company involves significant risks and has taken full cognizance of and understands all of the risks relating to the purchase of the Preferred Shares and an investment in the Company, including those risks set forth in the Offering Circular and in the Company's filings with the SEC.

(d) Subscriber Determination of Suitability. Subscriber has evaluated the risks of an investment in the Preferred Shares including those described in the section of the Offering Circular captioned "Risk Factors", and has determined that the investment is suitable for Subscriber. Subscriber has adequate financial resources for an investment of this character, and at this time Subscriber could bear a complete loss of Subscriber's investment in the Company.

------

(e) Accredited Investor Status or Investment Limits. Subscriber represents that either:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)Subscriber is an "accredited investor" within the meaning of Rule 501 of Regulation D under the Securities Act. Subscriber represents and warrants that the information set forth in response to question (c) on the signature page hereto concerning Subscriber is true and correct; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)The purchase price set out in the signature page to this Subscription Agreement, together with any other amounts previously used to purchase the Preferred Shares in this offering, does not exceed 10% of the greater of the Subscriber's annual income or net worth.

Subscriber represents that to the extent it has any questions with respect to its status as an accredited investor, or the application of the investment limits, it has sought professional advice.

5. SURVIVAL OF REPRESENTATIONS AND INDEMNITY. The representations, warranties and covenants made by the Subscriber herein shall survive the Termination Date of this Agreement. The Subscriber agrees to indemnify and hold harmless the Company and its respective officers, directors and affiliates, and each other person, if any, who controls the Company within the meaning of Section 15 of the Securities Act against any and all loss, liability, claim, damage and expense whatsoever (including, but not limited to, any and all reasonable attorneys' fees, including attorneys' fees on appeal) and expenses reasonably incurred in investigating, preparing or defending against any false representation or warranty or breach of failure by the Subscriber to comply with any covenant or agreement made by the Subscriber herein or in any other document furnished by the Subscriber to any of the foregoing in connection with this transaction.

6. JURISDICTION. The parties hereto hereby submit to the exclusive jurisdiction of any United States District Court for the District of Delaware and of any Delaware state court for purposes of all legal proceedings arising out of, or relating to, this Agreement or the transactions contemplated hereby. Each of the parties hereto hereby irrevocably waives, to the fullest extent possible, any objection it may now or hereafter have to the venue of any such proceeding and any claim that any such proceeding has been brought in an inconvenient forum. This shall not apply to claims arising under the Securities Act and the Exchange Act.

7. GOVERNING LAW. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO OR IN CONNECTION WITH THIS AGREEMENT, THE RELATIONSHIP OF THE PARTIES, AND/OR THE INTERPRETATION AND ENFORCEMENT OF THE RIGHTS AND DUTIES OF THE PARTIES WILL BE GOVERNED BY THE LAWS OF THE STATE OF DELAWARE WITHOUT REGARD TO ANY CONFLICTS OF LAW PRINCIPLE. THIS SHALL NOT APPLY TO CLAIMS ARISING UNDER THE SECURITIES ACT AND THE EXCHANGE ACT.

------

sending and receiving e-mail messages to and from the Company Parties. To print the documents, Subscriber will need access to a printer compatible with his or her hardware and the required software; (c) if these software or hardware requirements change in the future, a Company Party will notify the Subscriber through written notification. To facilitate these services, Subscriber must provide the Company with his or her current e-mail address and update that information as necessary. Unless otherwise required by law, Subscriber will be deemed to have received any electronic Communications that are sent to the most current e-mail address that the Subscriber has provided to the Company in writing; (d) none of the Company Parties will assume liability for non-receipt of notification of the availability of electronic Communications in the event Subscriber's e-mail address on file is invalid; Subscriber's e-mail or Internet service provider filters the notification as "spam" or "junk mail"; there is a malfunction in Subscriber's computer, browser, internet service or software; or for other reasons beyond the control of the Company Parties; and (e) solely with respect to the provision of tax documents by a Company Party, Subscriber agrees to each of the following: (1) if Subscriber does not consent to receive tax documents electronically, a paper copy will be provided, and (2) Subscriber's consent to receive tax documents electronically continues for every tax year of the Company until Subscriber withdraws its consent by notifying the Company in writing.

9. RELIANCE UPON REPRESENTATIONS. I understand that the Company is relying upon the accuracy of the representations and warranties which I have made in this agreement. I agree to indemnify the Company (and any control persons of such entities) for any loss they may suffer as the result of any false or misleading warranty, representation or statement of facts which I have made in connection with the purchase of the Securities.

10. APPLICABLE LAW/ARBITRATION. This Subscription Agreement shall be governed by and construed in accordance with the laws of Delaware and, to the extent it involves any United States statute, in accordance with the laws of the United States. Any dispute, claim or controversy involving this Subscription Agreement, or the circumstances surrounding the sale of the securities described in this Subscription Agreement shall be settled through binding arbitration in accordance with the Commercial Rules of the American Arbitration Association in Newark, New Jersey.

11. NOTICES. Notice, requests, demands and other communications relating to this Subscription Agreement and the transactions contemplated herein shall be in writing and shall be deemed to have been duly given if and when (a) delivered personally, on the date of such delivery; or (b) mailed by registered or certified mail, postage prepaid, return receipt requested, in the third day after the posting thereof; or (c) emailed on the date of such delivery to the address of the respective parties as follows:

If to the Company:61 W. Palisade Ave.

Englewood, NJ 0763

If to a Subscriber, to the Subscriber's address as shown on the signature page hereto or to such other address as may be specified by written notice from time to time by the party entitled to receive such notice.

12. MISCELLANEOUS.

(a) All pronouns and any variations thereof shall be deemed to refer to the masculine, feminine, neuter, singular or plural, as the identity of the person or persons or entity or entities may require.

(b) This Subscription Agreement is not transferable or assignable by Subscriber.

(c) The representations, warranties and agreements contained herein shall be deemed to be made by and be binding upon Subscriber and its heirs, executors, administrators and successors and shall inure to the benefit of the Company and its successors and assigns.

(d) None of the provisions of this Subscription Agreement may be waived, changed or terminated orally or otherwise, except as specifically set forth herein or except by a writing signed by the Company and Subscriber.

(e) In the event any part of this Subscription Agreement is found to be void or unenforceable, the remaining provisions are intended to be separable and binding with the same effect as if the void or unenforceable part were never the subject of agreement.

------

(f) The invalidity, illegality or unenforceability of one or more of the provisions of this Subscription Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Subscription Agreement in such jurisdiction or the validity, legality or enforceability of this Subscription Agreement, including any such provision, in any other jurisdiction, it being intended that all rights and obligations of the parties hereunder shall be enforceable to the fullest extent permitted by law.

(g) This Subscription Agreement supersedes all prior discussions and agreements between the parties with respect to the subject matter hereof and contains the sole and entire agreement between the parties hereto with respect to the subject matter hereof.

(h) The terms and provisions of this Subscription Agreement are intended solely for the benefit of each party hereto and their respective successors and assigns, and it is not the intention of the parties to confer, and no provision hereof shall confer, third-party beneficiary rights upon any other person.

(i) The headings used in this Subscription Agreement have been inserted for convenience of reference only and do not define or limit the provisions hereof.

(j) This Subscription Agreement may be executed in any number of counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.

(k) If any recapitalization or other transaction affecting the capital stock of the Company is effected, then any new, substituted or additional Preferred Shares or other property which is distributed with respect to the Preferred Shares shall be immediately subject to this Subscription Agreement, to the same extent that the Preferred Shares, immediately prior thereto, shall have been covered by this Subscription Agreement.

(l) No failure or delay by any party in exercising any right, power or privilege under this Subscription Agreement shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law.

13. SUBSCRIPTION PROCEDURE FOR ONLINE PLATFORMS ONLY.

Each Subscriber, by providing his or her name and subscription amount and clicking "accept" and/or checking the appropriate box on the Platform ("Online Acceptance"), confirms such Subscriber's investment through the Platform and confirms such Subscriber's electronic signature to this Agreement. Subscriber agrees that his or her electronic signature as provided through Online Acceptance is the legal equivalent of his or her manual signature on this Agreement and Online Acceptance establishes such Subscriber's acceptance of the terms and conditions of this Agreement.

------

Please make your check payable to:

Enterprise Bank & Trust, Escrow Agent for SpotitEarly, Inc.

Checks should be sent to: ENTERPRISE BANK

150 N. Meramec Avenue Clayton, MO 63105

If a check is preferred, please include the check (personal or corporate account is acceptable - cashier's check is not required) with the signed subscription agreement to the address above by overnight delivery.

A wire transfer for payment of the subscription to the bank account below is easiest for processing.

**WIRE INSTRUCTIONS:**

ABA # XXXXXXX ENTERPRISE BANK

150 N. MERAMEC AVENUE, CLAYTON MO 63105

CREDIT CLIENT'S NAME & ACCOUNT NUMBER

Account Name: Enterprise Bank & Trust, Escrow Agent for SpotitEarly, Inc.

Account Number: XXXXXXX

**One Time Purchase:**

Amount: $____________

Number of shares: ___________

**Monthly Purchase:**

Monthly Purchase amount: $____________

Number of shares: ___________

**Subscriber details:**

Name:

Street Address:

City:

State:

Postal Code:

Country:

Phone Number:

Email Address:

IN WITNESS WHEREOF, the undersigned has executed this Subscription Agreement on the date set forth below.

_________________, 2025 _________________________________ <br> Date Name of Subscriber

---

| | |
|:---|:---|
| $_________________ | _________________________________ |
| Subscription Amount | Signature |

---

__________________ _________________________________ <br> # of Shares Title (if the Subscriber is not a natural person)

------

The foregoing subscription is hereby accepted on behalf of SpotitEarly Inc., this ______ day of _________________, 2025.

---

| |
|:---|
| SPOTITEARLY, INC. |
| By: |
| Name: |
| Title: |

---

------

## Ex1A-6

------

**EXHIBIT 6**

**Manhattan Street Capital Engagement Agreement**

Effective Date: April 16, 2025

SpotitEarly Inc.

61 W Palisade Ave,

Englewood,

NJ 07631

Re: Advisory, Technology and Administrative Services

This agreement (this "Agreement") will confirm the arrangements under which FundAthena, Inc., DBA Manhattan Street Capital, Inc. ("MSC") and Spotitearly, Inc., a Delaware Corporation, and its present and future subsidiaries and any entity used thereby to facilitate the Financings contemplated hereby (collectively, the "Client"), to act as the Client's advisor in connection with a possible Financing (as defined below) and the Client's use of MSC's proprietary technology platform (the "MSC Platform").

1. Retention. During the term of this engagement, and as mutually agreed upon by MSC and the Client, MSC shall provide Client with project management, technology, administrative services and assistance with and introductions to resources needed to conduct Reg A+ Reg D and Reg S offering campaigns, (any of the foregoing, a "Financing"). Client agrees to be bound by the MSC Platform standard terms and conditions in connection with any actions and obligations specifically arising from Company's use of the MSC Platform, (the "Platform Terms") which are attached hereto. Access to the MSC Platform will not be provided without Client's acceptance of the Platform Terms.

2. Cooperation. The Client shall furnish MSC and/or upload to the MSC Platform all current and historical materials and information regarding the business and financial condition of the Client that are in its possession and relevant to, and reasonably required for, the Financing, and all other information and data, and access to the Client's officers, directors, employees and professional advisors, which MSC reasonably requests in connection with MSC's activities hereunder. All such materials, information and data shall be to the Client's knowledge, complete and accurate in all material respects and not misleading. Client understands that MSC is not and does not provide any assurance that the contemplated Financing(s) will succeed, or that they will achieve any particular performance level or cost efficiency. The Client agrees to promptly advise MSC of all developments materially affecting the Client, any proposed Financing or the completeness or accuracy of the information previously furnished to MSC, and agrees that no material initiatives relating to the proposed Financing will be taken without MSC having been consulted in advance thereof.

MSC undertakes, warrants and represents that (i) it will comply with all applicable federal, state, and local laws, regulations, and ordinances in connection with the services provided under this Agreement; (ii) it possesses the necessary expertise, experience, and resources to provide the services outlined in this Agreement; (iii) it will take reasonable steps to provide the Client with timely and accurate information regarding any material changes to applicable regulations or the status of compliance that impact the services or the Client's obligations recognizing that MSC is not a securities attorney; and (iv) it will facilitate necessary guidelines to support the Client's offerings

3. Compensation. The Client agrees to promptly pay MSC the MSC Fees (the "Fees"), listed below:

a) Project management retainer fee of $10,000 USD paid monthly in advance. The first 3-month period from the Effective Date will be paid in advance upon execution of the agreement, and the same value (i.e. $10,000 USD) of ten-year cashless exercise warrants for Preferred Class A1 non-voting shares (the "Warrant Shares") will be paid at the end of each 3-month period (for such 3 month period based on the warrant amount that was earned during such period), at a price of $5.55 per share.

The monthly fee will be paid from the Effective Date and will continue while the offering is active in any of these formats; Reg D, Reg A+ or Reg S. The warrant fee will be paid from January 1<sup>st</sup> 2025.

b) MSC technology admin and service fees;

------

Reg A+;

$25.00 USD per investment in the Reg A+ Financing made through the MSC Platform, and the same value of ten-year cashless exercise warrant for Warrant Shares with a price per share of $5.55. The MSC technology admin and service fee is constant regardless of the investment amount, and it is not dependent on the total size of the capital raised. For purposes of calculating this fee, an "investment" is defined as a transaction where a person or entity invests money as part of the Financing through the MSC platform. The number of Warrant Shares will be determined by dividing the product of $25.00 and the total number of investments in this offering, by $5.55.

<br>For investments made in the Reg A+ Financing through the MSC Platform by US IRA accounts, Trusts or by US companies, LLCs or LPs, MSC charges a per investment technology, admin, and service fee of $100 instead plus warrants defined and calculated as described above using the $100 fee.

For investments made in the Reg A+ through the MSC Platform by US Investment Entities (VC firms, Private Equity firms, Family Offices, investment management companies and similar), MSC charges a per investment technology, admin, and service fee of $5,000 instead plus warrants defined and calculated as described above using the $5000 fee

Reg D;

<br>For Reg D investments by individuals made through the MSC Platform, a fee of $250.00 USD (plus $50 for Accreditation verification) per investment in the Red D Financing, and the same value of ten-year cashless exercise warrants for Warrant Shares priced at $5.55 per share.

The MSC technology admin, verification and service fee is constant regardless of the investment amount, and it is not dependent on the total size of the capital raised. For purposes of calculating this fee, an investment is defined as a transaction where a person or entity invests money as part of this Financing through the MSC Platform. The number of warrant shares will be determined by dividing the product of $250.00 and the total number of investments made by these individuals in this offering, by $5.55. The $250 plus $50 MSC technology admin, verification and service fee includes fees for accreditation verification of US Reg D investors, which may be paid to third-party service providers on behalf of the Client.

For investments made in the Reg D Financing through the MSC Platform by US IRA accounts Trusts or by US companies, LLCs or LPs, MSC charges a per investment technology, admin, and service fee of $1,000 instead plus warrants defined and calculated as described above using the $1000 fee.

For investments made in the Reg D Financing through the MSC Platform by US Investment Entities (VC firms, Private Equity firms, Family Offices, Investment management companies and similar), MSC charges a per investment technology, admin, and service fee of $5,000 instead plus warrants defined and calculated as described above using the $5000 amount.

Reg S:

For Reg S investments made by individuals through the MSC Platform, a fee of $25.00, and the same value of ten-year cashless exercise warrants for Warrant Shares at a price of $5.55 per share. The MSC technology admin, verification and service fee is constant regardless of the investment amount, and it is not dependent on the total size of the capital raise. For purposes of calculating this fee, an investment is defined as a transaction where a person or entity invests money as part of the Financing through the MSC's platform. The number of warrants will be determined by dividing the product of $25.00 and the total number of investments made by these individuals in this Financing, by $5.55.

For investments made in Reg S Financing through the MSC Platform by non-US corporate entities and Trusts, MSC charges a per investment technology, admin, and service fee of $100 instead plus warrants defined and calculated as described above applied to the $100 amount.

For investments made in Reg S Financing through the MSC Platform by non-US Investment Entities (VC firms, Private Equity firms, Family Offices, investment management companies and similar), MSC charges a per investment technology, admin, and service fee of $5,000 instead plus warrants defined and calculated as described above applied to the $5,000 amount

------

To clarify, the fee obligations described in Section 3b will only apply to investments initiated as part of Financing through the MSC Platform during the term of this Agreement. These fee obligations will not apply to any investments in that Financing that were initiated or presented to their respective investors after this Agreement has terminated or expired or that were initiated or presented to investors during this agreement outside of the MSC platform.

c) Listing fee of $5,000 USD per month while the offering is live for investment or reservations, including TestTheWaters (TM), and the same value of ten-year cashless exercise warrants for Warrant Shares priced at $5.55 per share.

The MSC Fees above do not include fees for back-end services including, but not limited to: payment processing, digital currency conversion, escrow and technology fees. Back-end service fees paid by MSC may be paid to third-party service providers on behalf of the Client, and will be invoiced by MSC to Client, subject to the receipt of Client's prior written approval before such fees are incurred. MSC fees above do not include costs for marketing agency, legal service provider, broker-dealer or transfer agent. Reasonable direct expenses incurred by MSC on behalf of Client will be reimbursed by Client, subject to the receipt of Client's prior written approval before such expenses are incurred.

It is expressly understood that all MSC Fees are not contingent on the success of reaching the total fundraising amount of the Financing. The Fees are an obligation of the Client regardless of the final outcome of the Financing.

It is expressly understood that a separate MSC Service Fee shall be payable in respect to each Financing in the event that more than one Financing occurs. Examples may include the addition of a Reg D convertible note offering proceeding or in parallel with the Reg A+ offering, or a simultaneous regional Reg A+ offering in another region. In the event of an additional Financing, the rates listed above shall apply on such additional Financing, unless otherwise agreed by the parties.

Payment terms.

Project management retainer fees will be invoiced monthly by MSC, 15 days prior to the first day of the service period. Cash payment will be due on the first day of the service period.

MSC technology admin and service fees will be invoiced periodically by MSC, at the close of each period for the previous period. Cash payment will be due 15 days from date of invoice.

Listing fees will be invoiced monthly by MSC, at the close of the month for the previous month period. Cash payment will be due 15 days from date of invoice.

Back-end service fees will be invoiced monthly by MSC, at the close of the month for the previous month period, with the exception of monthly escrow and platform license fees which will be billed in advance for current month. Cash payment will be due 15 days from date of invoice.

Delinquent invoices, 15 days past due, are subject to interest of 1.0% per month on any outstanding balance, or the maximum permitted by law, whichever is less, plus all expenses of collection. MSC reserves the right to suspend your listing on the MSC Platform and pause advisory services if your account becomes delinquent.

Delivery of warrants.

During the course of the Financing there will be two separate issuances of Warrants as described below:

a) The first Warrant will represent the amount earned as Project management retainer fees up front for the first three months, as defined in section 3a above, and will be delivered upon the initial execution of this Agreement in the form approved by both parties, and attached to this Agreement as Appendix 1 - Warrant Agreement.[ For purposes of the earning of Warrant Project Management Fees, the date of commencement of the Project Management monthly and subsequent months is January 1<sup>st</sup> 2025, at the rate of $10k per month consistent with the temporary engagement of MSC that began Jan 1<sup>st</sup> 2025.

b) The second and subsequent Warrant deliveries will be earned during the course of the Financing, and will represent warrants earned as Project Management, MSC technology admin and service fees and Listing fees, as defined in

------

Sections 3a, 3b and 3c above. The Client commits to deliver these warrants quarterly from the Effective Date within 15 days of the completion of each Quarter, or the termination of the Financing, in the form, approved by both parties, and attached to this Agreement as Appendix 1 - Warrant Agreement.

It is expressly understood that warrants are not contingent on the success of the offering. The delivery of warrants are an obligation of the Client regardless of the outcome of the offering.

The Warrants will have an exercise price per share of $5.55, and will terminate upon the earlier to occur of (i) the lapse of 10 years from the date of the issuance of each warrant; or (ii) a Deemed Liquidation Event (as defined below in the Warrant agreement – Appendix 1).

4. Confidentiality. Each party acknowledges that, in the course of evaluating the Financing and in connection with this Agreement, it (the "Receiving Party") may obtain information relating to the other party's business (the "Disclosing Party") (all such information the "Confidential Information"). Such Confidential Information shall belong solely to the Disclosing Party. For sake of clarity, information is considered Confidential Information for so long as it has not been made known to the general public by the Disclosing Party or through the rightful actions of a third party, and for so long as the information holds value, as reasonably determined by the Disclosing Party, by virtue of remaining confidential. During the Term and after its termination, the Receiving Party: (a) shall not use, other than as required for the Financing, or disclose Confidential Information without the prior written consent of the Disclosing Party, or unless such Confidential Information becomes part of the public domain without breach of this Agreement by the Receiving Party, its officers, directors, employees or agents; (b) agrees to take all reasonable measures to maintain the Confidential Information in confidence, but not less than those it takes to safeguard its own confidential information; and (c) will disclose the Confidential Information only to those of its employees and consultants as are necessary for the uses licensed hereunder and are bound by obligations of confidentiality. Upon the termination of this Agreement, the Receiving Party shall return or destroy all Confidential Information, as requested by the Disclosing Party.

5. Termination. The Agreement has a term of 24 months from execution, unless terminated by either party for any or no reason by providing the other party with forty five (45) days prior written notice. Upon any termination of this Agreement, the rights and obligations of the parties hereunder shall terminate, except for the following: (a) Company shall remain obligated to pay the service fees set forth in Sections 3b, but only for investments made by investors who were introduced to the Company through MSC's Platform prior to the termination date. (b) Company shall have no obligation to continue paying project management retainer fee under Section 3a after the effective date of termination; (c) the obligations set forth in Section 3c (for the period prior to termination), 4 and 7-9 (inclusive), which shall survive termination of this Agreement.. The agreement will automatically renew at its end date unless one or both parties indicate in writing within 30 days of the end date that they want to prevent auto renewal. Each renewal term shall be for a period of 12 months and subject to the same terms and conditions as set forth herein, unless otherwise agreed in writing. For purposes of this Agreement, an investor shall be deemed 'introduced' to the Company through MSC's Platform when such investor first registers interest in the Company's offering through the MSC Platform or is otherwise directly connected to the Company by MSC prior to the termination date.

6. Exclusivity. Notwithstanding else to the contrary in the Platform Terms, during the term of this Agreement, the Client will not, and will not permit any security holder, affiliate, advisor or representative of the Client to engage any other party to perform any services or act in any capacity which is related to, or comparable, to the Financing without the prior written approval of MSC. For the avoidance of doubt, the Client may engage founders or its internal representatives to directly approach investors outside of the MSC platform during the offering.

7. Indemnification. Client agrees to indemnify and hold harmless MSC and its affiliates, and each of their respective officers, directors, managers, members, partners, employees and agents, and any other persons controlling MSC or any of its affiliates (collectively, "Indemnified Persons"), to the fullest extent lawful, from and against any claims, liabilities, losses, damages, costs and expenses (or any action, claim, suit or proceeding in respect thereof), as incurred, related to or arising out of or in connection with MSC services (whether occurring before, at or after the date hereof) under the Agreement, the Financing or any proposed Financing contemplated by the Agreement or any Indemnified Person's role in connection therewith ("Losses"), provided, however, that the Client shall not be responsible for any Losses that arise out of or are based on any action of or failure to act by MSC to the extent such Losses are determined, by a final, non-appealable judgment by a court, to have resulted primarily and directly from MSC's gross negligence or willful misconduct.

------

8. Limitation on Liability. EXCEPT FOR A PARTY'S BREACH OF SECTION 3, CONFIDENTIALITY OBLIGATIONS OR CLIENT'S INDEMNIFICATION OBLIGATIONS, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OF ANY NATURE, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, AND REGARDLESS OF WHETHER THE CLAIM OR LIABILITY IS BASED UPON ANY CONTRACT, TORT, BREACH OF WARRANTY OR OTHER LEGAL OR EQUITABLE THEORY.

EXCEPT FOR A PARTY'S BREACH OF SECTION 3, CONFIDENTIALITY OBLIGATIONS OR CLIENT'S INDEMNIFICATION OBLIGATIONS, THE TOTAL LIABILITY OF EITHER PARTY, WHETHER BASED IN CONTRACT, TORT (INCLUDING NEGLIGENCE OR STRICT LIABILITY), OR OTHERWISE, WILL NOT EXCEED, IN THE AGGREGATE, THE FEES PAID TO MSC. THE FOREGOING LIMITATIONS WILL APPLY NOTWITHSTANDING ANY FAILURE OF ESSENTIAL FINANCING OF ANY LIMITED REMEDY.

9. Independent Contractor. The Client acknowledges and agrees that (i) MSC will act as an independent contractor hereunder, its responsibility is solely owed to the Client and contractual in nature, and MSC does not owe the Client, or any other person or entity (including, without limitation, any security holders, affiliates, creditors or employees of the Client), any fiduciary or similar duty as a result of its engagement hereunder or otherwise; (ii) MSC and its affiliates will not be liable for any losses, claims, damages or liabilities arising out of the actions taken, omissions of or advice given by other parties who are providing services to the Client; (iii) MSC is not an advisor as to legal, tax, accounting or regulatory matters in any jurisdiction; (iv) the Client has consulted, and will consult, as appropriate, with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of this Agreement and the Financings contemplated hereby, and that MSC and its affiliates shall have no responsibility or liability with respect thereto; and (v) the Client is capable of evaluating the merits and risks of such Financings and the fees payable in connection therewith and that it understands and accepts the terms, conditions, and risks of such Financings and fees.

10. Dispute Resolution, Mediation, and Arbitration: MSC and the Client shall attempt in good faith to resolve any dispute arising out of or related to this Agreement promptly by negotiation between MSC and a representative of the Client who has authority to settle the controversy on behalf of the Client. Either party may give the other party written notice of any dispute not resolved in the normal course of business. Within five (5) days after delivery of notice of any dispute, the receiving party shall submit to the other a written response. The notice and the response shall include a statement of each party's position, a summary of arguments supporting that position and shall include a reference to any authority available to support the position. Within fifteen (15) days after delivery of the disputing party's notice, the parties shall meet in person at a mutually acceptable time and place, or by phone, and thereafter as often as they reasonably deem necessary, to attempt to resolve the dispute. All reasonable requests for information made by one party to the other will be honored.

a) Mediation. If the matter has not been resolved within thirty (30) days of the disputing party's first notice, or if the parties fail to meet within fifteen (15) days, either party may initiate mediation of the controversy or claim before a mediator appointed by the mediation service JAMS. In any event, the parties agree first to try in good faith to settle any dispute by negotiation and mediation before resorting to arbitration or any other dispute resolution procedure.

b) Arbitration. If the parties are unable to resolve the matter through mediation within 15 (days) of beginning mediation, then any controversy or claim arising out of or relating to this Agreement or any alleged breach thereof shall be settled by binding arbitration by a single arbitrator appointed by the arbitration service JAMS, and judgment upon the award rendered by the arbitration shall be final and may be entered in any court having jurisdiction. (Notwithstanding the foregoing, nothing in this Agreement shall be interpreted to bar any party hereto from seeking injunctive relief with respect to any controversy or claim arising out of or relating to this Agreement.) The arbitrators shall comply with the commercial arbitration rules of the American Arbitration Association as then in effect. The arbitration shall be conducted, unless the parties otherwise agree, in San Diego, California, United States of America.

11. Miscellaneous. This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware and all claims shall be exclusively commenced in the state or federal courts located in Wilmington, Delaware. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof, and may not be amended or modified except in writing signed by each party hereto; provided, however, that if Client agrees to the Platform Terms, the Platform Terms shall govern Client's use of the MSC Platform and to the extent there is a conflict or inconsistency between this Agreement and the Platform Terms, this Agreement shall control and take precedence. This Agreement may not be assigned by Client hereto without the prior written consent

------

of MSC. Any attempted assignment of this Agreement made without such consent shall be void and of no effect. This Agreement is solely for the benefit of the Client and MSC. If any provision hereof shall be held by a court of competent jurisdiction to be invalid, void or unenforceable in any respect, or against public policy, such determination shall not affect such provision in any other respect nor any other provision hereof. Headings used herein are for convenience of reference only and shall not affect the interpretation or construction of this Agreement. This Agreement may be executed in facsimile or other electronic counterparts, each of which will be deemed to be an original and all of which together will be deemed to be one and the same document. This Agreement has been reviewed by each of the signatories hereto and its counsel. There shall be no construction of any provision against MSC because this Agreement was drafted by MSC, and the parties waive any statute or rule of law to such effect.

Please sign below and return to MSC to indicate the Client's acceptance of the terms set forth herein, and once executed by each of MSC and the Client, this Agreement shall constitute a binding agreement between the Client and MSC as of the date first written above.

Signed: _______________________Printed Name:Roi Ophir

Title: _______________________Telephone: _____________

SpotitEarly Inc.

61 W Palisade Ave,

Englewood,

NJ 07631

Signed: ________________________Printed Name:Rod Turner

Title: CEO Telephone: 760-622-9566

FundAthena, Inc., D/B/A Manhattan Street Capital.

5694 Mission Center Road, Suite 602-468<br>San Diego CA 92108

------

**APPENDIX 1 – WARRANT AGREEMENT**

Warrant No. XXX

Right To Purchase 000,000 Securities of Company Name

**STOCK PURCHASE WARRANT**

THIS WARRANT entitles FundAthena, DBA Manhattan Street Capital, or its assignees, to purchase on or before a date 10 years from the Issue Date, XX shares of fully paid, non-assessable Preferred Class A1 non-voting securities of SpotitEarly Inc., a Delaware Corporation ("this Company") at an exercise price of $5.55 per security (the "Exercise Price"), on exercise of this Warrant together with presentation of the full exercise price, or the election of cashless exercise, subject to the terms and conditions set forth below and to the satisfaction of the requirements of the state and federal corporate and securities laws.

Issue Date: _________________SpotitEarly Inc.

By: ______________________

Name: ______________________

Its: ______________________

------

**TERMS AND CONDITIONS**

1. While then warrants are exercisable, this Company shall reserve a sufficient number of securities to provide for the delivery of stock pursuant to this and other warrants.

2. Any changes in the structure of this Company or in its outstanding securities that affect the rights and participation to which the holder of this warrant would be entitled as of the date of exercising this warrant shall result in the proportionate adjustment of the shares that may be purchased pursuant to this Warrant.

3. Until the valid exercise of this Warrant, the holder shall not be entitled to any shareholder rights.

4. To exercise this Warrant, the exercise form below must be completed and delivered to the warrant agent, together with the exercise price.

5. This Warrant may not be sold, transferred, assigned or hypothecated without the prior written consent of the Company. .

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Term. This Warrant may be exercised, in whole or in part, during the period beginning on the date hereof and ending on the date which is the earlier of (i) ten (10) years following the date of this Warrant;; or (b) immediately prior to the consummation of a Deemed Liquidation Event (as defined below)

"Deemed Liquidation Event" shall mean (i) the closing of a transaction involving the sale of all or substantially all of the Company's assets; or (ii) the merger or consolidation of the Company with another entity, as a result of which the stockholders of the Company prior to such event do not own, by virtue of their shareholdings in the Company prior to such event, a majority of the shares of the surviving entity (which surviving entity may be the Company), or (iii) sale, assignment or disposal by the Company of all or substantially all of the issued and outstanding shares of the Company; or (iv) the transfer, sale, lease, grant or other disposition of or the grant of an exclusive license over all or substantially all of its assets with the same economic effect to that of a sale of all or substantially all of the assets of the Company and its subsidiaries taken as a whole; or (v) any other transaction, except for a financing round, following which the stockholders of the Company prior to the closing of such transaction own, directly and indirectly, by virtue of their shareholdings in the Corporation prior to such transaction, less than 50% (fifty percent) of the voting power of the surviving entity; in each case other than a sale to a wholly owned subsidiary of the Company or a reorganization for the purpose of change of domicile that does not affect the percentage ownership interest of the stockholders

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Cashless Exercise. The Holder of this Warrant may also exercise this Warrant as to any or all of the Securities and, in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate Purchase Price, elect instead to receive upon such exercise a reduced number of Securities (the "Net Number") determined according to the following formula (a "Cashless Exercise"):

Net Number = A x (B - C)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;---------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B

------

For purposes of the foregoing formula:

A= the total number of Securities with respect to which this Warrant is then being exercised in a Cashless Exercise.

B= the Market Price on the Trading Day immediately preceding the date of the Exercise of the warrants.

C= the Exercise Price for the applicable Securities at the time of such exercise.

There cannot be a Cashless Exercise unless "B" exceeds "C."

**Illustrative Example:** For the avoidance of doubt, the following example demonstrates the calculation of the Net Number of shares to be issued upon a cashless exercise of the warrants. If MSC elects to exercise 10,000 warrants on a cashless basis when the Market Price on the Trading Day immediately preceding the exercise is $8.00 per share and the Exercise Price is $5.00 per share, the Net Number of shares to be issued shall be calculated as follows:

Net Number = 10,000×(8-5)/8=10,000×3/8=3,750 shares

Accordingly, upon the exercise of 10,000 warrants, MSC shall receive 3,750 common shares without any cash payment required.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)For the purpose of this Warrant, the term "Trading Day" means (x) if the Securities are not listed on the NYSE Euronext or NYSE AMEX but sale prices of the Securities are reported on Nasdaq Global Market, Nasdaq Global Select Market, Nasdaq Capital Market or another automated quotation system, a day on which trading is reported on the principal automated quotation system on which sales of the Securities are reported, (y) if the Securities are listed on the NYSE Euronext or NYSE AMEX, a day on which there is trading on such stock exchange, (z) if clauses (x) and (y) are both inapplicable, a day on which quotations are reported by National Quotation Bureau Incorporated, or, if clauses (x), (y) and (z) are each inapplicable, any day which is not a Saturday, a Sunday or a day on which banking institutions are not required to be open in the State of New York.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)For the purpose of this Warrant, the term "Market Price" means, of any date, the value of the Security determined as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)If the Security is listed on any established stock exchange or a national market system, including without limitation the NYSE Euronext, NYSE AMEX, Nasdaq Global Market, the Nasdaq Global Market Select or the Nasdaq Capital Market, its Market Price will be the closing sales price for such stock (or the closing bid, if no sales were reported) as quoted on such exchange or system on the day of determination, as reported in *The Wall Street Journal* or such other source as the parties hereto mutually agree;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)If the Security is regularly quoted by a recognized securities dealer but selling prices are not reported, the Market Price will be the mean between the high bid and low asked prices for the Security on the day of determination (or, if no bids and asks were reported on that date, as applicable, on the last trading date such bids and asks were reported), as reported in *The Wall Street Journal* or such other source as the parties hereto mutually agree; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)In the absence of an established market for the Security, the Market Price will be determined in good faith by the Board, and agreed upon by both parties.

------

**EXERCISE OF WARRANT**

We hereby elect to exercise the purchase rights, pursuant to the provisions of the Warrant, as follows:

_______Securities, and tenders herewith payment in cash of the Purchase Price for the Securities in full, together with all applicable transfer taxes, if any.

_______Cashless Exercise with respect to the Net Number of Securities.

Securities subscribed for: _________

Subscription price: $________

Total cost: $________

Net Number of Securities: $________ (In the event of cashless exercise)

Dated:_______________Company Name

By: _____________________

Name: ______________________

Its:__________________________

------

**TERMS OF USE**

FundAthena, Inc., a Delaware corporation doing business as "Manhattan Street Capital" ("Manhattan Street Capital" or "MSC"), brings together prospective investors and companies ("Company" or "Companies") seeking growth capital. On this website platform (the "Platform") companies seeking growth equity can post information about their business, fundraising plans and value proposition and solicit feedback and test interest from prospective investors and industry advisers that they can use to refine and improve their fundraising pitches and presentations before filing their offering documentation with the federal Securities and Exchange Commission ("SEC") under newly implemented Regulation A+ ("Reg A+"), which allows investors of all financial backgrounds and investment experience to participate in capital market investments. MSC also helps companies make their Reg D 506C offerings which are restricted to accredited investors and Reg S offerings which are restricted to non-US investors.

Whether you are a prospective investor, a Company seeking capital, a casual visitor or a registered user of the Platform, your use of the Platform is governed by the following terms and conditions ("Terms of Use"), as well as the Manhattan Street Capital Privacy Policy, Indemnification Terms below and other operating rules, minimum qualifications and cautions posted throughout the Platform or presented to you individually during the course of your use of the Platform (collectively, the "Agreed Terms"). The Agreed Terms govern your use of the Platform and Manhattan Street Capital reserves the right to update or replace the Agreed Terms any time without notice and you are advised to review the Agreed Terms for any changes when you visit the Platform even if you have not received a notification of changes as you are bound by them even if you have not reviewed them. Your viewing and use of the Platform after such change constitutes your acceptance of the Agreed Terms and any changes to such terms. If at any time you do not want to be bound by the Agreed Terms you should exit and cease using the Platform immediately.

Intended Use of Platform

Manhattan Street Capital provides a platform that enables businesses seeking growth advice and capital, individuals, and firms seeking investment opportunities and advisors seeking to support growing companies to gather in one place and utilize cutting-edge technologies and revolutionary advancements in the SEC's regulations to foster business and financial opportunity. Companies seeking feedback can post information about their business and fundraising goals on the Platform for others to view and assess and such posting does not mean that the Company has offered or agreed to complete an offering.

Manhattan Street Capital is not a broker-dealer or placement agent. At no time does Manhattan Street Capital offer, broker, advise, purchase, sell or otherwise transact in securities regulated by the SEC or federal or state law. Manhattan Street Capital does not accept, hold or transfer cash or securities. Manhattan Street Capital does not guarantee that a Company seeking investment will achieve any level of fundraising or that any proposed offering will qualify under applicable federal and state securities laws.

Manhattan Street Capital is not a personal financial advisor. Manhattan Street Capital, whether through the Platform or otherwise, does not provide personal financial advice, loans or credit, banking, consumer credit ratings, credit decisions, financial products, brokerage accounts, insurance, tax advice, legal advice, or financial or legal services of any kind. Even if featured on the Platform, unless expressly stated otherwise, Manhattan Street Capital does not provide endorsement to or for any advisor/Company seeking capital or investment opportunity.

Manhattan Street Capital does not guarantee any result to anyone. All users of the Platform are responsible for making their own decisions to use the Platform and for any activity taken on the Platform, including without limitation registering, posting information about their Company and any proposed financing, reserving an investment, making an investment or otherwise.

User Registration

You may browse the Platform without being a registered user, however, certain features are only accessible to registered users. If you are accepting the Agreed Terms on behalf of an organization or entity, rather than in an individual capacity, you represent and warrant that you are authorized to accept the Agreed Terms on that organization or entity's behalf and bind them to these Agreed Terms (in which case, the references to "you" and "your" in these Terms, except for in this sentence, refer to that organization or entity).

------

Only real persons at or above the age of 18 may register for an account and use the Platform. Registering for an account on the Platform creates no commitment or obligation on the registered user to make any investment or seek any investment. All information you provide to the Platform must be truthful, accurate and complete in all material respects. Our registration process may use third-party validation technology, including those provided by third-party social media sites, to attempt to confirm your qualification to use the Platform. Manhattan Street Capital may reject any application to register an individual or an organization or entity for failure to achieve validation through available methods or otherwise meet Manhattan Street Capital's registration requirements.

Your registration and the use of any third-party site is subject to the terms and conditions and policies of such sites and Manhattan Street Capital is not responsible or liable for any harm resulting from the use or misuse of those sites, including when such harm could or does affect your account on this Platform or use of the Platform. If you wish to disconnect your Platform account from your validation account, please following instructions provided on the Platform or contact our customer service department. Such disconnection may result in your inability to access your account.

Registered Account Obligations

The named registered user of an account is the only person that may use the account and it may not be transferred to anyone else. If you are a control person on a Company Offering page, you may transfer responsibility for the page to another individual through mechanisms made available on the Platform or by contacting customer service. If you represent a firm considering or managing an investment on the Platform or providing advisory services, your replacement representative must register for his/her own account and establish any links from that account that may be available on the site to the firm.

You are responsible for maintaining the confidentiality of your user name and password and to periodically change your password to maintain security. If you have concerns that your user name or password may have been compromised and suspect that unauthorized access to your account or the Platform has occurred, you must immediately contact Manhattan Street Capital's customer service through a secure method (which may not be through your Platform account).

Content Use Limitations

Your use of the Platform and its videos, webinars, images, infographics, alerts, texts, articles, assessments, checklists, forms, ratings, design, data, source code, analytics, photos, software, trademarks, copyrights, and other information ("Content") may only be used for the lawful and intended purposes expressly authorized by Manhattan Street Capital. If you access this Platform from outside the United States, you are solely responsible for ensuring compliance with the laws of your specific jurisdiction, as well as any restrictions that you may be subject to by a department of the United States government. Any misuse or unauthorized use of the Platform and its Content, or other violations of the Agreed Terms may violate Applicable Law (see below), including without limitation SEC regulations and applicable state securities laws, copyright laws (including the Digital Millennium Copyright Act), trademark laws, the laws of privacy, laws of publicity, identity theft and communications statutes and regulations, in which case Manhattan Street Capital is authorized to terminate your account and access to the Platform at any time and without notice and report you to the appropriate authorities and other interested parties, such as a claimed intellectual property owner. See Manhattan Street Capital's Privacy Policy for further information.

Even if such Content or activity does not violate Applicable Law, you are prohibited from posting or transmitting any material on or through the Platform that, in Manhattan Street Capital's sole opinion, is or could be offensive, fraudulent, unlawful, threatening, disingenuous, libelous, defamatory, obscene, scandalous, inflammatory, pornographic or profane, constitutes anti-competitive collaboration or antitrust violations, or any material that could constitute or encourage conduct that would be considered a criminal offense, give rise to civil liability, or otherwise violate any law. Manhattan Street Capital will fully cooperate with any law enforcement authorities or court order requesting or directing Manhattan Street Capital to disclose the identity of anyone posting any such information or materials on the Platform.

By posting Content on the Platform, you represent and warrant that you have all necessary rights to make the Content available on the Platform and acknowledge that all postings on the Platform are not confidential and are available for public viewing.

------

Prospective Investor Accounts

Any person or entity that is considering making or makes a reservation of investment with a Company that posts its fundraising plans on the Platform, or, after the fundraising plan becomes a qualified offering under the SEC's rules, makes an investment, does so at his or her own risk. All investment carries the risk that you may lose some or all of your investment. No Content on the Platform is a replacement for performing your own due diligence, exercising good judgment and seeking financial, investment, tax or legal advice from qualified and licensed professionals with knowledge of your personal circumstances. Any registered financial, legal or tax representatives or firm working for or with Manhattan Street Capital or communicating with you or users in general through the Platform are not your personal advisors and do not have knowledge about your personal circumstances and anything they post is for informational purposes only and may not be accurate to your situation and you agree that you shall not rely on Content on the Platform in making personal decisions about an investment or the potential legal, tax or financial consequences of such investment. You are encouraged to seek personal professional advice from qualified and licensed professionals.

You are solely responsible for your investment decisions. While you may be asked about your identity, individual financial circumstance and investment experience and sophistication during your engagement with the Platform, Manhattan Street Capital and its advisors and vendors are not responsible to verify the veracity of the information that you provide, even if you certify to its truth or undergo a suitability review. Whether you are an "Accredited Investor", as such is defined under securities law, or a non-accredited investor, or an institutional investor, Manhattan Street Capital and the Companies seeking investment are relying on your representations with respect to your investment experience, your financial status and your eligibility to invest. You may, further, be held personally liable for your fraud, negligence and other bad acts that may result from any false representations you make.

Company Accounts

Companies that establish Offerings on the Platform or that use the investment software included in the Platform to seek or process investments or loans or to seek feedback, including reservations on a potential fundraising and the potential offering of securities for purchase are bound to adhere to these Terms. The Company by virtue of posting or having a third party post Content on behalf of the Company provides Manhattan Street Capital and its affiliates a perpetual, irrevocable, non-exclusive license to the Content. Other Company employees and advisors with accounts may manage the Content on the Company page. Such individuals are responsible to and must accept, read and understand all policies, procedures, directions and communications from Manhattan Street Capital. No such individual may be an individual who is prohibited from making securities offerings in the United States or country of residence. The registered individuals and the Company are solely responsible for the Content that they post on the Platform, including any changes to the Content made by its employees and advisors. Each registered individual must disclose their affiliation with and interests in the Company in any Content, post or rating they make on the Platform with respect to their Company and offering, including pages outside the Company page. All Content posted on the Platform must be truthful, accurate and complete in all material respects. Manhattan Street Capital is not obligated to pre-screen, police, edit or monitor Content posted to the site by users. If any Content is found to be unlawful or fraudulent, the Content and the entire Company page may be removed by Manhattan Street Capital without notice. The Content may not be reposted until it is corrected. If it is believed to be uncorrectable by Manhattan Street Capital or its advisors, the registered individuals and the Company may be banned from the Platform.

All Companies seeking to post Content on this site about their business and fundraising plans, as well as their officers and directors, must apply for eligibility and are subject to certain verifications requirements with which they must cooperate. Manhattan Street Capital may request additional information to host your Company page on the Platform. Companies are advised to consult with appropriate and qualified legal counsel before making or registering any offering.

Each Company and registered individual associated with and posting for the Company is solely responsible for the Content such Company posts on the Platform and, by registering with the Platform and posting Content on the Platform represents and warrants that: (i) he/she/it has and will comply with all applicable laws, regulations, rules, ordinances, judgments, decrees, injunctions, arbitration awards or order of any governmental agency, authority and regulatory body or anybody duly authorized to exercise any administrative, judicial, executive, legislative, police, regulatory or taxing authority power or authority ("Applicable Law"); and (ii) such Content does not contain any untrue statement of a material fact or omit to state a material fact required to be stated or necessary to make such statements not

------

misleading in light of the circumstances under which they are made. The Company, further, is responsible for and shall take reasonable steps to determine the suitability of any prospective investor.

Platform Fees and Payment Terms

Use of the Platform may be subject to certain fees or charges (collectively the "Fees"). MSC will invoice your business for fees due using the contact information you have provided to Manhattan Street Capital. Prompt payment of fees in accordance with payment terms is required to maintain your Company's live listing on the Platform. All Fees are non-refundable. Penalties may be applied for late payments. Third party service costs that are incurred on behalf of a Company by MSC will be paid by Company. You should check here for changes to the fees to stay up to date on them. Manhattan Street Capital's currently applicable Fees and payment terms can be found at: https://www.manhattanstreetcapital.com/faq/for-fundraisers/what-fee-does-manhattan-street-capital-charge.

Exclusivity Terms

By preparing a Company offering to be shown on or offered through Manhattan Street Capital, or a RegA+Audition(TM), or when a service provider or employee that works on behalf of Company establishes a draft offering for Company on The Platform, Company agrees that for 12 months after Company offering first goes live to the public, Company will not use any other on-line funding platform to raise, solicit, or otherwise obtain Reg A+, Reg D or Reg S funding, whichever applies.

For a 12-month term of engagement with Manhattan Street Capital, the Company will not, and will not permit any security holder, affiliate, advisor or representative of the Company to engage any other party to perform any services or act in any capacity which is related to, or comparable, to the Offering without the prior written approval of MSC.

If the Company elects to engage a broker-dealer or other party to raise funds in the Offering, using means outside of the MSC Platform, the Company agrees to compensate MSC as defined in Platform Fees and Payment Terms, as if the investment transactions were processed through the MSC Platform. Manhattan Street Capital's currently applicable Fees and payment terms can be found at: https://www.manhattanstreetcapital.com/faq/for-fundraisers/what-fee-does-manhattan-street-capital-charge.

Advisor Accounts

Individuals registering as or acting as advisors, analysts or other persons of knowledge or who are such advisors and analysts by trade are required to disclose their licenses, ownership positions and relevant affiliations, including whether a Company is a client, in all interactions with the Platform and with other users of the Platform. Advisors and analysts are solely responsible for the Content they post and any advice or analysis they provide to their client companies or to users of the Platform. Manhattan Street Capital accepts no responsibility or liability for Content posted by third parties.

Termination of Account

Manhattan Street Capital may suspend or terminate your account and your ability to use the Platform at any time for any lawful reason and Manhattan Street Capital accepts no liability for any harm that may be caused, directly or indirectly, by such suspension or termination, including without limitation loss of the opportunity to gain investors, complete a fundraising or any fees or gains you did not achieve.

Reserve My Investment

Making a "Reserve My Investment" indication with a Company page involves no obligation or commitment of any kind. No money or other consideration is being solicited or accepted. Offers to buy securities or pay part of the purchase price cannot be received for any investment in a company making a Regulation A+ offering until a Form 1-A offering document filed by the applicable company is qualified by the SEC for that investment and through a registered entity. You may withdraw your reservation of investment at any time until a qualified offer of the sale of securities is made and accepted after the SEC offering qualification date. While you keep a reservation, you will be notified if a filing with the SEC is made for a company that you reserved an investment possibility in, when it is amended and when it is qualified. If a preliminary or final offering statement is filed with the SEC, it will be made available to you and you are encouraged to read the offering in full as it will provide you with more detailed information about the company, the terms and conditions of any potential offering and the risk, uncertainties and timing associated with any potential offering.

------

Ownership & Use of the Platform and Content

The entire Platform and all intellectual property rights related to the Platform belong to Manhattan Street Capital. Intellectual property rights related to the Content posted by a Company and or advisor, and licensed to Manhattan Street Capital hereunder, belong to the applicable licensor.

You agree that the Content cannot by copied, reproduced, distributed, republished, displayed, posted, or transmitted in any form or by any means without the express advance written consent of an officer of Manhattan Street Capital or the applicable licensor. You may not modify, participate in the sale or transfer of, or create any derivative works based on any part of all of the Content. Using Content, including by linking, framing, or mirroring for any purpose, is prohibited without the express advance written consent of an officer of Manhattan Street Capital.

Opinions expressed, or material appearing, on this website are not shared or endorsed by Manhattan Street Capital and Manhattan Street Capital should not be regarded as the publisher of such opinions or material. Please be aware that Manhattan Street Capital is not responsible for the privacy practices, or Content of third parties. Evaluate the security and trustworthiness of any other site connected to the Platform and any advisor you access through this Platform before disclosing any personal information to them. Manhattan Street Capital will not accept any responsibility for any loss or damage in whatever manner, howsoever caused, resulting from your interactions with third parties.

All licensors of Content warrant to Manhattan Street Capital that they have full rights to share the Content on the Platform and with Manhattan Street Capital and any other user of the Platform. Companies seeking investment are solely responsible for the Content that they post and the responses they provide. Manhattan Street Capital may, but is not required to, suspend or terminate any user and remove their Content if Manhattan Street Capital has reasonable grounds to believe that the registration and any Content is untrue, inaccurate, not current or incomplete. Manhattan Street Capital does not validate the information for accuracy or ownership rights or whether it is current. Manhattan Street Capital expressly disclaims any responsibility and all warranties of accuracy, truthfulness and completeness of the information posted.

Availability of Platform

Manhattan Street Capital does not warrant the Platform, its Content or any services provided or offered on the Platform or any content or services you obtain through your use of the Platform (such as hiring an advisor or making an investment decision) will be uninterrupted, timely, or virus or error free. Manhattan Street Capital and its advisors do not guarantee that any financial, legal, tax or other professional you may require will be available or meet your expectations or be able to address all issues you may raise or require. You agree not to modify, damage, disrupt, disable, overburden, impair, alter or interfere with the use, features, functions, operation, security or maintenance of the Platform or the rights or use and enjoyment of the Platform by any other person or entity in any manner. By using the Platform you release Manhattan Street Capital, its employees, contractors, advisors, vendors, agents, and affiliates against any and all loss, damage, and claims, in whatever manner, howsoever caused arising from or related to your use of the Platform and any advisor you retain or rely on or any investment decision you may make.

Information and Investments Are Selected and Used at Your Own Risk

Content is provided for educational purposes only and shall not be construed as professional advice. Manhattan Street Capital is not responsible for pre-screening, policing, editing or monitoring Content posted to the site by users. Because Content only provides general coverage of the subject area without considering your individual financial situation or complexities in the law that might apply to you, before acting on any Content you should consult with a competent professional who can advise you about your specific financial objectives. Any action you take on Content or because of using this website is at your own risk.

You are solely responsible for using your own judgment in using the Platform, including deciding which financial professional to hire and what products and services you may use and purchase. You are solely responsible for your selection of any advisor or investment, even if the advisor or Company seeking investment was featured as a sponsor of Content. Companies seeking investment, investors, and advisors on the Platform are solely responsible for the information they provide on this website and to you, and for the services and products they provide. Manhattan Street

------

Capital is not responsible for the conduct of any third party and shall not be liable for any damages or costs of any type arising out of or in any way connected with your use of such services and products.

You may lose all money that you invest in a company seeking feedback or investment on the Platform. If you cannot afford to lose all of your investment, you should not invest.

Disclaimers, Exclusions, and Limitations of Liability

The Platform and its Content are provided on an "as is" and "as available" basis and use of the Platform in any manner is solely at your own risk. To the fullest extent permitted by law, Manhattan Street Capital:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• DOES NOT GUARANTEE, AND EXPRESSLY EXCLUDE ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, RELATING TO THE PLATFORM AND ITS CONTENT AND PROFESSIONAL SERVICES, WHETHER PROVIDED BY MANHATTAN STREET CAPITAL, OUR AFFILIATES, OUR CUSTOMERS, COMPANIES SEEKING INVESTMENT, ADVISORS, INVESTORS OR ANY OTHER THIRD PARTY, INCLUDING IN RELATION TO ANY INACCURACIES, ERRORS, OR OMISSIONS IN THE PLATFORM, ITS CONTENT, FINANCIAL ADVICE, AND/OR MARKETING MATERIALS. SOME JURISDICTIONS DO NOT ALLOW THE EXCLUSION OF IMPLIED WARRANTIES, SO THE ABOVE EXCLUSION MAY NOT APPLY TO YOU;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•EXCLUDES ALL LIABILITY FOR DAMAGES ARISING OUT OF OR IN CONNECTION WITH YOUR USE, DELAY, OR UNAVAILABILITY OF THE PLATFORM AND ITS CONTENT, INCLUDING LOSS OF MONEY, INABILITY TO CONCLUDE AN INVESTMENT, SUSPENSION OR TERMINATION OF YOUR ACCOUNT AND FOR ANY DAMAGE CAUSED TO YOUR COMPUTER, COMPUTER SOFTWARE, SYSTEMS, PROGRAMS, AND THE DATA THEREON. UNDER NO CIRCUMSTANCES WILL MANHATTAN STREET CAPITAL OR ITS AFFILIATES, ADVISORS AND VENDORS BE LIABLE FOR ANY DAMAGES, INCLUDING GENERAL, SPECIAL, PUNITIVE, DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR ANY OTHER DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS OR BUSINESS INTERRUPTION) OF ANY KIND WHETHER IN AN ACTION IN CONTRACT, TORT, OR NEGLIGENCE ARISING OR RELATING IN ANY WAY TO THE USE OR INABILITY TO USE BY ANY PARTY OF THE PLATFORM, THE CONTENT, OR ANY THIRD-PARTY WEBSITE THAT IS LINKED TO BY THE PLATFORM, OR IN CONNECTION WITH ANY FAILURE OF PERFORMANCE, ERROR, OMISSION, INTERRUPTION, DEFECT, DELAY IN OPERATION OR TRANSMISSION, COMPUTER VIRUS, OR LINE OR SYSTEM FAILURE, EVEN IF MANHATTAN STREET CAPITAL IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, LOSSES, OR EXPENSES.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Is not liable for any defamatory, offensive or illegal conduct of any Platform user. Your sole remedy for dissatisfaction with the Platform is to stop using the Platform. If using materials from the Platform results in the need for servicing, repair or correction of equipment or data, you assume any costs; and,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If any or all the foregoing limitations are found to be invalid, in whole or in part, you agree that our total liability for all damages, losses, or causes of action of any kind or nature shall be limited to compensatory damages and limited to the greatest extent permitted by Applicable Law.

Indemnification Terms

By using the Platform for Offerings to seek investments or loans on or through use of the Platform software, or to seek feedback, including reservations on a potential fundraising and the potential offering of securities for purchase Company representatives individually and on behalf of their Company hereby agree to indemnify, defend and hold Manhattan Street Capital, shareholders, investors, officers, directors, employees, consultants, advisors, service providers, suppliers, vendors, advertisers, agents ("Related Parties") and its affiliates and their Related Parties in accordance with these Indemnification Terms. The Indemnification Terms constitute Agreed Terms hereunder. You are cautioned and advised to review the Indemnification Terms in full.

Company agrees to indemnify and hold harmless Manhattan Street Capital ("MSC") and its respective directors, officers, employees, agents and controlling persons (MSC and each such person being an "Indemnified Party") from and against all losses, claims, damages and liabilities (or actions, including shareholder actions, in respect thereof), joint or several, to which such Indemnified Party may become subject under any applicable federal or state law, or

------

otherwise, which are related to or result from the performance by MSC of the services contemplated by or the engagement of MSC and will promptly reimburse any Indemnified Party for all reasonable expenses (including reasonable counsel fees and expenses) as they are incurred in connection with the investigation of, preparation for or defense arising from any threatened or pending claim, whether or not such Indemnified Party is a party and whether or not such claim, action or proceeding is initiated or brought by the Company. The Company will not be liable to any Indemnified Party under the foregoing indemnification and reimbursement provisions:, (i) for any settlement by an Indemnified Party affected without its prior written consent (not to be unreasonably withheld); or (ii) to the extent that any loss, claim, damage or liability is found in a final, non-appealable judgment by a court of competent jurisdiction to have resulted primarily from MSC's willful misconduct or gross negligence. The Company also agrees that no Indemnified Party shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company or its security holders or creditors related to or arising out of the engagement of MSC pursuant to, or the performance by MSC of the services contemplated by, the Agreement except to the extent that any loss, claim, damage or liability is found in a final, non-appealable judgment by a court of competent jurisdiction to have resulted primarily from MSC's willful misconduct or gross negligence.

Promptly after receipt by an Indemnified Party of notice of any intention or threat to commence an action, suit or proceeding or notice of the commencement of any action, suit or proceeding, such Indemnified Party will, if a claim in respect thereof is to be made against the Company pursuant hereto, promptly notify the Company in writing of the same. In case any such action is brought against any Indemnified Party and such Indemnified Party notifies the Company of the commencement thereof, the Company may elect to assume the defense thereof, with counsel reasonably satisfactory to such Indemnified Party, and an Indemnified Party may employ counsel to participate in the defense of any such action provided, that the employment of such counsel shall be at the Indemnified Party's own expense, unless (i) the employment of such counsel has been authorized in writing by the Company, (ii) the Indemnified Party has reasonably concluded (based upon advice of counsel to the Indemnified Party) that there may be legal defenses available to it or other Indemnified Parties that are different from or in addition to those available to the Company, or that a conflict or potential conflict exists (based upon advice of counsel to the Indemnified Party) between the Indemnified Party and the Company that makes it impossible or inadvisable for counsel to the Indemnifying Party to conduct the defense of both the Company and the Indemnified Party (in which case the Company will not have the right to direct the defense of such action on behalf of the Indemnified Party), or (iii) the Company has not in fact employed counsel reasonably satisfactory to the Indemnified Party to assume the defense of such action within a reasonable time after receiving notice of the action, suit or proceeding, in each of which cases the reasonable fees, disbursements and other charges of such counsel will be at the expense of the Company; provided, further, that in no event shall the Company be required to pay fees and expenses for more than one firm of attorneys (in addition to local counsel) representing Indemnified Parties unless the defense of one Indemnified Party is unique or separate from that of another Indemnified Party subject to the same claim or action. Any failure or delay by an Indemnified Party to give the notice referred to in this paragraph shall not affect such Indemnified Party's right to be indemnified hereunder, except to the extent that such failure or delay causes actual harm to the Company, or prejudices its ability to defend such action, suit or proceeding on behalf of such Indemnified Party.

If the indemnification provided for in the Agreement is for any reason held unenforceable by or unavailable to an Indemnified Party, the Company agrees to contribute to the losses, claims, damages and liabilities for which such indemnification is held unenforceable or unavailable (i) in such proportion as is appropriate to reflect the relative benefits to the Company, on the one hand, and MSC, on the other hand, of the Agreement and any potential offering or, (ii) if (but only if) the allocation provided for in clause (i) is for any reason unenforceable or unavailable, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) but also the relative fault of the Company, on the one hand, and MSC, on the other hand, as well as any other relevant equitable considerations. The Company agrees that for the purposes of this paragraph the relative benefits to the Company and MSC of the Agreement and any potential offering as contemplated shall be deemed to be in the same proportion that the total value received or contemplated to be received by the Company or its shareholders, as the case may be, as a result of or in connection with the Agreement and any potential offering bear to the fees paid or to be paid to MSC under the Agreement. Notwithstanding the foregoing, the Company expressly agrees that MSC shall not be required to contribute any amount in excess of the amount by which fees paid MSC hereunder (excluding reimbursable expenses), exceeds the amount of any damages which MSC has otherwise been required to pay.

The Company agrees that without MSC's prior written consent, which shall not be unreasonably withheld, it will not, and will not permit any of its affiliates to, settle, compromise or consent to the entry of any judgment in any pending or threatened claim, action or proceeding in respect of which indemnification or contribution could be sought under

------

the provisions of the Agreement, unless such settlement, compromise or consent includes an unconditional release of each Indemnified Party from all liability arising out of such claim, action or proceeding.

In the event that an Indemnified Party is requested or required to appear as a witness in any action brought by or on behalf of or against the Company in which such Indemnified Party is not named as a defendant, the Company agrees to promptly reimburse MSC on a monthly basis for all expenses incurred by it in connection with such Indemnified Party's appearing and preparing to appear as such a witness, including, without limitation, the reasonable fees and disbursements of its legal counsel. In addition to any reimbursed fees, expenses or costs outlined hereunder, MSC shall also receive from the Company cash compensation of $2,000.00 per person, per day, plus reasonable out-of-pocket expenses and costs should MSC be required to provide testimony in any formal or informal proceeding regarding the Company.

If multiple claims are brought with respect to at least one of which indemnification is permitted under applicable law and provided for under the Agreement, the Company agrees that any judgment or arbitration award shall be conclusively deemed to be based on claims as to which indemnification is permitted and provided for, except to the extent the judgment or arbitration award expressly states that it, or any portion thereof, is based solely on a claim as to which indemnification is not available.

Waiver and Severance

Failure of Manhattan Street Capital to insist upon strict performance of any provision of the Agreed Terms or the failure of Manhattan Street Capital to exercise any right or remedy to which it is entitled shall not constitute a waiver thereof and shall not affect the validity of the Agreed Terms, or any part, or Manhattan Street Capital's right to enforce each and every provision. If any of the Agreed Terms are deemed invalid or unenforceable for any reason (including, but not limited to the exclusions and limitations set out above), then the invalid or unenforceable provision will be severed from the Agreed Terms and the remaining Agreed Terms will continue to apply.

Choice of Law, Time Limit and Arbitration

The laws of the State of Delaware govern these Agreed Terms. Manhattan Street Capital makes no representation that the Platform is operated in compliance with the laws of any nation but the United States. If you are located outside the United States, you view this website and access the Platform at your own risk and initiative.

This Platform and the Content posted on it or made available through it shall not constitute an offer or solicitation and may not be treated as an offer or solicitation: (i) in any jurisdiction where such an offer or solicitation is against the law; (ii) to anyone to whom it is unlawful to make such an offer or solicitation; or (iii) if the person making the offer or solicitation is not qualified to do so. Any securities that may be offered on the Platform can only be marketed in certain jurisdictions. You acknowledge and agree that it is solely your responsibility to be aware of the applicable laws and regulations of your country of residence.

You must bring all disputes with Manhattan Street Capital within one year of obtaining knowledge of the cause of action forming the basis of the dispute.

By accessing the Platform you agree that in the event of any dispute between you and Manhattan Street Capital and its Related Parties, and its affiliates and their Related Parties, you will first attempt in good faith to resolve any dispute by negotiation between MSC and a representative of the Company who has authority to settle the controversy on behalf of the Company. Either party may give the other party written notice of any dispute not resolved in the normal course of business. Within five (5) days after delivery of notice of any dispute, the receiving party shall submit to the other a written response. The notice and the response shall include a statement of each party's position, a summary of arguments supporting that position and shall include a reference to any authority available to support the position. Within fifteen (15) days after delivery of the disputing party's notice, the parties shall meet in person at a mutually acceptable time and place, or by phone, and thereafter as often as they reasonably deem necessary, to attempt to resolve the dispute. All reasonable requests for information made by one party to the other will be honored.

a) Mediation. If the matter has not been resolved within thirty (30) days of the disputing party's first notice, or if the parties fail to meet within fifteen (15) days, either party may initiate mediation of the controversy or claim before a mediator appointed by the mediation service JAMS. In any event, the parties agree first to try in good faith to settle any dispute by negotiation and mediation before resorting to arbitration or any other dispute resolution procedure.

------

b) Arbitration. If the parties are unable to resolve the matter through mediation within 15 (days) of beginning mediation, then any controversy or claim arising out of or relating to this Agreement or any alleged breach thereof shall be settled by binding arbitration by a single arbitrator appointed by the arbitration service JAMS, and judgment upon the award rendered by the arbitration shall be final and may be entered in any court having jurisdiction. (Notwithstanding the foregoing, nothing in this Agreement shall be interpreted to bar any party hereto from seeking injunctive relief with respect to any controversy or claim arising out of or relating to this Agreement.) The arbitrators shall comply with the commercial arbitration rules of the American Arbitration Association as then in effect. The arbitration shall be conducted, unless the parties otherwise agree, in San Diego, California, United States of America.

To the full extent allowable by law, you agree that no arbitration proceeding or other dispute resolution proceeding shall be joined with any other party or decided on a class-action basis.

Content Information

To contact MSC about these Agreed Terms or any other questions, we can be reached at: Support@manhattanstreetcapital.com.

------

## Ex1A-7

------

**EXHIBIT 7**

**SECURITY TRANSFER AGREEMENT**

This Security Transfer Agreement (the "**Agreement**") is made and entered into as of this 9th day of April, 2025, by and among (i) Spotitearly, Inc., a Delaware corporation (the "**Company**"), (ii) the securityholders of SpotItEarly Ltd. listed in **Exhibit A** attached hereto (each a "**Securityholder**", and together the "**Securityholders**"), and (iii) SpotItEarly Ltd., a company incorporated under the laws of the State of Israel ("**SpotItEarly ISR**").

**RECITALS**

**WHEREAS**, it is the intention of SpotItEarly ISR and the Securityholders to reorganize its corporate structure, by way of an exchange of all issued and outstanding shares of SpotItEarly ISR held by the Securityholders solely in exchange for shares of capital stock of the Company, in accordance, among others, with the requirements of section 104B of the Israel Income Tax Ordinance [New Version], 1961 and the regulations promulgated thereunder (respectively "**Section 104B**" and the "**Income Tax Ordinance**") and thereby causing SpotItEarly ISR to become a wholly owned subsidiary of the Company (the "**Reorganization**");

**WHEREAS**, the entire issued and outstanding share capital of SpotItEarly ISR, as of immediately prior to the consummation of the exchange of the shares contemplated by this Agreement, consists of 8,684,618 Ordinary Shares of SpotItEarly ISR, having no par value, 3,401,794, series Seed Preferred Shares, having no par value of SpotItEarly ISR, 4,903,357 series Seed-1 Preferred Shares, having no par value of SpotItEarly ISR, all of which are held by the Securityholders (collectively, the "**ISR Shares**");

**WHEREAS,** prior to the date hereof, SpotItEarly ISR has executed with each SAFE holder listed in **Exhibit A** (each, a "**SAFE Holder**" and collectively, the "**SAFE Holders**") certain SAFE agreements (collectively, the "**SAFEs**" and together with the ISR Shares, "**Transferred Securities**") reflecting the investment amount provided by such SAFE Holder to SpotItEarly ISR in such amount as set forth opposite its name in **Exhibit A**, which are convertible to certain securities of SpotItEarly ISR, pursuant to the terms and conditions set forth in the SAFEs;

**WHEREAS**, each Securityholder wishes to transfer all of its/his/her (i) ISR Shares as held by such Securityholder on the Exchange Effective Date (as defined below), in exchange for, and the Company has agreed to issue to the Securityholders, such number of shares of Common Stock or series of Preferred Stock of the Company, set forth opposite such Securityholder's name on **Exhibit A** (collectively, the "**New Shares**"), (ii) SAFE, along with all of such rights, titles and interests in such SAFE as held by such Securityholder on the Exchange Effective Date (as defined below), in exchange for, and the Company has agreed to issue to such Securityholder, a substantially similar rights of SAFE issued by the Company, set forth opposite such Securityholder's name on **Exhibit A** (the "**New SAFE**" and together with the New Shares, "**New Securities**"), all pursuant to the terms and conditions of this Agreement. The transfer of Transferred Securities to the Company in exchange for the issuance of the New Securities, shall be collectively referred to herein as the "**Exchange**";

**WHEREAS**, the Securityholders intend for the transactions contemplated by this Agreement to qualify for a tax deferral for Israeli tax purposes pursuant to the provisions of Section 104B of Income Tax Ordinance; and

**WHEREAS**, SpotItEarly ISR and the Securityhoders have applied for a tax ruling from the Israeli Tax Authority concerning the Israeli tax consequences arising from the Exchange, in the from attached hereto as **Exhibit B** (the "**Tax Ruling**").

**NOW, THEREFORE**, in consideration of the mutual promises, representations, warranties and agreements made herein, the parties hereby agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.**Effective Date and Acceptance of the offer by SpotItEarly ISR** **.** 

1.1.Each Securityholder agrees that the closing of the Exchange , shall become effective on the first business day subject to and following the fulfillment of all the conditions set forth in Section ‎8 hereof, by electronic exchange of documents, or at such other time, place and date as shall be agreed upon between the Company and the holders of the majority of ISR Shares (the "**Exchange Effective Date**" and "**Securityholders Majority**" respectively).

------

1.2.Each Securityholder acknowledges that this Agreement is entered as part of the Reorganization and that in order to affect such Reorganization and as a condition thereto this Agreement shall be executed by all Securityholders of SpotItEarly ISR.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.**Transfer and Exchange of the Shares**.

2.1.On and as of the Exchange Effective Date, each Securityholder shall transfer, exchange, assign and deliver all of his/her Transferred Securities to the Company, together with any and all rights, titles and interests which such Securityholder may have with respect thereto, in consideration for the issuance and grant by the Company to such Securityholder of such number of shares of Common Stock or series of Preferred Stock of the Company, set forth opposite such Securityholder's name on **Exhibit A** and with respect to SAFE Holders, in consideration for the issuance by the Company to such Securityholder of the New SAFEs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.**Closing; Deliverables**.

3.1.Transactions at the Exchange Effective Date. On or prior to the Exchange Effective Date, the following transactions shall occur, which transactions shall be deemed to take place simultaneously and no transaction shall be deemed to have been completed or any document delivered until all such transactions have been completed and all required documents delivered:

3.1.1.the Company shall:

a.have adopted and filed with the Secretary of State of the State of Delaware the Amended and Restated Certificate of Incorporation in the form of **Schedule ‎3.1.1(a)(1)** attached to this Agreement (the "**Restated Certificate**"). The Company shall provide to each Securityholder a copy of the Restated Certificate duly stamped to indicate filing with, and acceptance by, the Secretary of State of the State of Delaware, and a copy of the Bylaws of the Company in the form attached hereto as **Schedule ‎3.1.1(a)(2)**.

b.issue stock certificate(s), in the form attached hereto as **Schedule ‎3.1.1(b)(1)**, evidencing each Securityholder's ownership of the New Shares as set forth opposite such Securityholder's name on **Exhibit A** together with a stock ledger in the form attached hereto as **Schedule ‎3.1.1(b)(2)**, which shall be delivered to the Trustee (as defined below);

c.deliver to the applicable Securityholders a copy of the executed New SAFEs, as indicated in Exhibit A attached hereto.

3.1.2.Each Securityholder shall execute and deliver to the Company a share transfer deed, in the form attached hereto as **Schedule ‎3.1.1.d(a)**, effecting the transfer of the ISR Shares to the Company.

3.1.3.SpotItEarly ISR shall make the relevant entries with respect to the Exchange in its shareholders' register

3.1.4.In addition to the foregoing, at or prior to the Exchange Effective Date, each Securityholder, SpotItEarly ISR and the Company shall take such actions and execute such additional documents, certificates and instruments and take such other steps as shall be reasonably necessary or desirable to consummate more fully such Exchange expeditiously, and shall take such actions following the Exchange Effective Date as may be reasonably necessary or appropriate in furtherance of the agreements and covenants contained herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.**Effect of Exchange**.

4.1.Each Securityholder acknowledges and agrees that the issuance of New Securities in the amount, class and type as set forth in this Agreement, constitute adequate, sufficient and final consideration for the transfer of his/her Transferred Securities and such Securityholders are not entitled to receive any additional consideration, in cash, securities or otherwise with respect thereto.

4.2.Upon Exchange Effective Date, subject to the issuance of the New Securities in accordance with the terms of this Agreement, each Securityholder forfeits all rights, preferences, privileges and obligations incident or related to its ownership and/or rights of its/his/her shares and/or SAFEs and/or other equity securities of SpotItEarly ISR which rights, preferences, privileges and obligations shall automatically terminate thereupon and any share certificate related to shares of SpotItEarly ISR issued in the name of any Securityholder, which is not surrendered in

------

accordance with this Agreement, if any, shall be deemed void and canceled concurrently with the issuance of the New Securities.

4.3. Accordingly if, at any time commencing the Exchange Effective Date and ending on the earlier of (i) immediately prior to the consummation of the equity financing of the Company against the issuance of the Company's capital stock, or (ii) immediately prior to the consummation of a Deemed Liquidation Event (following which the Securityholders do not hold shares of the Company), or an IPO (as such terms are defined in the Restated Certificate), it becomes apparent that the Exchange, adoption of the Restated Certificate or the execution of any other document executed and delivered in connection with the Exchange under this Agreement (the "**Transaction Documents**") resulted in a substantial disparity of any rights, preferences, privileges and obligations incidental or related to any class of ISR Shares or personal or named rights of Securityholder or group of Securityholders as set forth in SpotItEarly ISR's Articles of Association as in effect immediately prior to the Exchange Effective Date (the "**Articles**"), or other document to which SpotItEarly ISR is a party, as in effect immediately prior to the Exchange Effective Date and which confer such rights on such Securityholder or group of Securityholders, in each case, in comparison to the corresponding rights, preferences, privileges and obligations incidental or related to, or are otherwise not attached to, the corresponding class of New Securities or Securityholder or group of Securityholders, as set forth in the Restated Certificate, the Transaction Documents or other document to which the Company is a party and which confer such rights on such Securityholder or group of Securityholders, then, at the request of any Securityholder adversely affected by such disparity, each of Company and the Securityholders hereby agree to take such actions, including to vote, or cause to be voted all New Securities owned by such Securityholder, as shall be reasonably necessary to ensure the amendment of the Restated Certificate, the Transaction Documents, or other document to which the Company is a party and which confer such rights on such Securityholder or group of Securityholders, as the case may be, in order to remedy the disparity in said rights, preferences, privileges and obligations *mutatis mutandis*, and subject to any applicable law. Notwithstanding the above, Securityholders holding a majority of the class of shares whose rights were adversely affected by said disparity may elect to waive the amendment of the Restated Certificate and/or the Transaction Documents, and/or other document to which the Company is a party and which confer such rights on such Securityholder or group of Securityholders, which waiver shall be binding upon all Securityholders, provided however that a disparity adversely affecting a specific Securityholder or group of Securityholders in a different manner than the effect on other Securityholder(s) (except for a different manner resulting solely from the number of securities held by each Securityholder), then such waiver shall also require the written consent of Securityholder or group of Securityholders.

4.4.On the Exchange Effective Date, all then outstanding options to purchase Ordinary Shares of SpotItEarly ISR ("**ISR Ordinary Shares**") previously granted to SpotItEarly ISR's (or it affiliates') employees and consultants (respectively, the "**Options**" and the "**Options Holders**") pursuant to SpotItEarly ISR's 2021 Share Option Plan (the "**Plan**") shall be exchanged for options to purchase shares of Common Stock of the Company (the "**Company Options**"), and the Options shall terminate and be of no further force and effect. The number of Common Stock of the Company subject to each Company Option shall be equal to the number of ISR Ordinary Shares subject to the corresponding Option for which such Company Option was exchanged. The exercise price per share of each Company Option shall be equal to the exercise price per share of the corresponding Option for which such Company Option was exchanged. Immediately after the Exchange Effective Date, each Company Option shall be subject to the same terms and conditions as applied to the corresponding Option for which such Company Option was exchanged (including expiration date), subject to any conforming changes determined by Company to be necessary or desirable to reflect the Reorganization, to reflect the foregoing. Company shall adopt a new equity incentive plan ("**Company's Plan**") on substantially the same terms and conditions as the Plan, subject to any conforming changes necessary or desirable to reflect the Reorganization. The Company shall issue notices and/or new award agreements to the Options Holders confirming the exchange of the Options for Company Options on the terms set forth herein. The exchange of the Options for Israeli Option Holders shall be made in accordance with the terms and conditions of the Tax Ruling.

4.5.For the avoidance of doubt, the Exchange will not result in, or be construed to constitute, a grant or assignment of Intellectual Property Rights by SpotItEarly ISR to the Company. **"Intellectual Property Rights"** shall mean patent rights, copyrights, trademark rights and any and all other intellectual property rights in inventions, improvements, designs, ideas, concepts, innovations, designs, original works of authorship, formulas, concepts, techniques, know how, methods, systems, processes, compositions of matter, computer software programs, databases, mask works, and trade secrets; each of the above whether or not patentable, copyrightable or protectable as trade secrets, irrespective of whether it has been registered in a patent, copyright, trademark or other form, and irrespective of whether it constitutes a commercial or professional secret.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.**Securityholders' Representations, Warranties and Covenants**.

------

Each Securityholder represents and warrants, severally, to the Company, as of the date hereof and as of the Exchange Effective Date, and acknowledges that the Company is entering into this Agreement in reliance thereon, that:

5.1.The respective numbers of New Securities of the Company issued to each Securityholder hereunder constitute the exclusive, final and maximal number of New Securities of the Company that such holder is entitled to receive under this Agreement and the transactions contemplated herein. Such Securityholder acknowledges that as of the Exchange Effective Date, the rights, preferences, privileges and obligations attached to the New Securities shall be as set forth in the Restated Certificate and the By-Laws of the Company, as each may be amended from time to time.

5.2.Each Securityholder has good and marketable title to its Transferred Securities, and such holder is the sole beneficial record owner of such Transferred Securities.

5.3.Each Securityholder has all required legal and corporate power and authority to (i) execute and deliver this Agreement (including all schedules and exhibits hereto), (ii) sell, convey, transfer and assign its Transferred Securities to the Company, and (iii) carry out and perform his/her/its obligations under the terms of this Agreement and the transactions contemplated herein. All actions on the part of such Securityholder necessary for the authorization, execution, delivery and performance of this Agreement (including all schedules and exhibits hereto) and the obligations hereunder have been duly taken and shall be in full force and effect as of the Exchange Effective Date.

5.4.This Agreement has been duly executed and delivered by each Securityholder, and constitutes a legal, valid and binding obligation of and with respect to each Securityholder, enforceable against each Securityholder in accordance with its terms, except (i) as limited by laws of general application relating to bankruptcy, insolvency and the relief of debtors, and (ii) as limited by rules of law governing specific performance, injunctive relief or other equitable remedies and by general principles of equity. The Exchange with respect to such Securityholder's rights does not require the consent, approval of any third party or filing with any authority and is not subject to any third party right.

5.5.Each Securityholder confirms that it has the required experience and knowledge and is capable of evaluating and understanding the risks vested in the contemplated Exchange and those potentially associated with the transactions contemplated under this Agreement including any tax implications of the Company, SpotItEarly ISR and of the Securityholders.

5.6.Each Securityholder represents that (i) it has diligently reviewed and/or is familiar with the provisions of Section 104B of the Income Tax Ordinance, and (ii) it intends for the transactions contemplated by this Agreement to qualify for a tax deferral pursuant to Section 104B of the Income Tax Ordinance, and irrevocably agrees to be obligated by and to comply with any and all of the restrictions provided under Section 104B of the Income Tax Ordinance and the Tax Ruling, as may be amended from time to time.

5.7.Each Securityholder agrees and undertakes to take such actions or to refrain from taking such actions, and to execute such documents as may be reasonably requested by SpotItEarly ISR and/or the Company and/or any other Securityholder from time to time in order for the transactions contemplated by this Agreement to qualify for a tax deferral pursuant to Section 104B of the Income Tax Ordinance and the Tax Ruling.

5.8.Each Securityholder acknowledges and agrees that (i) in accordance and compliance with the Tax Ruling, the New Securities and the ISR Shares that the Company holds in SpotItEarly ISR as contemplated by this Agreement shall be held in trust in accordance with Section ‎9 hereof and as required by the Tax Ruling, pursuant to a Trust Agreement (as defined below) to be executed by and among the Securityholders, the Company and the Trustee as required in the Tax Ruling; and (ii) the Trustee shall hold the New Securities and the ISR Shares of the Company in SpotItEarly ISR in trust to ensure compliance with Section 104B of the Income Tax Ordinance and the Tax Ruling.

5.9.Each Securityholder agrees not to transfer, assign, encumber or otherwise dispose of any of its New Securities unless the sale, transfer, assignment, encumbrance or other disposition is in compliance with the provisions of Section 104B of the Income Tax Ordinance and the Tax Ruling, all as may be amended from time to time.

5.10.Each Securityholder shall bear his/her/its own expenses, with respect to the transactions contemplated hereby. Without derogating from the foregoing, each Securityholder alone will be responsible for the filing of any tax returns or other filings required by the applicable taxing authority (if any).

------

5.11.Each Securityholder hereby acknowledges, confirms and agrees that any and all title, interest and right, of any type or nature whatsoever, in any Intellectual Property Rights, as defined below, of SpotItEarly ISR shall in accordance with the Tax Ruling remain the sole and exclusive property of SpotItEarly ISR for all intents and purposes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.**Company Representations and Covenants**.

The Company represents and warrants as of the date hereof and as of the Exchange Effective Date that:

6.1.The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted. The Company has and will have on the Exchange Effective Date the corporate power and authority to execute and deliver this Agreement and to carry out and perform its obligations under the terms of this Agreement. All corporate actions on the part of the Company necessary for the authorization, execution, delivery and performance of this Agreement and the obligations hereunder have been taken. This Agreement has been duly executed and delivered by the Company and constitute a valid and binding obligation of the Company, enforceable against it in accordance with its terms, except (i) as limited by laws of general application relating to bankruptcy, insolvency and the relief of debtors and (ii) as limited by rules of law governing specific performance, injunctive relief or other equitable remedies and by general principles of equity.

6.2.Upon their issuance in accordance with the terms of this Agreement, and subject to the truth and accuracy of each of the Securityholder's representations in Section ‎5, the New Shares shall be duly authorized, validly issued, fully paid, non-assessable, and having the rights and privileges set forth in the Restated Certificate and the By-Laws of the Company, as amended from time to time.

6.3.The authorized share capital of the Company is or will be on the date of the Exchange Effective Date as set forth in the Restated Certificate and such number of issued and outstanding shares of each class as set forth in the capitalization table appended as **Schedule ‎6.3** attached hereto (the "**Company Capitalization Table**") will immediately following the Exchange Effective Date be issued and outstanding. Effective as of the Exchange Effective Date, the issued and outstanding shares of the Company, will be owned by and registered in the names or held by the Trustee (unless an approval, certificate or other instructions were received from the Israel Tax Authority with respect to such holding by the Trustee), for the benefit of, such security holders, and in such numbers as specified in the Company Capitalization Table. As of the date of signing hereof and immediately following the Exchange Effective Date, there will be no outstanding share capital, options, warrants, rights (including conversion, preemptive rights, rights of first refusal or similar rights) or agreements for the purchase from the Company of any of its share capital, or any securities convertible into or exchangeable for shares of the Company (whether now or hereinafter authorized or issued), or that could require the Company to issue, sell, transfer or otherwise cause the Company to issue any of Company capital stock or securities convertible or exercisable into shares thereof, all other than as set forth in the Company Capitalization Table, the Restated Certificate and other organizational documents of the Company.

6.4.The Company (i) has diligently reviewed and is familiar with the provisions of Section 104B and any related terms and provisions of the Income Tax Ordinance; (ii) it intends for the transaction contemplated by this Agreement to qualify for a tax deferral pursuant to Section 104B of the Income Tax Ordinance; and (iii) it irrevocably agrees to be obligated by and to comply with any and all of the restrictions provided under Section 104B of the Income Tax Ordinance and the Tax Ruling.

6.5.The Company agrees and undertakes (a) to execute such documents as may be reasonably required in order for the transactions contemplated by this Agreement to qualify for a tax deferral pursuant to Section 104B of the Income Tax Ordinance and the Tax Ruling; and (b) not to transfer, assign, encumber or otherwise dispose of any of the ISR Shares transferred to it under this Agreement not in compliance with the Tax Ruling and Section 104B of the Income Tax Ordinance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.**SpotItEarly ISR Representations and Covenants**.

SpotItEarly ISR represents and warrants as of the date hereof and as of the Exchange Effective Date that:

------

7.1.SpotItEarly ISR is a private company with limited liability duly organized and existing under the laws of the State of Israel. All corporate actions on the part of the SpotItEarly ISR necessary for the authorization, execution and performance of this Agreement and the obligations hereunder have been taken. This Agreement constitutes a valid and binding obligation of SpotItEarly ISR, enforceable in accordance with its terms.

7.2.The issued and outstanding share capital of SpotItEarly ISR on a fully diluted basis, as of immediately prior to the Exchange Effective Date, will be as set forth in the capitalization table attached hereto as Schedule ‎7.2 hereto (the "**SpotItEarly ISR Capitalization Table**"). There are no outstanding share capital, options, warrants, rights (including conversion, preemptive rights, rights of first refusal or similar rights) or agreements for the purchase from SpotItEarly ISR of any of its share capital, or any securities convertible into or exchangeable for shares of SpotItEarly ISR (whether now or hereinafter authorized or issued), or that could require SpotItEarly ISR to issue, sell, transfer or otherwise cause SpotItEarly ISR to issue any of SpotItEarly ISR's share capital or securities convertible or exercisable into shares thereof, all other than as set forth in SAFEs, the SpotItEarly ISR Capitalization Table and the Articles.

7.4.The execution, delivery and performance of this Agreement, and the consummation of the Exchange will not result in any such violation, default, conflict or breach, nor will such consummation constitute, with or without the passage of time and giving of notice, an event that results in (a) the creation of any lien, charge or encumbrance upon any assets of SpotItEarly ISR, or (b) the suspension, revocation, impairment, forfeiture, or nonrenewal of any material permit, license, authorization, or approval applicable to SpotItEarly ISR, its business or operations or any of its assets or properties.

7.5.There is no action, suit, proceeding or investigation pending or, to SpotItEarly ISR's knowledge, currently threatened against SpotItEarly ISR that questions the validity of this Agreement, or the right of SpotItEarly ISR to enter into such agreements, or to consummate the transactions contemplated hereby or thereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.**Conditions to Exchange**.

The obligations of each of the Parties hereto to consummate the Exchange are subject to the fulfillment on or before the Exchange Effective Date of the following conditions precedent, any one or more of which may be waived in whole or in part by the applicable Party:

8.1.Representations and Warranties. The representations and warranties made by each Party in this Agreement shall have been true and correct when made and shall be true and correct as of the Exchange Effective Date, as if made on the date thereof.

8.2.Covenants. All covenants, agreements, and conditions contained in this Agreement to be performed or complied with by each Party at or prior to the Exchange Effective Date shall have been performed or complied with by such Party (as applicable) prior to or at the Exchange Effective Date.

8.3.Delivery of Documents. All of the documents to be delivered by a Party at or prior to the Exchange Effective Date pursuant to Section ‎3 shall have been executed and delivered to the other Parties, as applicable.

8.4.Tax Ruling. SpotItEarly ISR and the Securityholders have obtained the Tax Ruling, which provides, among others, that subject to the terms therein the Exchange shall not be subject to tax [and all Parties completed and filed all required documents under the Tax Ruling to the Israel Tax Authority].

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.**Trustee**.

9.1.Notwithstanding anything stated to the contrary herein, the Company and each Securityholder shall deposit the share certificates evidencing the New Securities subject to this Agreement, as well the share certificates evidencing the ISR Shares, with [●] (the "**Trustee**") to hold the same in trust for the Securityholders or the Company, as the case may be, in accordance with the requirements of the Tax Ruling, the Income Tax Ordinance and the Trust Agreement to be executed by and between the Company, SpotItEarly ISR, the Securityholders and the Trustee (the "**Trust Agreement**"), accepting the terms and conditions required in the Tax Ruling in order to execute the Exchange such that the Exchange will comply with the requirements of Section 104B of the Israel Tax Ordinance and the Tax Ruling.

9.2.Any Securities deposited with the Trustee may be released from the trust, subject to the payment of any applicable taxes as determined by the Trustee in accordance with Section 104B of the Israel Tax Ordinance and the Tax Ruling or pursuant to a valid certificate issued by the Israel Tax Authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.**General Provisions**.

10.1.Each Securityholder releases the Company and SpotItEarly ISR (and any of their respective agents, representatives, affiliates, successors and assigns) from all claims, actions, and proceedings against the Company and SpotItEarly ISR (and any of their respective agents, representatives, affiliates, successors and assigns) with respect to the issuance of the New Securities pursuant hereto, other than claims arising from (i) a breach of the provisions of this Agreement, or (ii) fraud or willful misconduct. Each Securityholder ****agrees to not bring, support or continue any such claim, action or proceeding against the Company or SpotItEarly ISR (or any of their respective agents, representatives, affiliates, successors and assigns). Each Securityholder ****hereby agrees to indemnify and hold harmless the Company and/or SpotItEarly ISR against all claims, actions and proceedings which are the subject of this release, and which may be made by any person claiming through, by, on behalf of or under such Securityholder. Each Securityholder has considered the possibility that he/she/it may not now fully know the nature or value of the claims released pursuant to this Agreement. Nevertheless, such Securityholder intends to assume the risk of releasing such unknown claims. It is clarified and acknowledged that nothing herein shall constitute a waiver or otherwise abrogate a Securityholder's recourse in respect of claims derived from or otherwise relating to the acquisition of the ISR Shares arising from representations and warranties provided to such Securityholder under the agreement governing the purchase of ISR Shares and, for the avoidance of doubt, notwithstanding anything to the contrary in this Agreement, the right to sue in connection with any such claims shall not be transferred or forfeited in connection with the Exchange.

10.2.This Agreement, and any and all rights, duties and obligations hereunder, shall not be assigned, transferred, delegated or sublicensed by any of the Securityholders, without the prior written consent of the Company. Any attempt by any of the Securityholders to assign, transfer, delegate or sublicense any rights, duties or obligations without such permission shall be void. Subject to the foregoing, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties.

10.3.The captions and headings used in this Agreement are for convenience only and do not in any way limit or amplify the terms and provisions hereof.

10.4.This Agreement (including its Exhibits and Schedules) constitutes the entire agreement and understanding of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings relating to such subject matter. Any term of this Agreement may be amended or terminated and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company, SpotItEarly ISR and the Securityholders Majority, provided that, in the event that such amendment, termination or waiver shall have the effect of amending any representation or warranty of a Securityholder, or in any way increasing any Securityholder's obligations or liabilities hereunder, or in any way amending or derogating from a personal or named right conferred upon a Securityholder or group of Securityholders, or effecting any Securityholder(s) in a different manner than effecting other Securityholder(s) (except for a different manner resulting solely from the number of securities held by each Securityholder), then such amendment, termination or waiver shall also require the written consent of the affected Securityholders, and provided, further, that such amendment shall cause no default, violation or exception whatsoever from the terms and provisions of the Tax Ruling. No waivers of or exceptions to any term, condition or provision of this Agreement, in any one or more instances, shall be deemed to be, or construed as, a further or continuing waiver of any such term, condition or provision, unless so expressly stated.

------

10.5.The warranties, representations and covenants of the Company, SpotItEarly ISR and each Securityholder contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement, the Exchange and the termination of this Agreement, and shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of Securityholders, SpotItEarly ISR or the Company.

10.6.In the event that any provision of this Agreement or the application thereof, becomes or is declared by a court of competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement will continue in full force and effect and the application of such provision to other persons or circumstances will be interpreted so as reasonably to effect the intent of the parties hereto and especially the requirements of Section 104B of the Israel Tax Ordinance and the Tax Ruling. The parties further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that will achieve, to the extent possible, the economic, business, tax and other purposes of such void or unenforceable provision.

10.7.This Agreement and all acts and transactions pursuant hereto, with the exception of the actual transfer of the ISR Shares, and the rights and obligations of the parties hereto shall be governed in all respects by the laws of the State of Delaware (USA), without giving effect to the principles of conflict of laws thereof. The Exchange of the ISR Shares and any limitations or requirements imposed on the Securityholders, SpotItEarly ISR or the Company thereof will be governed by the laws of the State of Israel, without giving effect to the principles of conflict of laws thereof.

10.8.This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

[***Signature Pages Immediately Follow***s]

------

**IN WITNESS WHEREOF**, the parties hereto have executed and delivered this Security Transfer Agreement as of the date first above written.

**COMPANY**

**SPOTITEARLY, INC.**

By: /s/ Roi Ophir

Name:Roi Ophir

Title: Chairman of the Board

**SPOTITEARLY ISR**

**SPOTITEARLY LTD.** 

By: /s/ Udi Bobrovsky

Name: Udi Bobrovsky

Title: Chief Operating Officer

*[Signature page – Security Transfer Agreement]*

------

**IN WITNESS WHEREOF**, the parties hereto have executed and delivered this Security Transfer Agreement as of the date first above written.

**SECURITYHOLDERS**

---

| | |
|:---|:---|
| /s/ Roi Ophir | /s/ Ohad Sharon |
| Roi Ophir | Ohad Sharon |
| /s/ Ariel Ben Dayan | /s/ Ariel Ben Dayan |
| Ariel Ben Dayan | Ariel Ben Dayan Entrepreneurship and |
|  | Investment Ltd. |
| /s/ Yossi Melamed | /s/ Assaf Rabinowicz |
| Yossi Melamed | Assaf Rabinowicz |
| /s/ Geoffrey M. Mason | /s/ Geoffrey M. Mason |
| The Sidney W. Swartz | The Sidney W. Swartz 2007 |
| 1982 Family Trust A f/b/o Jeffrey Swartz | Investment Nominee Trust |
| Name: Geoffrey M. Mason | Name: Geoffrey M. Mason |
| Title: Trustee | Title: Trustee |
| /s/ Patrick Rosenbaum | /s/ Erez Zelnik |
| Cybernetics Holdings Limited | Naska Medical, Limited Partnership |
| Name: Patrick Rosenbaum | Name: Erez Zelnik |
| Title: Director | Title: CEO |
| /s/ Chen Inbar | /s/ Noam Shamir |
| Chen Inbar | Global N.T.M Ltd. |
|  | Name: Noam Shamir |
|  | Title: Chief Financial Officer |
| /s/ Shmuel Weiss | /s/ Shmuel Weiss |
| EYSY Consulting and Assets Ltd. | Shmuel Weiss |
| Name: Shmuel Weiss |  |
| Title: Director |  |
| /s/ Michael Eisenberg | /s/ Ido Nouberger |
| Michael Eisenberg | ValueBase Ltd. |
|  | Name: Ido Nouberger |
|  | Title: Chief Executive Officer |
| /s/ Harel Wiesel | /s/ Ido Nouberger |
| Harel Eliezer Wiesel (by proxy of Value Base Ltd.) | Ido Nouberger (by proxy of Value Base Ltd.) |
| /s/ Danny Rimoni | /s/ Zeev Feldman |
| Dan Rimoni (by proxy of Value Base Ltd.) | Arya Trust Property Holdings |
|  | Company Ltd. for the benefit of |
|  | Avishai Abrahami |
|  | Name: Zeev Feldman |
|  | Title: Director |
| /s/ Nadav Abrahami | /s/ Nir Zohar |
| Nadav Abrahami | Nir Zohar |
| /s/ Omer Shai | /s/ Alon Lifschitz |
| Omer Shai | HANACO II L.P. |
|  | Name: Alon Lifschitz |
|  | Title: Partner |

---

------

---

| | |
|:---|:---|
| /s/ Michael Salkind | /s/ Yifat Zivony |
| Michael Salkind | Yifat Zivony |
| /s/ Revital Rosenfeld | /s/ Sunny Sassoon |
| Revital Rosenfeld | Sunny Sassoon |
|  | Name: Sunny Sassoon |
|  | Title: Chief Executive Officer |
| /s/ Ran Shaham | /s/ Yair Lowenstien |
| Altshuler Shaham Investment House Ltd. | Lowenstien Yair Holdings |
| Name: Ran Shaham | Name: Yair Lowenstien |
| Title: Manage | Title: Chief Executive Officer |
| /s/ Sinclair Haberman | /s/ Mitchell Julis |
| Julis-Hilgard Holdings, LLC | Mitchell and Linda Joleen Julis 1995 Trust |
| Name: Sinclair Haberman | Name: Mitchell Julis |
| Title: Independent Trustee | Title: Trustee |
| /s/ Steven Heilborn | /s/ Oded Meirov |
| Steven Heilborn | B.Y.M More Investment House |
|  | Name: Oded Meirov |
|  | Title: Partner |
| /s/ Oded Meirov | /s/ Rongfred Koletschka |
| Chaim Levine | V Ventures |
|  | Name: Rongfred Koletschka |
|  | Title: Director |
| /s/ Humberto Goncalves | /s/ Salim Hilwy |
| Menomedin Holdings AG Ltd. | Menomadin Fountation for Social Impact |
| Name: Humberto Goncalves | Name: Salim Hilwy |
| Title: Director | Title: Chief Financial Officer |
| /s/ Tzuika Bernstein | /s/ Tzuika Bernstein |
| IBI Trust Management in Trust <br>for Assaf Rabinowicz | IBI Trust Management in Trust <br>for Revital Rosenfield |
| Name: Tzuika Bernstein | Name: Tzuika Bernstein |
| Title: Managing Partner | Title: Managing Partner |
| /s/ Tzuika Bernstein |  |
| IBI Trust Management in Trust <br>for Yifat Zivoni |  |
| Name: Tzuika Bernstein |  |
| Title: Managing Partner |  |

---

*[Signature page – Security Transfer Agreement]*

------

**EXHIBIT A**

**List of Securityholders**

**Shareholders**

---

| | | | |
|:---|:---|:---|:---|
| **Securityholder** | **Address** | Type and Number of ISR Shares | **Type and Number of New Securities** |
| Roi Ophir | Ben Shaprut 19, Tel Aviv | 2,752,775 Ordinary Shares | 2,752,775 <br> Shares of Common Stock  |
| Roi Ophir | Ben Shaprut 19, Tel Aviv | 257,122 Series Seed-1 Preferred Shares | 257,122 Series Seed-1 Preferred Stocks |
| Ohad Sharon | Hamaapil 435 | 2,539,241 Ordinary Shares | 2,539,241 Shares of Common Stock |
| Ariel Ben Dayan | Igal Alon 9, Kiryat Ono | 2,752,775 Ordinary Shares | 2,752,775 Shares of Common Stock |
| Ariel Ben Dayan Entrepreneurship and Investment Ltd. | Igal Alon 9, Kiryat Ono | 135,327 Series Seed-1 Preferred Shares | 135,327 Series Seed-1 Preferred Stocks |
| Yossi Melamed | Harei Edom 28b, Rehovot | 156,337 Ordinary Shares | 156,337 Shares of Common Stock |
| Assaf Rabinowicz | Bialik 15, Bat-Yam | 57,196 Ordinary Shares | 57,196 Shares of Common Stock |
| The Sidney W. Swartz 2007 Investment Nominee Trust | 800 Boylston Street, Boston, MA 02199 | 87,442 Series Seed Preferred Shares  | 87,442 Series Seed Preferred Stocks |
| The Sidney W. Swartz 2007 Investment Nominee Trust | 800 Boylston Street, Boston, MA 02199 | 669,588 Series Seed-1 Preferred Shares | 669,588 Series Seed-1 Preferred Stocks |
| The Sidney W. Swartz 1982 Family Trust A f/b/o Jeffrey Swartz | 800 Boylston Street, Boston, MA 02199 | 87,442 Series Seed Preferred Shares  | 87,442 Series Seed Preferred Stocks |
| The Sidney W. Swartz 1982 Family Trust A f/b/o Jeffrey Swartz | 800 Boylston Street, Boston, MA 02199 | 338,318 Series Seed-1 Preferred Shares | 338,318 Series Seed-1 Preferred Stocks |
| Cybernetics Holdings Limited | Seychelle | 451,091 Series Seed-1 Preferred Shares | 451,091 Series Seed-1 Preferred Stocks |
| Naska Medical, Limited Partnership | Bialik Blvd. 64, Ramat HaSharon | 451,091 Series Seed-1 Preferred Shares | 451,091 Series Seed-1 Preferred Stocks |
| Chen Inbar | Bialik 15, Bat-Yam | 119,821 Series Seed-1 Preferred Shares | 119,821 Series Seed-1 Preferred Stocks |
| Global N.T.M Ltd. | Masada 7, Bnei Brak | 451,091 Series Seed-1 Preferred Shares | 451,091 Series Seed-1 Preferred Stocks |
| EYSY Consulting and Assets Ltd. | Derech Menachem Begin 121, Tel Aviv | 225,546 Series Seed-1 Preferred Shares | 225,546 Series Seed-1 Preferred Stocks |
| Shmuel Weiss | Dagan 1, Savyon | 225,545 Series Seed-1 Preferred Shares | 225,545 Series Seed-1 Preferred Stocks |
| Michael Eisenberg | Ha Matsor 6, Jerusalem | 58,295 Series Seed Preferred Shares  | 58,295 Series Seed Preferred Stocks |
| Michael Eisenberg | Ha Matsor 6, Jerusalem | 225,545 Series Seed-1 Preferred Shares | 225,545 Series Seed-1 Preferred Stocks |
| ValueBase Ltd. | Yehuda Halevi 23, Tel Aviv | 225,545 Series Seed-1 Preferred Shares | 225,545 Series Seed-1 Preferred Stocks |
| Harel Eliezer Wiesel | HaGiva 62, Savyon | 225,545 Series Seed-1 Preferred Shares | 225,545 Series Seed-1 Preferred Stocks |
| Ido Nouberger | HaRimon 11, Ramat HaSharon | 225,545 Series Seed-1 Preferred Shares | 225,545 Series Seed-1 Preferred Stocks |
| Dan Rimoni | HaShikma 41, Savyon | 225,545 Series Seed-1 Preferred Shares | 225,545 Series Seed-1 Preferred Stocks |
| Arya Trust Property Holdings Company Ltd. for the benefit of Avishai Abrahami | Dizengoff 61, Tel Aviv | 112,773 Series Seed-1 Preferred Shares | 112,773 Series Seed-1 Preferred Stocks |
| Nadav Abrahami | Ve'Idat Katowits 37a, Tel Aviv | 112,773 Series Seed-1 Preferred Shares | 112,773 Series Seed-1 Preferred Stocks |
| Nir Zohar | Hadasa 6, Tel Aviv | 112,773 Series Seed-1 Preferred Shares | 112,773 Series Seed-1 Preferred Stocks |
| Omer Shai | HaShomron 5, Ramat HaSharon | 112,773 Series Seed-1 Preferred Shares | 112,773 Series Seed-1 Preferred Stocks |
| Hanaco II L.P. | Cayman Islands | 2,976,570 Series Seed Preferred Shares | 2,976,570 Series Seed Preferred Stocks |
| Michael Salkind | HaGderot 53, Savyon | 192,045 Series Seed Preferred Shares | 192,045 Series Seed Preferred Stocks |

---

------

**SAFE HOLDERS**

---

| | | | |
|:---|:---|:---|:---|
| **Securityholder** | **Address** | **Investment Amount**<br>| **Date of Execution of SAFE**<br>|
| Hanaco II LP | Cayman Islands | SAFE 2 – USD$1,000,000 | September 8, 2022 |
| Hanaco II LP | Cayman Islands | SAFE 3 - USD$750,000 | April 22, 2023 |
| Hanaco II LP | Cayman Islands | SAFE 4 – USD$1,500,000 | December 12, 2024 |
| Menomadin Foundation for Social Impact Ltd. |  | USD$1,750,000 | September 1, 2022 |
| Sunny Sassoon | 9641 S. Santa Monica Blvd. Beverly Hills, CA 90210 | SAFE 2 – USD$250,000 | November 29, 2022 |
| Sunny Sassoon | 9641 S. Santa Monica Blvd. Beverly Hills, CA 90210 | SAFE 3 – USD$250,000 | April 16, 2023 |
| Altshuler Shaham invesments house Ltd. |  | USD$250,000 | April 24, 2023 |
| Lowenstien Yair Holdings |  | USD$250,000 | April 24, 2023 |
| Julis-Hilgard Holdings, LLC |  | USD$250,000 | April 16, 2023 |
| Mitchell and Linda Joleen Julis 1995 Trust |  | USD$250,000 | April 16, 2023 |
| Steven Heilborn |  | USD$625,000 | March 9, 2023 |
| B.Y.M More investment house |  | USD$400,000 | June 26, 2023 |
| Chaim Livne |  | USD$100,000 | September 21, 2023 |
| Menomedin holdings AG |  | SAFE 3 – USD$875,000 | September 11, 2023 |
| Menomedin holdings AG |  | SAFE 3 – USD$1,000,000 | November 21, 2024 |
| V Ventures |  | USD$1,000,000 | November 30, 2023 |

---

------

## Ex1A-8

------

**EXHIBIT 8**

**BI-PARTY ESCROW AGREEMENT**

This ESCROW AGREEMENT ("Agreement") is made and entered into as of March 27, 2025, by and among SPOTITEARLY INC., a Delaware corporation (the "Company"), and ENTERPRISE BANK & TRUST, a Missouri chartered trust company with banking powers (in its capacity as escrow holder, the "Escrow Agent").

RECITALS

This Agreement is being entered into in reference to the following facts:

&nbsp;&nbsp;&nbsp;&nbsp;(a)The Company intends to offer and sell to prospective investors ("Investors"), as disclosed in its offering materials, in a registered offering pursuant to the Securities Act of 1933, as amended (the "Securities Act"), or as exemption from registration thereunder (the "Offering"), the equity, debt, or other securities of the Company (the "Securities") with no minimum (the "Minimum") and a maximum of $50,000,000 (Fifty Million) (the "Maximum") as described in the Company's disclosure materials and the Subscription Agreement (the "Subscription Agreement") applicable to the Offering.

&nbsp;&nbsp;&nbsp;&nbsp;(b)In connection with the Offering, the Company desires to establish an Escrow Account (as defined herein) on the terms and subject to the conditions set forth herein.

ARTICLE 1-ESCROW FUNDS

&nbsp;&nbsp;&nbsp;&nbsp;1.1Appointment of Escrow Agent. The Company hereby appoints the Escrow Agent to act as escrow holder for the Escrow Funds (as defined below) under the terms of this Agreement. The Escrow Agent hereby accepts such appointment, subject to the terms, conditions, and limitations hereof.

&nbsp;&nbsp;&nbsp;&nbsp;1.2Establishment of Escrow. Immediately following the Escrow Agent's execution of this Agreement, the Escrow Agent will open a non-interest bearing bank checking account with Escrow Agent (the "Escrow Account") for the purpose of receiving and holding Cash Deposits (as defined below) and the remaining portion of the Total Purchase Price (as defined below) payable by each Investor (as defined below) in connection with the Offering (the "Escrow Funds").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3Escrow Funds.

(a)Each Investor will be instructed by the Company or its Intermediary (as defined herein) to remit to the Company, a predetermined cash deposit (the "Cash Deposit"), as indicated on the applicable Subscription Agreement (as defined below), in the form of a check, draft, wire or ACH payable to the order of "Enterprise Bank & Trust, as Escrow Agent for "SPOTITEARLY INC.". Following receipt by the Company of an Investor's Cash Deposit, the Company or its Intermediary will promptly: (i) send to the Escrow Agent the Investor's name, address, executed IRS Form W-9 and total purchase price to be remitted for the Securities to be purchased by the Investor (the "Total Purchase Price"), and (ii) remit to the Escrow Agent the Cash Deposit. Escrow Agent shall promptly deposit the Cash Deposit into the Escrow Account, which deposit shall occur within two (2) business days after the Escrow Agent's receipt of the Cash Deposit. For purposes of this Agreement, "Intermediary" shall mean a broker registered under Section 15(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or a funding portal registered under Regulation CF, 17 C.F.R. Part 227, and includes, where relevant, an associated person of the registered broker or registered funding portal. Notwithstanding the above, if the Company has retained an Intermediary, the Intermediary may instruct an Investor to remit the Cash Deposit amount in a method authorized by such Intermediary's portal or other website hosted by the Company or Intermediary in connection with the Offering, which may be remitted in the form of a credit card, wire, ACH payment, or other method, payable to the order of "Enterprise Bank & Trust, as Escrow Agent for "SPOTITEARLY INC." as applicable. Such Cash Deposit amounts shall be paid into the Escrow Account.

------

(b)On or prior to the consummation of the Offering, each Investor may be further instructed by the Company or its Intermediary to remit directly to the Escrow Agent an amount equal to the difference between such Investor's Total Purchase Price and the amount of such Investor's Cash Deposit, in a form of payment as described in Section 1.3(a), payable to the order of "Enterprise Bank & Trust, as Escrow Agent for "SPOTITEARLY INC." as applicable.

(c)Escrow Agent shall have no obligation to accept Escrow Funds or documents from any party other than the Investors or the Company. Any checks that are made payable to a party other than the Escrow Agent shall be returned to the party submitting the check, and if received by the Company shall not be remitted to the Escrow Agent. Proceeds in the form of wire or other electronic funds transfers are deemed deposited into the Escrow Account and considered "Collected Funds" when received by the Escrow Agent. Any Proceeds deposited in the form of a check, draft or similar instrument are deemed deposited when the collectability thereof has been confirmed; after such time, such Proceeds are considered "Collected Funds." The Escrow Agent shall have no duty or responsibility to enforce the collection or demand payment of any funds deposited into the Escrow Account. Should any check be deemed uncollectible for any reason, the Escrow Agent will notify the Company of the amount of such return check, the name of the Investor and the reason for return and return the check to the Investor.

(d)Escrow Agent will hold all Escrow Funds in escrow, free from any liens, claims or offsets, and such monies shall not become the property of the Company or the Investor, nor shall such monies become subject to the debts thereof or the debts of the Escrow Agent, unless and until the conditions set forth in these instructions to disbursement of such monies have been fully satisfied.

(e)The Escrow Funds shall be disbursed by the Escrow Agent from the Escrow Account by wire transfer or by a check payable to the appropriate payee(s) in accordance with the provisions of this Agreement.

(f)Escrow Agent shall not be required to take any action under this Section 1.3 or any other section hereof until it has received proper written instruction from an Authorized Representative of the Company or authorized representative of its Intermediary, delivered in compliance with all applicable laws and pursuant to the terms of this Agreement. Such written instructions shall be in the form prescribed by the applicable Exhibit and signed by all required parties. Except as otherwise expressly contemplated herein, all parties hereby direct and instruct Escrow Agent to accept any payment or other instructions provided by an Authorized Representative of the Company or authorized representative of its Intermediary, and Escrow Agent shall have no duty or obligation to authenticate such payment or other instructions or the authorization thereof. The Escrow Agent shall not be required to release any funds that constitute Escrow Funds unless the funds represented thereby are Collected Funds.

(g)The Company and any Intermediary shall conduct all aspects of the Offering in full compliance with all applicable law, including all federal and state securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4Investments.

&nbsp;&nbsp;&nbsp;&nbsp;(a)All funds in the Escrow Account will be held by Escrow Agent in a non-interest bearing bank account at Escrow Agent. The Escrow Funds will not earn interest.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.5Cancellation of Subscriptions.

(a)The Company may reject or cancel any Investor's offer to purchase Securities (the "Subscription"), in whole or in part. If all or any portion of the Total Purchase Price for such rejected or canceled Subscription has been delivered to the Escrow Agent, then the Company oritsIntermediary will inform Escrow Agent in writing of the rejection or cancellation, and instruct Escrow Agent in writing in the form of Exhibit "C" attached hereto to refund some or all of the Escrow Funds. Such instruction must be made and delivered in compliance with all applicable state and federal rules and regulations, including, but not limited to, the Securities Act and signed by an Authorized Representative of the Company or authorized representative of the Intermediary.

------

ARTICLE 2-DISBURSEMENT PROCEDURES

&nbsp;&nbsp;&nbsp;&nbsp;2.1Disbursement of Proceeds. Escrow Agent shall hold and disburse the Escrow Funds in accordance with the following procedures:

(a)Subject to the provisions of Section 2.1(b) through Section 2.1(g), in the event Escrow Agent receives Collected Funds for the Minimum Offering prior to the termination of this Agreement, and for any point thereafter, and from time to time, promptly after the Escrow Agent's receipt of written instructions from an Authorized Representative of the Company or authorized representative of its Intermediary, in the form of Exhibit "A" attached hereto, the Escrow Agent shall disburse (by wire transfer or by a check payable to the appropriate payee(s)) the principal amount of all Escrow Funds then held by Escrow Agent, or such lesser amount as may be specified in such written instructions (but not less than the amount covered by the Minimum Offering) in accordance with such written instructions, as provided from time to time. Escrow Funds shall be distributed within one (1) business day of the Escrow Agent's receipt of such written instructions, which must be received by the Escrow Agent no later than 1:00 p.m. Central Standard time on a business day for the Escrow Agent to process such instructions that business day.

(b)Escrow Agent shall continue to accept deposits of additional Escrow Funds until a date (the "Final Closing Date") which is the earlier of (i) the date on which the Escrow Agent receives written notification, signed by an Authorized Representative of the Company or an authorized representative of the Intermediary, that the Company has accepted Subscriptions for the Maximum Offering, or (ii) the date on which the Escrow Agent receives written notification, signed by an Authorized Representative of the Company or an authorized representative of the Intermediary, of a final closing date for receipt of Escrow Funds. Promptly from and after the Final Closing Date, the Escrow Agent shall return directly to the Investor, the principal amount of any Escrow Funds received by the Escrow Agent after the Final Closing Date and shall cease to accept any additional Escrow Funds.

(c)If an Authorized Representative of the Company or authorized representative of its Intermediary gives written notice to the Escrow Agent of the termination or withdrawal of the Offering, in the form of Exhibit "B" attached hereto, then promptly after such notification, the Escrow Agent shall return, as a complete distribution, each Investor's Escrow Funds, without deduction, penalty, or expense, to such Investor in the same method as the Investor caused payment pursuant to Section 1.3(a); provided, however, that to the extent an Investor's Escrow Funds were received by Escrow Agent from a qualified intermediary, such funds shall be returned to such qualified intermediary. In the event of the termination of the Offering pursuant to this Section 2.1(c), the Escrow Funds shall not under any circumstance be returned to the Company. The Company represents, warrants, and agrees that the Escrow Funds returned to each Investor (or to such Investor's qualified intermediary) are and shall be free and clear of any and all claims of the Company and its creditors.

(d)If an Investor is entitled to terminate its Subscription, or the Company rejects such Subscription in whole or in part, for which the Escrow Agent has received Escrow Funds, the Escrow Agent shall, upon a written instruction signed by an Authorized Representative of the Company or authorized representative of its Intermediary, in the form of Exhibit "C" attached hereto, promptly return directly to such Investor that portion of the Escrow Funds associated with such Investor and specified in the written instruction in the same method as the Investor caused payment pursuant to Section 1.3(a). If the Escrow Agent has not yet collected funds but has submitted the Investor's check for collection, the Escrow Agent shall promptly return the funds in the amount of the Investor's check to such Investor after such funds have been collected. If the Escrow Agent has not yet submitted such Investor's check for collection, the Escrow Agent shall promptly remit the Investor's check directly to the Investor. If applicable, any disbursement instructions shall be delivered in compliance with Regulation CF, 17 C.F.R. 227.304.

(e)If an Investor elects to remit the Total Purchase Price for such Investor's purchase of the Securities in lieu of applying the Investor's Cash Deposit to the Purchase Price, the Escrow Agent shall, upon the written request of an Authorized Representative of the Company or authorized representative of its Intermediary, promptly return directly to such Investor, in the same method as the Investor caused payment pursuant to Section 1.3(a), the Cash Deposit deposited in the Escrow Account on behalf of such Investor. If the Escrow Agent has not yet collected funds but has submitted the Investor's check for the Cash Deposit for collection, the Escrow Agent

------

shall promptly return the funds in the amount of the Investor's check to such Investor after such funds have been collected. If the Escrow Agent has not yet submitted such Investor's check for collection, the Escrow Agent shall promptly remit the Investor's check directly to the Investor.

(f)If any date that is a deadline under this Agreement for giving the Escrow Agent notice or instructions or for the Escrow Agent to take action is not a business day, then such date shall be the business day that immediately precedes such date. A "business day" is any day other than a Saturday, Sunday or any other day on which banking institutions located in the state of Missouri, are authorized or obligated by law or executive order to close.

(g)Any delivery of written disbursement and other instructions by an Authorized Representative of the Company or an authorized representative of an Intermediary pursuant to this Article 2 shall be made in compliance with all applicable state and federal rules and regulations, including, but not limited to, the Securities Act and the Exchange Act.

ARTICLE 3- GENERAL ESCROW PROCEDURES

&nbsp;&nbsp;&nbsp;&nbsp;3.1Accounts and Records. Escrow Agent shall keep accurate books and records of all transactions hereunder. The Company shall be responsible for maintaining accurate books and records as to owners of the beneficial interest in the Escrow. The Company and Escrow Agent shall each have reasonable access to one another's books and records concerning the Offering and the Escrow Account. Upon final disbursement of the Escrow Funds, the Escrow Agent shall deliver to the Company a complete accounting of all transactions relating to the Escrow Account.

&nbsp;&nbsp;&nbsp;&nbsp;3.2Duties. Escrow Agent's duties and obligations hereunder shall be determined solely by the express provisions of this Agreement. Escrow Agent's duties and obligations are purely ministerial in nature, and nothing in this Agreement shall be construed to give rise to any fiduciary obligations of the Escrow Agent with respect to the Investors or to the other parties to this Agreement. Without limiting the generality of the foregoing, the Escrow Agent is not charged with any duties or responsibilities with respect to any documentation associated with the Offering and shall not otherwise be concerned with the terms thereof. The Escrow Agent shall not be required to notify or obtain the consent, approval, authorization, or order of court or governmental body to perform its obligations under this Agreement, except as expressly provided herein. The parties agree that Escrow Agent shall not be required to expend or risk any of its own funds or otherwise incur any liability, financial or otherwise, in the performance of any of its duties hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;3.3Liability Limited. Escrow Agent shall not be liable to anyone whatsoever by any reason of error of judgment or for any act done or step taken or omitted by them in good faith or for any mistake of fact or law or for anything which they may do or refrain from doing in connection herewith unless caused by or arising out of their own gross negligence or willful misconduct. In no event shall the Escrow Agent be liable for any indirect, special, consequential damages, or punitive damages. Escrow Agent shall have no responsibility to ensure anyone's compliance with any securities laws in connection with the Offering, and Escrow Agent shall not be required to inquire as to the performance or observation of any obligation, term or condition under any other agreements or arrangements.

&nbsp;&nbsp;&nbsp;&nbsp;3.4Fees. The Company shall pay the Escrow Agent the fees based on the fee schedule attached hereto as Exhibit "D". In addition, the Company shall be obligated to reimburse the Escrow Agent for all fees, costs and expenses incurred or that become due in connection with this Agreement or the Escrow Account, including reasonable attorneys' fees. Neither the modification, cancellation, termination or rescission of this Agreement nor the resignation or termination of the Escrow Agent shall affect the right of the Escrow Agent to retain the amount of any fee which has been paid, or to be reimbursed or paid any amount which has been incurred or becomes due, prior to the effective date of any such modification, cancellation, termination, resignation or rescission. Escrow Agent is hereby authorized by the Company to deduct from the Escrow Fund any fees not timely paid, and any unpaid fees before final distribution of the Escrow Fund to the Company in accordance with this Agreement; provided, however, that no fees shall be deducted from any amount of Escrow Funds to be returned to Investors. To the extent the Escrow Agent has incurred any such expenses, or any such fee becomes

------

due, prior to any closing, the Escrow Agent shall advise the Company and the Company shall direct all such amounts to be paid directly at any such closing.

&nbsp;&nbsp;&nbsp;&nbsp;3.5Exculpation. Escrow Agent's duties hereunder shall be strictly limited to the safekeeping of monies, instruments or other documents received by the Escrow Agent and any further responsibilities expressly provided in this Agreement. The Escrow Agent will not be liable for:

(a)the genuineness, sufficiency, correctness as to form, manner or execution or validity of any instrument deposited in the Escrow, nor the identity, authority or rights of any person executing the same;

(b)any misrepresentation or omission in any documentation associated with the Offering or any failure to keep or comply with any of the provisions of any agreement, contract, or other instrument referred to therein; or

(c)the failure of any Investor to transmit, or any delay in transmitting, any Investor's Purchase Price to the Company or Escrow Agent.

&nbsp;&nbsp;&nbsp;&nbsp;3.6Interpleader. If (i) conflicting demands are made or notice served upon the Escrow Agent with respect to the escrow or (ii) the Escrow Agent is otherwise uncertain as to its duties or rights hereunder, then the Escrow Agent shall have the absolute right at its election to do either or both of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)withhold and stop all further proceedings in, and performance of, this Agreement; or

(b)file a suit in interpleader and obtain an order from the court requiring the parties to litigate their several claims and rights among themselves. In the event such interpleader suit is brought, the Escrow Agent shall be fully released from any obligation to perform any further duties imposed upon it hereunder, and the Company shall pay the Escrow Agent actual costs, expenses and reasonable attorney's fees expended or incurred by Escrow Agent, the amount thereof to be fixed and a judgment thereof to be rendered by the court in such suit.

&nbsp;&nbsp;&nbsp;&nbsp;3.7Indemnification and Contribution. The Company agrees to defend, indemnify and hold Escrow Agent and its affiliates and their respective directors, officers, agents ("Indemnified Parties") harmless from and against all costs, damages, judgments, attorneys' fees, expenses, obligations and liabilities of any kind or nature ("Damages") to the fullest extent permitted by law, from and against any Damages or liabilities related to or arising out of this Agreement which the Indemnified Parties may reasonably incur or sustain in connection with or arising out of the escrow or this Agreement and will reimburse the Indemnified Parties for all expenses (including attorneys' fees) as they are incurred by the Indemnified Parties in connection with investigating, preparing or defending any such action or claim whether or not in connection with pending or threatened litigation in which the Indemnified Parties is or are a party; provided, however, the Company will not be responsible for Damages or expenses which are finally judicially determined to have resulted from an Indemnified Party's gross negligence or willful misconduct. The provisions of this section shall survive the termination of this Agreement and any resignation of the Escrow Agent.

&nbsp;&nbsp;&nbsp;&nbsp;3.8Compliance with Orders. If at any time Escrow Agent is served with any judicial or administrative order, judgment, decree, writ or other form of judicial or administrative process which in any way affects the Escrow Funds (including but not limited to orders of attachment or any other forms of levies or injunctions or stays relating to the transfer of the Escrow Funds), Escrow Agent is authorized to comply therewith in any manner as it or its legal counsel of its own choosing deems appropriate; and if Escrow Agent complies with any such judicial or administrative order, judgment, decree, writ or other form of judicial or administrative process, Escrow Agent shall not be liable to any of the parties hereto or to any other person or entity even though such order, judgment, decree, writ or process may be subsequently modified or vacated or otherwise determined to have been without legal force or effect.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9Resignation.

&nbsp;&nbsp;&nbsp;&nbsp;(a) Escrow Agent may resign as escrow holder hereunder upon fourteen (14) days prior written notice to the Company and shall thereupon be fully released from any obligation to perform any further duties imposed upon it hereunder. The Company shall promptly appoint a successor escrow agent. The Escrow Agent will transfer all files and records relating to the Escrow and Escrow Account to any successor escrow holder mutually agreed to in writing by the Company upon receipt of a copy of the executed escrow instructions designating such successor. If the Company has failed to appoint a successor escrow agent prior to the expiration of fourteen (14) calendar days following the delivery of such notice of resignation from Escrow Agent, the Escrow Agent may petition any court of competent jurisdiction for the appointment of a successor escrow agent or for other appropriate relief, and any such resulting appointment shall be binding upon the Company. The Company shall be liable for Escrow Agent's costs and expenses including attorneys incurred in such proceeding.

&nbsp;&nbsp;&nbsp;&nbsp;(b)In the case of a resignation of the Escrow Agent, the Escrow Agent shall have no responsibility for the appointment of a successor escrow agent hereunder. The successor escrow agent appointed by the Company shall execute, acknowledge and deliver to the Escrow Agent and the other parties an instrument in writing accepting its appointment hereunder. Thereafter, the Escrow Agent shall deliver all of the then-remaining balance of the Escrow Funds, less any expenses then incurred by and unpaid to the Escrow Agent, to such successor escrow agent in accordance with the written direction of the Company and upon receipt of the Escrow Funds, the successor escrow agent shall be bound by all of the provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;3.10Filings and Resolution. Concurrently or prior to the execution and delivery of this Agreement, the Company shall deliver to the Escrow Agent a copy of its certificate of formation or other charter documents, resolutions, and any other account agreements requested by Escrow Agent.

&nbsp;&nbsp;&nbsp;&nbsp;3.11Authorized Representatives. The Company hereby identifies to Escrow Agent the officers, employees or agents designated on Schedule I attached hereto as an authorized representative (each, an "Authorized Representative") with respect to any notice, certificate, instrument, demand, request, direction, instruction, waiver, receipt, consent or other document or communication required or permitted to be furnished to Escrow Agent. Schedule I may be amended and updated by written notice to Escrow Agent. Escrow Agent shall be entitled to rely on such original or amended Schedule I with respect to any party until a new Schedule I is furnished by such party to Escrow Agent. If applicable, the Company hereby identifies to Escrow Agent the officers, employees or agents of any Intermediary designated on Schedule I attached hereto as an authorized representative of the Intermediary with respect to any instruction or notice that such Intermediary is required or eligible to give pursuant to this Agreement, including with respect to the disbursement of Escrow Funds and other cash.

&nbsp;&nbsp;&nbsp;&nbsp;3.12Term. The term of this Agreement shall commence as of the date first above written and shall end on the date that all funds in the Escrow Account are disbursed pursuant to this Agreement and all reporting obligations specified herein have been satisfied.

&nbsp;&nbsp;&nbsp;&nbsp;3.13Identification Number. The Company represents and warrants that (a) its Federal tax identification number ("TIN") specified on the signature page of this Agreement underneath its signature is correct and is to be used for 1099 tax reporting purposes, and (b) it is not subject to backup withholding. The Company shall provide the Escrow Agent with the TIN and verification that the person or entity is not subject to backup withholding for any person or entity to whom interest is paid on any of the Proceeds, if applicable. Such verification may be evidenced by providing the Escrow Agent a Subscription Agreement containing appropriate language or a copy of a W-9.

&nbsp;&nbsp;&nbsp;&nbsp;3.14Reliance. When Escrow Agent acts on any communication (including, but not limited to, communication with respect to the transfer of funds) sent by electronic transmission, Escrow Agent, absent gross negligence or willful misconduct, shall not be responsible or liable in the event such communication is not an authorized or authentic communication of the party involved or is not in the form the party involved sent or intended to send (whether due to fraud, distortion or otherwise). Escrow Agent shall not be liable for any losses, costs or expenses arising directly or indirectly from Escrow Agent's reliance upon and compliance with such

------

instructions notwithstanding such instructions conflict or are inconsistent with a subsequent written instruction. The Company agrees to assume all risks arising out of the use of such electronic transmission to submit instructions and directions to Escrow Agent, including without limitation the risk of Escrow Agent acting on unauthorized instructions, and the risk or interception and misuse by third parties.

&nbsp;&nbsp;&nbsp;&nbsp;3.15Force Majeure. Escrow Agent shall not incur liability for not performing any act or not fulfilling any duty, obligation or responsibility hereunder by reason of any occurrence beyond the control of Escrow Agent (including but not limited to any act or provision of any present or future law or regulation or governmental authority, pandemic or public health emergency, any act of God or war, terrorism or the unavailability of the Federal Reserve Bank or other wire or communication facility).

ARTICLE 4- GENERAL PROVISIONS

&nbsp;&nbsp;&nbsp;&nbsp;4.1Notice. Any notice, request, demand or other communication provided for hereunder to be given shall be in writing and shall be delivered personally, by certified mail, return receipt requested, postage prepaid, or by transmission by a telecommunications device, and shall be effective (a) on the day when personally served, including delivery by overnight mail and courier service, (b) on the third business day after its deposit in the United States mail, and (c) on the business day of confirmed transmission by telecommunications device. The addresses of the parties hereto (until notice of a change thereof is served as provided in this Section 4.1) shall be as follows:

To the Company:

SPOTITEARLY INC.

61 W Palisade Ave

Englewood, NJ, 07631 Attn: Shai Lankry

617-599-2043

shai@spotitearly.com

To the Escrow Agent:

Enterprise Bank & Trust

Attn: Specialty Banking Group

1281 N. Warson

St. Louis, Missouri 63132

sbg@enterprisebank.com

with a copy to:

Legal Department via email legaltracking@enterprisebank.com

&nbsp;&nbsp;&nbsp;&nbsp;4.2Amendments. Except as otherwise permitted herein, this Agreement may be modified only by a written amendment signed by the parties hereto, and no waiver of any provision hereof will be effective unless expressed in a writing signed by the parties hereto.

&nbsp;&nbsp;&nbsp;&nbsp;4.3Wiring Instructions. In the event fund transfer instructions are given, such instructions must be communicated to Escrow Agent in writing delivered pursuant to Section 4.1. Escrow Agent shall seek confirmation of such instructions by telephone call-back to an Authorized Representative (in the case of the Company), authorized representative of the Intermediary, or other authorized person, and Escrow Agent may rely upon the confirmations of anyone purporting to be the Authorized Representative of the Company, authorized representative of the Intermediary, or other authorized person so designated. Escrow Agent and the beneficiary's bank in any funds transfer may rely solely upon any account numbers or similar identifying numbers provided by the Company or the Intermediary to identify (i) the beneficiary, (ii) the beneficiary's bank, or (iii) an intermediary bank. Escrow Agent may apply any of the Escrow Funds for any payment order it executes using any such

------

identifying number, even when its use may result in a person other than the beneficiary being paid, or the transfer of funds to a bank other than the beneficiary's bank or an intermediary bank designated. The parties to this Agreement acknowledge that such security procedure is commercially reasonable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4Notifications.

(a)The Escrow Agent may, but need not, honor and follow instructions, amendments or other orders ("orders") which shall be provided by telephone facsimile transmission ("faxed") to the Escrow Agent in connection with this Agreement and may act thereon without further inquiry and regardless of whom or by what means the actual or purported signature of the Company may have been affixed thereto if such signature in Escrow Agent's sole judgment resembles the signature of the Company. The Company indemnifies and holds the Escrow Agent free and harmless from any and all liability, suits, claims or causes of action which may arise from loss or claim of loss resulting from any forged, improper, wrongful or unauthorized faxed order. The Company shall pay all actual attorney fees and costs reasonably incurred by the Escrow Agent (or allocable to its in-house counsel), in connection with said claim(s).

(b)Furthermore, all parties hereby agree that all current and future notices, confirmations and other communications regarding this Agreement specifically, and future communications in general between the parties, may be made by email, sent to the email address of record as set forth above or, solely with regards to business in the normal course, as otherwise from time to time changed or updated, directly by the party changing such information, without necessity of confirmation of receipt, delivery or reading, and such form of electronic communication is sufficient for all matters regarding the relationship between the parties. If any such electronically-sent communication fails to be received for any reason, including but not limited to such communications being diverted to the recipients' spam filters by the recipients email service provider or technology, or due to a recipients' change of address, or due to technology issues by the recipients' service provider, the parties agree that the burden of such failure to receive is on the recipient and not the sender, and that the sender is under no obligation to resend communications via any other means, including but not limited to postal service or overnight courier, and that such communications shall for all purposes, including legal and regulatory, be deemed to have been delivered and received.

(c)The Company is responsible for the accuracy and completeness of all communications given by it including those given pursuant to electronic means, including but not limited to email, internet, facsimile or text. Escrow Agent shall not be responsible for any interruption in such communication services and the Company shall be responsible for security of all such services.

&nbsp;&nbsp;&nbsp;&nbsp;4.5Assignment. Except as permitted in this Section 4.5, neither this Agreement nor any rights or obligations hereunder may be assigned by any party hereto without the express written consent of each of the other parties hereto. This Agreement shall inure to and be binding upon the parties hereto and their respective successors, heirs and permitted assigns. Any corporation into which Escrow Agent may be merged or converted or with which it may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which Escrow Agent will be a party, or any corporation succeeding to all or substantially all the business of Escrow Agent will be the successor of Escrow Agent hereunder without the execution or filing of any paper with any party hereto or any further act on the part of any of the parties hereto except where an instrument of transfer or assignment is required by law to effect such succession, anything herein to the contrary notwithstanding.

&nbsp;&nbsp;&nbsp;&nbsp;4.6USA PATRIOT Act. The Company shall provide to Escrow Agent such information as Escrow Agent may reasonably require to permit Escrow Agent to comply with its obligations under the federal USA PATRIOT Act (Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001). Escrow Agent shall not make any payment of all or a portion of the Escrow Fund, to any person unless and until such person has provided to Escrow Agent such documents as Escrow Agent may require to permit Escrow Agent to comply with its obligations under such Act. Further, Company represents and warrants to Escrow Agent that if it is a hedge fund, it will promptly notify Escrow Agent and enter into any agreement or provide any documentation requested by Escrow Agent.

------

&nbsp;&nbsp;&nbsp;&nbsp;4.7Termination. This Agreement shall terminate when all the Escrow Funds have been disbursed or returned in accordance with the provisions of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8Time of Essence. Time is of the essence of these and all additional or changed instructions.

&nbsp;&nbsp;&nbsp;&nbsp;4.9Counterparts. This Agreement may be executed in counterparts, each of which so executed shall, irrespective of the date of its execution and delivery, be deemed an original, and said counterparts together shall constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;4.10Governing Law and Jurisdiction. This Agreement shall be governed by, and shall be construed according to, the laws of the State of Missouri. The parties hereby irrevocably submit to the exclusive jurisdiction of the state courts of St. Louis County, Missouri or, if proper subject matter jurisdiction exists, the United States District Court for the Eastern District of Missouri, in any action or proceeding arising out of or relating to this Agreement. Each party hereto further irrevocably consents to the service of any complaint, summons, notice or other process relating to any such action or proceeding by delivery thereof to it by hand or by registered or certified mail, return receipt requested, in the manner provided for herein. Each party hereto hereby expressly and irrevocably waives any claim or defense in any such action or proceeding based on improper venue or *forum non conveniens* or any similar basis.

&nbsp;&nbsp;&nbsp;&nbsp;4.11Waiver of Jury Trial. TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW THAT CANNOT BE WAIVED, EACH PARTY HEREBY EXPRESSLY, INTENTIONALLY, AND DELIBERATELY WAIVES, AND COVENANTS THAT IT WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE), ANY RIGHT TO TRIAL BY JURY IN ANY FORUM IN RESPECT OF ANY ISSUE, CLAIM, DEMAND, ACTION OR CAUSE OF ACTION ARISING IN WHOLE OR IN PART UNDER, RELATED TO, BASED ON OR IN CONNECTION WITH THIS AGREEMENT OR THE SUBJECT MATTER HEREOF, WHETHER NOW EXISTING OR HEREAFTER ARISING AND WHETHER SOUNDING IN TORT OR CONTRACT OR OTHERWISE (EACH, A "CLAIM"). ANY PARTY HERETO MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS SECTION 4.11 WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF EACH SUCH PARTY TO THE WAIVER OF ITS RIGHT TO TRIAL BY JURY. In the event that the waiver of jury trial set forth in the previous sentence is not enforceable under the law applicable to this Agreement, the parties to this Agreement agree that any Claim, including any question of law or fact relating thereto, shall, at the written request of any party, be determined by judicial reference pursuant to Missouri law. The parties shall select a single neutral referee, who shall be a retired state or federal judge. In the event that the parties cannot agree upon a referee, the court shall appoint the referee. The referee shall report a statement of decision to the court. Nothing in this paragraph shall limit the right of any party at any time to exercise self- help remedies, foreclose against collateral or obtain provisional remedies. The parties shall bear the fees and expenses of the referee equally, unless the referee orders otherwise. The referee shall also determine all issues relating to the applicability, interpretation, and enforceability of this paragraph. The parties acknowledge that if a referee is selected to determine the Claims, then the Claims will not be decided by a jury.

&nbsp;&nbsp;&nbsp;&nbsp;4.12Use of Name. The Company will not make any reference to Enterprise Bank & Trust in connection with the Offering except with respect to its role as Escrow Agent hereunder, and in no event will the Company state or imply the Escrow Agent has investigated or endorsed the Offering in any manner whatsoever.

[SIGNATURE PAGE FOLLOWS]

------

IN WITNESS WHEREOF, the parties have executed this Agreement pursuant to due authority as of the date set forth above.

Company:

---

| | |
|:---|:---|
| **SPOTITEARLY INC.,** | **SPOTITEARLY INC.,** |
| a Delaware corporation  | a Delaware corporation  |
| EIN: 33-3773069 | EIN: 33-3773069 |
| By: | ![](spotex8_1.jpg)  |
| Name: Shai Lankry | Name: Shai Lankry |
| Its: CFO | Its: CFO |
| 3/31/2025 \| 4:07 PM PDT | 3/31/2025 \| 4:07 PM PDT |
| **Escrow Agent:** | **Escrow Agent:** |
| Enterprise Bank & Trust | Enterprise Bank & Trust |
| By: | ![](spotex8_2.jpg)  |
| Name: Ernesto Maldonado | Name: Ernesto Maldonado |
| Its: SVP, Specialty Escrow Officer | Its: SVP, Specialty Escrow Officer |
| 3/27/2025 \| 10:21 AM PDT | 3/27/2025 \| 10:21 AM PDT |

---

------

**EXHIBIT A** 

**DISBURSEMENT NOTICE**

**DISBURSEMENT OF OFFERING PROCEEDS**

To the Escrow Agent:

Enterprise Bank & Trust

Attn: Specialty Banking Group 1281 N. Warson

St. Louis, Missouri 63132

[DATE]

Re:Escrow Account No.SE-73069

Dear Escrow Agent:

&nbsp;&nbsp;&nbsp;&nbsp;1.Reference is made to that certain Escrow Agreement dated as of March 27, 2025 (the "Escrow Agreement") by and SPOTITEARLY INC., a Delaware corporation (the "Company"), and ENTERPRISE BANK & TRUST (in its capacity as escrow holder, the "Escrow Agent"). All terms used but not defined herein shall have the respective meanings given such terms in the Escrow Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;2.You are hereby directed to disburse Escrow Funds in the amount of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to the Company as follows:

______________________

[SIGNATURE PAGE FOLLOWS]

------

IN WITNESS WHEREOF, the undersigned has executed this statement as of the date first hereinabove set forth.

**Company:**

SPOTITEARLY INC.,

a Delaware corporation

EIN; 33-3773069

By: _________________

Name: Shai Lankry

Its: CFO

**Escrow Agent:**

Enterprise Bank & Trust

By: _________________

Name: Ernesto Maldonado

Its: SVP, Specialty Escrow Officer

------

**EXHIBIT B** 

**DISBURSEMENT NOTICE TERMINATION**

To the Escrow Agent:

Enterprise Bank & Trust

Attn: Specialty Banking Group 1281 N. Warson

St. Louis, Missouri 63132

[DATE]

Re: Escrow Account No. SE-73069 Dear Escrow Agent:

&nbsp;&nbsp;&nbsp;&nbsp;1.Reference is made to that certain Escrow Agreement dated as of March 27, 2025 (the "Escrow Agreement") by and among SPOTITEARLY INC., a Delaware corporation (the "Company"), and ENTERPRISE BANK & TRUST (in its capacity as escrow holder, the "Escrow Agent"). All terms used but not defined herein shall have the respective meanings given such terms in the Escrow Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;2.The Company has terminated the Offering prior to the disbursement of offering proceeds pursuant to Section 2.1(c) of the Escrow Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.You are hereby directed to disburse the Escrow Funds to Investors as follows:

[SIGNATURE PAGE FOLLOWS]

------

IN WITNESS WHEREOF, the undersigned has executed this statement as of the date first hereinabove set forth.

**Company:**

SPOTITEARLY INC.,

a Delaware corporation

EIN; 33-3773069

By: ____________________

Name: Shai Lankry

Its: CFO

**Escrow Agent:**

Enterprise Bank & Trust

By: ____________________

Name: Ernesto Maldonado

Its: SVP, Specialty Escrow Officer

------

**EXHIBIT C**

**DISBURSEMENT NOTICE CANCELLATION OF SUBSCRIPTION**

To the Escrow Agent:

Enterprise Bank & Trust

Attn: Specialty Banking Group 1281 N. Warson

St. Louis, Missouri 63132

[DATE]

Re: Escrow Account No. SE-73069 Dear Escrow Agent:

&nbsp;&nbsp;&nbsp;&nbsp;1.1. Reference is made to that certain Escrow Agreement dated as of March 27, 2025 (the "Escrow Agreement") by and among SPOTITEARLY INC., a Delaware corporation (the "Company"), and ENTERPRISE BANK & TRUST (in its capacity as escrow holder, the "Escrow Agent"). All terms used but not defined herein shall have the respective meanings given such terms in the Escrow Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;2.The Investor has terminated Investor's Subscription or the Company has rejected Investor's Subscription, in whole or in part, prior to the disbursement of offering proceeds pursuant to Section 2.1(d) of the Escrow Agreement and, if applicable, in compliance with Regulation CF, 17 C.F.R. 227.304.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.You are hereby directed to disburse the Escrow Funds to the Investor as follows:

_____________________

[SIGNATURE PAGE FOLLOWS]

------

IN WITNESS WHEREOF, the undersigned has executed this statement as of the date first hereinabove set forth.

**Company:**

SPOTITEARLY INC.,

a Delaware corporation

EIN; 33-3773069

By: _____________________

Name: Shai Lankry

Its: CFO

**Escrow Agent:**

Enterprise Bank & Trust

By:______________________

Name: Ernesto Maldonado

Its: SVP, Specialty Escrow Officer

------

**EXHIBIT D**

**ESCROW AGENT SCHEDULE OF FEES**

Escrow Account Servicing Fee (Annually):$1,000.00

Tax Reporting:$10.00/per 1099 filing

Outgoing Domestic Wire$25.00 per wire

Incoming Domestic Wire$12.50 per wire

International Wire$40.00 per wire

Escrow Repaper$500.00

Additional Disbursements$100.00 per disbursement

Demand Statements$6.00 per statement

\*Escrow fees due upon account opening. Disbursement fees may apply

NOTE: All other standard bank fees apply. Please see current fee schedule for a summary of all bank fees.

**The Escrow Account Servicing Fee, if not paid at the time of final disbursement of the funds, may debited by Escrow Agent from the balance remaining in the Escrow Account upon final disbursement of the funds to the Company in accordance with the Agreement.**

------

**SCHEDULE I**

**ESCROW ACCOUNT SIGNING AUTHORITY**

**Authorized Representative(s) of Company**

The undersigned certifies that each of the individuals listed below is an authorized representative of the Company with respect to any instruction or other action to be taken in connection with the Escrow Agreement and Enterprise Bank & Trust shall be entitled to rely on such list until a new list is furnished to Enterprise Bank & Trust.

---

| | |
|:---|:---|
| Signature: | Signature: |
| Print Name: | Print Name: |
| Title: | Title: |
| Phone:  | Phone:  |
| Email: | Email: |

---

The undersigned further certifies that he or she is duly authorized to sign this Escrow Account Signing Authority.

Signature: \*\*

Name:

Its:

Date:

\*\*To be signed by corporate secretary/assistant secretary. When the secretary is among those authorized above, the president must sign in the additional signature space provided below. For entities other than corporations, an authorized signatory not signing above should sign this Escrow Account Signing Authority.

(Additional signature, if required)`

Signature: \*\*

Name:

Its:

Date:

If Company is using an Intermediary, (as defined by Regulation CF, 17 C.F.R. Part 227), the following shall be authorized representatives of the Intermediary:

---

| | |
|:---|:---|
| Signature: | Signature: |
| Print Name: | Print Name: |
| Title: | Title: |
| Phone:  | Phone:  |
| Email: | Email: |

---

------

## Ex1A-11

**EXHIBIT 11.1**

**Consent of Independent Auditors**

We consent to the use in this Offering Circular on Form 1-A of our report dated July 25, 2025, relating to the ﬁnancial statements of SpotitEarly Ltd. We also consent to the reference to us under the heading "Experts" in such Offering Circular.

/s/ Brightman Almagor Zohar & Co.

Certiﬁed Public Accountants

A Firm in the Deloitte Global Network

Tel Aviv, Israel

July 25, 2025

------

**Consent of Independent Auditors**

We consent to the use in this Offering Circular on Form 1-A of our report dated July 25, 2025, relating to the ﬁnancial statements of SpotitEarly Inc. We also consent to the reference to us under the heading "Experts" in such Offering Circular.

/s/ Brightman Almagor Zohar & Co.

Certiﬁed Public Accountants

A Firm in the Deloitte Global Network

Tel Aviv, Israel

July 25, 2025

------

## Ex1A-11

**EXHIBIT 11.2**

**CONSENT OF ATTORNEYS**

Reference is made to the Offering Statement of SpotitEarly, Inc., whereby the Company proposes to sell shares of its Series A-1 Preferred Stock. Reference is also made to Exhibit 12 included as part of this Offering Statement relating to the validity of the securities proposed to be sold.

We hereby consent to the use of our opinion concerning the validity of the securities proposed to be issued and sold.

HART & HART, LLC

/s/ *William T. Hart*

Denver, Colorado

July 25, 2025

------

## Ex1A-12

**EXHIBIT 12**

***HART & HART, LLC***

ATTORNEYS AT LAW

1624 Washington Street

Denver, CO 80203

________harttrinen@aol.com

(303) 839-0061Fax: (303) 839-5414

July 25, 2025

SpotItEarly, Inc.

61 W. Palisade Ave.

Englewood, NJ 0763

This letter will constitute an opinion upon the legality of the sale by SpotItEarly, Inc., a Delaware corporation, (the "Company") of up to 10,489,509 shares of its Series A-1 Preferred Stock all as referred to in the Company's Offering Statement and Offering Circular filed with the Securities and Exchange Commission pursuant to Regulation A.

We have examined the Certificate of Incorporation, the Bylaws and the minutes of the Board of Directors of the Company, the applicable laws of the state of Delaware, and a copy of the Company's Offering Statement and Offering Circular. Based upon the foregoing, in our opinion the shares of Series A-1 Preferred Stock mentioned above, when sold in the manner described in the Company's Offering Statement and Offering Circular, will be legally issued and these shares will represent fully paid and non-assessable shares of the Company's Series A-1 Preferred Stock

---

| |
|:---|
| Very truly yours, |
| HART & HART, LLC |
| */s/ William T. Hart* |
| William T. Hart |

---

------

## Add

**EXHIBIT 99.1**

**SPOTITEARLY, INC.**

**2025 EQUITY INCENTIVE PLAN**

**ARTICLE 1**<br>**ESTABLISHMENT, PURPOSE, EFFECTIVE DATE, EXPIRATION DATE**

**1.1** **ESTABLISHMENT**. SpotitEarly, Inc., a Delaware corporation (the "Company"), hereby establishes the SpotitEarly, Inc. Equity Incentive Plan (the "Plan").

**1.2** **PURPOSE**. The purpose of the Plan is to advance the interests of the Company and its shareholders by enhancing the Company's ability to attract and retain qualified persons to perform services for the Company, by providing incentives to such persons to put forth maximum efforts for the Company and by rewarding persons who contribute to the achievement of the Company's economic objectives. To further these objectives, the Plan provides for the grant of Options, Restricted Stock and Stock Grants.

**1.3** **EFFECTIVE DATE**. The Plan will become effective on the date it is approved by the Company's Board of Directors and its shareholders (the "Effective Date").

**ARTICLE 2**<br>**GLOSSARY; CONSTRUCTION**

**2.1** **GLOSSARY**. When a word or phrase appears in this Plan document with the initial letter capitalized, and the word or phrase does not commence a sentence, the word or phrase will generally be given the meaning ascribed to it in Article 1 or in the attached Glossary, which is incorporated into and is part of the Plan. All of these key terms are listed in the Glossary. Whenever these key terms are used, they will be given the defined meaning unless a clearly different meaning is required by the context.

**2.2** **CONSTRUCTION**. The masculine gender, where appearing in the Plan, shall include the feminine gender (and vice versa), and the singular shall include the plural, unless the context clearly indicates to the contrary. If any provision of this Plan is determined to be for any reason invalid or unenforceable, the remaining provisions shall continue in full force and effect.

**ARTICLE 3**<br>**ELIGIBILITY AND PARTICIPATION**

**3.1** **GENERAL ELIGIBILITY**. Persons eligible to participate in this Plan include all employees, officers, Directors of, and Consultants to, the Company or any Affiliate. Awards may also be granted to prospective employees or Directors but no portion of any such Award will vest, become exercisable, be issued, or become effective prior to the date on which such individual begins to provide services to the Company or its Affiliates.

**3.2** **ACTUAL PARTICIPATION**. Subject to the provisions of the Plan, the Committee may, from time to time, select from among all eligible individuals, those to whom Awards will be granted and will determine the nature and amount of each Award.

**ARTICLE 4**<br>**ADMINISTRATION**

**4.1** **GENERAL**. The Plan shall be administered by the Board or a committee appointed by the Board. All references in the Plan to the "Committee" shall refer to the Committee or Board, as applicable. The Committee, by majority action thereof, is authorized to interpret the Plan, to prescribe, amend, and rescind rules and regulations as it may deem necessary or advisable to administer the Plan, to provide for conditions and assurances deemed necessary or advisable to protect the interests of the Company, and to make all other determinations necessary or advisable for the administration of the Plan, but only to the extent not contrary to the express provisions of the Plan. Determinations, interpretations, or other actions made or taken by the Committee in good faith pursuant to the provisions of the Plan shall be final, binding and conclusive for all purposes of the Plan.

------

**4.2** **COMMITTEE RESPONSIBILITIES**. Subject to the provisions of the Plan, the Committee shall have the authority to: (a) designate the Participants who are entitled to receive Awards under the Plan; (b) determine the types of Awards and the times when Awards will be granted; (c) determine the number of Awards to be granted and the number of shares of Stock to which an Award will relate; (d) determine the terms and conditions of any Award, including, but not limited to, the purchase price or exercise price or base value, the grant price, the period(s) during which such Awards shall be exercisable (whether in whole or in part); (e) any restrictions or limitations on the Award, any schedule for lapse of restrictions or limitations, and vesting terms, accelerations or waivers thereof, based in each case on such considerations as the Committee determines; (f) determine whether, to what extent, and in what circumstances an Award may be settled in, or the exercise price or purchase price of an Award may be paid in cash, Stock, or other Awards, or other property, or whether an Award may be canceled, forfeited, exchanged or surrendered; (g) prescribe the form of each Award Agreement, which need not be the same for each Participant; (h) decide all other matters that must be determined in connection with an Award; (i) interpret the terms of, and determine any matter arising pursuant to, the Plan or any Award Agreement; and (j) make all other decisions or determinations that may be required pursuant to the Plan or an Award Agreement as the Committee deems necessary or advisable to administer the Plan. The Committee shall also have the authority to modify existing Awards to the extent that such modification is within the power and authority of the Committee as set forth in the Plan.

**4.3** **DECISIONS FINAL**. The Committee shall have the authority to interpret the Plan and subject to the provisions of the Plan, any Award Agreement, and all decisions and determinations by the Committee with respect to the Plan are final, binding and conclusive on all parties. No member of the Committee shall be liable for any action or determination made in good faith with respect to the Plan or any Award granted under the Plan.

**ARTICLE 5**<br>**SHARES AVAILABLE FOR GRANT**

**5.1** **NUMBER OF SHARES**. Subject to adjustment as provided in Section 5.4, the aggregate number of shares of Stock reserved and available for grant pursuant to the Plan shall be 5,000,000. The shares of Stock delivered pursuant to any Award may consist, in whole or in part, of authorized by unissued Stock, treasury Stock not reserved for any other purposes, or Stock purchased on the open market.

**5.2** **SHARE COUNTING**. The following rules shall apply solely for purposes of determining the number of shares of Stock available for grant under the Plan at any given time:  ****

(a)In the event any Award granted under the Plan is terminated, expired, forfeited, or canceled for any reason, the number of shares of Stock subject to such Award will again be available for grant under the Plan (i.e., any prior charge against the limit set forth in Section 5.1 shall be reversed).

(b)Shares of Stock withheld or otherwise relinquished by a Participant to satisfy a tax withholding obligation arising in connection with an Award will not again become Stock available for grant under the Plan.

(c)If the provisions of this Section 5.2 are inconsistent with the requirements of any regulations issued pursuant to Section 422 of the Code, the provisions of such regulations shall control over the provisions of this Section 5.2, but only as this Section 5.2 relates to Incentive Stock Options.

(d)The Committee may adopt such other reasonable rules and procedures as it deems to be appropriate for determining the number of shares of Stock that are available for grant under Section 5.1.

**5.3** **AWARD LIMITS**. Notwithstanding any other provision in the Plan, and subject to adjustment as provided in Section 5.4:

(a)The maximum number of shares of Stock that may be issued as Incentive Stock Options under the Plan shall be the same numeric limit set forth in Section 5.1. ****

**5.4** **ADJUSTMENT IN CAPITALIZATION**. In the event of any change in the outstanding shares of Stock by reason of a Stock dividend or split, recapitalization, liquidation, merger, consolidation, combination, exchange of shares, or other similar corporate change, the Committee shall make a proportionate adjustment in: (a) the number and class of shares of Stock made available for grant pursuant to Section 5.1; (b) the number of shares of Stock set forth in Section 5.3, 11.9, and any other similar numeric limit expressed in the Plan; (c) the number and class of and/or price of shares of Stock subject to then

------

outstanding Awards; or (d) any other terms of an Award that are affected by the event. Moreover, in the event of such transaction or event, the Committee, in its discretion may provide in substitution for any or all outstanding awards under the Plan such alternative consideration (including cash) as it, in good faith, may determine to be equitable under the circumstances and may require in connection therewith the surrender of all Awards so replaced. Any action taken pursuant to this Section 5.4 shall be taken in a manner consistent with the requirements of Section 409A of the Code and, in the case of Incentive Stock Options, in accordance with the requirements of Section 424(a) of the Code.

**5.5** **REPLACEMENT AWARDS**. In the event of any corporate transaction in which the Company or an Affiliate acquires a corporate entity which, at the time of such transaction, maintains an equity compensation plan pursuant to which awards of stock options, stock appreciation rights, restricted stock, or any other form of equity based compensation are then outstanding (the "Acquired Plan"), the Committee may make Awards to assume, substitute or convert such outstanding awards in such manner as may be determined to be appropriate and equitable by the Committee; provided, however, that the number of shares of Stock subject to any Award shall always be a whole number by rounding any fractional share to the nearest whole share. Options issued pursuant to this Section 5.5 shall not be subject to the requirement that the exercise price of such Award not be less than the Fair Market Value of Stock on the date the Award is granted. Shares used in connection with an Award granted in substitution for an award outstanding under an Acquired Plan under this Section 5.5 shall not be counted against the number of shares of Stock available for grant under Section 5.1.

**5.6** **FRACTIONAL SHARES**. No fractional shares of Stock shall be issued pursuant to the Plan. Unless the Committee specifies otherwise in the Award Agreement, or pursuant to any policy adopted by the Committee, cash will be given in lieu of fractional shares. In the event of adjustment as provided in Section 5.4 or the issuance of replacement awards as provided in Section 5.5, the total number of shares of Stock subject to any affected Award shall always be a whole number by rounding any fractional share to the nearest whole share.

**ARTICLE 6**<br>**STOCK OPTIONS**

**6.1** **OPTIONS**. Subject to the terms and provisions of the Plan the Committee, at any time and from time to time, may grant Options to one or more Participants upon such terms and conditions and in such amounts, as shall be determined by the Committee. Options are also subject to the following additional terms and conditions:

(a)**Exercise Price**. No Option shall be granted at an exercise price that is less than the Fair Market Value of one share of Stock on the Grant Date. Notwithstanding the foregoing, the Committee may grant an Option with an exercise price per share that is less than 100 percent of the Fair Market Value on the Grant Date to Participants who are not subject to U.S. income tax as of the Grant Date, including pursuant to any sub-plan of the Plan.

(b)**Exercise of Option**. Options shall be exercisable at such times and in such manner, and shall be subject to such restrictions or conditions, as the Committee shall in each instance approve, which need not be the same for each grant or for each Participant.

(c)**Notice of Exercise**. The signing by the Participant, and delivery to the Company (at its principal office), of an exercise notice, in such form as prescribed by the Company, which will include the following: (i) the identity of the Participant, (ii) the number of Options to be exercised per each grant, and (iii) the Exercise Price to be paid (the "**Notice of Exercise**"). The Committee may require, as specified in the applicable Award Agreement, that the Participant provide any additional documents, forms, or declarations necessary for the Company or its Affiliates to comply with applicable laws. If the Participant fails to timely and properly deliver all such required documentation, the Company shall have the right to withhold the issuance of the shares underlying the Award, and the Participant's right to receive such shares shall be forfeited without any further obligation or liability on the part of the Company or its Affiliates.

(d)**Term of Option**. Each Option shall expire at such time as determined by the Committee; provided, however, that no Option shall be exercisable later than the tenth (10th) anniversary the Grant Date.

(e)**Vesting Schedule.** Options that are granted on a certain date shall, subject to continued employment with or service to the Company or any of its Affiliates by the Participant, become (i) vested and exercisable, with respect to Options in accordance with the vesting schedule as shall be determined by the Board for each Participant and detailed in the respective Award Agreement. Unless otherwise determined by the Board, in its sole discretion, or except as required by applicable Law, the vesting of Options shall be suspended during any unpaid leave of absence by the Participant, and such

------

Options shall not continue to vest during such period. Upon the lapse of such period of un-paid leave and subject to return to employment or service by Participant, the vesting shall continue and each of the remaining vesting dates shall be postponed by the number of days of such period of un-paid leave (i.e. shifting the entire remaining vesting schedule and extending it by the number of unpaid leave days). Despite the aforementioned, it is hereby clarified that statutory paid maternity/paternity leave and/or military reserve duty shall not be deemed "unpaid leave of absence" and shall not suspend or postpone the vesting of the Options.

(f)**Expenses**. All costs and expenses including broker fees and bank commissions, derived from the exercise of the Options or issuance of the underlying shares, shall be borne solely by the Participant.

(g)**Repricing of Options** **.** With the approval of the Board of Directors, (i) an Option may be amended, modified or repriced to reduce the exercise price after the Grant Date, and (ii) an Option also may be surrendered in consideration of a new Option having an exercise price below the exercise price of the Option being surrendered or exchanged.

(h)**Non-transferability of Options**. No Option may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution. Further, all Options granted to a Participant shall be exercisable during his or her lifetime only by such Participant or his or her legal representative. Notwithstanding the foregoing, the Committee may, in its discretion, permit the transfer of an Option to a Family Member, trust or partnership, or to a charitable organization, provided that no value or consideration is received by the Participant with respect to such transfer.

**6.2** **INCENTIVE STOCK OPTIONS**. Incentive Stock Options shall be granted only to Participants who are employees and the terms of any Incentive Stock Options granted pursuant to the Plan must comply with the following additional provisions of this Section 6.2:

(a)**Exercise Price**. Subject to Section 6.2(e), the exercise price per share of Stock pursuant to any Incentive Stock Option shall be set by the Committee, provided that the exercise price for any Incentive Stock Option shall not be less than the Fair Market Value of one share of Stock as of the Grant Date.

(b)**Term of Incentive Stock Option**. In no event may any Incentive Stock Option be exercisable for more than ten (10) years from the Grant Date.

(c)**Lapse of Option**. An Incentive Stock Option shall lapse in the following circumstances:

(1)The Incentive Stock Option shall lapse ten (10) years from the Grant Date, unless an earlier time is set in the Award Agreement;

(2)The Incentive Stock Option shall lapse upon a Termination of Employment for any reason other than the Participant's death or Disability, unless otherwise provided in the Award Agreement; and

(3)If the Participant incurs a Termination of Employment on account of Disability or death before the Option lapses pursuant to paragraph (i) or (ii) above, the Incentive Stock Option shall lapse, unless it is previously exercised, on the earlier of: (a) the scheduled termination date of the Option; or (b) twelve months after the date of the Participant's Termination of Employment on account of death or Disability. Upon the Participant's death or Disability, any Incentive Stock Options exercisable at the Participant's death or Disability may be exercised by the Participant's legal representative or representatives, by the person or persons entitled to do so pursuant to the Participant's last will and testament, or, if the Participant fails to make testamentary disposition of such Incentive Stock Option or dies intestate, by the person or persons entitled to receive the Incentive Stock Option pursuant to the applicable laws of descent and distribution.

(d)**Individual Dollar Limitation**. The aggregate Fair Market Value (determined as of the time an Award is made) of all shares of Stock with respect to which Incentive Stock Options are first exercisable by a Participant in any calendar year may not exceed $100,000 or such other limitation as imposed by Section 422(d) of the Code, or any successor provision. To the extent that Incentive Stock Options are first exercisable by a Participant in excess of such limitation, the excess shall be considered Non-Qualified Stock Options.

------

(e)**Ten Percent Owners**. An Incentive Stock Option may be granted to any individual who, at the Grant Date, owns stock possessing more than ten percent (10%) of the total combined voting power of all classes of Stock of the Company only if such Option is granted at a price that is not less than 110% of Fair Market Value on the Grant Date and the Option is exercisable for no more than five (5) years from the Grant Date.

(f)**Right to Exercise**. Except as provided in Section 6.2(c)(iii), an Incentive Stock Option may be exercised only by the Participant during the Participant's lifetime.

(g)**Limitation on Number of Shares Subject to Awards**. In accordance with Section 5.3(a), but subject to adjustment as provided in Section 5.4, the maximum number of shares of Stock that may be issued as Incentive Stock Options under the Plan shall be the same numeric limit set forth in Section 5.1.

**ARTICLE 7**<br>**RESTRICTED STOCK**

**7.1** **RESTRICTED STOCK**. Subject to the terms and provisions of the Plan, the Committee, at any time and from time to time, may grant Restricted Stock to one or more Participants upon such terms and conditions, and in such amounts, as shall be determined by the Committee. Restricted Stock Awards are also subject to the following additional terms and conditions:

(a)**Issuance and Restrictions**. Restricted Stock shall be subject to such conditions and/or restrictions as the Committee may impose (including, without limitation, limitations on transferability, the right to receive dividends, or the right to vote the Restricted Stock), which need not be the same for each grant or for each Participant. These restrictions may lapse separately or in combination at such times, pursuant to such circumstances, in such installments, or otherwise, as determined by the Committee.

(b)**Forfeiture**. Except as otherwise provided in the Award Agreement, upon a Termination of Employment (or Termination of Service in the case of a Consultant or Director) during the applicable period of restriction, Restricted Stock that is at that time subject to restrictions shall be forfeited.

(c)**Evidence of Ownership for Restricted Stock**. Restricted Stock granted pursuant to the Plan may be evidenced in such manner as the Committee shall determine, which may include an appropriate book entry credit on the books of the Company or a duly authorized transfer agent of the Company. If certificates representing shares of Restricted Stock are registered in the name of the Participant, the certificates must bear an appropriate legend referring to the terms, conditions, and restrictions applicable to such Restricted Stock, and the Company may, in its discretion, retain physical possession of the certificate until such time as all applicable restrictions lapse.

**ARTICLE 8**<br>**CHANGE IN CONTROL**

**8.1** **PARTICIPANT CONSENT NOT REQUIRED**. Except as provided in the Delaware General Corporation law, nothing in this Section 10 or any other provision of this Plan is intended to provide any Participant with any right to consent to or object to any transaction that might result in a Change in Control and each provision of this Plan shall be interpreted in a manner consistent with this intent. Similarly, nothing in any provision of this Plan is intended to provide any Participant with any right to consent to or object to any action taken by the Board or Committee in connection with a Change in Control transaction.

**ARTICLE 9**<br>**OTHER PROVISIONS APPLICABLE TO AWARDS**

**9.1** **AWARD AGREEMENTS.** All Awards shall be evidenced by an Award Agreement. The Award Agreement shall include such terms and provisions as the Committee determines appropriate. The terms of the Award Agreement may vary depending on the type of Award, the employee or classification of the employee to whom the Award is made and such other factors as the Committee deems appropriate.

------

**9.2** **TERMINATION OF EMPLOYMENT OR SERVICE**. Subject to the provisions of this Plan, the Committee shall determine and set forth in the applicable Award Agreement the extent to which a Participant shall have the right to retain and/or exercise an Award following a Termination of Employment or (Termination of Service in the context of a Consultant or Director). Such provisions need not be uniform among all types of Awards and may reflect distinctions based on the reasons for such terminations, including, but not limited to, death, Disability, a termination for Cause or reasons relating to the breach or threatened breach of restrictive covenants.

9.2.1If a Participant ceases to be an employee, director, or Consultant of the Company or any of its Affiliates for any reason ("**Termination of Employment**") other than death, Retirement, Disability or Cause, then (A) any vested but unexercised Options on the date of Termination of Employment (as shall be determined by the Company, in its sole discretion), may be exercised, if not previously expired, not later than the earlier of (i) 3 months after the date of Termination of Employment, unless otherwise determined by the Committee; or (ii) the Term of the Options.

9.2.2All other unvested Options or Restricted Stocks (that were subject to revesting) shall expire upon the date of Termination of Employment.

9.2.3In the event of Termination of Employment of a Participant for Cause, then (A) the Participant's right to exercise any unexercised Options, granted to such Participant, whether vested or not on the date of Termination of Employment, shall cease as of such date of Termination of Employment, and the Options shall thereupon expire and (B) the rights to any underlying Shares or Restricted Stocks shall terminate and expire, and any such shares shall be forfeited by the Company, on the day the Participant is notified of his dismissal or on such earlier date as the Committee may determine, in its sole discretion.

9.2.4If subsequent to the Participant's Termination of Employment, but prior to the exercise of Options granted to such Participant, the Administrator determines that either prior or subsequent to the Participant's Termination of Employment, the Participant engaged in conduct which would constitute Cause, then the Participant's right to exercise the Options granted to such Participant shall immediately cease upon such determination and the Options shall thereupon expire.

9.2.5The determination by the Committee as to the occurrence of Cause shall be final and conclusive for all purposes of this Plan.

9.2.6 *Death*. If Termination of Employment is by reason of death of the Participant, then (1) his/her estate, personal representative or beneficiaries may exercise the Participant's Options, to the extent it was vested within the 60th day after the Participant's death, at any time but not later than the first to occur of: (i) one (1) year following Participant's death; or (ii) the end of the Term of the Options and (2) any rights upon vested Shares shall be delivered to Participant's estate, personal representative or beneficiaries but only to the extent it was vested within the 60th day after Participant's death. All other Options or unvested Shares for the benefit of a Participant and which have not vested within 60 days after the date of Death, shall expire upon the lapse of such period.

9.2.7 *Disability and Retirement*. If Termination of Employment is by reason of Retirement or Disability of the Participant, then the Participant (1) may exercise any portion of the Options which have vested within 60 days after the date of Retirement or Disability, at any time but not later than the first to occur of: (i) one (1) year after the date of Retirement or Disability, as the case may be; or (ii) the end of the Term of the Options and (2) shall be entitled to any rights upon vested Shares to be delivered to Participant's estate, personal representative or beneficiaries but only to the extent it was vested within the 60th day after the date of Retirement or Disability. All other Options or Shares for the benefit of a Participant and which have not vested within 60 days after the date of Disability or Retirement, as the case may be, shall expire upon the lapse of such period, as applicable.

9.2.8Exceptions. In special circumstances, pertaining to the Termination of Employment of a certain Participant, the Committee may in its discretion decide to extend any of the periods stated above in Section 9.2.1-9.2.7. Any and all tax consequence of such extension of such exercise periods, if any, shall be solely borne by the Participant.

9.2.9Transfer of Employment or Services. A Participant's right to Options or Granted Shares that were granted or issued to him or her under this Plan, shall not be terminated or expire or forfeited, and no Termination of Employment shall be deemed to occur, solely as a result of (i) the fact that the Participant's employment or service as an employee, director or Consultant changes from the Company to an Affiliate or vice versa; or (ii) a change in Participant's engagement status between an employee, director or Consultant and vice versa, provided in case of the foregoing clauses (i) and (ii) above, that

------

the Participant has remained continuously employed by and/or in the service of the Company and its Affiliates throughout such period. Any and all tax consequence of such a transfer, if any, shall be solely borne by the Participant.

**9.3** **FORM OF PAYMENT**. Subject to the provisions of this Plan, the Award Agreement and any applicable law, payments or transfers to be made by the Company or any Affiliate on the grant or exercise of any Award shall be made in cash, unless the Committee determines otherwise. The Committee may authorize that any payment or transfer to be made including, without limitation, in cash, Stock, other Awards, or other property, or any combination thereof, and may further determine whether such payment or transfer may be made in a single payment or transfer, in installments, or any combination thereof, in each case in accordance with rules adopted by the Committee and as shall be allowed by any applicable law. The Committee may also prescribe in the applicable Award Agreement, other methods by which the exercise price of an Option may be paid and the form of payment including, without limitation, any net-issuance arrangement or other property acceptable to the Committee (including broker-assisted "cashless exercise" arrangements), and the methods by which shares of Stock shall be delivered or deemed to be delivered to Participants.

**9.4** **LIMITS ON TRANSFER**.

(a)**General**. Except as provided elsewhere in this Plan, no Award granted under the Plan may be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution or pursuant to a domestic relations order (that would otherwise qualify as a qualified domestic relations order as defined in the Code or Title I of ERISA but for the fact that the order pertains to an Award) in favor of a spouse or, if applicable, until the expiration of any period during which any restrictions are applicable as determined by the Committee.

(b)**Transfer to Family Members**. The Committee shall have the authority to adopt a written policy that is applicable to existing Awards, new Awards, or both, which permits a Participant to transfer Awards during his or her lifetime to any Family Member. In the event an Award is transferred as permitted by such policy, such transferred Award may not be subsequently transferred by the transferee (other than another transfer meeting the conditions set forth in the policy) except by will or the laws of descent and distribution. A transferred Award shall continue to be governed by and subject to the terms and limitations of the Plan and relevant Award Agreement, and the transferee shall be entitled to the same rights as the Participant, as if the transfer had not taken place.

**9.5** **BENEFICIARIES**. Notwithstanding Section 11.4(a), a Participant may, in the manner determined by the Committee, designate a beneficiary to exercise the rights of the Participant and to receive any distribution with respect to any Award upon the Participant's death, and in accordance with Section 6.2(c)(iii), upon the Participant's Disability. A beneficiary, legal guardian, legal representative, or other person claiming any rights pursuant to the Plan is subject to all terms and conditions of the Plan and any Award Agreement applicable to the Participant, except to the extent the Plan and Award Agreement otherwise provide, and to any additional restrictions deemed necessary or appropriate by the Committee. If no beneficiary has been designated or survives the Participant, payment shall be made to the person entitled thereto pursuant to the Participant's will or the laws of descent and distribution. Subject to the foregoing, a beneficiary designation may be changed or revoked by a Participant at any time provided the change or revocation is provided to the Committee.

**9.6** **EVIDENCE OF OWNERSHIP**. Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any certificates, make any book entry credits, or take any other action to evidence shares of Stock pursuant to the exercise of any Award, unless and until the Company has determined, with advice of counsel, that the issuance and delivery of such certificates, book entry credits, or other evidence of ownership is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange or quotation system on which the shares of Stock are listed, quoted or traded. All Stock certificates, book entry credits, or other evidence of ownership delivered pursuant to the Plan are subject to any stop-transfer orders and other restrictions as the Company deems necessary or advisable to comply with Federal, state, or foreign jurisdiction, securities or other laws, rules and regulations and the rules of any national securities exchange or automated quotation system on which the Stock is listed, quoted, or traded. The Company may place legends on any Stock certificate to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Company may require that a Participant make such reasonable covenants, agreements, and representations as the Company, in its discretion, deems advisable in order to comply with any such laws, regulations, or requirements.

**9.7** **CLAWBACK**. Every Award issued pursuant to this Plan is subject to potential forfeiture or recovery to the fullest extent called for by law, any applicable listing standard, or any current or future clawback policy that may be adopted by the Company from time to time. By accepting an Award, each Participant consents to the potential forfeiture or recovery of his or her Awards pursuant to the Company clawback policy, and agrees to be bound by and comply with the clawback

------

policy and to return the full amount required by the clawback policy. As a condition to the receipt of any Award, a Participant may be required to execute any requested additional documents consenting to and agreeing to abide by the Company clawback policy as it may be amended from time to time.

**ARTICLE 10**<br>**AMENDMENT, MODIFICATION, AND TERMINATION**

**10.1** **AMENDMENT, MODIFICATION AND TERMINATION OF THE PLAN**. The Board may at any time, and from time to time, terminate, amend or modify the Plan; provided however, that any such action of the Board shall be subject to approval of the shareholders to the extent required by law or regulation. Notwithstanding the above, to the extent permitted by law, the Board may delegate to the Committee or the CEO the authority to approve non-substantive amendments to the Plan. Except as provided in Section 5.4, neither the Board, the CEO, nor the Committee may, without the approval of the shareholders: (a) reduce the exercise price or base value of any outstanding Award, including any Option; (b) increase the number of shares available under the Plan; (c) grant Options with an exercise price or base value that is below Fair Market Value on the Grant Date; (d) reprice previously granted Options or take any action relative to any Options that would be treated as a repricing; (e) cancel any Option in exchange for cash or any other Award or in exchange for any Option with an exercise price or base value that is less than the exercise price or base value for the original Option; (f) extend the exercise period or term of any Option beyond 10 years from the Grant Date; (g) expand the types of Award available for grant under the Plan; or (h) expand the class of individuals eligible to participant in the Plan.

**10.2** **AWARDS PREVIOUSLY GRANTED**. No amendment, modification, or termination of the Plan or any Award under the Plan shall in any manner adversely affect in any material way the rights of the holder under any Award previously granted pursuant to the Plan without the prior written consent of the holder of the Award. Such consent shall not be required if the change: (a) is required by law or regulation; (b) does not adversely affect in any material way the rights of the holder; (c) is required to cause the benefits under the Plan to comply with the requirements of Section 409A of the Code; or (d) is made pursuant to any adjustment described in Section 5.4.

**ARTICLE 11**<br>**TAX WITHHOLDING**

The Company shall have the power to withhold, or require a Participant to remit to the Company, the minimum amount necessary to satisfy federal, state, and local withholding tax requirements on any Award under the Plan. The Company may permit the Participant to satisfy a tax withholding obligation by: (a) directing the Company to withhold shares of Stock to which the Participant is entitled pursuant to the Award in an amount necessary to satisfy the Company's applicable federal, state, local or foreign income and employment tax withholding obligations with respect to such Participant; (b) tendering previously-owned shares of Stock held by the Participant for six (6) months or longer to satisfy the Company's applicable federal, state, local, or foreign income and employment tax withholding obligations with respect to the Participant (which holding period may be waived in accordance with Section 6.1(d)); (c) a broker-assisted "cashless" transaction; or (d) personal check or other cash equivalent acceptable to the Company.

**ARTICLE 12**<br>**INDEMNIFICATION**

Each person who is or shall have been a member of the Committee or of the Board shall be indemnified and held harmless by the Company against and from any loss, cost, liability, or expense that may be imposed upon or reasonably incurred by him or her in connection with or resulting from any claim, action, suit, or proceeding to which he or she may be a party or in which he or she may be involved by reason of any action taken or failure to act under the Plan and against and from any and all amounts paid by him or her in settlement thereof, with the Company's approval, or paid by him or her in satisfaction of any judgment in any such action, suit, or proceeding against him or her, provided he or she shall give the Company an opportunity, at its own expense, to handle and defend the same before he undertakes to handle and defend it on his or her behalf. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which such person may be entitled under the Company's articles of incorporation, bylaws, resolution or agreement, as a matter of law, or otherwise.

------

**ARTICLE 13**<br>**GENERAL PROVISIONS**

**13.1** **NO RIGHTS TO AWARDS**. No Participant or other person shall have any claim to be granted any Award and neither the Company nor the Committee is obligated to treat Participants and other persons uniformly.

**13.2** **CONTINUED EMPLOYMENT**. Nothing in the Plan or any Award Agreement shall interfere with or limit in any way the right of the Company or any Affiliate to terminate any Participant's employment or service at any time, nor confer upon any Participant any right to continue in the employ or service of the Company.

**13.3** **FUNDING**. The Company shall not be required to segregate any of its assets to ensure the payment of any Award under the Plan. Neither the Participant nor any other persons shall have any interest in any fund or in any specific asset or assets of the Company or any other entity by reason of any Award, except to the extent expressly provided hereunder. The interests of each Participant and former Participant hereunder are unsecured and shall be subject to the general creditors of the Company.

**13.4** **EXPENSES**. The expenses of administering the Plan shall be borne by the Company.

**13.5** **NO SHAREHOLDERS RIGHTS**. No Award gives the Participant any of the rights of a shareholder of the Company unless and until shares of Stock are in fact issued to such person in connection with such Award.

**13.6** **TITLES AND HEADINGS**. The titles and headings of the Sections in the Plan are for convenience of reference only and, in the event of any conflict, the text of the Plan, rather than such titles or headings, shall control.

**13.7** **SUCCESSORS AND ASSIGNS**. The Plan shall be binding upon and inure to the benefit of the successors and permitted assigns of the Company, including without limitation, whether by way of merger, consolidation, operation of law, assignment, purchase, or other acquisition of substantially all of the assets or business of the Company, and any and all such successors and assigns shall absolutely and unconditionally assume all of the Company's obligations under the Plan.

**13.8** **SURVIVAL OF PROVISIONS**. The rights, remedies, agreements, obligations and covenants contained in or made pursuant to this Plan, any Agreement, and any other notices or agreements in connection therewith, shall survive the execution and delivery of such notices and agreements and the delivery and receipt of such shares of Stock.

**13.9** **REQUIREMENTS OF LAW**. The granting of Awards and the issuance of shares and/or cash under the Plan shall be subject to all applicable laws, rules, and regulations as may be required. The Company shall be under no obligation to register pursuant to the Securities Act of 1933, any of the shares of Stock paid pursuant to the Plan. If the shares of Stock paid pursuant to the Plan may in certain circumstances be exempt from registration pursuant to the Securities Act of 1933, the Company may restrict the transfer of such shares in such manner as it deems advisable to ensure the availability of any such exemption. The Committee shall impose such restrictions on any Award as it may deem advisable, including without limitation, restrictions under applicable federal securities law, and under any other blue sky or state securities law applicable to such Award.

**13.10** **GOVERNING LAW**. The place of administration of the Plan shall be conclusively deemed to be within the State of Delaware, and the rights and obligations of any and all persons having or claiming to have had an interest under the Plan or any Award Agreement shall be governed by and construed exclusively and solely in accordance with the laws of the State of Delaware without regard to the conflict of law provisions of any jurisdictions. All parties agree to submit to the jurisdiction of the state and federal courts of Delaware with respect to matters relating to the Plan and agree not to raise or assert the defense that such forum is not convenient for such party. The Plan is an unfunded performance-based bonus plan for a select group of management or highly compensated employees and is **not** intended to be either an employee pension or welfare benefit plan subject to ERISA.

------

**13.11** **SECTION 409A OF THE CODE**.

(a)**General Compliance**. Some of the Awards that may be granted pursuant to the Plan (including, but not necessarily limited to, Restricted Stock Units Awards, and Stock Unit Awards) may be considered to be "nonqualified deferred compensation" subject to Section 409A of the Code. If an Award is subject to Section 409A of the Code, the Company intends (but cannot and does not guarantee) that the Award Agreement and this Plan comply with and meet all of the requirements of Section 409A of the Code or an exception thereto and the Award Agreement shall include such provisions, in addition to the provisions of this Plan, as may be necessary to assure compliance with Section 409A of the Code or an exception thereto.

(b)**Prohibition on Acceleration or Deferral**. Under no circumstances may the time or schedule of any payment for any Award that is subject to the requirements of Section 409A of the Code be accelerated or subject to further deferral except as otherwise permitted or required pursuant to regulations and other guidance issued pursuant to Section 409A of the Code. If the Company fails to make any payment pursuant to the payment provisions applicable to an Award that is subject to Section 409A of the Code, either intentionally or unintentionally, within the time period specified in such provisions, but the payment is made within the same calendar year, such payment will be treated as made within the specified time period. In addition, in the event of a dispute with respect to any payment, such payment may be delayed in accordance with the regulations and other guidance issued pursuant to Section 409A of the Code.

------

**GLOSSARY**

**(a)**"Affiliate" means any member of a "controlled group of corporations" (within the meaning of Section 414(b) of the Code as modified by Section 415(h) of the Code) that includes the Company as a member of the group. In applying Section 1563(a)(1), (2) and (3) of the Code for purposes of determining the members of a controlled group of corporations under Section 414(b) of the Code, the language "at least 50 percent" shall be used instead of "at least 80 percent" each place it appears in Section 1563(a)(1), (2) and (3).

**(b)**"Award" means any Option or Restricted Stock granted to a Participant under the Plan.

**(c)**"Award Agreement" means any written agreement, contract, or other instrument or document, including an electronic agreement or document, evidencing an Award.

**(d)**"Board" means the Company's Board of Directors, as constituted from time to time.

**(e)**"Cause" means any of the following:

(1)Participant's commission of, or assistance to or conspiracy with others to commit, fraud, misrepresentation, theft or embezzlement of Company assets;

(2)Participant's material intentional violations of law or of material Company policies;

(3)Participant's repeated insubordination or willful failure to substantially perform his or her employment duties or duties as a Director; or

(4)Participant's willful engagement in conduct that is demonstrably and materially injurious to the Company or any Affiliate.

**(f)**"CEO" means the Chief Executive Officer of the Company.

**(g)**"Change in Control" means any of the following:

(1)The sale, lease, exchange or other transfer of all or substantially all of the Company's assets in one transaction or in a series of related transactions;

(2)any person (as such term is used in Section 13(d) and 14(d) of the Exchange Act) becoming directly or indirectly the "beneficial owner" (as defined in Rule 13d-3 under the Exchange Act), of securities representing 50% or more of the combined voting power of the Company's outstanding securities ordinarily having the right to vote at the elections of directors; or

(3)individuals who constitute the Board as of the Effective Date cease for any reason to constitute at least a majority of the Board, provided that any person becoming a director subsequent to the Effective Date whose election, or nomination for election by the Company's shareholders, was approved by a vote of at least a majority of the directors comprising or deemed pursuant hereto to comprise the Board as of the Effective Date (either by a specific vote or by approval of the proxy statement of the Company in which such person is named as a nominee for director) shall be, for purposes of this clause, considered as though such person were a member of the Board as of the Effective Date of the Plan.

(4)For sake of clarity, a "Change in Control" will not be deemed to have occurred for purposes of the Plan until the transaction (or services of transactions) that would otherwise be considered a "Change in Control" closes. The transfer of Stock or assets of the Company in connection with a bankruptcy filing by or against the Company under Title 11 of the United States Code will not be considered to be a "Change in Control" for purposes of this Plan. Notwithstanding the foregoing a "Change in Control" shall not occur for purposes of this Plan in the case of Awards that are subject to the requirements of Section 409A of the Code unless such "Change in Control" constitutes a "change in control event" as defined in Section 409A of the Code and the regulations thereunder. ****

------

**(h)**"Code" means the Internal Revenue Code of 1986, as amended. All references to the Code shall be interpreted to include a reference to any applicable regulations, rulings or other official guidance promulgated pursuant to such section of the Code.

**(i)**"Committee" except as set forth in Section 4.1, means the Committee appointed by the Board.

**(j)**"Company" means SpotitEarly, Inc., a Delaware Company.

**(k)**"Consultant" means a consultant or adviser that provides bona fide services to the Company or an Affiliate as an independent contractor and not as an employee; provided, however that such person may become a Participant in the Plan only if the Consultant: (i) is a natural person, including any individual engaged by an entity providing services to the Company or an Affiliate; and (ii) does not provide services in connection with the offer or sale of the Company's securities in a capital-raising transaction and do not promote or maintain a market for the Company's securities.

**(l)**"Disability" means the inability of a Participant to engage in any substantially gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than 12 months. The permanence and degree of impairment shall be supported by medical evidence. For purposes of an Incentive Stock Option, "Disability" shall have the meaning ascribed to it in Section 22(e)(3) of the Code.

**(m)**"Effective Date" means the date the Plan is approved by the Board.

**(n)**"ERISA" means the Employee Retirement Income Security Act of 1974, as amended. All references to a section of ERISA shall be interpreted to include a reference to any applicable regulations, rulings or other official guidance promulgated pursuant to such section of ERISA.

**(o)**"Exchange Act" means the Securities Exchange Act of 1934, as amended from time to time. All references to the Exchange Act shall be interpreted to include a reference to any applicable regulations, rulings or other official guidance promulgated pursuant to such section of the Exchange Act.

**(p)**"Expiration Date" means the tenth (10th) anniversary of the Effective Date.

**(q)**"Fair Market Value" means, the fair market value of Stock on a particular date determined by the reasonable application of reasonable valuation methods or procedures as may be established from time to time by the Board. The Board shall use such procedures to determine fair market value in compliance with Section 409A of the Code and the regulations issued thereunder. Notwithstanding anything in the Plan to the contrary, the Board may not delegate its authority to determine fair market value.

**(r)**"Family Member" means a Participant's spouse and any parent, stepparent, grandparent, child, stepchild, or grandchild, including adoptive relationships or a trust or any other entity in which these persons (or the Participant) have more than 50% of the beneficial interest.

**(s)**"Good Reason" means any of the following:

(1)A material reduction of Participant's duties, authority or responsibilities, in effect immediately prior to such reduction;

(2)A material reduction of Participant's then-existing base salary; or

(3)The Company's decision to relocate a Participant's principal place of work by more than 50 miles.

**(t)**"Grant Date" means the date the Committee approves the Award or a date in the future on which the Committee determines the Award will become effective.

------

**(u)**"Incentive Stock Option" means an Option that is intended to meet the requirements of Section 422 of the Code or any successor provision thereto.

**(v)**"Director" means a member of the Company's Board.

**(w)**"Non-Qualified Stock Option" means an Option that is not intended to be an Incentive Stock Option.

**(x)**"Option" means a right granted to a Participant under Section 6. An Option may be either an Incentive Stock Option or a Non-Qualified Stock Option.

**(y)**"Participant" means a person who has been granted an Award under the Plan.

**(z)**"Plan" means this SpotitEarly, Inc. Equity Incentive Plan, as amended from time to time.

**(aa)**"Restricted Stock" means Stock granted to a Participant under Section 7.

**(bb)**"Retirement" means the termination of a Participant's employment as a result of his or her reaching the earlier of (i) the age of retirement as defined by applicable law; or (ii) the age of retirement specified in the Participant's employment agreement.

**(cc)**"Securities Act" means the Securities Act of 1933, as amended from time to time. All references to the Securities Act shall be interpreted to include a reference to any applicable regulations, rulings or other official guidance promulgated pursuant to such section of the Securities Act.

**(dd)**"Separation from Service" is a term that applies only in the context of an Award that the Company concludes is subject to Section 409A of the Code. In that limited context, the term "Separation from Service" means either: (i) the termination of a Participant's employment with the Company and all Affiliates due to death, retirement or other reasons; or (ii) a permanent reduction in the level of bona fide services the Participant provides to the Company and all Affiliates to an amount that is less than 50% of the average level of bona fide services the Participant provided to the Company and all Affiliates in the immediately preceding 36 months, with the level of bona fide service calculated in accordance with Treasury Regulation Section 1.409A-1(h)(1)(ii). Solely for purposes of determining whether a Participant has a "Separation from Service," a Participant's employment relationship is treated as continuing while the Participant is on military leave, medical or sick leave, or other bona fide leave of absence (if the period of such leave does not exceed six (6) months, or if longer, so long as the Participant's right to reemployment with the Company or an Affiliate is provided either by statute or contract). If the Participant's period of leave exceeds six (6) months and the Participant's right to reemployment is not provided either by statute or by contract, the employment relationship is deemed to terminate on the first day immediately following the expiration of such six (6) month period. Whether a Termination of Employment has occurred will be determined based on all of the facts and circumstances and in accordance with Section 409A of the Code.

In the case of a Director, Separation from Service means that such member has ceased to be a member of the Board. Whether an independent contractor consultant has incurred a Separation from Service will be determined in accordance with Treasury Regulation Section 1.409A-1(h).

**(ee)** "Stock" means the common stock of the Company and such other securities of the Company that may be substituted for Stock pursuant to Section 5.

**(ff)**"Stock Grant" means a right granted to a Participant under Section 7.

**(gg)**"Termination of Employment" or Termination of Service" means the cessation of performance of services for the Company. For this purpose, the transfer of a Participant among the Company and any Affiliate, or transfer from a position as a member of the Board to Employee, shall not be considered a Termination of Service or a Termination of Employment with the Company. In the context of an Award that is subject to the requirements of Section 409A of the Code, the terms "Termination of Service" and "Termination of Employment" mean a Separation from Service.

------

**ISRAELI SUB-PLAN**

**TO SPOTITEARLY, INC.** 

**2025 EQUITY INCENTIVE PLAN**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.** **General**

This Israeli Sub-Plan to Spotitearly, Inc. 2025 Equity Incentive Plan (this "**Sub-Plan**" and the "**Plan**" respectively) is to be read as a part of the Plan, and the Plan and this Sub-Plan shall be deemed one integrated document.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1The provisions of the Plan shall apply to Awards (as defined below) granted under this Sub-Plan, subject to the modifications set forth below. In the event of any conflict between the Plan and this Sub-Plan, the terms of this Sub-Plan shall govern with respect to Awards granted to Israeli Participants (as defined below).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2This Sub-Plan shall only apply to, and modify Awards granted to, Israeli Participants so that such Awards will be governed by the terms of this Sub-Plan and comply with the requirements of the Israeli law, and specifically with the provisions of Section 3(i) and Section 102 of the Ordinance (as defined below). For the avoidance of doubt, this Sub-Plan shall not modify the Plan with respect to any other category of Participant (as defined in the Plan).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.** **Definitions**

Unless otherwise defined in this Sub-Plan, all capitalized terms used herein shall have the same meanings given to such terms in the Plan. Capitalized terms used herein that are the plural forms or singular forms of defined terms shall have the corresponding plural or singular meanings of the corresponding defined terms. The following terms shall have the meanings set forth below unless the context requires a different meaning:

"**Affiliate**" means any "Employing Company" within the meaning of Section 102(a) of the Ordinance.

"**102 Award**" means an Award granted pursuant to Section 102 of the Ordinance to any person who is an Israeli Employee Participant.

"**3(i) Award**" means an Award granted pursuant to Section 3(i) of the Ordinance to any person who is an Israeli Non-Employee.

"**102 Capital Gains Award**" means a Trustee 102 Award elected and designated by the Employing Company to qualify for Capital Gains tax treatment in accordance with the provisions of Section 102(b)(2) or Section 102(b)(3) of the Ordinance.

"**102 Ordinary Income Award**" means a Trustee 102 Award elected and designated by the Employing Company to qualify for ordinary income tax treatment in accordance with the provisions of Section 102(b)(1) of the Ordinance.

"**Award**" means any Award granted under the Plan that is required to be settled solely in shares of Common Stock, unless otherwise approved by the ITA. StockStock"**Award Agreement**" means an Award Agreement under the Plan all amended and adjusted to Israeli legal requirements or any other document to be signed between the Company and an Israeli Participant, to set out and inform the Israeli Participant with respect to the terms and conditions of the grant of an Award under the Plan and this Sub-Plan and including any document attached to such agreement.

"**Capital Gains**" means a Trustee 102 Award granted under the capital gains tax treatment in accordance with the provisions of Section 102(b)(2) or Section 102(b)(3) of the Ordinance.

"**Controlling Shareholder**" shall have the meaning ascribed to it in Section 32(9) of the Ordinance.

"**Date of Grant**" means the date the applicable Award was approved by the Board or the Committee unless otherwise determined by the Board or the Committee and set forth in the Israeli Participant Award Agreement.

------

"**Employing Company**" means a company as the meaning ascribed to it in Section 102(a) of the Ordinance.

"**Exercise Price**" means the price for each share of Common Stock subject to an Option.

"**Holding Period**" means the requisite period prescribed by Section 102 or such other period as may be required by the ITA, with respect to Trustee 102 Awards, during which Awards or 102 Shares granted or issued by the Company must be held by the Trustee for the benefit of the Israeli Employee Participant.

"**Israeli Employee Participant**" means an individual employed by an Israeli resident Affiliate or an individual who is serving as a *Nose Misra* - Office Holder (as such term is defined in the Israeli Companies' Law, 5759-1999, including directors) of an Israeli resident Affiliate, who is not a Controlling Shareholder prior to the issuance of the relevant Award or as a result thereof.

"**Israeli Non-Employee Participant**" means a person who is not an Israeli Employee Participant, and *inter alia*, shall include a consultant, adviser or service provider of an Israeli Affiliates and a Controlling Shareholder (whether or not an employee of the Company or its Affiliates) of an Israeli Affiliate.

"**Israeli Participant**" means Israeli Employee Participants and Israeli Non-Employee Participants.

"**ITA**" means the Israeli Income Tax Authority or any successor agency.

"**Non-Trustee 102 Award**" means an Award granted to an Israeli Employee Participant pursuant to Section 102(c) of the Ordinance, which is not required to be held in trust by a Trustee.

"**Option**" means a right granted to a Participant to purchase one share of Common Stock of the Company at a specified exercise price, subject to the terms and conditions set forth in the Plan and the applicable Award Agreement.

"**Ordinance**" means the Israeli Income Tax Ordinance [New Version], 1961 or any successor statute, as amended from time to time.

"**Rules**" means the Income Tax Rules (Tax Relief in the Issuance of Shares to Employees), 2003.

"**Section 102**" means Section 102 of the Ordinance and the Rules and any regulations, rules, orders, promulgated thereunder as now in effect or as amended or replaced from time to time.

"**Tax**" means any tax (including, without limitation, any income tax, capital gains tax, value-added tax, sales tax, property tax, gift tax, or estate tax), levy, assessment, tariff, duty (including any customs duty), deficiency, or other fees, and any related charge or amount (including any fine, penalty, interest, linkage differentials or addition to Tax), imposed, assessed, or collected by or under the authority of any governmental body.

"**Trustee**" means any person or entity appointed by the Company or its Subsidiaries or Affiliates, as applicable, and approved by the ITA, to serve as a trustee, all in accordance with the provisions of Section 102(a) of the Ordinance, as may be replaced from time to time subject to the provisions of Section 102.

"**Trustee 102 Award**" means an Award granted pursuant to Section 102(b) of the Ordinance and held in trust by a Trustee for the benefit of the Israeli Employee Participant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.** **Issuance of Awards**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1Without derogating from the provisions of the Plan: (i) Israeli Employee Participants may be granted only with 102 Awards; and (ii) Israeli Non-Employee Participants may be granted only with 3(i) Awards. In each case, such Awards shall be subject to the terms and conditions of the Ordinance and specifically Section 102.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.2The Employing Company may, pursuant to Section 102, designate 102 Awards granted to Israeli Employee Participants as Non-Trustee 102 Awards or as Trustee 102 Awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.** **Trustee 102 Awards**

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1Trustee 102 Awards may be granted only to Israeli Employee Participants under this Sub-Plan duly approved and adopted by the Board and as approved by the respective Tax assessing officer within ninety (90) days from its Submission (as defined below) or by the passage of such ninety (90) days.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2Trustee 102 Awards shall be classified as either 102 Capital Gains Awards or 102 Ordinary Income Awards, subject to the terms and conditions of Section 102 and the provisions of the Plan and this Sub-Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3The Board shall have the right to determine the Employing Company's Election of the type of Trustee 102 Awards to be granted to Israeli Employee Participants, being either 102 Capital Gains Awards or 102 Ordinary Income Awards (the "**Election**"). Such Election is to be appropriately filed with the ITA together with the Plan and Sub-Plan in accordance with the provisions of the Ordinance and Section 102 (the: "**Submission**"). After making an Election, the Company may grant only the type of Trustee 102 Awards it has elected (i.e., 102 Capital Gains Awards or 102 Ordinary Income Awards). The Election shall become effective beginning the first Date of Grant of a Trustee 102 Award under the Plan and Sub-Plan and shall apply to all grants to Israeli Employee Participants of Trustee 102 Awards until such Election is changed pursuant to the provisions of Section 102(g) of the Ordinance. The Employing Company may change such Election only after the passage of at least one year after the end of the year, during which the applicable Employing Company first granted Trustee 102 Awards in accordance with the previous Election. For the avoidance of doubt, such Election shall not prevent the Company from granting Non-Trustee 102 Awards or 3(i) Awards. For the avoidance of any doubt, no Trustee 102 Awards may be granted under this Plan to any eligible Israeli Employee Participants, unless and until the Election made by the Employing Company is appropriately filed with the ITA together with the Plan in accordance with the provisions of the Ordinance and Section 102. Notwithstanding the above and for the avoidance of doubt, the Election shall not prevent the Employing Company from granting Non-Trustee 102 Awards under this Sub-Plan either before the Election is filled or simultaneously thereafter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.4Trustee 102 Awards may be granted under this Sub-Plan duly adopted and approved by the Board and only after the passage of thirty (30) days following the Submission Notwithstanding the above if within ninety (90) days from Submission, the respective Tax assessing officer notifies the Employing Company and/or the Trustee of his or her decision not to approve the Plan (including this Sub-Plan) or the Trustee, the Awards that were intended to be classified as a Trustee 102 Awards shall be deemed to be Non-Trustee 102 Awards unless otherwise determined by the tax assessing officer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.5All Trustee 102 Awards granted and/or issued under the Plan and/or this Sub-Plan and/or any/all 102 Shares (as defined below), and/or any/all other rights resulting from such Trustee 102 Award, including bonus shares or any other shares as a result of any adjustments made under the Plan, shall be deposited with the Trustee and held in trust by the Trustee for the benefit of the Israeli Employee Participant to which such Award was granted all in accordance with the provisions of Section 102. All certificates representing 102 Shares, including bonus shares, shall be issued in the Trustee's name for the benefit of the Israeli Employee Participant, and be deposited with the Trustee, and be held by the Trustee until such time that such 102 Shares are released from the trust or with accordance with any instructions of the ITA in this regard. In the event the requirements for Trustee 102 Awards and/or 102 Shares are not met, the Trustee 102 Awards and/or 102 Shares may be regarded as Non-Trustee 102 Award, or as Awards and/or shares of Common Stock of the Company which are not subject to Section 102, all in accordance with the provisions of Section 102.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.6With respect to 102 Capital Gains Awards and 102 Ordinary Income Awards, such Awards or any shares of Common Stock granted and/or issued upon the vesting and/or exercise thereof (the: "**102 Shares**") and all rights resulting from such Awards or shares of Common Stock, including bonus shares, will be held by the Trustee, from the Date of Grant and for at least the end of the applicable Holding Period or such shorter period as approved by the ITA, under the terms set forth in Section 102.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.7In accordance with Section 102, the Israeli Employee Participant shall not sell, cause the release from trust, or otherwise dispose of, any Trustee 102 Award and/or any 102 Share, or any rights resulting from such Award or Share until, at least, the end of the applicable Lockup Period. Notwithstanding the foregoing but without derogating from the provisions of the Plan and the terms and conditions set forth in the Award Agreement, if any such sale, release, or the disposition occurs during the Holding Period and no authorization or instructions in this regard were received from ITA allowing such sell, release from the trust or any other disposition without breaching the provisions of Section 102, then the provisions of Section 102 relating to non-compliance with the

------

Holding Period will apply and all sanctions and liability under Section 102 shall be borne by the Israeli Employee Participant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.8Anything herein to the contrary notwithstanding, the Trustee shall not release any unexercised Trustee 102 Awards, 102 Shares, or any rights thereunder, including bonus shares, resulting from such Trustee 102 Awards or 102 Shares, prior to the full payment of the Exercise Price set to such Award (if applicable) and the Israeli Employee Participant's tax liability arising from the Trustee 102 Awards granted to him or her.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.9Upon receipt of a Trustee 102 Award, the Israeli Employee Participant will sign the Award Agreement under which such Participant will sign an undertaking of his/her consent and agreement to the grant of the Award under Section 102, and to undertake to comply with the terms of Section 102 and to be subject to the trust agreement between the Company or its Affiliates and the Trustee, stating, *inter alia*, that the Trustee will be released from any liability in respect of any action or decision taken or executed in good faith with respect to this Sub-Plan, or any Trustee 102 Award or 102 Share issued to him or her thereunder, or right resulting therefrom, including bonus shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.10Without derogating from the above and/or from the provisions of Section 102, the Company and/or its Affiliate (as applicable) shall have the authority to determine specific procedures and conditions of the trusteeship with the Trustee in a separate agreement between the Company and/or the Affiliate (as applicable) and the Trustee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.** **Non-Trustee 102 Awards**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1Non-Trustee 102 Awards may be granted only to Israeli Employee Participants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2Non-Trustee 102 Awards that shall be granted pursuant to the Plan may be issued directly to the Israeli Employee Participant or a trustee appointed by the Board in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.3In the event that an Israeli Employee Participant was granted with a Non-Trustee 102 Award and thereafter such Israeli Employee Participant's employment by the Company or its Subsidiaries or Affiliates terminates for any reason, such Israeli Employee Participant will be obligated to provide her or his employer, upon the termination of her or his employment, with security or guarantee to cover any future tax obligation resulting from the grant, exercise or disposition of the Award, the Shares granted and/or issuable upon the vesting or exercise thereof, or any rights resulting therefrom, in a form satisfactory to such employer in such employer's sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.** **3(i) Awards**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1Awards granted pursuant to this Section 6 are intended to constitute 3(i) Awards and are subject to the provisions of Section 3(i) of the Ordinance and the general terms and conditions specified in the Plan and this Sub-Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.23(i) Awards may be granted to Israeli Non-Employee Participants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.33(i) Awards granted pursuant to the Plan may be issued directly to the Israeli Non-Employee Participant or a trustee appointed by the Board in its sole discretion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4Shares pursuant to 3(i) Awards shall not be issued, unless the Israeli Non- Employee Participant delivers to the Company or its Affiliate payment in a form acceptable to the Company or to its Affiliate of all withholding taxes due, if any, on account of the Israeli Participant acquiring Shares under the Option or the Israeli Non- Employee Participant provides other assurance satisfactory to the Company or its Affiliate of the payment of those withholding taxes or provides any certificate issued by the ITA allowing for an exemption from withholding Tax or including any other instructions to the Company or its Affiliate with respect to the withholding of Tax.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.** **The Award Agreement**

The terms and conditions upon which the Awards shall be issued and exercised shall be as specified in an Award Agreement to be executed pursuant to the Plan and this Sub-Plan. Each Award Agreement shall state, *inter alia*, the number of shares of Common Stock granted under the Award, the type of Award granted thereunder (whether such Award is a Trustee 102 Award, and if so, whether it is a 102 Capital Gains Award or 102 Ordinary Income Award, or a Non-Trustee 102 Award, or a 3(i) Award), the vesting provisions, the term of the Award, and the Exercise Price, if applicable. Awards may differ in the number of shares covered hereby, the terms and conditions applying to them or on the Israeli Participant or in any other respect (including, that there should not be any expectation (and it is hereby disclaimed)) that a certain treatment, interpretation or position granted to one shall be applied to the other, regardless of whether or not the facts or circumstances are the same or similar).

**Fair Market Value For Israeli Tax Purposes** **.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1If the Shares are listed on any established stock exchange or a national market system, the Fair Market Value of the Shares shall be the average closing sales price for such Shares (or the closing bid, if no sales were reported) as quoted on such exchange or system for a period determined by the Board, in its sole discretion, prior to the time of determination;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2If the Shares are regularly quoted by a recognized securities dealer but selling prices are not reported, their Fair Market Value shall be the difference between the high bid, and low asked prices for the Shares on the last market trading day prior to the day of determination;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3In the absence of an established market for the Shares, the Fair Market Value thereof shall be determined by a reputable third party appraiser appointed by the Board or by any other method determined in good faith by the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4Without derogating from the bove and solely for the purpose of determining the tax liability pursuant to Section 102(b)(3) of the Ordinance, if at the Date of Grant of a 102 Capital Gains Award the Company's Shares are listed on any established stock exchange or a national market system, or if the Company's shares are registered for trading within ninety (90) days following the Date of Grant of the 102 Capital Gains Award, the fair market value of the shares of Common Stock of the Company at the Date of Grant shall be determined in accordance with the average value of the Company's shares of Common Stock on the thirty (30) trading days preceding the Date of Grant or on the thirty (30) trading days following the date of registration for trading, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.** **Exercise of Awards**

Awards shall be exercised (including form of payment) in accordance with the provisions of the Plan and the Award Agreement and in accordance with the requirements of Section 102.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**9.** **Assignability and Sale of Awards**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1Notwithstanding any other provision of the Plan to the contrary, no Awards, or any right with respect thereto or purchasable thereunder, whether fully paid or not, shall be assignable, transferable or given as collateral or any right with respect thereto granted to any third party whatsoever, other than by will or by laws of descent and distribution, or as specifically otherwise allowed under the Plan or any other law, without the prior written consent of the Board, and subject to the Ordinance. Any purported assignment, transfer, a grant of collateral, or pledge of Awards, or any right with respect thereto or purchasable thereunder, contrary to the provisions of this Section, directly or indirectly, whether contemplated to be effective immediately or in the future, shall be null and void and cause the applicable Award to expire immediately. During the lifetime of the Israeli Participant, all of such Israeli Participant's rights to purchase Shares or to otherwise exercise an Award hereunder shall be exercisable only by the Israeli Participant or as otherwise allowed by the law.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2Without derogating from the above, for as long as Trustee 102 Awards and/or 102 Shares are held by the Trustee on behalf of the Israeli Employee Participant, all rights of the Israeli Employee Participant with respect to such Awards and Shares shall be personal, and may not be transferred, assigned, pledged or mortgaged, all in accordance with the provisions of Section 102 unless other than by the last will, the laws of descent and distribution, or any other law allowing for such transfer or assignment and after the required taxes and payments have been entirely made or secured. In the event that such Awards and/or Shares have been transferred by will, laws of descent and distribution, or any other law allowing for such transfer or assignment, the provisions of Section 102 shall continue to apply on the heirs and transferees, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**10.** **Integration of Section 102 And Tax Assessing Officer's Permit**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1With respect to Trustee 102 Awards, the provisions of the Plan, this Sub-Plan and the Award Agreement shall be subject to the provisions of Section 102 and the Tax assessing officer's permit (to the extent that such permit is required, issued and acceptable to the Company) (the "**Permit**"), and the provisions of the Permit shall be deemed integrated with, and a part of, the Plan, this Sub-Plan and the Award Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2Any provision of Section 102 and/or the Permit and/or tax ruling(s) and/or guidance issued by which is necessary in order to receive and/or to obtain and/or preserve any tax benefit pursuant to Section 102, which is not expressly specified in the Plan, this Sub-Plan, or the Award Agreement and all acceptable by the Company, shall be deemed to be incorporated into this Sub-Plan and binding upon the Company and the Participants who are Israeli Participants.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.3The repurchase, clawback or buy back rights if, and to the extent to be implemented under the Plan shall be subject to and implemented in accordance with the requirements of Section 102, and, if applicable, with the instructions of the ITA and (if required) tax ruling received from the ITA approving such mechanism only.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.4With respect to Israeli Participants, any determination, interpretation, or construction of any provision of the Plan, including in the event of any ambiguity or uncertainty, shall be made in a manner intended to comply with the requirements of Section 102.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**11.** **Dividends**

Without derogating from the provisions of the Plan, an Israeli Participant shall be entitled to receive dividends with respect to shares of Common Stock of the Company granted and/or issued upon the vesting, exercise of his or her Awards (whether such shares are held by the Participant or by the Trustee for his or her benefit), in accordance with the provisions of the Company's certificate of incorporation (including all amendments thereto), subject to any applicable taxation on distribution of dividends and, when applicable, subject to the provisions of Section 102.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**12.** **Tax Consequences**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.1Any liability for any Tax arising with respect to the Awards and the shares of Common Stock, including, but not limited to, as a result of the grant of Awards, the vesting or exercise of an Award for shares, the receipt of cash, the transfer, waiver, or expiration of Awards or shares or the disposal of shares, shall be borne solely by the Israeli Participants, and in the event of their death, by their estates or heirs. Neither the Company nor any of its Subsidiaries or Affiliates nor the Trustee shall be required to pay such Taxes, directly or indirectly, nor shall they be required to gross-up such Taxes in the Israeli Participants' salaries or remuneration. The applicable Tax may be deducted from any cash to be provided to the Israeli Participant or from the proceeds of the disposal of the shares or shall be paid to the Trustee or to the Company or its Subsidiaries or Affiliates by the Israeli Participants at their request, or may be provided via any combination of the above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.2The Company, its Subsidiaries or Affiliates, and the Trustee shall be entitled to withhold Taxes according to the requirements of any applicable laws, rules, and regulations, including by withholding Taxes at source.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.3The Israeli Participants undertake to indemnify the Company, its Subsidiaries or Affiliates and the Trustee, immediately upon their request, for any Tax for which the Israeli Participant is liable under any applicable law, under the Plan or this Sub-Plan, and which was paid by the Company or the Trustee, or which the Company or the Trustee are required to pay. The Company may exercise its right to such indemnification by deducting the Tax subject to indemnification from Participant's salary or remuneration.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.4The Board or, when applicable, the Trustee shall not be required to release any Awards, Shares, rights resulting therefrom, including bonus shares, or stock certificates, to an Israeli Participant until all required Tax payments and other payments to be borne by such Israeli Participant have been fully made. In the event that the Company, or its Affiliates, or the Trustee, as applicable, is uncertain as to the sum of the full tax payment due or which is subject to withholding, the Company or the Trustee, as applicable, may refuse to release the Shares until such time as the ITA verifies the sum of the full tax payment which is due, and the Israeli Participant shall not have any claims in connection with such refusal.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.5The Company and its Subsidiaries and its Affiliates do not undertake or assume any liability or responsibility to the effect that any Award shall qualify with any particular tax regime or rules applying to specific tax treatment, or benefit from any particular tax treatment or tax advantage of any type and subject to the requirements of applicable law. No assurance is made by the Company or any of its Subsidiaries and its Affiliates that any particular tax treatment on the Date of Grant will continue to exist or that the Award would qualify at the time of vesting or exercise or disposition thereof with any particular tax treatment. The Company does not undertake or assume any liability to contest a determination or interpretation (whether written or unwritten) of any tax authorities, including in respect of the qualification under any particular tax regime or rules applying to specific tax treatment. If the Awards do not qualify under any specific tax treatment, it could result in adverse tax consequences to the Israeli Participant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.6Notwithstanding any other provision, no Israeli Participant shall have any of the rights of a shareholder with respect to any Shares until the Israeli Participant pays all payments required to be paid with respect to such Shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**13.** **Governing Law and Jurisdiction**

The Plan and all Awards (and any 102 Share received subsequently following any realization of rights derived from the Awards) granted thereunder are governed by the laws of the State of Delaware as provided in section 13.10 of the Plan, excluding the principles of conflicts of laws thereof; provided, however, that all aspects of the Awards which relate to Section 102, the Israeli Sub - Plan, the trust agreement signed between the Company and/or the Employing Company and the Trustee and/or Section 3(i) of the Ordinance, shall be governed by and interpreted in accordance with the laws of the State of Israel, without giving effect to the principles of the conflicts of laws thereof. All such Awards (and 102 Shares) shall be subject to the laws and requirements of the State of Israel, and the terms and conditions on which each such Award (or 102 Share) is granted are deemed modified to the extent necessary or advisable to comply with the applicable Israeli laws.

\*\*\*\*\*\*\*\*

------

## Add

**EXHIBIT 99.2**

**SpotitEarly, Inc.** 

**Code of Ethics**

**Introduction**

In keeping with our commitment to honest business practices, SpotitEarly, Inc., and its wholly-owned subsidiary (the "Company") have adopted this company-wide Code of Ethics to assist our directors, officers, consultants and employees ("Company Representatives") in complying with both our corporate policies and with the law.

Although this Code of Ethics covers many different business practices and procedures, it does not cover every issue that may arise. Instead, our Code sets forth the clear principles and standards to which we expect Company Representatives to adhere and certain principles regarding enforcement of the Code. Our goal is to conduct ourselves in a manner that avoids even the appearance of impropriety.

This Code should be read in conjunction with our other corporate policies. If a law conflicts with a policy in this Code, you must comply with the law. If you have questions about this Code, other our other policies, or how to comply with the law in a certain situation, it is important that you immediately bring your questions to one of the Company's officers. *If you are in or observe a situation that you believe may violate or lead to a violation of this Code, you should refer to Section F of our Code for guidance on how to report questionable behavior.*

Company Representatives who violate the standards of this Code will be subject to disciplinary action. Such action may include termination of employment.

**A.** **Compliance with All Laws, Rules and Regulations**

The Company requires that Company Representatives strictly adhere to local, state, and federal laws, as well as the laws of the other countries in which we conduct business. If you have questions about what laws we are subject to, or about how to comply with certain laws, it is important that you alert an officer of the Company to your question. We rely on you not only to act ethically, but also to assist your fellow employees and management in following the law. When appropriate, the Company will provide information and training to promote compliance with laws, rules, and regulations, including insider-trading laws.

Each Company Representative has a responsibility to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·maintain a safe and healthy work environment;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·promote a workplace that is free from discrimination or harassment based on race, color, religion, sex, sexual orientation, age, national origin, disability or other factors that are unrelated to the Company's business interests;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·support fair competition and laws prohibiting restraints of trade and other unfair trade practices;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·conduct our activities in full compliance with all applicable environmental laws;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·keep the political activities of our directors, officers and employees separate from our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·refrain from making any illegal payments, gifts, or gratuities to any government officials or political party;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·refrain from the unauthorized use, reproduction, or distribution of Company and/or any third party's trade secrets, copyrighted information or confidential information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·comply with all applicable securities laws, including insider trading laws which require Company Representatives to refrain from trading in the Company's securities while in possession of confidential non-public information concerning the Company and "tipping" others who might make an investment decision on the basis of on such information.

------

**B.** **Conflicts of Interest and Ethical Conduct**

Company Representatives are expected to make or participate in business decisions and actions based on the best interests of the Company as a whole, and not based on personal relationships or personal gain. As defined, a "conflict of interest" exists when a Company Representative's private interest interferes in any way with the interest of the Company, or creates an appearance of impropriety. A conflict situation can arise when you have interests that make it difficult for you to perform your work objectively, or when a Company Representative receives improper personal benefits as a result of his or her position with the Company. Conflicts of interest are prohibited as a matter of Company policy, unless authorized by the Board of Directors or under guidelines approved by the Board of Directors.

It is almost always a conflict of interest for a Company Representative to work simultaneously for a competitor, customer, or supplier. You should avoid any relationship that would cause a conflict of interest with your duties and responsibilities at the Company. In order to avoid a conflict of interest, or even an appearance of a conflict of interest, Company Representatives will not:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·possess any personal financial interest in any business transaction of the Company or its agents or representatives unless such interest is first approved by the Board;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·acquire or maintain any influential interest in or position with any other business enterprise whose activities are in competition with the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·accept gifts, gratuities, bribes, kickbacks, or similar renumeration or consideration given by any person or organization in order to attract or influence business activity; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·use information concerning the Company's business for personal gain or profit.

Members of our Board of Directors have a special responsibility to the Company and to our shareholders. To avoid conflicts of interest, directors are required to disclose to their fellow directors any personal interest they may have in a transaction being considered by the Board and, when appropriate, to recuse themselves from any decision in which there may be a conflict of interest. Waivers of a conflict of interest or this Code involving executive officers and directors require approval by the Board of Directors.

In addition to raising a potential conflict of interest, certain transactions with any director, officer, or shareholder that beneficially owns 5% or more of the Company's securities are considered to be a "related party transaction" due to the related person's relationship with the Company and the direct or indirect material interest in the transaction. All related party transactions must be disclosed to the Audit Committee or a special independent committee of the Board of Directors for review and approval.

Our Board of Directors and officers also have a duty to refrain from taking for themselves any opportunity discovered through use of Company property, information, or position, using Company property for personal gain, and from competing with the Company. The Company's officers and directors will advance the Company's legitimate interests when the opportunity to do so arises.

In addition to the foregoing, all Company Representatives shall:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·act honestly and ethically in the performance of his or her duties at the Company, avoiding actual or apparent conflicts of interest in personal and professional relationships;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·comply with rules and regulations of federal, state, provincial, local and foreign governments, as well as those of other appropriate private and public regulatory agencies that affect the conduct of the Company's business and the Company's financial reporting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·act in good faith, responsibly, with due care, competence and diligence, without misrepresenting material facts or allowing one's independent judgment to be subordinated;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·share knowledge and maintain skills relevant to carrying out the Company Representatives' duties within the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·proactively promote and set an example of ethical behavior as a responsible partner among peers and colleagues in the work environment and community;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·achieve responsible use of and control over all assets and resources of the Company to which they are entrusted;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·honestly and accurately maintain the books, records, accounts, and financial statements of the Company in reasonable detail to appropriately reflect the Company's transactions and to conform with the Company's system of internal controls and meet all applicable legal requirements, and retain such records in accordance with the Company's document retention policies; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·report any discovery of a violation of the Code or potential or existing conflict of interest in accordance with the procedures set forth in Section F of this Code.

**C.** **Our Commitment to Full, Fair, Accurate, Timely and Plain English Disclosure**

As a respected public company, it is critical that the Company's filings with the Securities and Exchange Commission be complete, timely and accurate in all material respects.

Company Representatives are charged with the responsibility of providing management with accurate and complete information to assure we are complying with our public disclosure requirements and our commitment to our shareholders.

In addition to this general duty of Company Representatives to assist the Company's senior management in meeting its obligations for public reporting compliance purposes, the CEO and senior financial management employees each agree that he or she will:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·provide information that is accurate, complete, objective, relevant, timely and understandable to ensure full, fair, accurate, timely, and understandable disclosure in reports and documents filed with or submitted to the SEC or used in other public communications by the Company; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·promptly bring to the attention of the Company's Chief Executive Officer or the Audit Committee (if one is appointed), any information concerning (a) any conduct believed to be a violation of law or business ethics, or this Code, including any transaction or relationship that reasonably could be expected to give rise to such a conflict; (b) significant deficiencies in the design or operation of internal controls which could adversely affect the Company's ability to record, process, summarize and report financial data or (c) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company's financial reporting, disclosures, or internal controls.

**D.** **Payments to Government Personnel**

The U.S. Foreign Corrupt Practices Act (FCPA) prohibits giving anything of value directly or indirectly to officials of foreign governments or foreign political candidates in order to obtain or retain business. Company Representatives are strictly prohibited from making illegal payments to government officials of any country.

In addition, the U.S. government and other foreign governments have a number of laws and regulations regarding business gratuities, which if violated would not only violate this Code but could also be a criminal offense. The U.S. government has laws and regulations concerning disclosure of payments to foreign governments. Any such payments should be promptly brought to the attention of a senior financial management employee or the Company's Chief Executive Officer.

------

**E.** **Confidentiality**

Company Representatives shall respect and maintain the confidentiality of information acquired in the course of one's work and shall not disclose such confidential information except when authorized or legally obligated to do so. Further, confidential information acquired in the course of performing one's duties for the Company will not be used for personal advantage or gain. The responsibility to keep such confidential information continues even after your employment relationship with the Company ends.

**F.** **Reporting and Treatment of Violations**

The Board of Directors has the power to monitor, investigate, make determinations and take action with respect to violations of this Code. In determining whether to take disciplinary action, the Board of Directors may take into account, among other factors:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·the nature and severity of the violation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·whether the violation was a single occurrence or involved repeated occurrences;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·whether the violation appears to have been intentional or inadvertent;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·whether the person in question had been advised prior to the violation as to the proper course of action;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·whether the person in question had committed other violations in the past; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;·such other facts and circumstances as the Board of Directors shall deem advisable in the context of the alleged violation.

Any waiver of this Code for Company Representatives may be made only by the Board of Directors. Any director seeking a waiver may not participate in the Board action related to such waiver. A waiver of this Code for any officer or director will be promptly disclosed to the Company's shareholders.

------

**ACKNOWLEDGEMENT OF CODE OF ETHICS**

By signing below, I acknowledge I have received and reviewed a copy of SpotitEarly, Inc.'s Code of Ethics. I understand this acknowledgement will be maintained in my employment file.

Acknowledged:

    <br> (name and title) Date

REPORTING SUSPECTED VIOLATIONS OF THE CODE OF ETHICS SHOULD BE MADE TO

SpotitEarly, Inc.

Attn: Chief Executive Officer

61 W. Palisade Ave.

Englewood, NJ 07631

------

**SIGNATURES**

Pursuant to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A and has duly caused this Offering Statement to be signed on its behalf by the undersigned thereunto duly authorized, in the City of Englewood, New Jersey on July 24, 2025.

---

| | | |
|:---|:---|:---|
| (Exact name of issuer as specified in its charter): | **SpotitEarly, Inc.** | **SpotitEarly, Inc.** |
| July 24, 2025 | By: | /s/ Shlomi Madar |
|  |  | Shlomi Madar, Chief Executive Officer |
|  |  | (Principal Executive Officer) |
| July 24, 2025 | By: | /s/ Shai Lankry |
|  |  | Shai Lankry, Chief Financial Officer |
|  |  | (Principal Financial Officer, Principal |
|  |  | Accounting Officer) |

---

**SIGNATURES OF DIRECTORS**

---

| | |
|:---|:---|
| /s/ Shlomi Madar | July 24, 2025 |
| Shlomi Madar |  |
| /s/ Shai Lankry | July 24, 2025 |
| Shai Lankry |  |
| /s/ Roi Ophir | July 24, 2025 |
| Roi Ophir |  |
| /s/ Ariel Ben Dayan | July 24, 2025 |
| Ariel Ben Dayan |  |
| /s/ Alon Lifschitz | July 24, 2025 |
| Alon Lifschitz |  |

---

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 1-A

### REGULATION A OFFERING STATEMENT
### UNDER THE SECURITIES ACT OF 1933

### Item 1. Issuer Information

**Exact name of issuer:** SpotitEarly, Inc.

**Jurisdiction of Incorporation/Organization:** DE

**Year of Incorporation:** 2024

**CIK:** 0002077992

**I.R.S. Employer Identification Number:** 33-3773069

**Primary Standard Industrial Classification Code:** 8000

**Total number of full-time employees:** 23

**Total number of part-time employees:** 0

**Address of Principal Executive Offices:** 61 W. Palisade Ave., —, Englewood, NJ 07631

**Company Phone:** 551-355-6554

**Person to contact:** Hart & Hart, LLC

### Financial Statements

**Balance Sheet Information**

| Metric                                   | Amount   |
|:---|:---|
| Cash and Cash Equivalents                | $0.00    |
| Investment Securities                    | $0.00    |
| Accounts and Notes Receivable            | $0.00    |
| Property, Plant and Equipment (PP&E)     | $0.00    |
| Total Assets                             | $0.00    |
| Accounts Payable and Accrued Liabilities | $0.00    |
| Long-Term Debt                           | $0.00    |
| Total Liabilities                        | $0.00    |
| Total Stockholders' Equity               | $0.00    |
| Total Liabilities and Equity             | $0.00    |

**Statement of Comprehensive Income Information**

| Metric                                    | Amount   |
|:---|:---|
| Total Revenues                            | $0.00    |
| Costs and Expenses Applicable to Revenues | $0.00    |
| Depreciation and Amortization             | $0.00    |
| Net Income                                | $0.00    |
| Earnings Per Share - Basic                | 0.00     |
| Earnings Per Share - Diluted              | 0.00     |

**Auditor Information**

| Metric          | Amount   |
|:---|:---|
| Name of Auditor | N/A      |

### Outstanding Securities

| Class            |   Outstanding | CUSIP   | Publicly Traded   |
|:---|---:|:---|:---|
| Common Equity    |       8684618 | None    | None              |
| Preferred Equity |      11409198 | None    | None              |
| Debt Securities  |             0 | None    | None              |

### Item 2. Issuer Eligibility
- [x] The issuer certifies that all of the statements in this part are true.

### Item 3. Application of Rule 262
- [x] The issuer certifies that it is not disqualified and has not been involved in any disqualifying event.

### Item 4. Summary Information Regarding the Offering

**Tier:** Tier2

**Financial Statement Status:** Audited

**Type of Securities Offered:** Equity (common or preferred stock)

**Is this a delayed or continuous offering?** Yes

**Was or is the offering to take place within one year after qualification?** Yes

**Was or is the offering to commence within two days after qualification?** No

**Is this a best efforts offering?** Yes

**Was there any solicitation of interest?** Yes

**Are there any resale securities by affiliates of the issuer?** No

**Offering Amounts**

| Description                                                     | Amount       |
|:---|:---|
| Number of securities offered                                    | 9712509      |
| Number of securities outstanding                                | 0            |
| Price per security                                              | $7.15        |
| Issuer's aggregate offering price                               | $69444439.00 |
| Aggregate offering price of securities held by security holders | $0.00        |
| Aggregate price of securities offered concurrently              | $0.00        |
| Total aggregate offering price                                  | $69444439.00 |

**Anticipated Fees**

| Service Provider   | Name             | Fees      |
|:---|:---|:---|
| Auditor            | Deloitte Israel  | $80000.00 |
| Legal              | Hart & Hart, LLC | $35000.00 |
| Promoters          |  |  |

**Estimated Net Proceeds to the Issuer:** $69324439.00

### Item 5. Jurisdictions in Which Securities are to be Offered

- All States and Territories

### Item 6. Unregistered Securities Issued or Sold Within One Year

**Name of Such Issuer:** SpotitEarly, Inc.

**Title of Securities Issued:** Common Shares

**Total Amount of Securities Issued:** 8684618

**Amount of such securities sold by principal security holders:** 0

**Aggregate consideration:** All outstanding common and preferred shares of SpotitEarly, Ltd.

**Basis for aggregate consideration:** —

**Securities Act Exemption:** The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information.